[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAchEuYSqpMVLq3AwXdcmiHWwXMXfQP6SeaNmupPFWzs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"University of Pennsylvania",[4],1638,false,362,76,43822372,169,1106,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Obesity",69,{"name":18,"count":19},"Depression",38,{"name":21,"count":22},"Healthy",36,{"name":24,"count":25},"Hypertension",31,{"name":27,"count":28},"Diabetes",28,{"name":30,"count":31},"Stroke",23,{"name":33,"count":34},"Heart Failure",22,{"name":36,"count":37},"Anxiety",21,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04275453","Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET\u002FCT Serial Imaging","2022-01-05","FDG",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04225039","Anti-GITR\u002FAnti-PD1\u002FStereotactic Radiosurgery, in Recurrent Glioblastoma","2022-09-08","INCMGA00012",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03697408","Itacitinib + Everolimus in Hodgkin Lymphoma","2024-05-20","Itacitinib",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03933904","Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease","2024-06-30","Sirolimus",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04323189","Effects of Sitagliptin in Individuals With Genetically Decreased DPP4","2025-02-27","Sitagliptin 100mg",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT03189485","Tau PET Imaging in the NACC Study Cohort","2025-10-08","the radiotracer 18F-AV-1451",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06065657","Effect of Nutritional Ketosis on Alcohol Metabolism","2025-12-01","Ethanol",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04582383","Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne","2026-02-13","Spironolactone",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06419335","Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study","2026-04-30","CoQ10",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT00481546","Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations","2026-06","rAAV2-CBSB-hRPE65",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,139,175,219,244,270,295,313,336,359,383,401,419,445,480,498,516,534,552,570,588,606,633,651,677,709,743,767,792,814,840,867,885,911,929,955,1108,1137,1190,1223,1271,1309,1346,1383,1429,1460,1488,1526,1554,1572,1596,1614,1638,1656,1674,1699,1727,1745,1763,1781,1805,1831,1855,1881,1899,1924,1949,1974,1997,2015,2039,2063,2088,2106,2124,2150,2168,2186,2208,2235,2260,2278,2296,2321,2346,2371,2397,2474,2523,2554,2616,2722,2752,2788,2821,2843,2904,2940,2976,3001,3019,3044,3062,3080,3104,3129,3147,3165,3191,3209,3234,3252,3270,3295,3321,3339,3362,3384,3408,3431,3449,3472,3493,3520,3538,3556,3574,3598,3616,3634,3652,3679,3697,3715,3741,3769,3787,3809,3835,3853,3871,3902,3927,3950,3973,3996,4019,4044,4065,4088,4106,4130,4148,4171,4193,4220,4242,4266,4284,4306,4329,4354,4372,4396,4428,4446,4464,4482,4504,4527,4645,4685,4734,4767,4798,4833,4867,4904,4940,4970,5000,5025,5043,5066,5091,5113,5137,5162,5187,5211,5239,5257,5275,5300,5327,5350,5375,5393,5418,5436,5459,5482,5500,5524,5547,5572,5590,5613,5640,5658,5676,5694,5720,5738,5760,5784,5807,5825,5843,5874,5892,5910,5928,5946,5964,5982,6000,6018,6036,6054,6072,6090,6108,6132,6157,6175,6200,6225,6243,6267,6285,6312,6330,6348,6373,6398,6416,6442,6460,6478,6496,6521,6554,6589,6611,6640,6662,6680,6704,6729,6751,6777,6795,6817,6842,6860,6878,6902,6925,6950,6968,6986,7010,7032,7055,7080,7098,7116,7140,7158,7176,7198,7221,7239,7257,7282,7306,7332,7350,7445,7495,7541,7588,7625,7667,7703,7734,7756,7787,7822,7852,7882,7912,7942,7970,8002,8040,8062,8084,8116,8150,8175,8198,8216,8238,8261,8285,8306,8329,8347,8365,8390,8408,8431,8453,8474,8492,8513,8531,8555,8573,8597,8615,8638,8656,8680,8704,8728,8750,8775,8793,8819,8837,8860,8878,8896,8918,8940,8963,8981,8999,9025,9043,9067,9085,9107,9125,9149,9167,9185,9203,9221,9245,9263,9286,9304,9328,9351,9376,9394,9412,9430,9451,9472,9499,9521,9543,9567,9591,9614,9636,9660,9684,9707,9725,9749,9772,9794,9817,9839,9862,9880,9905,9927,9953,9978,9999,10024,10042,10064,10089,10113,10136,10158,10180,10198,10216,10234,10252,10270,10292,10336,10365,10397,10431,10458,10482,10508,10533,10556,10582,10600,10622,10643,10666,10684,10706,10724,10746,10769,10787,10805,10832,10850,10868,10895,10918,10939,10961,10979,10997,11015,11039,11057,11075,11093,11111,11133,11155,11178,11202,11225,11243,11261,11284,11306,11330,11354,11377,11395,11413,11436,11459,11477,11502,11520,11543,11565,11583,11601,11619,11642,11664,11682,11703,11725,11749,11771,11795,11818,11836,11857,11882,11900,11924,11948,11974,11992,12010,12034,12058,12076,12098,12123,12141,12164,12187,12211,12229,12252,12277,12295,12313,12337,12359,12382,12439,12485,12524,12567,12596,12633,12678,12719,12752,12789,12828,12860,12882,12907,12935,12966,12988,13013,13043,13067,13097,13130,13158,13182,13200,13218,13236,13263,13281,13299,13320,13343,13368,13393,13417,13443,13461,13483,13506,13529,13551,13575,13598,13621,13639,13661,13683,13705,13727,13750,13773,13791,13809,13832,13857,13879,13900,13921,13950,13968,13986,14004,14022,14040,14063,14081,14104,14122,14146,14164,14190,14208,14226,14249,14267,14285,14309,14331,14353,14377,14395,14422,14443,14461,14479,14505,14523,14541,14563,14587,14608,14626,14647,14669,14687,14713,14731,14749,14767,14792,14810,14828,14850],{"intervention":98,"totalTrials":99,"cells":100},"Levothyroxine Sodium",2,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":122,"PHASE4":124,"NA":137},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":121,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":87,"enrollment":114,"conditions":115,"interventions":117},"NCT07424183","T4\u002FT3 Therapy in Hypothyroidism","NOT_YET_RECRUITING",[92],"2027-06",60,[116],"Hypothyroidism Primary",[118,119,120],"Liothyronine","Levothyroxine Sodium (LT4)","Liothyronine (LT3) placebo",1,{"trials":123,"activeCount":103},[],{"trials":125,"activeCount":121,"soonestReadout":131},[126],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT06073665","Dosing of LT4 in Older Individuals","RECRUITING",[94],"2028-04-01","2024-01-31",228,[135],"Hypothyroidism",[98],{"trials":138,"activeCount":103},[],{"intervention":78,"totalTrials":99,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":159,"PHASE4":161,"NA":173},{"trials":142,"activeCount":103},[],{"trials":144,"activeCount":103},[],{"trials":146,"activeCount":103},[147],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT02285920","Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial","COMPLETED",[92],"2017-06","2017-07-30","2014-11",129,[157],"End-Stage Renal Disease",[78],{"trials":160,"activeCount":103},[],{"trials":162,"activeCount":121,"soonestReadout":77},[163],{"nctId":75,"briefTitle":76,"status":164,"phases":165,"primaryCompletion":77,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"ACTIVE_NOT_RECRUITING",[94],"2026-07-31","2022-03-30",350,[170],"Acne",[78,172],"Doxycycline Hyclate",{"trials":174,"activeCount":103},[],{"intervention":176,"totalTrials":99,"cells":177},"Vancomycin",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":200,"PHASE4":202,"NA":217},{"trials":179,"activeCount":103},[],{"trials":181,"activeCount":103},[],{"trials":183,"activeCount":103},[184],{"nctId":185,"briefTitle":186,"status":150,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT02765256","Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease",[92],"2018-12","2016-08",8,[192],"Crohn's Disease",[194,176,195,196,197,198,199],"Fluconazole","Neomycin","Ciprofloxacin","Polyethylene Glycol 3350","Promethazine","Fluconazole placebo",{"trials":201,"activeCount":103},[],{"trials":203,"activeCount":121,"soonestReadout":208},[204],{"nctId":205,"briefTitle":206,"status":129,"phases":207,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT06954129","A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients",[94],"2029-05","2029-07","2026-01-28",750,[213],"Acute Kidney Injury",[176,215,216],"Piperacillin-tazobactam","Cefepime",{"trials":218,"activeCount":103},[],{"intervention":220,"totalTrials":121,"cells":221},"Pharmacotherapy with paroxetine or venlafaxine XR",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":242},{"trials":223,"activeCount":103},[],{"trials":225,"activeCount":103},[],{"trials":227,"activeCount":103},[],{"trials":229,"activeCount":103},[],{"trials":231,"activeCount":121,"soonestReadout":236},[232],{"nctId":233,"briefTitle":234,"status":164,"phases":235,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT04961190","A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD",[94],"2026-07-15","2022-05-25",302,[240],"Posttraumatic Stress Disorder",[220],{"trials":243,"activeCount":103},[],{"intervention":245,"totalTrials":121,"cells":246},"Seasonal influenza vaccine",{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":268},{"trials":248,"activeCount":103},[],{"trials":250,"activeCount":103},[],{"trials":252,"activeCount":103},[],{"trials":254,"activeCount":103},[],{"trials":256,"activeCount":121,"soonestReadout":261},[257],{"nctId":258,"briefTitle":259,"status":129,"phases":260,"primaryCompletion":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":267},"NCT05108818","Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults",[94],"2027-04-01","2028-03-31","2021-10-07",700,[266],"Influenza, Human",[245],{"trials":269,"activeCount":103},[],{"intervention":271,"totalTrials":121,"cells":272},"Inactivated influenza vaccine",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":293},{"trials":274,"activeCount":103},[],{"trials":276,"activeCount":103},[],{"trials":278,"activeCount":103},[],{"trials":280,"activeCount":103},[],{"trials":282,"activeCount":121,"soonestReadout":287},[283],{"nctId":284,"briefTitle":285,"status":164,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT03315975","Flu Vaccine Responses in the Setting of Melanoma Treatment",[94],"2026-07-01","2017-10-20",40,[291],"Viral Vaccines",[271],{"trials":294,"activeCount":103},[],{"intervention":172,"totalTrials":121,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":311},{"trials":298,"activeCount":103},[],{"trials":300,"activeCount":103},[],{"trials":302,"activeCount":103},[],{"trials":304,"activeCount":103},[],{"trials":306,"activeCount":121,"soonestReadout":77},[307],{"nctId":75,"briefTitle":76,"status":164,"phases":308,"primaryCompletion":77,"completion":166,"start":167,"enrollment":168,"conditions":309,"interventions":310},[94],[170],[78,172],{"trials":312,"activeCount":103},[],{"intervention":63,"totalTrials":121,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":334},{"trials":316,"activeCount":103},[],{"trials":318,"activeCount":103},[],{"trials":320,"activeCount":103},[],{"trials":322,"activeCount":103},[],{"trials":324,"activeCount":121,"soonestReadout":62},[325],{"nctId":60,"briefTitle":61,"status":164,"phases":326,"primaryCompletion":62,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":333},[94],"2026-02-28","2020-08-26",20,[331,332,33],"Genetics Disease","Type2 Diabetes",[63],{"trials":335,"activeCount":103},[],{"intervention":337,"totalTrials":121,"cells":338},"Influenza vaccination",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":357},{"trials":340,"activeCount":103},[],{"trials":342,"activeCount":103},[],{"trials":344,"activeCount":103},[],{"trials":346,"activeCount":103},[],{"trials":348,"activeCount":121,"soonestReadout":287},[349],{"nctId":350,"briefTitle":351,"status":129,"phases":352,"primaryCompletion":287,"completion":287,"start":288,"enrollment":353,"conditions":354,"interventions":356},"NCT03346772","Study of Immune Responses to Influenza Vaccination",[94],75,[355],"Influenza Vaccination",[337],{"trials":358,"activeCount":103},[],{"intervention":360,"totalTrials":121,"cells":361},"Nexplanon 68 MG Drug Implant",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":381},{"trials":363,"activeCount":103},[],{"trials":365,"activeCount":103},[],{"trials":367,"activeCount":103},[],{"trials":369,"activeCount":103},[],{"trials":371,"activeCount":121,"soonestReadout":376},[372],{"nctId":373,"briefTitle":374,"status":129,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":34,"conditions":378,"interventions":380},"NCT05730205","Effects of the Contraceptive Implant in Women With Sickle Cell Disease",[94],"2026-06-15","2023-06-08",[379],"Sickle Cell Disease",[360],{"trials":382,"activeCount":103},[],{"intervention":215,"totalTrials":121,"cells":384},{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":399},{"trials":386,"activeCount":103},[],{"trials":388,"activeCount":103},[],{"trials":390,"activeCount":103},[],{"trials":392,"activeCount":103},[],{"trials":394,"activeCount":121,"soonestReadout":208},[395],{"nctId":205,"briefTitle":206,"status":129,"phases":396,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":397,"interventions":398},[94],[213],[176,215,216],{"trials":400,"activeCount":103},[],{"intervention":216,"totalTrials":121,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":417},{"trials":404,"activeCount":103},[],{"trials":406,"activeCount":103},[],{"trials":408,"activeCount":103},[],{"trials":410,"activeCount":103},[],{"trials":412,"activeCount":121,"soonestReadout":208},[413],{"nctId":205,"briefTitle":206,"status":129,"phases":414,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":415,"interventions":416},[94],[213],[176,215,216],{"trials":418,"activeCount":103},[],{"intervention":420,"totalTrials":121,"cells":421},"Depot medroxyprogesterone acetate",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":443},{"trials":423,"activeCount":103},[],{"trials":425,"activeCount":103},[],{"trials":427,"activeCount":103},[],{"trials":429,"activeCount":103},[],{"trials":431,"activeCount":121,"soonestReadout":436},[432],{"nctId":433,"briefTitle":434,"status":129,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":442},"NCT06665997","Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease",[94],"2028-07-31","2025-06-26",65,[440,441],"Sickle Cell Disease (SCD)","Vaso-Occlusive Pain Episode in Sickle Cell Disease",[420],{"trials":444,"activeCount":103},[],{"intervention":446,"totalTrials":121,"cells":447},"Diphenhydramine, 25 mg",{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":478},{"trials":449,"activeCount":103},[],{"trials":451,"activeCount":103},[],{"trials":453,"activeCount":103},[],{"trials":455,"activeCount":103},[],{"trials":457,"activeCount":121,"soonestReadout":462},[458],{"nctId":459,"briefTitle":460,"status":111,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":470},"NCT07542756","A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia",[94],"2032-01-01","2026-05",1200,[466,467,468,469],"Insomnia","Insomnia Disorder","Chronic Insomnia","Chronic Insomnia Disorder",[446,471,472,473,474,475,476,477],"Diphenhydramine, 50 mg","Doxepin, 3 mg","Doxepin, 6 mg","Trazodone, 50 mg","Trazodone, 100 mg","Zolpidem, 5 mg","Zolpidem, 10 mg",{"trials":479,"activeCount":103},[],{"intervention":471,"totalTrials":121,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":496},{"trials":483,"activeCount":103},[],{"trials":485,"activeCount":103},[],{"trials":487,"activeCount":103},[],{"trials":489,"activeCount":103},[],{"trials":491,"activeCount":121,"soonestReadout":462},[492],{"nctId":459,"briefTitle":460,"status":111,"phases":493,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":494,"interventions":495},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":497,"activeCount":103},[],{"intervention":472,"totalTrials":121,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":514},{"trials":501,"activeCount":103},[],{"trials":503,"activeCount":103},[],{"trials":505,"activeCount":103},[],{"trials":507,"activeCount":103},[],{"trials":509,"activeCount":121,"soonestReadout":462},[510],{"nctId":459,"briefTitle":460,"status":111,"phases":511,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":512,"interventions":513},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":515,"activeCount":103},[],{"intervention":473,"totalTrials":121,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":532},{"trials":519,"activeCount":103},[],{"trials":521,"activeCount":103},[],{"trials":523,"activeCount":103},[],{"trials":525,"activeCount":103},[],{"trials":527,"activeCount":121,"soonestReadout":462},[528],{"nctId":459,"briefTitle":460,"status":111,"phases":529,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":530,"interventions":531},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":533,"activeCount":103},[],{"intervention":474,"totalTrials":121,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":550},{"trials":537,"activeCount":103},[],{"trials":539,"activeCount":103},[],{"trials":541,"activeCount":103},[],{"trials":543,"activeCount":103},[],{"trials":545,"activeCount":121,"soonestReadout":462},[546],{"nctId":459,"briefTitle":460,"status":111,"phases":547,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":548,"interventions":549},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":551,"activeCount":103},[],{"intervention":475,"totalTrials":121,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":103},[],{"trials":557,"activeCount":103},[],{"trials":559,"activeCount":103},[],{"trials":561,"activeCount":103},[],{"trials":563,"activeCount":121,"soonestReadout":462},[564],{"nctId":459,"briefTitle":460,"status":111,"phases":565,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":566,"interventions":567},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":569,"activeCount":103},[],{"intervention":476,"totalTrials":121,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":586},{"trials":573,"activeCount":103},[],{"trials":575,"activeCount":103},[],{"trials":577,"activeCount":103},[],{"trials":579,"activeCount":103},[],{"trials":581,"activeCount":121,"soonestReadout":462},[582],{"nctId":459,"briefTitle":460,"status":111,"phases":583,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":584,"interventions":585},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":587,"activeCount":103},[],{"intervention":477,"totalTrials":121,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":604},{"trials":591,"activeCount":103},[],{"trials":593,"activeCount":103},[],{"trials":595,"activeCount":103},[],{"trials":597,"activeCount":103},[],{"trials":599,"activeCount":121,"soonestReadout":462},[600],{"nctId":459,"briefTitle":460,"status":111,"phases":601,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":602,"interventions":603},[94],[466,467,468,469],[446,471,472,473,474,475,476,477],{"trials":605,"activeCount":103},[],{"intervention":607,"totalTrials":121,"cells":608},"Nanozyme treatment",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":631},{"trials":610,"activeCount":103},[],{"trials":612,"activeCount":103},[],{"trials":614,"activeCount":103},[],{"trials":616,"activeCount":103},[],{"trials":618,"activeCount":121,"soonestReadout":113},[619],{"nctId":620,"briefTitle":621,"status":111,"phases":622,"primaryCompletion":113,"completion":623,"start":87,"enrollment":624,"conditions":625,"interventions":629},"NCT07518901","Nanozymes in Endodontics",[94],"2028-06",72,[626,627,628],"Apical Periodontitis","Endodontic Disease","Root Canal Infection",[607,630],"Control",{"trials":632,"activeCount":103},[],{"intervention":630,"totalTrials":121,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":649},{"trials":636,"activeCount":103},[],{"trials":638,"activeCount":103},[],{"trials":640,"activeCount":103},[],{"trials":642,"activeCount":103},[],{"trials":644,"activeCount":121,"soonestReadout":113},[645],{"nctId":620,"briefTitle":621,"status":111,"phases":646,"primaryCompletion":113,"completion":623,"start":87,"enrollment":624,"conditions":647,"interventions":648},[94],[626,627,628],[607,630],{"trials":650,"activeCount":103},[],{"intervention":652,"totalTrials":121,"cells":653},"XR-NTX 380 mg, intramuscular",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":675},{"trials":655,"activeCount":103},[],{"trials":657,"activeCount":103},[],{"trials":659,"activeCount":103},[],{"trials":661,"activeCount":103},[],{"trials":663,"activeCount":121,"soonestReadout":668},[664],{"nctId":665,"briefTitle":666,"status":129,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":114,"conditions":671,"interventions":674},"NCT05028062","Naltrexone in AUD Reward Drinkers",[94],"2027-07","2028-07","2022-03-07",[672,673],"Alcohol Use Disorder","Alcoholism",[652],{"trials":676,"activeCount":103},[],{"intervention":43,"totalTrials":99,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":691,"PHASE4":705,"NA":707},{"trials":680,"activeCount":103},[],{"trials":682,"activeCount":103},[],{"trials":684,"activeCount":121,"soonestReadout":42},[685],{"nctId":40,"briefTitle":41,"status":129,"phases":686,"primaryCompletion":42,"completion":687,"start":688,"enrollment":329,"conditions":689,"interventions":690},[91,92],"2023-01-05","2020-01-05",[21],[43],{"trials":692,"activeCount":121,"soonestReadout":698},[693],{"nctId":694,"briefTitle":695,"status":696,"phases":697,"primaryCompletion":698,"completion":699,"start":700,"enrollment":329,"conditions":701,"interventions":704},"NCT05015881","Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder","ENROLLING_BY_INVITATION",[92,93],"2026-12","2027-12","2021-11-01",[702,703],"Alcohol Use Disorder (AUD)","Alcohol Drinking",[43],{"trials":706,"activeCount":103},[],{"trials":708,"activeCount":103},[],{"intervention":710,"totalTrials":99,"cells":711},"Abatacept",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":727,"PHASE4":739,"NA":741},{"trials":713,"activeCount":103},[],{"trials":715,"activeCount":103},[],{"trials":717,"activeCount":103},[718],{"nctId":719,"briefTitle":720,"status":150,"phases":721,"primaryCompletion":722,"completion":722,"start":723,"enrollment":329,"conditions":724,"interventions":726},"NCT00468208","Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis",[91,92],"2011-08","2008-02",[725],"Wegener's Granulomatosis",[710],{"trials":728,"activeCount":121,"soonestReadout":733},[729],{"nctId":730,"briefTitle":731,"status":129,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":738},"NCT04474847","Abatacept for the Treatment of Giant Cell Arteritis",[93],"2029-12","2021-03-29",78,[737],"Giant Cell Arteritis",[710],{"trials":740,"activeCount":103},[],{"trials":742,"activeCount":103},[],{"intervention":73,"totalTrials":121,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":763,"NA":765},{"trials":746,"activeCount":103},[],{"trials":748,"activeCount":103},[],{"trials":750,"activeCount":103},[],{"trials":752,"activeCount":121,"soonestReadout":72},[753],{"nctId":70,"briefTitle":71,"status":164,"phases":754,"primaryCompletion":72,"completion":755,"start":756,"enrollment":31,"conditions":757,"interventions":762},[92,93],"2026-12-01","2024-02-29",[758,759,760,761,703],"Ketoses, Metabolic","Ketogenic Dieting","Alcohol Intoxication","Magnetic Resonance Imaging",[73],{"trials":764,"activeCount":103},[],{"trials":766,"activeCount":103},[],{"intervention":768,"totalTrials":121,"cells":769},"18F-AV-1451",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":788,"NA":790},{"trials":771,"activeCount":103},[],{"trials":773,"activeCount":103},[],{"trials":775,"activeCount":103},[],{"trials":777,"activeCount":121,"soonestReadout":782},[778],{"nctId":779,"briefTitle":780,"status":129,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":787},"NCT03143374","PET Tau - Neurodegenerative Disease Imaging",[92,93],"2030-09","2016-08-23",300,[786],"Neurodegenerative Disease",[768],{"trials":789,"activeCount":103},[],{"trials":791,"activeCount":103},[],{"intervention":793,"totalTrials":121,"cells":794},"Isocaloric dextrose placebo",{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":810,"NA":812},{"trials":796,"activeCount":103},[],{"trials":798,"activeCount":103},[],{"trials":800,"activeCount":103},[],{"trials":802,"activeCount":121,"soonestReadout":698},[803],{"nctId":804,"briefTitle":805,"status":129,"phases":806,"primaryCompletion":698,"completion":668,"start":807,"enrollment":329,"conditions":808,"interventions":809},"NCT04616781","Ketone Ester Intervention in Alcohol Use Disorder",[92,93],"2021-04-05",[703,672],[793],{"trials":811,"activeCount":103},[],{"trials":813,"activeCount":103},[],{"intervention":815,"totalTrials":121,"cells":816},"200mg mifepristone and 800mg misoprostol",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":836,"NA":838},{"trials":818,"activeCount":103},[],{"trials":820,"activeCount":103},[],{"trials":822,"activeCount":103},[],{"trials":824,"activeCount":121,"soonestReadout":829},[825],{"nctId":826,"briefTitle":827,"status":111,"phases":828,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT07506512","Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss",[93],"2031-07","2031-12","2026-07",1000,[834],"Early Pregnancy Loss",[815],{"trials":837,"activeCount":103},[],{"trials":839,"activeCount":103},[],{"intervention":841,"totalTrials":121,"cells":842},"Aspirin 162 mg",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":863,"NA":865},{"trials":844,"activeCount":103},[],{"trials":846,"activeCount":103},[],{"trials":848,"activeCount":103},[],{"trials":850,"activeCount":121,"soonestReadout":855},[851],{"nctId":852,"briefTitle":853,"status":129,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":861},"NCT06408181","APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia",[93],"2029-06","2024-06-12",1150,[859,860],"Pre-Eclampsia","Pregnancy Loss",[841,862],"Aspirin 81mg",{"trials":864,"activeCount":103},[],{"trials":866,"activeCount":103},[],{"intervention":862,"totalTrials":121,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":881,"NA":883},{"trials":870,"activeCount":103},[],{"trials":872,"activeCount":103},[],{"trials":874,"activeCount":103},[],{"trials":876,"activeCount":121,"soonestReadout":855},[877],{"nctId":852,"briefTitle":853,"status":129,"phases":878,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":879,"interventions":880},[93],[859,860],[841,862],{"trials":882,"activeCount":103},[],{"trials":884,"activeCount":103},[],{"intervention":886,"totalTrials":121,"cells":887},"Guselkumab",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":907,"NA":909},{"trials":889,"activeCount":103},[],{"trials":891,"activeCount":103},[],{"trials":893,"activeCount":103},[],{"trials":895,"activeCount":121,"soonestReadout":900},[896],{"nctId":897,"briefTitle":898,"status":129,"phases":899,"primaryCompletion":900,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":905},"NCT05669833","Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients",[93],"2026-10","2023-07-14",63,[904],"Psoriatic Arthritis",[886,906],"Golimumab",{"trials":908,"activeCount":103},[],{"trials":910,"activeCount":103},[],{"intervention":906,"totalTrials":121,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":925,"NA":927},{"trials":914,"activeCount":103},[],{"trials":916,"activeCount":103},[],{"trials":918,"activeCount":103},[],{"trials":920,"activeCount":121,"soonestReadout":900},[921],{"nctId":897,"briefTitle":898,"status":129,"phases":922,"primaryCompletion":900,"completion":900,"start":901,"enrollment":902,"conditions":923,"interventions":924},[93],[904],[886,906],{"trials":926,"activeCount":103},[],{"trials":928,"activeCount":103},[],{"intervention":930,"totalTrials":121,"cells":931},"[18F]-PI-2620",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":951,"NA":953},{"trials":933,"activeCount":103},[],{"trials":935,"activeCount":103},[],{"trials":937,"activeCount":103},[],{"trials":939,"activeCount":121,"soonestReadout":944},[940],{"nctId":941,"briefTitle":942,"status":129,"phases":943,"primaryCompletion":944,"completion":944,"start":945,"enrollment":624,"conditions":946,"interventions":950},"NCT05456503","PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620",[93],"2028-08","2022-09-19",[947,948,949],"Frontotemporal Lobar Degeneration","Alzheimer Disease","Cognitively Normal",[930],{"trials":952,"activeCount":103},[],{"trials":954,"activeCount":103},[],{"intervention":956,"totalTrials":957,"cells":958},"Varenicline",14,{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":1037,"PHASE4":1078,"NA":1098},{"trials":960,"activeCount":103},[],{"trials":962,"activeCount":103},[],{"trials":964,"activeCount":103},[965,976,987,997,1008,1017,1026],{"nctId":966,"briefTitle":967,"status":150,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":974},"NCT00567008","Chantix for Treating Cocaine Dependence",[92],"2009-09","2007-12",37,[973],"Cocaine Dependence",[975],"varenicline",{"nctId":977,"briefTitle":978,"status":150,"phases":979,"primaryCompletion":980,"completion":981,"start":982,"enrollment":983,"conditions":984,"interventions":986},"NCT01151813","Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving",[92],"2013-08","2013-12","2010-07",15,[985,973],"Alcohol Dependence",[956],{"nctId":988,"briefTitle":989,"status":150,"phases":990,"primaryCompletion":991,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":996},"NCT01680887","A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence",[92],"2018-01","2019-06","2012-08",156,[973],[956],{"nctId":998,"briefTitle":999,"status":150,"phases":1000,"primaryCompletion":1001,"completion":1002,"start":1003,"enrollment":1004,"conditions":1005,"interventions":1007},"NCT01098305","Efficacy of Varenicline for Smokeless Tobacco Use in India",[92],"2012-10","2013-10","2011-04",237,[1006],"Tobacco Use Disorder",[956],{"nctId":1009,"briefTitle":1010,"status":150,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":289,"conditions":1015,"interventions":1016},"NCT00705523","Varenicline (Chantix™) for the Treatment of Alcohol Dependence",[92],"2010-03","2011-12","2008-06",[673],[975],{"nctId":1018,"briefTitle":1019,"status":150,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1013,"enrollment":1022,"conditions":1023,"interventions":1025},"NCT01524627","Effects of Varenicline on Smoking Reminders",[92],"2015-11",124,[1024],"Nicotine Dependence",[956],{"nctId":1027,"briefTitle":1028,"status":150,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1036},"NCT00937235","Treatment of Smoking Among Individuals With PTSD",[92],"2015-12","2009-01",142,[1034,1024,1035,1006],"Cigarette Smoking","Post-traumatic Stress Disorder",[956],{"trials":1038,"activeCount":121,"soonestReadout":1051},[1039,1047,1058,1069],{"nctId":1040,"briefTitle":1041,"status":150,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1001,"enrollment":1044,"conditions":1045,"interventions":1046},"NCT01710137","Varenicline for Nicotine Dependence Among Those With HIV\u002FAIDS",[93],"2018-09",179,[1024],[956],{"nctId":1048,"briefTitle":1049,"status":129,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT04176172","Optimizing Tobacco Use Treatment for PLWHA",[93],"2026-08-31","2020-02-17",340,[1055,1024],"HIV\u002FAIDS",[956,1057],"Nicotine patch",{"nctId":1059,"briefTitle":1060,"status":150,"phases":1061,"primaryCompletion":981,"completion":1062,"start":1063,"enrollment":1064,"conditions":1065,"interventions":1067},"NCT01314001","Pharmacogenetics of Nicotine Addiction Treatment",[93],"2014-09","2010-12",1246,[1066],"Nicotine Addiction",[956,1068],"Transdermal Nicotine",{"nctId":1070,"briefTitle":1071,"status":150,"phases":1072,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1077},"NCT01756885","Extended Varenicline Treatment for Smoking Among Cancer Patients",[93],"2018-05-31","2013-01",207,[1024],[956],{"trials":1079,"activeCount":103},[1080,1090],{"nctId":1081,"briefTitle":1082,"status":150,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT00948649","Effects of Chantix on Relapse Prevention for Smoking Cessation",[94],"2007-08","2007-09","2006-09",62,[1024],[956],{"nctId":1091,"briefTitle":1092,"status":150,"phases":1093,"primaryCompletion":1094,"completion":1094,"start":1031,"enrollment":1095,"conditions":1096,"interventions":1097},"NCT00948155","Measuring Smoking Behaviors While Using Varenicline",[94],"2010-11",48,[1024],[956],{"trials":1099,"activeCount":103},[1100],{"nctId":1101,"briefTitle":1102,"status":150,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":19,"conditions":1106,"interventions":1107},"NCT00602927","Effects of Varenicline on Brain Activity During Nicotine Abstinence",[95],"2008-08","2007-11",[1024],[956],{"intervention":1057,"totalTrials":99,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1122,"NA":1124},{"trials":1111,"activeCount":103},[],{"trials":1113,"activeCount":103},[],{"trials":1115,"activeCount":103},[],{"trials":1117,"activeCount":121,"soonestReadout":1051},[1118],{"nctId":1048,"briefTitle":1049,"status":129,"phases":1119,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1120,"interventions":1121},[93],[1055,1024],[956,1057],{"trials":1123,"activeCount":103},[],{"trials":1125,"activeCount":103},[1126],{"nctId":1127,"briefTitle":1128,"status":150,"phases":1129,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT03169101","Cognition and Smoking Relapse (HCS)",[],"2022-04-21","2022-04-25","2016-07-01",274,[1135],"Smoking Cessation",[1057],{"intervention":1138,"totalTrials":1139,"cells":1140},"Tocilizumab",3,{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1170,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1142,"activeCount":103},[],{"trials":1144,"activeCount":121,"soonestReadout":1149},[1145,1159],{"nctId":1146,"briefTitle":1147,"status":111,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":831,"enrollment":1150,"conditions":1151,"interventions":1156},"NCT07594067","TCR1188-ABC Cells in KRAS-mutated Cancers",[91],"2042-07",30,[1152,1153,1154,1155],"Cholangiocarcinoma","Colorectal Cancer","Non-Small Cell Lung Cancer","Pancreatic Adenocarcinoma",[1157,1158,1138],"TCR1188-ABC cells","Fludarabine + Cyclophosphamide combination",{"nctId":1160,"briefTitle":1161,"status":150,"phases":1162,"primaryCompletion":1163,"completion":1164,"start":189,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT02906371","Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome",[91],"2020-03-11","2021-06-30",80,[1167],"Lymphoblastic Leukemia, Acute, Childhood",[1138,1138,1169],"CART 19",{"trials":1171,"activeCount":121,"soonestReadout":668},[1172],{"nctId":1173,"briefTitle":1174,"status":129,"phases":1175,"primaryCompletion":668,"completion":699,"start":1176,"enrollment":329,"conditions":1177,"interventions":1179},"NCT06941376","An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis",[92],"2025-08-01",[1178],"Relapsing Polychondritis",[1180,1181,1182,1183,1138],"Methotrexate","Azathioprine","Adalimumab","Infliximab",{"trials":1185,"activeCount":103},[],{"trials":1187,"activeCount":103},[],{"trials":1189,"activeCount":103},[],{"intervention":1181,"totalTrials":99,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1193,"activeCount":103},[],{"trials":1195,"activeCount":103},[],{"trials":1197,"activeCount":99,"soonestReadout":668},[1198,1213],{"nctId":1199,"briefTitle":1200,"status":129,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1210},"NCT02939573","A Randomized Multicenter Study for Isolated Skin Vasculitis",[92],"2028-12-31","2017-01-01",90,[1206,1207,1208,1209],"Primary Cutaneous Vasculitis","Cutaneous Polyarteritis Nodosa","IgA Vasculitis","Henoch-Schönlein Purpura",[1211,1212,1181],"Colchicine","Dapsone",{"nctId":1173,"briefTitle":1174,"status":129,"phases":1214,"primaryCompletion":668,"completion":699,"start":1176,"enrollment":329,"conditions":1215,"interventions":1216},[92],[1178],[1180,1181,1182,1183,1138],{"trials":1218,"activeCount":103},[],{"trials":1220,"activeCount":103},[],{"trials":1222,"activeCount":103},[],{"intervention":1224,"totalTrials":1139,"cells":1225},"Misoprostol",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1242,"PHASE4":1255,"NA":1269},{"trials":1227,"activeCount":103},[],{"trials":1229,"activeCount":103},[],{"trials":1231,"activeCount":121,"soonestReadout":236},[1232],{"nctId":1233,"briefTitle":1234,"status":129,"phases":1235,"primaryCompletion":236,"completion":236,"start":1236,"enrollment":1150,"conditions":1237,"interventions":1240},"NCT06452719","Letrozole and Misoprostol for Early Pregnancy Loss Management",[92],"2024-08-22",[834,1238,1239],"Miscarriage in First Trimester","Miscarriage",[1241,1224],"Letrozole",{"trials":1243,"activeCount":103},[1244],{"nctId":1245,"briefTitle":1246,"status":150,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":784,"conditions":1251,"interventions":1253},"NCT02012491","Comparative Effectiveness of Pregnancy Failure Management Regimens",[93],"2017-05-15","2019-06-15","2014-01",[1252],"Spontaneous Abortion",[1224,1254],"Mifepristone",{"trials":1256,"activeCount":103},[1257],{"nctId":1258,"briefTitle":1259,"status":150,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1267},"NCT04028765","Pitocin or Oral Misoprostol for PROM IOL",[94],"2022-12-08","2023-01-08","2019-08-12",108,[1266],"PROM",[1224,1268],"Oxytocin",{"trials":1270,"activeCount":103},[],{"intervention":1182,"totalTrials":1139,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1283,"PHASE4":1285,"NA":1307},{"trials":1274,"activeCount":103},[],{"trials":1276,"activeCount":103},[],{"trials":1278,"activeCount":121,"soonestReadout":668},[1279],{"nctId":1173,"briefTitle":1174,"status":129,"phases":1280,"primaryCompletion":668,"completion":699,"start":1176,"enrollment":329,"conditions":1281,"interventions":1282},[92],[1178],[1180,1181,1182,1183,1138],{"trials":1284,"activeCount":103},[],{"trials":1286,"activeCount":103},[1287,1299],{"nctId":1288,"briefTitle":1289,"status":150,"phases":1290,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1298},"NCT01553058","Vascular Inflammation in Psoriasis Trial (The VIP Trial)",[94],"2016-08-08","2016-10-27","2012-07",97,[1296,1297],"Psoriasis","Cardiovascular Disease",[1182],{"nctId":1300,"briefTitle":1301,"status":150,"phases":1302,"primaryCompletion":1291,"completion":1292,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1306},"NCT01866592","Vascular Inflammation in Psoriasis - Extension Study",[94],"2013-04",81,[1296,1297],[1182],{"trials":1308,"activeCount":103},[],{"intervention":1310,"totalTrials":99,"cells":1311},"Duloxetine",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1329,"PHASE4":1331,"NA":1344},{"trials":1313,"activeCount":103},[],{"trials":1315,"activeCount":103},[],{"trials":1317,"activeCount":121,"soonestReadout":1322},[1318],{"nctId":1319,"briefTitle":1320,"status":111,"phases":1321,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1328},"NCT07431606","Duloxetine in Inflammatory Bowel Diseases",[92],"2027-03-01","2027-10-31","2026-05-01",32,[1327],"Inflammatory Bowel Diseases",[1310],{"trials":1330,"activeCount":103},[],{"trials":1332,"activeCount":103},[1333],{"nctId":1334,"briefTitle":1335,"status":150,"phases":1336,"primaryCompletion":1337,"completion":1337,"start":1338,"enrollment":34,"conditions":1339,"interventions":1343},"NCT01035073","Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome",[94],"2009-05","2006-04",[1340,1341,1342],"Major Depressive Disorder","Soft Tissue Discomfort Syndrome","Pain",[1310],{"trials":1345,"activeCount":103},[],{"intervention":1180,"totalTrials":1139,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1368,"PHASE4":1379,"NA":1381},{"trials":1349,"activeCount":103},[],{"trials":1351,"activeCount":103},[],{"trials":1353,"activeCount":121,"soonestReadout":668},[1354,1364],{"nctId":1355,"briefTitle":1356,"status":1357,"phases":1358,"primaryCompletion":981,"completion":981,"start":1359,"enrollment":99,"conditions":1360,"interventions":1363},"NCT01800162","RCT for Women With a Persisting Pregnancy of Unknown Location","TERMINATED",[91,92],"2013-02",[1361,1362],"Persistent Pregnancy of Unknown Location","Ectopic Pregnancy",[1180],{"nctId":1173,"briefTitle":1174,"status":129,"phases":1365,"primaryCompletion":668,"completion":699,"start":1176,"enrollment":329,"conditions":1366,"interventions":1367},[92],[1178],[1180,1181,1182,1183,1138],{"trials":1369,"activeCount":103},[1370],{"nctId":1371,"briefTitle":1372,"status":150,"phases":1373,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1378},"NCT00194272","Two-Dose Methotrexate for Ectopic Pregnancy",[93],"2007-06","2001-03",100,[1362],[1180],{"trials":1380,"activeCount":103},[],{"trials":1382,"activeCount":103},[],{"intervention":1384,"totalTrials":1139,"cells":1385},"Potassium Nitrate",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1387,"activeCount":103},[],{"trials":1389,"activeCount":103},[],{"trials":1391,"activeCount":121,"soonestReadout":1396},[1392,1403,1415],{"nctId":1393,"briefTitle":1394,"status":129,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT04913805","Matching Perfusion and Metabolic Activity in HFpEF",[92],"2027-05-01","2021-10-11",53,[1400],"Heart Failure With Preserved Ejection Fraction",[1384,1402],"Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside",{"nctId":1404,"briefTitle":1405,"status":150,"phases":1406,"primaryCompletion":1407,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1413},"NCT03483051","Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)",[92],"2019-03-13","2019-05-23","2018-05-01",5,[1412],"Aortic Valve Stenosis",[1384,1414],"Potassium Chloride",{"nctId":1416,"briefTitle":1417,"status":150,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":189,"enrollment":1420,"conditions":1421,"interventions":1422},"NCT02840799","Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)",[92],"2022-08",84,[33],[1384,1414],{"trials":1424,"activeCount":103},[],{"trials":1426,"activeCount":103},[],{"trials":1428,"activeCount":103},[],{"intervention":53,"totalTrials":99,"cells":1430},{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1432,"activeCount":103},[],{"trials":1434,"activeCount":103},[],{"trials":1436,"activeCount":121,"soonestReadout":52},[1437,1447],{"nctId":1438,"briefTitle":1439,"status":1357,"phases":1440,"primaryCompletion":1441,"completion":1397,"start":1442,"enrollment":31,"conditions":1443,"interventions":1445},"NCT03425006","Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer",[92],"2021-06-17","2018-06-18",[1444],"Non Small Cell Lung Cancer",[53,1446],"Pembrolizumab",{"nctId":50,"briefTitle":51,"status":164,"phases":1448,"primaryCompletion":52,"completion":113,"start":1449,"enrollment":31,"conditions":1450,"interventions":1452},[91,92],"2019-02-11",[1451],"Classical Hodgkin Lymphoma",[53,1453],"Everolimus",{"trials":1455,"activeCount":103},[],{"trials":1457,"activeCount":103},[],{"trials":1459,"activeCount":103},[],{"intervention":1211,"totalTrials":99,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1474,"PHASE2":1476,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1463,"activeCount":103},[1464],{"nctId":1465,"briefTitle":1466,"status":150,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1470,"conditions":1471,"interventions":1473},"NCT06212271","Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease",[90],"2026-03-25","2024-09-25",24,[1472],"Peripheral Artery Disease",[1211],{"trials":1475,"activeCount":103},[],{"trials":1477,"activeCount":121,"soonestReadout":1202},[1478],{"nctId":1199,"briefTitle":1200,"status":129,"phases":1479,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1480,"interventions":1481},[92],[1206,1207,1208,1209],[1211,1212,1181],{"trials":1483,"activeCount":103},[],{"trials":1485,"activeCount":103},[],{"trials":1487,"activeCount":103},[],{"intervention":1489,"totalTrials":99,"cells":1490},"Amantadine",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1492,"activeCount":103},[],{"trials":1494,"activeCount":103},[],{"trials":1496,"activeCount":121,"soonestReadout":1501},[1497,1508],{"nctId":1498,"briefTitle":1499,"status":129,"phases":1500,"primaryCompletion":1501,"completion":1502,"start":1503,"enrollment":114,"conditions":1504,"interventions":1507},"NCT05140148","Promoting Recovery After STroke With Amantadine",[92],"2027-12-31","2028-06-30","2022-02-01",[1505,1506],"Stroke, Ischemic","Stroke Hemorrhagic",[1489],{"nctId":1509,"briefTitle":1510,"status":150,"phases":1511,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":1516,"interventions":1518},"NCT00158132","Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2",[92],"2005-03","2006-02","1999-09",199,[1517],"Cocaine-Related Disorders",[1519,1489],"Propranolol",{"trials":1521,"activeCount":103},[],{"trials":1523,"activeCount":103},[],{"trials":1525,"activeCount":103},[],{"intervention":1527,"totalTrials":121,"cells":1528},"PMT",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1530,"activeCount":103},[],{"trials":1532,"activeCount":103},[],{"trials":1534,"activeCount":121,"soonestReadout":1539},[1535],{"nctId":1536,"briefTitle":1537,"status":164,"phases":1538,"primaryCompletion":1539,"completion":1539,"start":1540,"enrollment":1325,"conditions":1541,"interventions":1547},"NCT05632315","PMT for MDRO Decolonization",[92],"2026-08","2024-08-19",[1542,1543,1544,1545,1546],"Multidrug Resistant Bacterial Infection","Enterobacteriaceae Infections","Pseudomonas Aeruginosa","VRE Infection","Methicillin-resistant Staphylococcus Aureus",[1527],{"trials":1549,"activeCount":103},[],{"trials":1551,"activeCount":103},[],{"trials":1553,"activeCount":103},[],{"intervention":120,"totalTrials":121,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1557,"activeCount":103},[],{"trials":1559,"activeCount":103},[],{"trials":1561,"activeCount":121,"soonestReadout":113},[1562],{"nctId":109,"briefTitle":110,"status":111,"phases":1563,"primaryCompletion":113,"completion":113,"start":87,"enrollment":114,"conditions":1564,"interventions":1565},[92],[116],[118,119,120],{"trials":1567,"activeCount":103},[],{"trials":1569,"activeCount":103},[],{"trials":1571,"activeCount":103},[],{"intervention":1573,"totalTrials":121,"cells":1574},"Ibudilast",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1576,"activeCount":103},[],{"trials":1578,"activeCount":103},[],{"trials":1580,"activeCount":121,"soonestReadout":1585},[1581],{"nctId":1582,"briefTitle":1583,"status":164,"phases":1584,"primaryCompletion":1585,"completion":1501,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1589},"NCT05414240","Ibudilast for Treating Alcohol Use Disorder",[92],"2026-12-31","2023-01-14",50,[702,673],[1573],{"trials":1591,"activeCount":103},[],{"trials":1593,"activeCount":103},[],{"trials":1595,"activeCount":103},[],{"intervention":1402,"totalTrials":121,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":103},[],{"trials":1601,"activeCount":103},[],{"trials":1603,"activeCount":121,"soonestReadout":1396},[1604],{"nctId":1393,"briefTitle":1394,"status":129,"phases":1605,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":1606,"interventions":1607},[92],[1400],[1384,1402],{"trials":1609,"activeCount":103},[],{"trials":1611,"activeCount":103},[],{"trials":1613,"activeCount":103},[],{"intervention":48,"totalTrials":121,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1617,"activeCount":103},[],{"trials":1619,"activeCount":103},[],{"trials":1621,"activeCount":121,"soonestReadout":47},[1622],{"nctId":45,"briefTitle":46,"status":164,"phases":1623,"primaryCompletion":47,"completion":1624,"start":1625,"enrollment":1626,"conditions":1627,"interventions":1629},[92],"2029-04-30","2020-06-23",39,[1628],"Glioblastoma",[48,1630,1631],"INCAGN01876","SRS",{"trials":1633,"activeCount":103},[],{"trials":1635,"activeCount":103},[],{"trials":1637,"activeCount":103},[],{"intervention":1630,"totalTrials":121,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1641,"activeCount":103},[],{"trials":1643,"activeCount":103},[],{"trials":1645,"activeCount":121,"soonestReadout":47},[1646],{"nctId":45,"briefTitle":46,"status":164,"phases":1647,"primaryCompletion":47,"completion":1624,"start":1625,"enrollment":1626,"conditions":1648,"interventions":1649},[92],[1628],[48,1630,1631],{"trials":1651,"activeCount":103},[],{"trials":1653,"activeCount":103},[],{"trials":1655,"activeCount":103},[],{"intervention":1631,"totalTrials":121,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1659,"activeCount":103},[],{"trials":1661,"activeCount":103},[],{"trials":1663,"activeCount":121,"soonestReadout":47},[1664],{"nctId":45,"briefTitle":46,"status":164,"phases":1665,"primaryCompletion":47,"completion":1624,"start":1625,"enrollment":1626,"conditions":1666,"interventions":1667},[92],[1628],[48,1630,1631],{"trials":1669,"activeCount":103},[],{"trials":1671,"activeCount":103},[],{"trials":1673,"activeCount":103},[],{"intervention":1675,"totalTrials":121,"cells":1676},"Cevostamab",{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1678,"activeCount":103},[],{"trials":1680,"activeCount":103},[],{"trials":1682,"activeCount":121,"soonestReadout":1687},[1683],{"nctId":1684,"briefTitle":1685,"status":164,"phases":1686,"primaryCompletion":1687,"completion":1688,"start":1689,"enrollment":1150,"conditions":1690,"interventions":1692},"NCT05801939","Cevostamab Following CAR T Cell Therapy for RRMM",[92],"2027-05","2028-05","2023-07-11",[1691],"Relapsed\u002FRefractory Multiple Myeloma",[1675],{"trials":1694,"activeCount":103},[],{"trials":1696,"activeCount":103},[],{"trials":1698,"activeCount":103},[],{"intervention":1700,"totalTrials":121,"cells":1701},"1% Clascoterone",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1703,"activeCount":103},[],{"trials":1705,"activeCount":103},[],{"trials":1707,"activeCount":121,"soonestReadout":1712},[1708],{"nctId":1709,"briefTitle":1710,"status":129,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":353,"conditions":1714,"interventions":1719},"NCT06286397","Topical Anti-Androgens in Pilonidal Sinus Disease",[92],"2028-01-01","2025-01-10",[1715,1716,1717,1718],"Pilonidal Disease","Pilonidal Disease of Natal Cleft","Pilonidal Sinus","Pilonidal Cyst",[1700,1720],"Vehicle Cream",{"trials":1722,"activeCount":103},[],{"trials":1724,"activeCount":103},[],{"trials":1726,"activeCount":103},[],{"intervention":1720,"totalTrials":121,"cells":1728},{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1730,"activeCount":103},[],{"trials":1732,"activeCount":103},[],{"trials":1734,"activeCount":121,"soonestReadout":1712},[1735],{"nctId":1709,"briefTitle":1710,"status":129,"phases":1736,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":353,"conditions":1737,"interventions":1738},[92],[1715,1716,1717,1718],[1700,1720],{"trials":1740,"activeCount":103},[],{"trials":1742,"activeCount":103},[],{"trials":1744,"activeCount":103},[],{"intervention":1212,"totalTrials":121,"cells":1746},{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1751,"PHASE3":1757,"PHASE4":1759,"NA":1761},{"trials":1748,"activeCount":103},[],{"trials":1750,"activeCount":103},[],{"trials":1752,"activeCount":121,"soonestReadout":1202},[1753],{"nctId":1199,"briefTitle":1200,"status":129,"phases":1754,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1755,"interventions":1756},[92],[1206,1207,1208,1209],[1211,1212,1181],{"trials":1758,"activeCount":103},[],{"trials":1760,"activeCount":103},[],{"trials":1762,"activeCount":103},[],{"intervention":1241,"totalTrials":121,"cells":1764},{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1766,"activeCount":103},[],{"trials":1768,"activeCount":103},[],{"trials":1770,"activeCount":121,"soonestReadout":236},[1771],{"nctId":1233,"briefTitle":1234,"status":129,"phases":1772,"primaryCompletion":236,"completion":236,"start":1236,"enrollment":1150,"conditions":1773,"interventions":1774},[92],[834,1238,1239],[1241,1224],{"trials":1776,"activeCount":103},[],{"trials":1778,"activeCount":103},[],{"trials":1780,"activeCount":103},[],{"intervention":1782,"totalTrials":121,"cells":1783},"inhaled nitric oxide",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1785,"activeCount":103},[],{"trials":1787,"activeCount":103},[],{"trials":1789,"activeCount":121,"soonestReadout":1794},[1790],{"nctId":1791,"briefTitle":1792,"status":696,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":19,"conditions":1796,"interventions":1798},"NCT05616910","Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury",[92],"2028-03-28","2025-04-06",[1797],"Traumatic Brain Injury",[1782],{"trials":1800,"activeCount":103},[],{"trials":1802,"activeCount":103},[],{"trials":1804,"activeCount":103},[],{"intervention":1806,"totalTrials":121,"cells":1807},"Botulinum Neurotoxin Type A",{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1809,"activeCount":103},[],{"trials":1811,"activeCount":103},[],{"trials":1813,"activeCount":121,"soonestReadout":1502},[1814],{"nctId":1815,"briefTitle":1816,"status":111,"phases":1817,"primaryCompletion":1502,"completion":1202,"start":287,"enrollment":329,"conditions":1818,"interventions":1824},"NCT07489430","DaxibotulinumtoxinA for Blepharospasm",[92],[1819,1820,1821,1822,1823],"Blepharospasm of Both Eyelids","Blepharospasm of Left Eyelid","Blepharospasm of Right Eyelid","Blepharospasm, Benign Essential","Blepharospasm",[1806],{"trials":1826,"activeCount":103},[],{"trials":1828,"activeCount":103},[],{"trials":1830,"activeCount":103},[],{"intervention":1832,"totalTrials":121,"cells":1833},"intra-arterial tenecteplase administration",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1835,"activeCount":103},[],{"trials":1837,"activeCount":103},[],{"trials":1839,"activeCount":121,"soonestReadout":1844},[1840],{"nctId":1841,"briefTitle":1842,"status":129,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":329,"conditions":1846,"interventions":1848},"NCT06904911","Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy",[92],"2026-09-30","2025-12-11",[1847],"Acute Ischemic Stroke From Large Vessel Occlusion",[1832],{"trials":1850,"activeCount":103},[],{"trials":1852,"activeCount":103},[],{"trials":1854,"activeCount":103},[],{"intervention":1856,"totalTrials":121,"cells":1857},"LFX\u002FPGB",{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1859,"activeCount":103},[],{"trials":1861,"activeCount":103},[],{"trials":1863,"activeCount":121,"soonestReadout":1051},[1864],{"nctId":1865,"briefTitle":1866,"status":129,"phases":1867,"primaryCompletion":1051,"completion":1051,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1873},"NCT05995535","Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal",[92],"2024-01-01",150,[1871,1872],"Opiate Withdrawal Syndrome","Opioid Use",[1856,1874],"LFX\u002FPLA-PGB",{"trials":1876,"activeCount":103},[],{"trials":1878,"activeCount":103},[],{"trials":1880,"activeCount":103},[],{"intervention":1874,"totalTrials":121,"cells":1882},{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1884,"activeCount":103},[],{"trials":1886,"activeCount":103},[],{"trials":1888,"activeCount":121,"soonestReadout":1051},[1889],{"nctId":1865,"briefTitle":1866,"status":129,"phases":1890,"primaryCompletion":1051,"completion":1051,"start":1868,"enrollment":1869,"conditions":1891,"interventions":1892},[92],[1871,1872],[1856,1874],{"trials":1894,"activeCount":103},[],{"trials":1896,"activeCount":103},[],{"trials":1898,"activeCount":103},[],{"intervention":1900,"totalTrials":121,"cells":1901},"Oral Contraceptives, Low-Dose",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1903,"activeCount":103},[],{"trials":1905,"activeCount":103},[],{"trials":1907,"activeCount":121,"soonestReadout":1912},[1908],{"nctId":1909,"briefTitle":1910,"status":129,"phases":1911,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":1376,"conditions":1914,"interventions":1917},"NCT06852365","Combined Oral Contraceptive Pill and Resistance Starch",[92],"2028-04","2025-06-10",[1915,1916],"Metabolic Syndrome","Polycystic Ovary Syndrome",[1900],{"trials":1919,"activeCount":103},[],{"trials":1921,"activeCount":103},[],{"trials":1923,"activeCount":103},[],{"intervention":1925,"totalTrials":121,"cells":1926},"Trimethoprim Sulfamethoxazole",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1928,"activeCount":103},[],{"trials":1930,"activeCount":103},[],{"trials":1932,"activeCount":121,"soonestReadout":1937},[1933],{"nctId":1934,"briefTitle":1935,"status":164,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":190,"conditions":1939,"interventions":1942},"NCT03919435","TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis",[91,92],"2027-12-30","2019-03-27",[1940,1941],"Granulomatosis With Polyangiitis","Wegener Granulomatosis",[1925],{"trials":1944,"activeCount":103},[],{"trials":1946,"activeCount":103},[],{"trials":1948,"activeCount":103},[],{"intervention":1950,"totalTrials":121,"cells":1951},"Conjugated Estrogen",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1953,"activeCount":103},[],{"trials":1955,"activeCount":103},[],{"trials":1957,"activeCount":121,"soonestReadout":1962},[1958],{"nctId":1959,"briefTitle":1960,"status":164,"phases":1961,"primaryCompletion":1962,"completion":1396,"start":1963,"enrollment":1150,"conditions":1964,"interventions":1966},"NCT03663543","Intravenous Estrogen in Kidney Transplant Study",[91,92],"2027-01-31","2016-08-26",[1965],"Ischemia Reperfusion Injury",[1950,1967],"Normal saline",{"trials":1969,"activeCount":103},[],{"trials":1971,"activeCount":103},[],{"trials":1973,"activeCount":103},[],{"intervention":58,"totalTrials":121,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1977,"activeCount":103},[],{"trials":1979,"activeCount":103},[],{"trials":1981,"activeCount":121,"soonestReadout":57},[1982],{"nctId":55,"briefTitle":56,"status":164,"phases":1983,"primaryCompletion":57,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1990},[92],"2026-06-30","2019-09-25",7,[1988,1989],"Castleman Disease","Castleman's Disease, Multicentric",[58],{"trials":1992,"activeCount":103},[],{"trials":1994,"activeCount":103},[],{"trials":1996,"activeCount":103},[],{"intervention":1183,"totalTrials":121,"cells":1998},{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2009,"PHASE4":2011,"NA":2013},{"trials":2000,"activeCount":103},[],{"trials":2002,"activeCount":103},[],{"trials":2004,"activeCount":121,"soonestReadout":668},[2005],{"nctId":1173,"briefTitle":1174,"status":129,"phases":2006,"primaryCompletion":668,"completion":699,"start":1176,"enrollment":329,"conditions":2007,"interventions":2008},[92],[1178],[1180,1181,1182,1183,1138],{"trials":2010,"activeCount":103},[],{"trials":2012,"activeCount":103},[],{"trials":2014,"activeCount":103},[],{"intervention":2016,"totalTrials":121,"cells":2017},"Psilocybin",{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2019,"activeCount":103},[],{"trials":2021,"activeCount":103},[],{"trials":2023,"activeCount":121,"soonestReadout":1396},[2024],{"nctId":2025,"briefTitle":2026,"status":129,"phases":2027,"primaryCompletion":1396,"completion":1396,"start":2028,"enrollment":1470,"conditions":2029,"interventions":2031},"NCT06810310","Psilocybin on Brain Mechanisms of Motivation in OUD",[92],"2025-12-22",[2030],"Opioid Use Disorder",[2016,2032],"psilocybin",{"trials":2034,"activeCount":103},[],{"trials":2036,"activeCount":103},[],{"trials":2038,"activeCount":103},[],{"intervention":2040,"totalTrials":121,"cells":2041},"Ruxolitinib",{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2043,"activeCount":103},[],{"trials":2045,"activeCount":103},[],{"trials":2047,"activeCount":121,"soonestReadout":436},[2048],{"nctId":2049,"briefTitle":2050,"status":129,"phases":2051,"primaryCompletion":436,"completion":1202,"start":2052,"enrollment":957,"conditions":2053,"interventions":2056},"NCT07085039","Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease",[92],"2025-12-18",[2054,2055],"Castleman's Disease (CD)","Idiopathic Multicentric Castleman's Disease",[2040],{"trials":2058,"activeCount":103},[],{"trials":2060,"activeCount":103},[],{"trials":2062,"activeCount":103},[],{"intervention":2064,"totalTrials":121,"cells":2065},"Empagliflozin + Potassium Chloride",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2067,"activeCount":103},[],{"trials":2069,"activeCount":103},[],{"trials":2071,"activeCount":121,"soonestReadout":2076},[2072],{"nctId":2073,"briefTitle":2074,"status":129,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":1398,"conditions":2078,"interventions":2079},"NCT05138575","SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial",[92],"2027-05-31","2022-01-24",[1400],[2064,2080,2081],"Empagliflozin + Potassium Nitrate","Potassium Chloride + Placebo for Empagliflozin",{"trials":2083,"activeCount":103},[],{"trials":2085,"activeCount":103},[],{"trials":2087,"activeCount":103},[],{"intervention":2080,"totalTrials":121,"cells":2089},{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2091,"activeCount":103},[],{"trials":2093,"activeCount":103},[],{"trials":2095,"activeCount":121,"soonestReadout":2076},[2096],{"nctId":2073,"briefTitle":2074,"status":129,"phases":2097,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":1398,"conditions":2098,"interventions":2099},[92],[1400],[2064,2080,2081],{"trials":2101,"activeCount":103},[],{"trials":2103,"activeCount":103},[],{"trials":2105,"activeCount":103},[],{"intervention":2081,"totalTrials":121,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2109,"activeCount":103},[],{"trials":2111,"activeCount":103},[],{"trials":2113,"activeCount":121,"soonestReadout":2076},[2114],{"nctId":2073,"briefTitle":2074,"status":129,"phases":2115,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":1398,"conditions":2116,"interventions":2117},[92],[1400],[2064,2080,2081],{"trials":2119,"activeCount":103},[],{"trials":2121,"activeCount":103},[],{"trials":2123,"activeCount":103},[],{"intervention":2125,"totalTrials":121,"cells":2126},"Odetiglucan",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2128,"activeCount":103},[],{"trials":2130,"activeCount":103},[],{"trials":2132,"activeCount":121,"soonestReadout":2137},[2133],{"nctId":2134,"briefTitle":2135,"status":129,"phases":2136,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":1376,"conditions":2140,"interventions":2142},"NCT07199764","Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer",[92],"2027-10","2028-12","2025-11-25",[2141],"Pancreatic Ductal Adenocarcinoma",[2125,2143],"Mitazalimab",{"trials":2145,"activeCount":103},[],{"trials":2147,"activeCount":103},[],{"trials":2149,"activeCount":103},[],{"intervention":2143,"totalTrials":121,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":103},[],{"trials":2155,"activeCount":103},[],{"trials":2157,"activeCount":121,"soonestReadout":2137},[2158],{"nctId":2134,"briefTitle":2135,"status":129,"phases":2159,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":1376,"conditions":2160,"interventions":2161},[92],[2141],[2125,2143],{"trials":2163,"activeCount":103},[],{"trials":2165,"activeCount":103},[],{"trials":2167,"activeCount":103},[],{"intervention":1453,"totalTrials":121,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":103},[],{"trials":2173,"activeCount":103},[],{"trials":2175,"activeCount":121,"soonestReadout":52},[2176],{"nctId":50,"briefTitle":51,"status":164,"phases":2177,"primaryCompletion":52,"completion":113,"start":1449,"enrollment":31,"conditions":2178,"interventions":2179},[91,92],[1451],[53,1453],{"trials":2181,"activeCount":103},[],{"trials":2183,"activeCount":103},[],{"trials":2185,"activeCount":103},[],{"intervention":2187,"totalTrials":121,"cells":2188},"Buprenorphine",{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2202,"PHASE4":2204,"NA":2206},{"trials":2190,"activeCount":103},[],{"trials":2192,"activeCount":103},[],{"trials":2194,"activeCount":121,"soonestReadout":1585},[2195],{"nctId":2196,"briefTitle":2197,"status":129,"phases":2198,"primaryCompletion":1585,"completion":1585,"start":2199,"enrollment":114,"conditions":2200,"interventions":2201},"NCT06379984","Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use",[92],"2025-05-08",[2030],[2187],{"trials":2203,"activeCount":103},[],{"trials":2205,"activeCount":103},[],{"trials":2207,"activeCount":103},[],{"intervention":2209,"totalTrials":121,"cells":2210},"Semaglutide Pen Injector",{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2212,"activeCount":103},[],{"trials":2214,"activeCount":103},[],{"trials":2216,"activeCount":121,"soonestReadout":2221},[2217],{"nctId":2218,"briefTitle":2219,"status":129,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":190,"conditions":2223,"interventions":2228},"NCT05746039","Feasibility of Semaglutide in Advanced Lung Disease",[91,92],"2027-12-28","2024-01-29",[15,2224,2225,2226,2227],"Interstitial Lung Disease","Chronic Obstructive Pulmonary Disease","Sarcoidosis, Pulmonary","Pulmonary Hypertension",[2209],{"trials":2230,"activeCount":103},[],{"trials":2232,"activeCount":103},[],{"trials":2234,"activeCount":103},[],{"intervention":2236,"totalTrials":121,"cells":2237},"Sildenafil Citrate low dose",{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2242,"PHASE3":2254,"PHASE4":2256,"NA":2258},{"trials":2239,"activeCount":103},[],{"trials":2241,"activeCount":103},[],{"trials":2243,"activeCount":121,"soonestReadout":1501},[2244],{"nctId":2245,"briefTitle":2246,"status":129,"phases":2247,"primaryCompletion":1501,"completion":1501,"start":2248,"enrollment":2249,"conditions":2250,"interventions":2251},"NCT05782244","Sildenafil for Microvasculopathy in Chronic TBI",[92],"2024-07-02",160,[1797],[2236,2252,2253],"Sildenafil medium dose","Sildenafil high dose",{"trials":2255,"activeCount":103},[],{"trials":2257,"activeCount":103},[],{"trials":2259,"activeCount":103},[],{"intervention":2252,"totalTrials":121,"cells":2261},{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2266,"PHASE3":2272,"PHASE4":2274,"NA":2276},{"trials":2263,"activeCount":103},[],{"trials":2265,"activeCount":103},[],{"trials":2267,"activeCount":121,"soonestReadout":1501},[2268],{"nctId":2245,"briefTitle":2246,"status":129,"phases":2269,"primaryCompletion":1501,"completion":1501,"start":2248,"enrollment":2249,"conditions":2270,"interventions":2271},[92],[1797],[2236,2252,2253],{"trials":2273,"activeCount":103},[],{"trials":2275,"activeCount":103},[],{"trials":2277,"activeCount":103},[],{"intervention":2253,"totalTrials":121,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2281,"activeCount":103},[],{"trials":2283,"activeCount":103},[],{"trials":2285,"activeCount":121,"soonestReadout":1501},[2286],{"nctId":2245,"briefTitle":2246,"status":129,"phases":2287,"primaryCompletion":1501,"completion":1501,"start":2248,"enrollment":2249,"conditions":2288,"interventions":2289},[92],[1797],[2236,2252,2253],{"trials":2291,"activeCount":103},[],{"trials":2293,"activeCount":103},[],{"trials":2295,"activeCount":103},[],{"intervention":2297,"totalTrials":121,"cells":2298},"Belantamab mafodotin",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2315,"PHASE4":2317,"NA":2319},{"trials":2300,"activeCount":103},[],{"trials":2302,"activeCount":103},[],{"trials":2304,"activeCount":121,"soonestReadout":2309},[2305],{"nctId":2306,"briefTitle":2307,"status":164,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":2311,"conditions":2312,"interventions":2314},"NCT04680468","Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma",[92],"2026-07-11","2021-06-02",41,[2313],"Myeloma",[2297],{"trials":2316,"activeCount":103},[],{"trials":2318,"activeCount":103},[],{"trials":2320,"activeCount":103},[],{"intervention":2322,"totalTrials":121,"cells":2323},"[18F]FTP PET\u002FCT",{"EARLY_PHASE1":2324,"PHASE1":2326,"PHASE2":2328,"PHASE3":2340,"PHASE4":2342,"NA":2344},{"trials":2325,"activeCount":103},[],{"trials":2327,"activeCount":103},[],{"trials":2329,"activeCount":121,"soonestReadout":87},[2330],{"nctId":2331,"briefTitle":2332,"status":164,"phases":2333,"primaryCompletion":87,"completion":87,"start":2334,"enrollment":1150,"conditions":2335,"interventions":2339},"NCT02815917","Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET\u002FCT",[91,92],"2016-06",[2336,2337,2338],"D3 Dopamine Receptor","Cocaine-dependent","Healthy Volunteer",[2322],{"trials":2341,"activeCount":103},[],{"trials":2343,"activeCount":103},[],{"trials":2345,"activeCount":103},[],{"intervention":2347,"totalTrials":121,"cells":2348},"Letermovir 480 MG [Prevymis]",{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2350,"activeCount":103},[],{"trials":2352,"activeCount":103},[],{"trials":2354,"activeCount":121,"soonestReadout":2359},[2355],{"nctId":2356,"briefTitle":2357,"status":129,"phases":2358,"primaryCompletion":2359,"completion":2359,"start":2360,"enrollment":1165,"conditions":2361,"interventions":2364},"NCT06066957","Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients",[92],"2026-08-15","2024-04-04",[2362,2363],"Cytomegalovirus Infections","Transplant-Related Disorder",[2347],{"trials":2366,"activeCount":103},[],{"trials":2368,"activeCount":103},[],{"trials":2370,"activeCount":103},[],{"intervention":2372,"totalTrials":121,"cells":2373},"Dulaglutide 0.75Mg\u002F0.5Ml Inj Pen",{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2375,"activeCount":103},[],{"trials":2377,"activeCount":103},[],{"trials":2379,"activeCount":121,"soonestReadout":2384},[2380],{"nctId":2381,"briefTitle":2382,"status":129,"phases":2383,"primaryCompletion":2384,"completion":1502,"start":2385,"enrollment":1150,"conditions":2386,"interventions":2390},"NCT04731272","GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance",[92],"2027-06-30","2021-07-16",[2387,2388,2389,27],"Cystic Fibrosis","Pancreatic Insufficiency","Abnormal Glucose Tolerance",[2372],{"trials":2392,"activeCount":103},[],{"trials":2394,"activeCount":103},[],{"trials":2396,"activeCount":103},[],{"intervention":2398,"totalTrials":2399,"cells":2400},"Indocyanine Green",6,{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2444,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2402,"activeCount":103},[],{"trials":2404,"activeCount":103},[2405,2413,2424,2433],{"nctId":2406,"briefTitle":2407,"status":150,"phases":2408,"primaryCompletion":2409,"completion":2409,"start":154,"enrollment":1095,"conditions":2410,"interventions":2412},"NCT02621268","Minimally Invasive Imagery With Indocyanine Green",[91],"2016-11",[2411],"Neoplasms",[2398],{"nctId":2414,"briefTitle":2415,"status":150,"phases":2416,"primaryCompletion":2417,"completion":2417,"start":2418,"enrollment":2419,"conditions":2420,"interventions":2423},"NCT03262636","Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)",[91],"2020-03-10","2015-06",363,[2421,2422],"Brain Tumor, Primary","Brain Tumor, Recurrent",[2398],{"nctId":2425,"briefTitle":2426,"status":150,"phases":2427,"primaryCompletion":2428,"completion":2428,"start":2429,"enrollment":1095,"conditions":2430,"interventions":2432},"NCT02280954","Indocyanine Green for Solid Tumors",[91],"2017-02","2013-11",[2431,2411],"Solid Tumor",[2398],{"nctId":2434,"briefTitle":2435,"status":150,"phases":2436,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":2441,"interventions":2443},"NCT01335893","Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green",[91],"2014-12","2014-12-14","2011-05",10,[2442],"Lung Neoplasms",[2398],{"trials":2445,"activeCount":121,"soonestReadout":2450},[2446],{"nctId":2447,"briefTitle":2448,"status":129,"phases":2449,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2455},"NCT04723810","TumorGlow Intraoperative Molecular Imaging (IMI)",[91,92],"2027-01-14","2024-08-14",500,[2454],"Tumor, Solid",[2398],{"trials":2457,"activeCount":103},[],{"trials":2459,"activeCount":103},[],{"trials":2461,"activeCount":103},[2462],{"nctId":2463,"briefTitle":2464,"status":150,"phases":2465,"primaryCompletion":2466,"completion":237,"start":1030,"enrollment":2467,"conditions":2468,"interventions":2473},"NCT02983786","Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor",[],"2018-10",29,[1797,2469,2470,2471,2472],"Ischemic Stroke","Intracerebral Hemorrhage","Subarachnoid Hemorrhage","Acute Anoxic Encephalopathy",[2398],{"intervention":118,"totalTrials":2475,"cells":2476},4,{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2478,"activeCount":103},[],{"trials":2480,"activeCount":103},[],{"trials":2482,"activeCount":121,"soonestReadout":113},[2483,2493,2497],{"nctId":2484,"briefTitle":2485,"status":150,"phases":2486,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":28,"conditions":2489,"interventions":2492},"NCT04112316","Developing Oral LT3 Therapy for Heart Failure - HFrEF",[91,92],"2023-10-31","2020-02-11",[2490,2491],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Low T3 Syndrome",[118],{"nctId":109,"briefTitle":110,"status":111,"phases":2494,"primaryCompletion":113,"completion":113,"start":87,"enrollment":114,"conditions":2495,"interventions":2496},[92],[116],[118,119,120],{"nctId":2498,"briefTitle":2499,"status":150,"phases":2500,"primaryCompletion":2487,"completion":2487,"start":2501,"enrollment":28,"conditions":2502,"interventions":2504},"NCT04111536","Developing Oral LT3 Therapy for Heart Failure - HFpEF",[91,92],"2020-03-08",[1400,2503],"Low Triiodothyronine Syndrome",[2505],"liothyronine",{"trials":2507,"activeCount":103},[],{"trials":2509,"activeCount":103},[],{"trials":2511,"activeCount":103},[2512],{"nctId":2513,"briefTitle":2514,"status":150,"phases":2515,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":957,"conditions":2518,"interventions":2520},"NCT02399475","Mechanistic Study of Subclinical Hypothyroidism In the Elderly",[95],"2019-09-30","2015-01-01",[2519],"Subclinical Hypothyroidism",[2521,118,2522],"Levothyroxine","Thyrotropin-Releasing Hormone",{"intervention":1967,"totalTrials":99,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":103},[],{"trials":2528,"activeCount":103},[],{"trials":2530,"activeCount":121,"soonestReadout":1962},[2531],{"nctId":1959,"briefTitle":1960,"status":164,"phases":2532,"primaryCompletion":1962,"completion":1396,"start":1963,"enrollment":1150,"conditions":2533,"interventions":2534},[91,92],[1965],[1950,1967],{"trials":2536,"activeCount":103},[],{"trials":2538,"activeCount":103},[],{"trials":2540,"activeCount":103},[2541],{"nctId":2542,"briefTitle":2543,"status":150,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":2547,"conditions":2548,"interventions":2550},"NCT01690663","Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%",[95],"2015-02","2012-09",89,[2549],"Post Surgical Pain",[2551,2552,2553],"Bupivacaine 0.25%","Dexamethasone","normal saline",{"intervention":2555,"totalTrials":1410,"cells":2556},"[18F]NOS",{"EARLY_PHASE1":2557,"PHASE1":2596,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2558,"activeCount":2475,"soonestReadout":2563},[2559,2569,2577,2586],{"nctId":2560,"briefTitle":2561,"status":164,"phases":2562,"primaryCompletion":2563,"completion":2563,"start":2564,"enrollment":2565,"conditions":2566,"interventions":2568},"NCT04401917","Evaluation of Neuroinflammation FNOS PET\u002FCT in HIV (+) and (-) Subjects With OUD and Healthy Controls",[90],"2026-12-07","2020-12-07",26,[2567,1872],"HIV Infections",[2555],{"nctId":2570,"briefTitle":2571,"status":164,"phases":2572,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2475,"conditions":2575,"interventions":2576},"NCT05885594","Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study",[90],"2027-03-15","2023-08-08",[672],[2555],{"nctId":2578,"briefTitle":2579,"status":164,"phases":2580,"primaryCompletion":1322,"completion":1322,"start":2581,"enrollment":2582,"conditions":2583,"interventions":2584},"NCT04274998","Neuroinflammation Imaging in AD",[90],"2020-03-03",9,[948,2338],[2555,2585],"[11C]PBR28",{"nctId":2587,"briefTitle":2588,"status":164,"phases":2589,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":2592,"conditions":2593,"interventions":2595},"NCT04062526","Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET\u002FCT",[90],"2027-04","2019-08-14",11,[2594,2338],"Parkinson Disease",[2555],{"trials":2597,"activeCount":121,"soonestReadout":2602},[2598],{"nctId":2599,"briefTitle":2600,"status":129,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":1376,"conditions":2604,"interventions":2607},"NCT03721822","Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation",[91],"2026-10-23","2018-10-23",[2605,2606,2338],"Smoking, Cigarette","Smoking E-cigarette",[2555],{"trials":2609,"activeCount":103},[],{"trials":2611,"activeCount":103},[],{"trials":2613,"activeCount":103},[],{"trials":2615,"activeCount":103},[],{"intervention":2617,"totalTrials":190,"cells":2618},"Cyclophosphamide",{"EARLY_PHASE1":2619,"PHASE1":2630,"PHASE2":2714,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2620,"activeCount":103},[2621],{"nctId":2622,"briefTitle":2623,"status":1357,"phases":2624,"primaryCompletion":1963,"completion":2625,"start":1030,"enrollment":1986,"conditions":2626,"interventions":2628},"NCT02623582","CD123 Redirected Autologous T Cells for AML",[90],"2016-11-18",[2627],"Relapsed or Refractory Acute Myeloid Leukemia",[2629,2617],"Autologous Anti-CD 123 CAR TCR\u002F4-1BB-expressing T-lymphocytes",{"trials":2631,"activeCount":99,"soonestReadout":2661},[2632,2647,2657,2668,2679,2689,2701],{"nctId":2633,"briefTitle":2634,"status":1357,"phases":2635,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2592,"conditions":2638,"interventions":2641},"NCT05442580","CART-38 in Adult AML and MM Patients",[91],"2025-02-09","2023-05-30",[2639,2640],"Acute Myeloid Leukemia (AML)","Multiple Myeloma (MM)",[2642,2643,2644,2645,2617,2646],"3x10(6) CART-38 cellls","7x10(5) CART-38 cells","7x10(6) CART-38 cells","3x10(7) CART-38 cells","Fludarabine",{"nctId":2648,"briefTitle":2649,"status":150,"phases":2650,"primaryCompletion":1043,"completion":2651,"start":2652,"enrollment":957,"conditions":2653,"interventions":2655},"NCT02388594","A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients",[91],"2019-03","2015-04",[2654],"Human Immunodeficiency Virus (HIV)",[2656,2617],"ZFN Modified CD4+ T Cells",{"nctId":2658,"briefTitle":2659,"status":164,"phases":2660,"primaryCompletion":2661,"completion":2662,"start":2663,"enrollment":31,"conditions":2664,"interventions":2666},"NCT03089203","CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer",[91],"2038-09-08","2038-12-08","2017-03-08",[2665],"Prostate Cancer",[2667,2617,2646],"CART-PSMA-TGFβRDN cells",{"nctId":2669,"briefTitle":2670,"status":1357,"phases":2671,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":2475,"conditions":2675,"interventions":2677},"NCT02465983","Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer",[91],"2017-09","2017-11","2015-05",[2676],"Pancreatic Cancer",[2678,2617],"CART-meso-19 T cells",{"nctId":2680,"briefTitle":2681,"status":150,"phases":2682,"primaryCompletion":2334,"completion":2334,"start":1104,"enrollment":2683,"conditions":2684,"interventions":2686},"NCT00683670","Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma",[91],17,[2685],"Melanoma",[2687,2688],"cyclophosphamide","Mature dendritic cell vaccine",{"nctId":2690,"briefTitle":2691,"status":164,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":2695,"conditions":2696,"interventions":2699},"NCT04877613","GFRα4 CAR T Cells in MTC Patients",[91],"2039-06-01","2021-08-19",18,[2697,2698],"Metastatic Medullary Thyroid Cancer","Recurrent Thyroid Gland Medullary Carcinoma",[2700,2646,2617],"single dose of CART-GFRa4 cells",{"nctId":2702,"briefTitle":2703,"status":1357,"phases":2704,"primaryCompletion":2705,"completion":2706,"start":2707,"enrollment":1139,"conditions":2708,"interventions":2712},"NCT03399448","NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)",[91],"2020-02-29","2020-10-09","2018-09-05",[2709,2685,2710,2711],"Multiple Myeloma","Synovial Sarcoma","Myxoid\u002FRound Cell Liposarcoma",[2713,2617,2646],"NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1",{"trials":2715,"activeCount":103},[],{"trials":2717,"activeCount":103},[],{"trials":2719,"activeCount":103},[],{"trials":2721,"activeCount":103},[],{"intervention":2646,"totalTrials":2475,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2744,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2725,"activeCount":103},[],{"trials":2727,"activeCount":99,"soonestReadout":2661},[2728,2732,2736,2740],{"nctId":2633,"briefTitle":2634,"status":1357,"phases":2729,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2592,"conditions":2730,"interventions":2731},[91],[2639,2640],[2642,2643,2644,2645,2617,2646],{"nctId":2658,"briefTitle":2659,"status":164,"phases":2733,"primaryCompletion":2661,"completion":2662,"start":2663,"enrollment":31,"conditions":2734,"interventions":2735},[91],[2665],[2667,2617,2646],{"nctId":2690,"briefTitle":2691,"status":164,"phases":2737,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":2695,"conditions":2738,"interventions":2739},[91],[2697,2698],[2700,2646,2617],{"nctId":2702,"briefTitle":2703,"status":1357,"phases":2741,"primaryCompletion":2705,"completion":2706,"start":2707,"enrollment":1139,"conditions":2742,"interventions":2743},[91],[2709,2685,2710,2711],[2713,2617,2646],{"trials":2745,"activeCount":103},[],{"trials":2747,"activeCount":103},[],{"trials":2749,"activeCount":103},[],{"trials":2751,"activeCount":103},[],{"intervention":2753,"totalTrials":99,"cells":2754},"[18F]fluoropropyl-trimethoprim",{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2756,"activeCount":103},[],{"trials":2758,"activeCount":99,"soonestReadout":831},[2759,2768],{"nctId":2760,"briefTitle":2761,"status":129,"phases":2762,"primaryCompletion":831,"completion":2763,"start":2764,"enrollment":329,"conditions":2765,"interventions":2767},"NCT04263792","[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET\u002FCT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects",[91],"2027-01","2020-02-07",[2766],"Bacterial Infections",[2753],{"nctId":2769,"briefTitle":2770,"status":129,"phases":2771,"primaryCompletion":2772,"completion":2773,"start":2774,"enrollment":2399,"conditions":2775,"interventions":2777},"NCT07343934","huCART19-IL18-eDHFR Cells in Relapsed\u002FRefractory Follicular Lymphoma",[91],"2027-11","2042-11","2026-05-18",[2776],"Relapsed or Refractory Follicular Lymphoma",[2778,2779],"huCART19-IL18-eDHFR cells","[18F]Fluoropropyl-Trimethoprim",{"trials":2781,"activeCount":103},[],{"trials":2783,"activeCount":103},[],{"trials":2785,"activeCount":103},[],{"trials":2787,"activeCount":103},[],{"intervention":2789,"totalTrials":99,"cells":2790},"CART-EGFR-IL13Ra2 Cells",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2813,"PHASE3":2815,"PHASE4":2817,"NA":2819},{"trials":2792,"activeCount":103},[],{"trials":2794,"activeCount":99,"soonestReadout":2799},[2795,2804],{"nctId":2796,"briefTitle":2797,"status":164,"phases":2798,"primaryCompletion":2799,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2803},"NCT05168423","CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM",[91],"2039-12-19","2023-02-24",67,[1628],[2789],{"nctId":2805,"briefTitle":2806,"status":129,"phases":2807,"primaryCompletion":1149,"completion":1149,"start":2808,"enrollment":2582,"conditions":2809,"interventions":2810},"NCT06973096","CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy",[91],"2025-07-18",[1628],[2811,2812,1158],"CART-EGFR-IL13Ra2 cells","Rituximab or Rituximab biosimilar",{"trials":2814,"activeCount":103},[],{"trials":2816,"activeCount":103},[],{"trials":2818,"activeCount":103},[],{"trials":2820,"activeCount":103},[],{"intervention":1158,"totalTrials":99,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2835,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2824,"activeCount":103},[],{"trials":2826,"activeCount":99,"soonestReadout":1149},[2827,2831],{"nctId":2805,"briefTitle":2806,"status":129,"phases":2828,"primaryCompletion":1149,"completion":1149,"start":2808,"enrollment":2582,"conditions":2829,"interventions":2830},[91],[1628],[2811,2812,1158],{"nctId":1146,"briefTitle":1147,"status":111,"phases":2832,"primaryCompletion":1149,"completion":1149,"start":831,"enrollment":1150,"conditions":2833,"interventions":2834},[91],[1152,1153,1154,1155],[1157,1158,1138],{"trials":2836,"activeCount":103},[],{"trials":2838,"activeCount":103},[],{"trials":2840,"activeCount":103},[],{"trials":2842,"activeCount":103},[],{"intervention":2844,"totalTrials":2475,"cells":2845},"huCART-meso cells",{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2896,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2847,"activeCount":103},[],{"trials":2849,"activeCount":121,"soonestReadout":2879},[2850,2865,2875,2887],{"nctId":2851,"briefTitle":2852,"status":150,"phases":2853,"primaryCompletion":2854,"completion":2855,"start":2856,"enrollment":438,"conditions":2857,"interventions":2864},"NCT03054298","CAR T Cells in Mesothelin Expressing Cancers",[91],"2023-11-09","2024-07-30","2017-04-06",[2858,2859,2860,2861,2862,2863],"Lung Adenocarcinoma","Ovarian Cancer","Peritoneal Carcinoma","Fallopian Tube Cancer","Mesotheliomas Pleural","Mesothelioma Peritoneum",[2844],{"nctId":2866,"briefTitle":2867,"status":1357,"phases":2868,"primaryCompletion":2869,"completion":2869,"start":2870,"enrollment":2871,"conditions":2872,"interventions":2874},"NCT03323944","CAR T Cell Immunotherapy for Pancreatic Cancer",[91],"2025-02-20","2017-09-15",54,[2676,2873],"Cancer of the Pancreas",[2844],{"nctId":2876,"briefTitle":2877,"status":164,"phases":2878,"primaryCompletion":2879,"completion":2879,"start":2880,"enrollment":2881,"conditions":2882,"interventions":2884},"NCT05057715","huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer",[91],"2038-09","2022-03-02",13,[2676,2883],"Serous Ovarian Cancer",[2885,2886],"VCN-01","huCART-meso Cells",{"nctId":2888,"briefTitle":2889,"status":1357,"phases":2890,"primaryCompletion":2891,"completion":2891,"start":2892,"enrollment":99,"conditions":2893,"interventions":2895},"NCT05623488","CAR T Cells in Mesothelin-Expressing Breast Cancer",[91],"2025-04-07","2023-02-06",[2894],"Breast Cancer",[2844],{"trials":2897,"activeCount":103},[],{"trials":2899,"activeCount":103},[],{"trials":2901,"activeCount":103},[],{"trials":2903,"activeCount":103},[],{"intervention":2905,"totalTrials":99,"cells":2906},"MOv19-BBz CAR T cells",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2932,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2908,"activeCount":103},[],{"trials":2910,"activeCount":121,"soonestReadout":2915},[2911,2922],{"nctId":2912,"briefTitle":2913,"status":129,"phases":2914,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":2440,"conditions":2917,"interventions":2920},"NCT07116057","MOv19-BBz CAR T Cells in FRa+ Cancers",[91],"2040-10","2025-10-07",[2918,2919],"Metastatic Non Small Cell Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma",[2905,2921],"Cyclophosphamide\u002FFludarabine",{"nctId":2923,"briefTitle":2924,"status":1357,"phases":2925,"primaryCompletion":2926,"completion":2926,"start":2927,"enrollment":2928,"conditions":2929,"interventions":2931},"NCT03585764","MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],"2024-03-26","2018-10-24",46,[2859,2861,2930],"Primary Peritoneal Carcinoma",[2905],{"trials":2933,"activeCount":103},[],{"trials":2935,"activeCount":103},[],{"trials":2937,"activeCount":103},[],{"trials":2939,"activeCount":103},[],{"intervention":2941,"totalTrials":99,"cells":2942},"CART123 cells; cyclophosphamide; fludarabine",{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2968,"PHASE3":2970,"PHASE4":2972,"NA":2974},{"trials":2944,"activeCount":103},[],{"trials":2946,"activeCount":121,"soonestReadout":2951},[2947,2958],{"nctId":2948,"briefTitle":2949,"status":164,"phases":2950,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":34,"conditions":2953,"interventions":2957},"NCT03766126","Lentivirally Redirected CD123 Autologous T Cells in AML",[91],"2033-12-03","2018-12-06",[2954,2955,2956],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia, Adult","Acute Myeloid Leukemia, Refractory",[2941],{"nctId":2959,"briefTitle":2960,"status":1357,"phases":2961,"primaryCompletion":2962,"completion":2962,"start":2963,"enrollment":2964,"conditions":2965,"interventions":2967},"NCT04678336","CD123 Redirected T Cells for AML in Pediatric Subjects",[91],"2025-05-09","2021-04-02",12,[2954,2966,2956],"Acute Myeloid Leukemia, Pediatric",[2941],{"trials":2969,"activeCount":103},[],{"trials":2971,"activeCount":103},[],{"trials":2973,"activeCount":103},[],{"trials":2975,"activeCount":103},[],{"intervention":2977,"totalTrials":121,"cells":2978},"2-[18F]-FA PET\u002FCT",{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2993,"PHASE3":2995,"PHASE4":2997,"NA":2999},{"trials":2980,"activeCount":103},[],{"trials":2982,"activeCount":121,"soonestReadout":2987},[2983],{"nctId":2984,"briefTitle":2985,"status":164,"phases":2986,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2881,"conditions":2989,"interventions":2991},"NCT03442413","Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction",[91],"2026-11-22","2018-06-28",[2990],"Smoking, Tobacco",[2977,2992],"I.V. Nicotine",{"trials":2994,"activeCount":103},[],{"trials":2996,"activeCount":103},[],{"trials":2998,"activeCount":103},[],{"trials":3000,"activeCount":103},[],{"intervention":2992,"totalTrials":121,"cells":3002},{"EARLY_PHASE1":3003,"PHASE1":3005,"PHASE2":3011,"PHASE3":3013,"PHASE4":3015,"NA":3017},{"trials":3004,"activeCount":103},[],{"trials":3006,"activeCount":121,"soonestReadout":2987},[3007],{"nctId":2984,"briefTitle":2985,"status":164,"phases":3008,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2881,"conditions":3009,"interventions":3010},[91],[2990],[2977,2992],{"trials":3012,"activeCount":103},[],{"trials":3014,"activeCount":103},[],{"trials":3016,"activeCount":103},[],{"trials":3018,"activeCount":103},[],{"intervention":3020,"totalTrials":121,"cells":3021},"PD-1inhibitor - LVGN 3616",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3036,"PHASE3":3038,"PHASE4":3040,"NA":3042},{"trials":3023,"activeCount":103},[],{"trials":3025,"activeCount":121,"soonestReadout":3030},[3026],{"nctId":3027,"briefTitle":3028,"status":164,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":2248,"enrollment":3031,"conditions":3032,"interventions":3034},"NCT06159621","CD40 Agonist and PD-1 Inhibitor in HNSCC",[91],"2028-03-01",27,[3033],"Head and Neck Squamous Cell Carcinoma",[3020,3035],"CD 40 Agonist - LVGN 7409",{"trials":3037,"activeCount":103},[],{"trials":3039,"activeCount":103},[],{"trials":3041,"activeCount":103},[],{"trials":3043,"activeCount":103},[],{"intervention":3035,"totalTrials":121,"cells":3045},{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3054,"PHASE3":3056,"PHASE4":3058,"NA":3060},{"trials":3047,"activeCount":103},[],{"trials":3049,"activeCount":121,"soonestReadout":3030},[3050],{"nctId":3027,"briefTitle":3028,"status":164,"phases":3051,"primaryCompletion":3030,"completion":3030,"start":2248,"enrollment":3031,"conditions":3052,"interventions":3053},[91],[3033],[3020,3035],{"trials":3055,"activeCount":103},[],{"trials":3057,"activeCount":103},[],{"trials":3059,"activeCount":103},[],{"trials":3061,"activeCount":103},[],{"intervention":2921,"totalTrials":121,"cells":3063},{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3072,"PHASE3":3074,"PHASE4":3076,"NA":3078},{"trials":3065,"activeCount":103},[],{"trials":3067,"activeCount":121,"soonestReadout":2915},[3068],{"nctId":2912,"briefTitle":2913,"status":129,"phases":3069,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":2440,"conditions":3070,"interventions":3071},[91],[2918,2919],[2905,2921],{"trials":3073,"activeCount":103},[],{"trials":3075,"activeCount":103},[],{"trials":3077,"activeCount":103},[],{"trials":3079,"activeCount":103},[],{"intervention":3081,"totalTrials":121,"cells":3082},"[18F]ISO-1",{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3096,"PHASE3":3098,"PHASE4":3100,"NA":3102},{"trials":3084,"activeCount":103},[],{"trials":3086,"activeCount":121,"soonestReadout":3091},[3087],{"nctId":3088,"briefTitle":3089,"status":164,"phases":3090,"primaryCompletion":3091,"completion":3091,"start":3092,"enrollment":1150,"conditions":3093,"interventions":3095},"NCT02284919","[18F]ISO-1 Positron Emission Tomography (PET\u002FCT) in Primary Breast Cancer",[91],"2026-11","2015-03-11",[2894,3094],"Breast Neoplasm",[3081],{"trials":3097,"activeCount":103},[],{"trials":3099,"activeCount":103},[],{"trials":3101,"activeCount":103},[],{"trials":3103,"activeCount":103},[],{"intervention":3105,"totalTrials":121,"cells":3106},"BCMA CART + huCART19",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3108,"activeCount":103},[],{"trials":3110,"activeCount":121,"soonestReadout":3115},[3111],{"nctId":3112,"briefTitle":3113,"status":164,"phases":3114,"primaryCompletion":3115,"completion":3115,"start":3116,"enrollment":289,"conditions":3117,"interventions":3118},"NCT03549442","Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma",[91],"2036-03","2018-05-09",[2709],[3105,3119,3120,3105],"CART BCMA or CART BCMA + huCART19","Single-dose infusion of CART BCMA or CART BCMA + huCART19",{"trials":3122,"activeCount":103},[],{"trials":3124,"activeCount":103},[],{"trials":3126,"activeCount":103},[],{"trials":3128,"activeCount":103},[],{"intervention":3119,"totalTrials":121,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3139,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":103},[],{"trials":3134,"activeCount":121,"soonestReadout":3115},[3135],{"nctId":3112,"briefTitle":3113,"status":164,"phases":3136,"primaryCompletion":3115,"completion":3115,"start":3116,"enrollment":289,"conditions":3137,"interventions":3138},[91],[2709],[3105,3119,3120,3105],{"trials":3140,"activeCount":103},[],{"trials":3142,"activeCount":103},[],{"trials":3144,"activeCount":103},[],{"trials":3146,"activeCount":103},[],{"intervention":3120,"totalTrials":121,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3150,"activeCount":103},[],{"trials":3152,"activeCount":121,"soonestReadout":3115},[3153],{"nctId":3112,"briefTitle":3113,"status":164,"phases":3154,"primaryCompletion":3115,"completion":3115,"start":3116,"enrollment":289,"conditions":3155,"interventions":3156},[91],[2709],[3105,3119,3120,3105],{"trials":3158,"activeCount":103},[],{"trials":3160,"activeCount":103},[],{"trials":3162,"activeCount":103},[],{"trials":3164,"activeCount":103},[],{"intervention":3166,"totalTrials":121,"cells":3167},"CART22-65s cells",{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3169,"activeCount":103},[],{"trials":3171,"activeCount":121,"soonestReadout":3176},[3172],{"nctId":3173,"briefTitle":3174,"status":164,"phases":3175,"primaryCompletion":3176,"completion":3176,"start":3177,"enrollment":31,"conditions":3178,"interventions":3181},"NCT03620058","CART22 Alone or in Combination With huCART19 for ALL",[91],"2036-01","2018-09-27",[3179,3180],"Chemotherapy Resistant Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia",[3166,3182],"huCART19 Cells",{"trials":3184,"activeCount":103},[],{"trials":3186,"activeCount":103},[],{"trials":3188,"activeCount":103},[],{"trials":3190,"activeCount":103},[],{"intervention":3182,"totalTrials":121,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3201,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3194,"activeCount":103},[],{"trials":3196,"activeCount":121,"soonestReadout":3176},[3197],{"nctId":3173,"briefTitle":3174,"status":164,"phases":3198,"primaryCompletion":3176,"completion":3176,"start":3177,"enrollment":31,"conditions":3199,"interventions":3200},[91],[3179,3180],[3166,3182],{"trials":3202,"activeCount":103},[],{"trials":3204,"activeCount":103},[],{"trials":3206,"activeCount":103},[],{"trials":3208,"activeCount":103},[],{"intervention":3210,"totalTrials":121,"cells":3211},"[18F]FLT",{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3226,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3213,"activeCount":103},[],{"trials":3215,"activeCount":121,"soonestReadout":3091},[3216],{"nctId":3217,"briefTitle":3218,"status":164,"phases":3219,"primaryCompletion":3091,"completion":3091,"start":1021,"enrollment":329,"conditions":3220,"interventions":3223},"NCT02608216","[18F]FLT PET\u002FCT in Rb+ Metastatic Breast Cancer",[91],[3094,3221,3222],"Metastatic Breast Cancer","Rb+ Breast Cancer",[3210,3224,3225],"ribociclib","paclitaxel",{"trials":3227,"activeCount":103},[],{"trials":3229,"activeCount":103},[],{"trials":3231,"activeCount":103},[],{"trials":3233,"activeCount":103},[],{"intervention":3224,"totalTrials":121,"cells":3235},{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3244,"PHASE3":3246,"PHASE4":3248,"NA":3250},{"trials":3237,"activeCount":103},[],{"trials":3239,"activeCount":121,"soonestReadout":3091},[3240],{"nctId":3217,"briefTitle":3218,"status":164,"phases":3241,"primaryCompletion":3091,"completion":3091,"start":1021,"enrollment":329,"conditions":3242,"interventions":3243},[91],[3094,3221,3222],[3210,3224,3225],{"trials":3245,"activeCount":103},[],{"trials":3247,"activeCount":103},[],{"trials":3249,"activeCount":103},[],{"trials":3251,"activeCount":103},[],{"intervention":3225,"totalTrials":121,"cells":3253},{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3262,"PHASE3":3264,"PHASE4":3266,"NA":3268},{"trials":3255,"activeCount":103},[],{"trials":3257,"activeCount":121,"soonestReadout":3091},[3258],{"nctId":3217,"briefTitle":3218,"status":164,"phases":3259,"primaryCompletion":3091,"completion":3091,"start":1021,"enrollment":329,"conditions":3260,"interventions":3261},[91],[3094,3221,3222],[3210,3224,3225],{"trials":3263,"activeCount":103},[],{"trials":3265,"activeCount":103},[],{"trials":3267,"activeCount":103},[],{"trials":3269,"activeCount":103},[],{"intervention":3271,"totalTrials":121,"cells":3272},"TmCD19-IL18",{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3287,"PHASE3":3289,"PHASE4":3291,"NA":3293},{"trials":3274,"activeCount":103},[],{"trials":3276,"activeCount":121,"soonestReadout":3281},[3277],{"nctId":3278,"briefTitle":3279,"status":129,"phases":3280,"primaryCompletion":3281,"completion":3282,"start":3283,"enrollment":1470,"conditions":3284,"interventions":3286},"NCT05989204","TmCD19-IL18 in CD19+ Cancers",[91],"2026-10-01","2041-10-01","2023-11-13",[3285],"Non Hodgkin Lymphoma",[3271],{"trials":3288,"activeCount":103},[],{"trials":3290,"activeCount":103},[],{"trials":3292,"activeCount":103},[],{"trials":3294,"activeCount":103},[],{"intervention":3296,"totalTrials":121,"cells":3297},"huCART19-IL18",{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3313,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3299,"activeCount":103},[],{"trials":3301,"activeCount":121,"soonestReadout":3306},[3302],{"nctId":3303,"briefTitle":3304,"status":164,"phases":3305,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":624,"conditions":3308,"interventions":3312},"NCT04684563","huCART19-IL18 in CD19+ Cancers",[91],"2036-05","2021-05-06",[3309,3310,3311],"Chronic Lymphocytic Leukemia","Non-hodgkin Lymphoma","Acute Lymphoblastic Leukemia",[3296],{"trials":3314,"activeCount":103},[],{"trials":3316,"activeCount":103},[],{"trials":3318,"activeCount":103},[],{"trials":3320,"activeCount":103},[],{"intervention":2885,"totalTrials":121,"cells":3322},{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3331,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3324,"activeCount":103},[],{"trials":3326,"activeCount":121,"soonestReadout":2879},[3327],{"nctId":2876,"briefTitle":2877,"status":164,"phases":3328,"primaryCompletion":2879,"completion":2879,"start":2880,"enrollment":2881,"conditions":3329,"interventions":3330},[91],[2676,2883],[2885,2886],{"trials":3332,"activeCount":103},[],{"trials":3334,"activeCount":103},[],{"trials":3336,"activeCount":103},[],{"trials":3338,"activeCount":103},[],{"intervention":3340,"totalTrials":121,"cells":3341},"Dorzagliatin",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3354,"PHASE3":3356,"PHASE4":3358,"NA":3360},{"trials":3343,"activeCount":103},[],{"trials":3345,"activeCount":121,"soonestReadout":668},[3346],{"nctId":3347,"briefTitle":3348,"status":129,"phases":3349,"primaryCompletion":668,"completion":668,"start":3350,"enrollment":983,"conditions":3351,"interventions":3353},"NCT06995651","Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis",[91],"2025-10-21",[2388,3352],"Cystic Fibrosis-related Diabetes",[3340],{"trials":3355,"activeCount":103},[],{"trials":3357,"activeCount":103},[],{"trials":3359,"activeCount":103},[],{"trials":3361,"activeCount":103},[],{"intervention":3363,"totalTrials":121,"cells":3364},"[18F]Fluortriopride",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3376,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3366,"activeCount":103},[],{"trials":3368,"activeCount":121,"soonestReadout":1539},[3369],{"nctId":3370,"briefTitle":3371,"status":164,"phases":3372,"primaryCompletion":1539,"completion":1539,"start":3373,"enrollment":2467,"conditions":3374,"interventions":3375},"NCT02379338","Study of Radiotracer [18F]Fluortriopride ([18F]FTP) by PET\u002FCT",[91],"2015-01",[21],[3363],{"trials":3377,"activeCount":103},[],{"trials":3379,"activeCount":103},[],{"trials":3381,"activeCount":103},[],{"trials":3383,"activeCount":103},[],{"intervention":3385,"totalTrials":121,"cells":3386},"Methadone hydrochloride",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3400,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3388,"activeCount":103},[],{"trials":3390,"activeCount":121,"soonestReadout":3395},[3391],{"nctId":3392,"briefTitle":3393,"status":129,"phases":3394,"primaryCompletion":3395,"completion":668,"start":3396,"enrollment":1470,"conditions":3397,"interventions":3399},"NCT06877858","MethaLoad Dose-Finding Study",[91],"2027-03","2025-09-25",[3398],"Opioid Use Disorder (OUD)",[3385],{"trials":3401,"activeCount":103},[],{"trials":3403,"activeCount":103},[],{"trials":3405,"activeCount":103},[],{"trials":3407,"activeCount":103},[],{"intervention":3409,"totalTrials":121,"cells":3410},"TmPSMA-02 CAR T Cells",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3429},{"trials":3412,"activeCount":103},[],{"trials":3414,"activeCount":121,"soonestReadout":1962},[3415],{"nctId":3416,"briefTitle":3417,"status":129,"phases":3418,"primaryCompletion":1962,"completion":3419,"start":132,"enrollment":1150,"conditions":3420,"interventions":3422},"NCT06046040","TmPSMA-02 in mCRPC",[91],"2042-01-31",[3421],"Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",[3409],{"trials":3424,"activeCount":103},[],{"trials":3426,"activeCount":103},[],{"trials":3428,"activeCount":103},[],{"trials":3430,"activeCount":103},[],{"intervention":2667,"totalTrials":121,"cells":3432},{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3441,"PHASE3":3443,"PHASE4":3445,"NA":3447},{"trials":3434,"activeCount":103},[],{"trials":3436,"activeCount":121,"soonestReadout":2661},[3437],{"nctId":2658,"briefTitle":2659,"status":164,"phases":3438,"primaryCompletion":2661,"completion":2662,"start":2663,"enrollment":31,"conditions":3439,"interventions":3440},[91],[2665],[2667,2617,2646],{"trials":3442,"activeCount":103},[],{"trials":3444,"activeCount":103},[],{"trials":3446,"activeCount":103},[],{"trials":3448,"activeCount":103},[],{"intervention":3450,"totalTrials":121,"cells":3451},"CD4 CAR+CCR5 ZFN T-cells",{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3464,"PHASE3":3466,"PHASE4":3468,"NA":3470},{"trials":3453,"activeCount":103},[],{"trials":3455,"activeCount":121,"soonestReadout":698},[3456],{"nctId":3457,"briefTitle":3458,"status":164,"phases":3459,"primaryCompletion":698,"completion":699,"start":3460,"enrollment":2964,"conditions":3461,"interventions":3463},"NCT03617198","CD4 CAR+ ZFN-modified T Cells in HIV Therapy",[91],"2019-07-31",[3462],"Hiv",[3450],{"trials":3465,"activeCount":103},[],{"trials":3467,"activeCount":103},[],{"trials":3469,"activeCount":103},[],{"trials":3471,"activeCount":103},[],{"intervention":88,"totalTrials":121,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3485,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3475,"activeCount":103},[],{"trials":3477,"activeCount":121,"soonestReadout":87},[3478],{"nctId":85,"briefTitle":86,"status":164,"phases":3479,"primaryCompletion":87,"completion":87,"start":3480,"enrollment":983,"conditions":3481,"interventions":3484},[91],"2007-07",[3482,3483],"Amaurosis of Leber","Retinal Diseases",[88],{"trials":3486,"activeCount":103},[],{"trials":3488,"activeCount":103},[],{"trials":3490,"activeCount":103},[],{"trials":3492,"activeCount":103},[],{"intervention":3494,"totalTrials":121,"cells":3495},"CART123 Cells",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3512,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3497,"activeCount":103},[],{"trials":3499,"activeCount":121,"soonestReadout":3504},[3500],{"nctId":3501,"briefTitle":3502,"status":164,"phases":3503,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":2964,"conditions":3506,"interventions":3509},"NCT06768476","CART123 + Ruxolitinib in Relapsed\u002FRefractory AML",[91],"2045-03","2025-02-28",[3507,3508],"Relapsed AML","Refractory AML",[3494,3510,3511],"Ruxolitinib 10 MG","Ruxolitinib 5 MG",{"trials":3513,"activeCount":103},[],{"trials":3515,"activeCount":103},[],{"trials":3517,"activeCount":103},[],{"trials":3519,"activeCount":103},[],{"intervention":3510,"totalTrials":121,"cells":3521},{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3530,"PHASE3":3532,"PHASE4":3534,"NA":3536},{"trials":3523,"activeCount":103},[],{"trials":3525,"activeCount":121,"soonestReadout":3504},[3526],{"nctId":3501,"briefTitle":3502,"status":164,"phases":3527,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":2964,"conditions":3528,"interventions":3529},[91],[3507,3508],[3494,3510,3511],{"trials":3531,"activeCount":103},[],{"trials":3533,"activeCount":103},[],{"trials":3535,"activeCount":103},[],{"trials":3537,"activeCount":103},[],{"intervention":3511,"totalTrials":121,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3548,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3541,"activeCount":103},[],{"trials":3543,"activeCount":121,"soonestReadout":3504},[3544],{"nctId":3501,"briefTitle":3502,"status":164,"phases":3545,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":2964,"conditions":3546,"interventions":3547},[91],[3507,3508],[3494,3510,3511],{"trials":3549,"activeCount":103},[],{"trials":3551,"activeCount":103},[],{"trials":3553,"activeCount":103},[],{"trials":3555,"activeCount":103},[],{"intervention":2812,"totalTrials":121,"cells":3557},{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3566,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3559,"activeCount":103},[],{"trials":3561,"activeCount":121,"soonestReadout":1149},[3562],{"nctId":2805,"briefTitle":2806,"status":129,"phases":3563,"primaryCompletion":1149,"completion":1149,"start":2808,"enrollment":2582,"conditions":3564,"interventions":3565},[91],[1628],[2811,2812,1158],{"trials":3567,"activeCount":103},[],{"trials":3569,"activeCount":103},[],{"trials":3571,"activeCount":103},[],{"trials":3573,"activeCount":103},[],{"intervention":3575,"totalTrials":121,"cells":3576},"CART-EGFR-IL13Ra2 T cells",{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3590,"PHASE3":3592,"PHASE4":3594,"NA":3596},{"trials":3578,"activeCount":103},[],{"trials":3580,"activeCount":121,"soonestReadout":3585},[3581],{"nctId":3582,"briefTitle":3583,"status":129,"phases":3584,"primaryCompletion":3585,"completion":3585,"start":3586,"enrollment":2964,"conditions":3587,"interventions":3589},"NCT07209241","Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM",[91],"2042-11-01","2025-12-03",[3588],"Recurrent Glioblastoma",[3575],{"trials":3591,"activeCount":103},[],{"trials":3593,"activeCount":103},[],{"trials":3595,"activeCount":103},[],{"trials":3597,"activeCount":103},[],{"intervention":1157,"totalTrials":121,"cells":3599},{"EARLY_PHASE1":3600,"PHASE1":3602,"PHASE2":3608,"PHASE3":3610,"PHASE4":3612,"NA":3614},{"trials":3601,"activeCount":103},[],{"trials":3603,"activeCount":121,"soonestReadout":1149},[3604],{"nctId":1146,"briefTitle":1147,"status":111,"phases":3605,"primaryCompletion":1149,"completion":1149,"start":831,"enrollment":1150,"conditions":3606,"interventions":3607},[91],[1152,1153,1154,1155],[1157,1158,1138],{"trials":3609,"activeCount":103},[],{"trials":3611,"activeCount":103},[],{"trials":3613,"activeCount":103},[],{"trials":3615,"activeCount":103},[],{"intervention":2700,"totalTrials":121,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3626,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3619,"activeCount":103},[],{"trials":3621,"activeCount":121,"soonestReadout":2693},[3622],{"nctId":2690,"briefTitle":2691,"status":164,"phases":3623,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":2695,"conditions":3624,"interventions":3625},[91],[2697,2698],[2700,2646,2617],{"trials":3627,"activeCount":103},[],{"trials":3629,"activeCount":103},[],{"trials":3631,"activeCount":103},[],{"trials":3633,"activeCount":103},[],{"intervention":2778,"totalTrials":121,"cells":3635},{"EARLY_PHASE1":3636,"PHASE1":3638,"PHASE2":3644,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3637,"activeCount":103},[],{"trials":3639,"activeCount":121,"soonestReadout":2772},[3640],{"nctId":2769,"briefTitle":2770,"status":129,"phases":3641,"primaryCompletion":2772,"completion":2773,"start":2774,"enrollment":2399,"conditions":3642,"interventions":3643},[91],[2776],[2778,2779],{"trials":3645,"activeCount":103},[],{"trials":3647,"activeCount":103},[],{"trials":3649,"activeCount":103},[],{"trials":3651,"activeCount":103},[],{"intervention":3653,"totalTrials":121,"cells":3654},"Cohort 1",{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3671,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3656,"activeCount":103},[],{"trials":3658,"activeCount":121,"soonestReadout":3663},[3659],{"nctId":3660,"briefTitle":3661,"status":164,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":2311,"conditions":3665,"interventions":3668},"NCT02650414","CD22 Redirected Autologous T Cells for ALL",[91],"2037-12","2016-01-13",[3666,3667],"B Cell Leukemias","B Cell Lymphomas",[3653,3669,3670],"Cohorts 2","Cohort 3",{"trials":3672,"activeCount":103},[],{"trials":3674,"activeCount":103},[],{"trials":3676,"activeCount":103},[],{"trials":3678,"activeCount":103},[],{"intervention":3669,"totalTrials":121,"cells":3680},{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3689,"PHASE3":3691,"PHASE4":3693,"NA":3695},{"trials":3682,"activeCount":103},[],{"trials":3684,"activeCount":121,"soonestReadout":3663},[3685],{"nctId":3660,"briefTitle":3661,"status":164,"phases":3686,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":2311,"conditions":3687,"interventions":3688},[91],[3666,3667],[3653,3669,3670],{"trials":3690,"activeCount":103},[],{"trials":3692,"activeCount":103},[],{"trials":3694,"activeCount":103},[],{"trials":3696,"activeCount":103},[],{"intervention":3670,"totalTrials":121,"cells":3698},{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3707,"PHASE3":3709,"PHASE4":3711,"NA":3713},{"trials":3700,"activeCount":103},[],{"trials":3702,"activeCount":121,"soonestReadout":3663},[3703],{"nctId":3660,"briefTitle":3661,"status":164,"phases":3704,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":2311,"conditions":3705,"interventions":3706},[91],[3666,3667],[3653,3669,3670],{"trials":3708,"activeCount":103},[],{"trials":3710,"activeCount":103},[],{"trials":3712,"activeCount":103},[],{"trials":3714,"activeCount":103},[],{"intervention":3716,"totalTrials":121,"cells":3717},"CD33KO-HSPC; CART33",{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3733,"PHASE3":3735,"PHASE4":3737,"NA":3739},{"trials":3719,"activeCount":103},[],{"trials":3721,"activeCount":121,"soonestReadout":3726},[3722],{"nctId":3723,"briefTitle":3724,"status":129,"phases":3725,"primaryCompletion":3726,"completion":3727,"start":3728,"enrollment":3729,"conditions":3730,"interventions":3732},"NCT05945849","CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory\u002FRelapsed AML",[91],"2029-02-23","2044-02-23","2024-02-23",16,[3731],"Leukemia, Myeloid, Acute",[3716],{"trials":3734,"activeCount":103},[],{"trials":3736,"activeCount":103},[],{"trials":3738,"activeCount":103},[],{"trials":3740,"activeCount":103},[],{"intervention":3742,"totalTrials":121,"cells":3743},"CART-45 cells",{"EARLY_PHASE1":3744,"PHASE1":3746,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3745,"activeCount":103},[],{"trials":3747,"activeCount":121,"soonestReadout":3752},[3748],{"nctId":3749,"briefTitle":3750,"status":111,"phases":3751,"primaryCompletion":3752,"completion":3752,"start":831,"enrollment":3753,"conditions":3754,"interventions":3759},"NCT07451054","CD45BE-HSPC + CART-45 Cells",[91],"2051-07",42,[3755,3756,3757,3758],"B-Cell Non-Hodgkin Lymphoma (NHL)","Richter's Transformation","T-Cell Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[3742,3760],"CD45BE-HSPC",{"trials":3762,"activeCount":103},[],{"trials":3764,"activeCount":103},[],{"trials":3766,"activeCount":103},[],{"trials":3768,"activeCount":103},[],{"intervention":3760,"totalTrials":121,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3772,"activeCount":103},[],{"trials":3774,"activeCount":121,"soonestReadout":3752},[3775],{"nctId":3749,"briefTitle":3750,"status":111,"phases":3776,"primaryCompletion":3752,"completion":3752,"start":831,"enrollment":3753,"conditions":3777,"interventions":3778},[91],[3755,3756,3757,3758],[3742,3760],{"trials":3780,"activeCount":103},[],{"trials":3782,"activeCount":103},[],{"trials":3784,"activeCount":103},[],{"trials":3786,"activeCount":103},[],{"intervention":3788,"totalTrials":121,"cells":3789},"CD19 redirected autologous T cells",{"EARLY_PHASE1":3790,"PHASE1":3792,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3791,"activeCount":103},[],{"trials":3793,"activeCount":121,"soonestReadout":669},[3794],{"nctId":3795,"briefTitle":3796,"status":111,"phases":3797,"primaryCompletion":669,"completion":669,"start":463,"enrollment":2964,"conditions":3798,"interventions":3800},"NCT04419909","Retreatment With CTL019\u002FCTL119",[91],[3799],"Lymphoma, B-Cell",[3788],{"trials":3802,"activeCount":103},[],{"trials":3804,"activeCount":103},[],{"trials":3806,"activeCount":103},[],{"trials":3808,"activeCount":103},[],{"intervention":3810,"totalTrials":121,"cells":3811},"Carfentanil, C-11",{"EARLY_PHASE1":3812,"PHASE1":3814,"PHASE2":3827,"PHASE3":3829,"PHASE4":3831,"NA":3833},{"trials":3813,"activeCount":103},[],{"trials":3815,"activeCount":121,"soonestReadout":3820},[3816],{"nctId":3817,"briefTitle":3818,"status":164,"phases":3819,"primaryCompletion":3820,"completion":3820,"start":3821,"enrollment":3822,"conditions":3823,"interventions":3824},"NCT05528848","Multi-System Analysis of Opioid Receptor Binding",[91],"2027-09","2022-09-20",25,[21,2030],[3810,3825,3826],"Naloxone","Loperamide Hydrochloride",{"trials":3828,"activeCount":103},[],{"trials":3830,"activeCount":103},[],{"trials":3832,"activeCount":103},[],{"trials":3834,"activeCount":103},[],{"intervention":3825,"totalTrials":121,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3838,"activeCount":103},[],{"trials":3840,"activeCount":121,"soonestReadout":3820},[3841],{"nctId":3817,"briefTitle":3818,"status":164,"phases":3842,"primaryCompletion":3820,"completion":3820,"start":3821,"enrollment":3822,"conditions":3843,"interventions":3844},[91],[21,2030],[3810,3825,3826],{"trials":3846,"activeCount":103},[],{"trials":3848,"activeCount":103},[],{"trials":3850,"activeCount":103},[],{"trials":3852,"activeCount":103},[],{"intervention":3826,"totalTrials":121,"cells":3854},{"EARLY_PHASE1":3855,"PHASE1":3857,"PHASE2":3863,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3856,"activeCount":103},[],{"trials":3858,"activeCount":121,"soonestReadout":3820},[3859],{"nctId":3817,"briefTitle":3818,"status":164,"phases":3860,"primaryCompletion":3820,"completion":3820,"start":3821,"enrollment":3822,"conditions":3861,"interventions":3862},[91],[21,2030],[3810,3825,3826],{"trials":3864,"activeCount":103},[],{"trials":3866,"activeCount":103},[],{"trials":3868,"activeCount":103},[],{"trials":3870,"activeCount":103},[],{"intervention":3872,"totalTrials":99,"cells":3873},"Sotagliflozin",{"EARLY_PHASE1":3874,"PHASE1":3884,"PHASE2":3886,"PHASE3":3888,"PHASE4":3890,"NA":3892},{"trials":3875,"activeCount":121,"soonestReadout":2590},[3876],{"nctId":3877,"briefTitle":3878,"status":129,"phases":3879,"primaryCompletion":2590,"completion":113,"start":3880,"enrollment":2565,"conditions":3881,"interventions":3883},"NCT06433050","Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy",[90],"2024-12-17",[3882],"Hypertrophic Cardiomyopathy Without Obstruction",[3872],{"trials":3885,"activeCount":103},[],{"trials":3887,"activeCount":103},[],{"trials":3889,"activeCount":103},[],{"trials":3891,"activeCount":103},[],{"trials":3893,"activeCount":121,"soonestReadout":1585},[3894],{"nctId":3895,"briefTitle":3896,"status":129,"phases":3897,"primaryCompletion":1585,"completion":1501,"start":3898,"enrollment":289,"conditions":3899,"interventions":3901},"NCT06510894","Diagnostic Utility of SGLT1\u002F2 Inhibition to Facilitate Myocardial Glucose Suppression",[],"2024-11-20",[3900],"Cardiac Sarcoidosis",[3872],{"intervention":3903,"totalTrials":121,"cells":3904},"Evolocumab",{"EARLY_PHASE1":3905,"PHASE1":3917,"PHASE2":3919,"PHASE3":3921,"PHASE4":3923,"NA":3925},{"trials":3906,"activeCount":121,"soonestReadout":3911},[3907],{"nctId":3908,"briefTitle":3909,"status":111,"phases":3910,"primaryCompletion":3911,"completion":3912,"start":755,"enrollment":3913,"conditions":3914,"interventions":3916},"NCT06081153","Mechanistic Clinical Trial of PCSK9 Inhibition for AAA",[90],"2029-01-15","2029-02-28",44,[3915],"Abdominal Aortic Aneurysm",[3903],{"trials":3918,"activeCount":103},[],{"trials":3920,"activeCount":103},[],{"trials":3922,"activeCount":103},[],{"trials":3924,"activeCount":103},[],{"trials":3926,"activeCount":103},[],{"intervention":3928,"totalTrials":121,"cells":3929},"18F-JSS20-183A PET",{"EARLY_PHASE1":3930,"PHASE1":3940,"PHASE2":3942,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3931,"activeCount":121,"soonestReadout":3936},[3932],{"nctId":3933,"briefTitle":3934,"status":129,"phases":3935,"primaryCompletion":3936,"completion":3936,"start":2962,"enrollment":1204,"conditions":3937,"interventions":3939},"NCT06932809","Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A",[90],"2030-04",[3938],"Tauopathies",[3928],{"trials":3941,"activeCount":103},[],{"trials":3943,"activeCount":103},[],{"trials":3945,"activeCount":103},[],{"trials":3947,"activeCount":103},[],{"trials":3949,"activeCount":103},[],{"intervention":3951,"totalTrials":121,"cells":3952},"11C-HY-2-15 PET",{"EARLY_PHASE1":3953,"PHASE1":3963,"PHASE2":3965,"PHASE3":3967,"PHASE4":3969,"NA":3971},{"trials":3954,"activeCount":121,"soonestReadout":436},[3955],{"nctId":3956,"briefTitle":3957,"status":129,"phases":3958,"primaryCompletion":436,"completion":436,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3962},"NCT06032026","Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15",[90],"2023-07-20",70,[3938],[3951],{"trials":3964,"activeCount":103},[],{"trials":3966,"activeCount":103},[],{"trials":3968,"activeCount":103},[],{"trials":3970,"activeCount":103},[],{"trials":3972,"activeCount":103},[],{"intervention":3974,"totalTrials":121,"cells":3975},"18F-PI-2620 PET\u002FCT",{"EARLY_PHASE1":3976,"PHASE1":3986,"PHASE2":3988,"PHASE3":3990,"PHASE4":3992,"NA":3994},{"trials":3977,"activeCount":121,"soonestReadout":699},[3978],{"nctId":3979,"briefTitle":3980,"status":164,"phases":3981,"primaryCompletion":699,"completion":699,"start":3982,"enrollment":2964,"conditions":3983,"interventions":3985},"NCT05651516","Tau PET Imaging in Opioid Use Disorder",[90],"2023-09-21",[3984],"Opioid-Related Disorders",[3974],{"trials":3987,"activeCount":103},[],{"trials":3989,"activeCount":103},[],{"trials":3991,"activeCount":103},[],{"trials":3993,"activeCount":103},[],{"trials":3995,"activeCount":103},[],{"intervention":3997,"totalTrials":121,"cells":3998},"11C-M503 PET",{"EARLY_PHASE1":3999,"PHASE1":4009,"PHASE2":4011,"PHASE3":4013,"PHASE4":4015,"NA":4017},{"trials":4000,"activeCount":121,"soonestReadout":4005},[4001],{"nctId":4002,"briefTitle":4003,"status":129,"phases":4004,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":3960,"conditions":4007,"interventions":4008},"NCT06303921","Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503",[90],"2029-02","2024-02-16",[3938],[3997],{"trials":4010,"activeCount":103},[],{"trials":4012,"activeCount":103},[],{"trials":4014,"activeCount":103},[],{"trials":4016,"activeCount":103},[],{"trials":4018,"activeCount":103},[],{"intervention":4020,"totalTrials":121,"cells":4021},"Tadekinig alfa",{"EARLY_PHASE1":4022,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4023,"activeCount":121,"soonestReadout":4028},[4024],{"nctId":4025,"briefTitle":4026,"status":129,"phases":4027,"primaryCompletion":4028,"completion":1912,"start":4029,"enrollment":2440,"conditions":4030,"interventions":4033},"NCT05306080","Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome",[90],"2028-01","2022-04-17",[4031,4032],"CRS - Cytokine Release Syndrome","HLH",[4020],{"trials":4035,"activeCount":103},[],{"trials":4037,"activeCount":103},[],{"trials":4039,"activeCount":103},[],{"trials":4041,"activeCount":103},[],{"trials":4043,"activeCount":103},[],{"intervention":83,"totalTrials":121,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4055,"PHASE2":4057,"PHASE3":4059,"PHASE4":4061,"NA":4063},{"trials":4047,"activeCount":121,"soonestReadout":82},[4048],{"nctId":80,"briefTitle":81,"status":164,"phases":4049,"primaryCompletion":82,"completion":4050,"start":4051,"enrollment":114,"conditions":4052,"interventions":4054},[90],"2026-06-01","2024-07-20",[4053,21],"Crohn Disease",[83],{"trials":4056,"activeCount":103},[],{"trials":4058,"activeCount":103},[],{"trials":4060,"activeCount":103},[],{"trials":4062,"activeCount":103},[],{"trials":4064,"activeCount":103},[],{"intervention":4066,"totalTrials":121,"cells":4067},"Aspirin 81 mg",{"EARLY_PHASE1":4068,"PHASE1":4078,"PHASE2":4080,"PHASE3":4082,"PHASE4":4084,"NA":4086},{"trials":4069,"activeCount":121,"soonestReadout":4028},[4070],{"nctId":4071,"briefTitle":4072,"status":111,"phases":4073,"primaryCompletion":4028,"completion":4074,"start":699,"enrollment":114,"conditions":4075,"interventions":4076},"NCT03590821","Timed Aspirin Chronobiome Study",[90],"2028-11",[21],[4066,4077],"Celecoxib 200mg",{"trials":4079,"activeCount":103},[],{"trials":4081,"activeCount":103},[],{"trials":4083,"activeCount":103},[],{"trials":4085,"activeCount":103},[],{"trials":4087,"activeCount":103},[],{"intervention":4077,"totalTrials":121,"cells":4089},{"EARLY_PHASE1":4090,"PHASE1":4096,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4091,"activeCount":121,"soonestReadout":4028},[4092],{"nctId":4071,"briefTitle":4072,"status":111,"phases":4093,"primaryCompletion":4028,"completion":4074,"start":699,"enrollment":114,"conditions":4094,"interventions":4095},[90],[21],[4066,4077],{"trials":4097,"activeCount":103},[],{"trials":4099,"activeCount":103},[],{"trials":4101,"activeCount":103},[],{"trials":4103,"activeCount":103},[],{"trials":4105,"activeCount":103},[],{"intervention":4107,"totalTrials":121,"cells":4108},"Stellate Ganglion Block",{"EARLY_PHASE1":4109,"PHASE1":4120,"PHASE2":4122,"PHASE3":4124,"PHASE4":4126,"NA":4128},{"trials":4110,"activeCount":121,"soonestReadout":4115},[4111],{"nctId":4112,"briefTitle":4113,"status":129,"phases":4114,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":329,"conditions":4117,"interventions":4119},"NCT05377216","Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation",[90],"2027-07-01","2022-09-01",[4118],"Ventricular Tachycardia",[4107],{"trials":4121,"activeCount":103},[],{"trials":4123,"activeCount":103},[],{"trials":4125,"activeCount":103},[],{"trials":4127,"activeCount":103},[],{"trials":4129,"activeCount":103},[],{"intervention":2585,"totalTrials":121,"cells":4131},{"EARLY_PHASE1":4132,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4133,"activeCount":121,"soonestReadout":1322},[4134],{"nctId":2578,"briefTitle":2579,"status":164,"phases":4135,"primaryCompletion":1322,"completion":1322,"start":2581,"enrollment":2582,"conditions":4136,"interventions":4137},[90],[948,2338],[2555,2585],{"trials":4139,"activeCount":103},[],{"trials":4141,"activeCount":103},[],{"trials":4143,"activeCount":103},[],{"trials":4145,"activeCount":103},[],{"trials":4147,"activeCount":103},[],{"intervention":4149,"totalTrials":121,"cells":4150},"Ketamine only",{"EARLY_PHASE1":4151,"PHASE1":4161,"PHASE2":4163,"PHASE3":4165,"PHASE4":4167,"NA":4169},{"trials":4152,"activeCount":121,"soonestReadout":2359},[4153],{"nctId":4154,"briefTitle":4155,"status":129,"phases":4156,"primaryCompletion":2359,"completion":2359,"start":4157,"enrollment":2440,"conditions":4158,"interventions":4160},"NCT06788249","Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine",[90],"2026-04-01",[4159],"Major Depressive Disorder (MDD)",[4149],{"trials":4162,"activeCount":103},[],{"trials":4164,"activeCount":103},[],{"trials":4166,"activeCount":103},[],{"trials":4168,"activeCount":103},[],{"trials":4170,"activeCount":103},[],{"intervention":4172,"totalTrials":121,"cells":4173},"Sodium Phenylbutyrate",{"EARLY_PHASE1":4174,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4189,"NA":4191},{"trials":4175,"activeCount":121,"soonestReadout":1712},[4176],{"nctId":4177,"briefTitle":4178,"status":111,"phases":4179,"primaryCompletion":1712,"completion":4180,"start":4050,"enrollment":1150,"conditions":4181,"interventions":4182},"NCT06645769","Na-Phenylbutyrate VAscular Trial",[90],"2029-06-01",[27],[4172],{"trials":4184,"activeCount":103},[],{"trials":4186,"activeCount":103},[],{"trials":4188,"activeCount":103},[],{"trials":4190,"activeCount":103},[],{"trials":4192,"activeCount":103},[],{"intervention":1268,"totalTrials":99,"cells":4194},{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4199,"PHASE3":4201,"PHASE4":4203,"NA":4209},{"trials":4196,"activeCount":103},[],{"trials":4198,"activeCount":103},[],{"trials":4200,"activeCount":103},[],{"trials":4202,"activeCount":103},[],{"trials":4204,"activeCount":103},[4205],{"nctId":1258,"briefTitle":1259,"status":150,"phases":4206,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":4207,"interventions":4208},[94],[1266],[1224,1268],{"trials":4210,"activeCount":121,"soonestReadout":1396},[4211],{"nctId":4212,"briefTitle":4213,"status":129,"phases":4214,"primaryCompletion":1396,"completion":1396,"start":4215,"enrollment":1376,"conditions":4216,"interventions":4219},"NCT07006896","Induction of Labor After Cesarean Using Foley Alone vs. Concurrent Foley and Oxytocin",[95],"2025-07-10",[4217,4218],"Labor Induction","Cesarean Delivery",[1268],{"intervention":4221,"totalTrials":121,"cells":4222},"64Cu-DOTA-ECL1i",{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4224,"activeCount":103},[],{"trials":4226,"activeCount":103},[],{"trials":4228,"activeCount":103},[],{"trials":4230,"activeCount":103},[],{"trials":4232,"activeCount":103},[],{"trials":4234,"activeCount":121,"soonestReadout":4239},[4235],{"nctId":4236,"briefTitle":4237,"status":129,"phases":4238,"primaryCompletion":4239,"completion":1624,"start":82,"enrollment":1150,"conditions":4240,"interventions":4241},"NCT07548099","Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET\u002FCT)",[],"2028-04-30",[3915],[4221],{"intervention":4243,"totalTrials":121,"cells":4244},"GLP-1",{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4246,"activeCount":103},[],{"trials":4248,"activeCount":103},[],{"trials":4250,"activeCount":103},[],{"trials":4252,"activeCount":103},[],{"trials":4254,"activeCount":103},[],{"trials":4256,"activeCount":121,"soonestReadout":698},[4257],{"nctId":4258,"briefTitle":4259,"status":129,"phases":4260,"primaryCompletion":698,"completion":698,"start":4261,"enrollment":4262,"conditions":4263,"interventions":4264},"NCT01851694","Beta-cell Response to Incretin Hormones in Cystic Fibrosis",[95],"2013-05",45,[2387,2388],[4243,4265],"GIP",{"intervention":4265,"totalTrials":121,"cells":4267},{"EARLY_PHASE1":4268,"PHASE1":4270,"PHASE2":4272,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4269,"activeCount":103},[],{"trials":4271,"activeCount":103},[],{"trials":4273,"activeCount":103},[],{"trials":4275,"activeCount":103},[],{"trials":4277,"activeCount":103},[],{"trials":4279,"activeCount":121,"soonestReadout":698},[4280],{"nctId":4258,"briefTitle":4259,"status":129,"phases":4281,"primaryCompletion":698,"completion":698,"start":4261,"enrollment":4262,"conditions":4282,"interventions":4283},[95],[2387,2388],[4243,4265],{"intervention":4285,"totalTrials":121,"cells":4286},"Imaging Drug FluorThanatrace",{"EARLY_PHASE1":4287,"PHASE1":4289,"PHASE2":4291,"PHASE3":4293,"PHASE4":4295,"NA":4297},{"trials":4288,"activeCount":103},[],{"trials":4290,"activeCount":103},[],{"trials":4292,"activeCount":103},[],{"trials":4294,"activeCount":103},[],{"trials":4296,"activeCount":103},[],{"trials":4298,"activeCount":121,"soonestReadout":4303},[4299],{"nctId":4300,"briefTitle":4301,"status":164,"phases":4302,"primaryCompletion":4303,"completion":4303,"start":1449,"enrollment":1587,"conditions":4304,"interventions":4305},"NCT03846167","Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET\u002FCT",[],"2027-02",[2894],[4285],{"intervention":4307,"totalTrials":121,"cells":4308},"AV-1451",{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4313,"PHASE3":4315,"PHASE4":4317,"NA":4319},{"trials":4310,"activeCount":103},[],{"trials":4312,"activeCount":103},[],{"trials":4314,"activeCount":103},[],{"trials":4316,"activeCount":103},[],{"trials":4318,"activeCount":103},[],{"trials":4320,"activeCount":121,"soonestReadout":699},[4321],{"nctId":4322,"briefTitle":4323,"status":129,"phases":4324,"primaryCompletion":699,"completion":733,"start":4325,"enrollment":1376,"conditions":4326,"interventions":4328},"NCT05658913","Tau PET\u002FCT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)",[],"2023-03-14",[4327],"Alzheimer's Disease",[4307],{"intervention":4330,"totalTrials":121,"cells":4331},"General anesthetic",{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4338,"PHASE4":4340,"NA":4342},{"trials":4333,"activeCount":103},[],{"trials":4335,"activeCount":103},[],{"trials":4337,"activeCount":103},[],{"trials":4339,"activeCount":103},[],{"trials":4341,"activeCount":103},[],{"trials":4343,"activeCount":121,"soonestReadout":2772},[4344],{"nctId":4345,"briefTitle":4346,"status":111,"phases":4347,"primaryCompletion":2772,"completion":2772,"start":463,"enrollment":4348,"conditions":4349,"interventions":4352},"NCT07334418","Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study",[95],600,[4350,4351],"Cesarean Section","Delivery; Trauma",[4330,4353],"Intravenous anesthetic",{"intervention":4353,"totalTrials":121,"cells":4355},{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4360,"PHASE3":4362,"PHASE4":4364,"NA":4366},{"trials":4357,"activeCount":103},[],{"trials":4359,"activeCount":103},[],{"trials":4361,"activeCount":103},[],{"trials":4363,"activeCount":103},[],{"trials":4365,"activeCount":103},[],{"trials":4367,"activeCount":121,"soonestReadout":2772},[4368],{"nctId":4345,"briefTitle":4346,"status":111,"phases":4369,"primaryCompletion":2772,"completion":2772,"start":463,"enrollment":4348,"conditions":4370,"interventions":4371},[95],[4350,4351],[4330,4353],{"intervention":4373,"totalTrials":121,"cells":4374},"[18F]AV-1451",{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4379,"PHASE3":4381,"PHASE4":4383,"NA":4385},{"trials":4376,"activeCount":103},[],{"trials":4378,"activeCount":103},[],{"trials":4380,"activeCount":103},[],{"trials":4382,"activeCount":103},[],{"trials":4384,"activeCount":103},[],{"trials":4386,"activeCount":121,"soonestReadout":1687},[4387],{"nctId":4388,"briefTitle":4389,"status":164,"phases":4390,"primaryCompletion":1687,"completion":1687,"start":4391,"enrollment":4392,"conditions":4393,"interventions":4395},"NCT05393388","Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study",[],"2022-07-06",111,[4394,948],"Cognitive Decline",[4373],{"intervention":4397,"totalTrials":121,"cells":4398},"Sodium-glucose cotransporter 2 inhibitors",{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4405,"PHASE4":4407,"NA":4409},{"trials":4400,"activeCount":103},[],{"trials":4402,"activeCount":103},[],{"trials":4404,"activeCount":103},[],{"trials":4406,"activeCount":103},[],{"trials":4408,"activeCount":103},[],{"trials":4410,"activeCount":121,"soonestReadout":4415},[4411],{"nctId":4412,"briefTitle":4413,"status":129,"phases":4414,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":4418,"conditions":4419,"interventions":4424},"NCT07444203","Transformative Research in Diabetic Nephropathy 2.0",[],"2027-05-30","2028-11-12","2025-11-12",200,[4420,4421,4422,4423],"Diabetic Nephropathies","Kidney Diseases","Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2",[4397,4425,4426,4427],"Renin-angiotensin-aldosterone system blockade","Glucagon-like peptide-1 receptor agonists","Mineralocorticoid Receptor Antagonists",{"intervention":4425,"totalTrials":121,"cells":4429},{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4434,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4431,"activeCount":103},[],{"trials":4433,"activeCount":103},[],{"trials":4435,"activeCount":103},[],{"trials":4437,"activeCount":103},[],{"trials":4439,"activeCount":103},[],{"trials":4441,"activeCount":121,"soonestReadout":4415},[4442],{"nctId":4412,"briefTitle":4413,"status":129,"phases":4443,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":4418,"conditions":4444,"interventions":4445},[],[4420,4421,4422,4423],[4397,4425,4426,4427],{"intervention":4426,"totalTrials":121,"cells":4447},{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4452,"PHASE3":4454,"PHASE4":4456,"NA":4458},{"trials":4449,"activeCount":103},[],{"trials":4451,"activeCount":103},[],{"trials":4453,"activeCount":103},[],{"trials":4455,"activeCount":103},[],{"trials":4457,"activeCount":103},[],{"trials":4459,"activeCount":121,"soonestReadout":4415},[4460],{"nctId":4412,"briefTitle":4413,"status":129,"phases":4461,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":4418,"conditions":4462,"interventions":4463},[],[4420,4421,4422,4423],[4397,4425,4426,4427],{"intervention":4427,"totalTrials":121,"cells":4465},{"EARLY_PHASE1":4466,"PHASE1":4468,"PHASE2":4470,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4467,"activeCount":103},[],{"trials":4469,"activeCount":103},[],{"trials":4471,"activeCount":103},[],{"trials":4473,"activeCount":103},[],{"trials":4475,"activeCount":103},[],{"trials":4477,"activeCount":121,"soonestReadout":4415},[4478],{"nctId":4412,"briefTitle":4413,"status":129,"phases":4479,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":4418,"conditions":4480,"interventions":4481},[],[4420,4421,4422,4423],[4397,4425,4426,4427],{"intervention":4483,"totalTrials":121,"cells":4484},"2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine",{"EARLY_PHASE1":4485,"PHASE1":4487,"PHASE2":4489,"PHASE3":4491,"PHASE4":4493,"NA":4495},{"trials":4486,"activeCount":103},[],{"trials":4488,"activeCount":103},[],{"trials":4490,"activeCount":103},[],{"trials":4492,"activeCount":103},[],{"trials":4494,"activeCount":103},[],{"trials":4496,"activeCount":121,"soonestReadout":2763},[4497],{"nctId":4498,"briefTitle":4499,"status":164,"phases":4500,"primaryCompletion":2763,"completion":2763,"start":1163,"enrollment":1869,"conditions":4501,"interventions":4503},"NCT04251130","Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI",[],[4502],"Mild Cognitive Impairment",[4483],{"intervention":68,"totalTrials":121,"cells":4505},{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4510,"PHASE3":4512,"PHASE4":4514,"NA":4516},{"trials":4507,"activeCount":103},[],{"trials":4509,"activeCount":103},[],{"trials":4511,"activeCount":103},[],{"trials":4513,"activeCount":103},[],{"trials":4515,"activeCount":103},[],{"trials":4517,"activeCount":121,"soonestReadout":67},[4518],{"nctId":65,"briefTitle":66,"status":164,"phases":4519,"primaryCompletion":67,"completion":4520,"start":4521,"enrollment":4522,"conditions":4523,"interventions":4526},[],"2026-05-31","2017-11-22",106,[4524,4525],"Normal Controls","MCI",[68],{"intervention":4528,"totalTrials":2592,"cells":4529},"Naltrexone",{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4556,"PHASE4":4575,"NA":4643},{"trials":4531,"activeCount":103},[],{"trials":4533,"activeCount":103},[],{"trials":4535,"activeCount":103},[4536,4546],{"nctId":4537,"briefTitle":4538,"status":150,"phases":4539,"primaryCompletion":1512,"completion":4540,"start":1514,"enrollment":4541,"conditions":4542,"interventions":4544},"NCT00142844","Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1",[92],"2008-01",208,[4543,673,1517],"Alcohol-Related Disorders",[4528,4545],"Disulfiram",{"nctId":4547,"briefTitle":4548,"status":150,"phases":4549,"primaryCompletion":4550,"completion":4550,"start":4551,"enrollment":4552,"conditions":4553,"interventions":4555},"NCT00270231","Effects of Naltrexone on Nicotine Reinforcement",[92],"2005-10","2004-03",64,[4554],"Tobacco Dependence",[4528],{"trials":4557,"activeCount":103},[4558,4568],{"nctId":4559,"briefTitle":4560,"status":150,"phases":4561,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":4566,"interventions":4567},"NCT00167232","Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence",[93],"2003-02","2003-07","1998-01",164,[973,673],[4528],{"nctId":4569,"briefTitle":4570,"status":150,"phases":4571,"primaryCompletion":1105,"completion":1105,"start":4572,"enrollment":4565,"conditions":4573,"interventions":4574},"NCT00218660","Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1",[93],"1998-04",[673,973],[4528],{"trials":4576,"activeCount":103},[4577,4587,4596,4606,4617,4625,4634],{"nctId":4578,"briefTitle":4579,"status":150,"phases":4580,"primaryCompletion":4581,"completion":4581,"start":4582,"enrollment":4583,"conditions":4584,"interventions":4586},"NCT00006489","Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)",[94],"2011-02","2000-12",165,[673,985,4585],"Post-Traumatic Stress Disorder",[4528],{"nctId":4588,"briefTitle":4589,"status":150,"phases":4590,"primaryCompletion":4591,"completion":4591,"start":4592,"enrollment":4593,"conditions":4594,"interventions":4595},"NCT00256451","Endophenotype for Alcohol Misuse in Healthy Minority Populations",[94],"2008-05","2005-11",43,[21],[4528],{"nctId":4597,"briefTitle":4598,"status":150,"phases":4599,"primaryCompletion":4600,"completion":4600,"start":4601,"enrollment":1325,"conditions":4602,"interventions":4605},"NCT02324725","Biomarkers of Injectable Extended Release Naltrexone Treatment",[94],"2021-12","2011-10",[4603,4604],"Heroin Dependence","Opioid Dependence",[4528],{"nctId":4607,"briefTitle":4608,"status":150,"phases":4609,"primaryCompletion":4610,"completion":1513,"start":4611,"enrollment":4612,"conditions":4613,"interventions":4614},"NCT00004554","Sertraline for Alcohol Dependence and Depression",[94],"2005-08","2000-01",171,[673,18],[4615,4616],"naltrexone","sertraline",{"nctId":4618,"briefTitle":4619,"status":150,"phases":4620,"primaryCompletion":4621,"completion":4622,"start":970,"enrollment":1470,"conditions":4623,"interventions":4624},"NCT00817089","Understanding Treatment Response With Naltrexone Among White Alcoholics",[94],"2010-04","2010-06",[673],[4528],{"nctId":4626,"briefTitle":4627,"status":150,"phases":4628,"primaryCompletion":4629,"completion":4630,"start":4631,"enrollment":238,"conditions":4632,"interventions":4633},"NCT00115037","Managing Alcoholism in People Who Do Not Respond to Naltrexone",[94],"2008-04","2008-07","2003-09",[673],[4528],{"nctId":4635,"briefTitle":4636,"status":150,"phases":4637,"primaryCompletion":4638,"completion":4638,"start":4639,"enrollment":1587,"conditions":4640,"interventions":4642},"NCT01052831","Naltrexone for Impulse Control Disorders in Parkinson's Disease",[94],"2012-12","2009-11",[4641,2594],"Impulse Control Disorder",[4528],{"trials":4644,"activeCount":103},[],{"intervention":4646,"totalTrials":1139,"cells":4647},"Atorvastatin",{"EARLY_PHASE1":4648,"PHASE1":4650,"PHASE2":4652,"PHASE3":4664,"PHASE4":4666,"NA":4683},{"trials":4649,"activeCount":103},[],{"trials":4651,"activeCount":103},[],{"trials":4653,"activeCount":103},[4654],{"nctId":4655,"briefTitle":4656,"status":150,"phases":4657,"primaryCompletion":4658,"completion":4658,"start":1014,"enrollment":3822,"conditions":4659,"interventions":4661},"NCT00728910","Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study",[92],"2009-08",[4660],"Dyslipidemia",[4646,4662,4663],"ABT335","ER Niacin",{"trials":4665,"activeCount":103},[],{"trials":4667,"activeCount":103},[4668,4677],{"nctId":4669,"briefTitle":4670,"status":150,"phases":4671,"primaryCompletion":4672,"completion":4672,"start":4673,"enrollment":1410,"conditions":4674,"interventions":4676},"NCT01263938","Modulation of Monocyte Activation by Atorvastatin in HIV Infection",[94],"2017-10","2011-09",[4675],"HIV Dementia",[4646],{"nctId":4678,"briefTitle":4679,"status":150,"phases":4680,"primaryCompletion":4672,"completion":4672,"start":1074,"enrollment":2592,"conditions":4681,"interventions":4682},"NCT01600170","Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)",[94],[4675],[4646],{"trials":4684,"activeCount":103},[],{"intervention":4686,"totalTrials":1139,"cells":4687},"Buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4692,"PHASE3":4709,"PHASE4":4719,"NA":4732},{"trials":4689,"activeCount":103},[],{"trials":4691,"activeCount":103},[],{"trials":4693,"activeCount":103},[4694],{"nctId":4695,"briefTitle":4696,"status":1357,"phases":4697,"primaryCompletion":4698,"completion":4698,"start":4699,"enrollment":735,"conditions":4700,"interventions":4707},"NCT04480554","Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1",[92],"2025-06-30","2023-01-30",[4701,4702,4703,4704,4705,2187,4528,4706],"Opioid-use Disorder","HIV-1-infection","Immune Activation","Inflammation","Methadone","Antiretroviral Treatment",[4705,4686,4708],"XR-Naltrexone",{"trials":4710,"activeCount":103},[4711],{"nctId":4712,"briefTitle":4713,"status":150,"phases":4714,"primaryCompletion":4715,"completion":4715,"start":4563,"enrollment":4716,"conditions":4717,"interventions":4718},"NCT00078130","Buprenorphine\u002FNaloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1",[93],"2006-01",223,[3984],[4686],{"trials":4720,"activeCount":103},[4721],{"nctId":4722,"briefTitle":4723,"status":150,"phases":4724,"primaryCompletion":167,"completion":4725,"start":4726,"enrollment":4727,"conditions":4728,"interventions":4730},"NCT03908437","Rapid Initiation of Drug Treatment Engagement",[94],"2023-06-30","2019-07-15",104,[4701,4729],"Overdose",[4731],"buprenorphine\u002Fnaloxone",{"trials":4733,"activeCount":103},[],{"intervention":4735,"totalTrials":99,"cells":4736},"Venlafaxine XR",{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4741,"PHASE3":4752,"PHASE4":4754,"NA":4765},{"trials":4738,"activeCount":103},[],{"trials":4740,"activeCount":103},[],{"trials":4742,"activeCount":103},[4743],{"nctId":4744,"briefTitle":4745,"status":150,"phases":4746,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":16,"conditions":4749,"interventions":4751},"NCT00620776","Combined Treatment for Generalized Anxiety Disorder (GAD)",[92],"2008-03","2006-10",[4750],"Generalized Anxiety Disorder",[4735],{"trials":4753,"activeCount":103},[],{"trials":4755,"activeCount":103},[4756],{"nctId":4757,"briefTitle":4758,"status":150,"phases":4759,"primaryCompletion":969,"completion":969,"start":4760,"enrollment":4761,"conditions":4762,"interventions":4764},"NCT00183274","Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR",[94],"2004-01",268,[4763],"Anxiety Disorders",[4735],{"trials":4766,"activeCount":103},[],{"intervention":4768,"totalTrials":99,"cells":4769},"Phentermine 15 MG",{"EARLY_PHASE1":4770,"PHASE1":4772,"PHASE2":4774,"PHASE3":4776,"PHASE4":4778,"NA":4796},{"trials":4771,"activeCount":103},[],{"trials":4773,"activeCount":103},[],{"trials":4775,"activeCount":103},[],{"trials":4777,"activeCount":103},[],{"trials":4779,"activeCount":103},[4780,4787],{"nctId":4781,"briefTitle":4782,"status":150,"phases":4783,"primaryCompletion":237,"completion":237,"start":4726,"enrollment":4784,"conditions":4785,"interventions":4786},"NCT03779048","Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment",[94],147,[15],[4768],{"nctId":4788,"briefTitle":4789,"status":150,"phases":4790,"primaryCompletion":4791,"completion":188,"start":4792,"enrollment":1869,"conditions":4793,"interventions":4794},"NCT02911818","Lifestyle Modification and Liraglutide",[94],"2018-11","2016-09",[15],[4795,4768],"Liraglutide 3.0mg",{"trials":4797,"activeCount":103},[],{"intervention":4799,"totalTrials":99,"cells":4800},"Venlafaxine",{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4805,"PHASE3":4807,"PHASE4":4819,"NA":4831},{"trials":4802,"activeCount":103},[],{"trials":4804,"activeCount":103},[],{"trials":4806,"activeCount":103},[],{"trials":4808,"activeCount":103},[4809],{"nctId":4810,"briefTitle":4811,"status":150,"phases":4812,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":994,"conditions":4815,"interventions":4816},"NCT00043550","Treatments for Depression: Drug Versus Psychotherapy",[93],"2009-06","2001-11",[18],[4817,4818,4799],"Sertraline","Pill Placebo",{"trials":4820,"activeCount":103},[4821],{"nctId":4822,"briefTitle":4823,"status":150,"phases":4824,"primaryCompletion":4825,"completion":4825,"start":970,"enrollment":4826,"conditions":4827,"interventions":4829},"NCT00602537","Antidepressant Therapy in Treating Bipolar Type II Major Depression",[94],"2013-06",140,[4828,18],"Bipolar Disorder",[4799,4830],"Lithium Carbonate",{"trials":4832,"activeCount":103},[],{"intervention":4834,"totalTrials":99,"cells":4835},"Escitalopram",{"EARLY_PHASE1":4836,"PHASE1":4838,"PHASE2":4840,"PHASE3":4842,"PHASE4":4844,"NA":4865},{"trials":4837,"activeCount":103},[],{"trials":4839,"activeCount":103},[],{"trials":4841,"activeCount":103},[],{"trials":4843,"activeCount":103},[],{"trials":4845,"activeCount":103},[4846,4856],{"nctId":4847,"briefTitle":4848,"status":150,"phases":4849,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":1264,"conditions":4852,"interventions":4855},"NCT02620150","SSRI Effects on Depression and Immunity in HIV\u002FAIDS",[94],"2022-03-31","2017-02-16",[18,4853,4854],"HIV","AIDS",[4834],{"nctId":4857,"briefTitle":4858,"status":1357,"phases":4859,"primaryCompletion":4860,"completion":4860,"start":723,"enrollment":2592,"conditions":4861,"interventions":4863},"NCT00523705","Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study",[94],"2009-10",[4862],"PMS",[4864],"escitalopram",{"trials":4866,"activeCount":103},[],{"intervention":4868,"totalTrials":99,"cells":4869},"Liposomal bupivacaine",{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4874,"PHASE3":4876,"PHASE4":4889,"NA":4902},{"trials":4871,"activeCount":103},[],{"trials":4873,"activeCount":103},[],{"trials":4875,"activeCount":103},[],{"trials":4877,"activeCount":103},[4878],{"nctId":4879,"briefTitle":4880,"status":4881,"phases":4882,"primaryCompletion":4883,"completion":4883,"start":4884,"enrollment":103,"conditions":4885,"interventions":4887},"NCT04461028","Liposomal Bupivacaine in Shoulder Arthroscopy","WITHDRAWN",[93],"2022-06-27","2019-02-21",[4886],"Rotator Cuff Tears",[4868,4888],"Bupivacaine with Dexamethasone Solution",{"trials":4890,"activeCount":103},[4891],{"nctId":4892,"briefTitle":4893,"status":1357,"phases":4894,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":2592,"conditions":4897,"interventions":4899},"NCT04749797","Cranial Blocks for Postoperative Anesthesia",[94],"2021-07-20","2020-09-02",[4898],"Craniotomy Surgery",[4868,4900,4901],"Bupivacaine","Saline",{"trials":4903,"activeCount":103},[],{"intervention":4905,"totalTrials":99,"cells":4906},"Mycophenolate mofetil",{"EARLY_PHASE1":4907,"PHASE1":4909,"PHASE2":4911,"PHASE3":4913,"PHASE4":4915,"NA":4938},{"trials":4908,"activeCount":103},[],{"trials":4910,"activeCount":103},[],{"trials":4912,"activeCount":103},[],{"trials":4914,"activeCount":103},[],{"trials":4916,"activeCount":103},[4917,4929],{"nctId":4918,"briefTitle":4919,"status":1357,"phases":4920,"primaryCompletion":4921,"completion":4921,"start":4550,"enrollment":2695,"conditions":4922,"interventions":4924},"NCT00596947","Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant",[94],"2009-03",[4923],"Transplants and Implants",[4925,4926,4927,4928,4905,4905],"prednisone","rabbit antithymocyte globulin","Tacrolimus","Prednisone",{"nctId":4930,"briefTitle":4931,"status":1357,"phases":4932,"primaryCompletion":4933,"completion":4933,"start":4934,"enrollment":971,"conditions":4935,"interventions":4936},"NCT00522548","Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients",[94],"2011-01","2007-03",[4923],[4937,4905],"Enteric coated mycophenolate sodium",{"trials":4939,"activeCount":103},[],{"intervention":4941,"totalTrials":99,"cells":4942},"Ranolazine",{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4947,"PHASE3":4949,"PHASE4":4951,"NA":4968},{"trials":4944,"activeCount":103},[],{"trials":4946,"activeCount":103},[],{"trials":4948,"activeCount":103},[],{"trials":4950,"activeCount":103},[],{"trials":4952,"activeCount":103},[4953,4961],{"nctId":4954,"briefTitle":4955,"status":150,"phases":4956,"primaryCompletion":4957,"completion":991,"start":4958,"enrollment":34,"conditions":4959,"interventions":4960},"NCT02829034","Targeting Right Ventricle in Pulmonary Hypertension Gilead",[94],"2017-12","2016-07",[2227],[4941],{"nctId":4962,"briefTitle":4963,"status":150,"phases":4964,"primaryCompletion":991,"completion":991,"start":4965,"enrollment":34,"conditions":4966,"interventions":4967},"NCT01839110","Targeting the Right Ventricle in Pulmonary Hypertension",[94],"2013-07",[2227],[4941],{"trials":4969,"activeCount":103},[],{"intervention":4971,"totalTrials":99,"cells":4972},"Vigabatrin",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4977,"PHASE3":4985,"PHASE4":4987,"NA":4998},{"trials":4974,"activeCount":103},[],{"trials":4976,"activeCount":103},[],{"trials":4978,"activeCount":103},[4979],{"nctId":4980,"briefTitle":4981,"status":1357,"phases":4982,"primaryCompletion":1303,"completion":981,"start":1003,"enrollment":1325,"conditions":4983,"interventions":4984},"NCT01335867","Vigabatrin for Cocaine and Alcohol Dependence",[92],[673,973],[4971],{"trials":4986,"activeCount":103},[],{"trials":4988,"activeCount":103},[4989],{"nctId":4990,"briefTitle":4991,"status":1357,"phases":4992,"primaryCompletion":1359,"completion":981,"start":4993,"enrollment":121,"conditions":4994,"interventions":4996},"NCT01266291","Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients",[94],"2010-08",[4995],"Complex Partial Seizures",[4997],"vigabatrin",{"trials":4999,"activeCount":103},[],{"intervention":5001,"totalTrials":121,"cells":5002},"follitropin beta",{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5007,"PHASE3":5009,"PHASE4":5011,"NA":5023},{"trials":5004,"activeCount":103},[],{"trials":5006,"activeCount":103},[],{"trials":5008,"activeCount":103},[],{"trials":5010,"activeCount":103},[],{"trials":5012,"activeCount":103},[5013],{"nctId":5014,"briefTitle":5015,"status":150,"phases":5016,"primaryCompletion":5017,"completion":1014,"start":5018,"enrollment":329,"conditions":5019,"interventions":5021},"NCT00225433","Luteal Phase FSH in the IVF Poor Responder",[94],"2006-12","2005-09",[5020],"Infertility",[5001,5022],"ganirelix acetate",{"trials":5024,"activeCount":103},[],{"intervention":5022,"totalTrials":121,"cells":5026},{"EARLY_PHASE1":5027,"PHASE1":5029,"PHASE2":5031,"PHASE3":5033,"PHASE4":5035,"NA":5041},{"trials":5028,"activeCount":103},[],{"trials":5030,"activeCount":103},[],{"trials":5032,"activeCount":103},[],{"trials":5034,"activeCount":103},[],{"trials":5036,"activeCount":103},[5037],{"nctId":5014,"briefTitle":5015,"status":150,"phases":5038,"primaryCompletion":5017,"completion":1014,"start":5018,"enrollment":329,"conditions":5039,"interventions":5040},[94],[5020],[5001,5022],{"trials":5042,"activeCount":103},[],{"intervention":5044,"totalTrials":121,"cells":5045},"Ustekinumab",{"EARLY_PHASE1":5046,"PHASE1":5048,"PHASE2":5050,"PHASE3":5052,"PHASE4":5054,"NA":5064},{"trials":5047,"activeCount":103},[],{"trials":5049,"activeCount":103},[],{"trials":5051,"activeCount":103},[],{"trials":5053,"activeCount":103},[],{"trials":5055,"activeCount":103},[5056],{"nctId":5057,"briefTitle":5058,"status":150,"phases":5059,"primaryCompletion":5060,"completion":5060,"start":5061,"enrollment":4593,"conditions":5062,"interventions":5063},"NCT02187172","Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)",[94],"2018-09-11","2014-07",[1296,1297],[5044],{"trials":5065,"activeCount":103},[],{"intervention":5067,"totalTrials":121,"cells":5068},"Miconazole nitrate",{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5075,"PHASE4":5077,"NA":5089},{"trials":5070,"activeCount":103},[],{"trials":5072,"activeCount":103},[],{"trials":5074,"activeCount":103},[],{"trials":5076,"activeCount":103},[],{"trials":5078,"activeCount":103},[5079],{"nctId":5080,"briefTitle":5081,"status":150,"phases":5082,"completion":5083,"start":5084,"enrollment":2964,"conditions":5085,"interventions":5088},"NCT00194324","Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina",[94],"2004-10","2004-07",[5086,5087],"Health","Vulvovaginal Candidiasis",[5067],{"trials":5090,"activeCount":103},[],{"intervention":5092,"totalTrials":121,"cells":5093},"Timing of prophylactic antibiotic administration",{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5111},{"trials":5095,"activeCount":103},[],{"trials":5097,"activeCount":103},[],{"trials":5099,"activeCount":103},[],{"trials":5101,"activeCount":103},[],{"trials":5103,"activeCount":103},[5104],{"nctId":5105,"briefTitle":5106,"status":1357,"phases":5107,"primaryCompletion":5108,"completion":5108,"start":5084,"conditions":5109,"interventions":5110},"NCT00133029","The Timing of Prophylactic Antibiotics in Cesarean Section and the Risk of Post-operative Febrile Morbidity",[94],"2006-07",[4350],[5092],{"trials":5112,"activeCount":103},[],{"intervention":5114,"totalTrials":121,"cells":5115},"Solriamfetol 75 MG",{"EARLY_PHASE1":5116,"PHASE1":5118,"PHASE2":5120,"PHASE3":5122,"PHASE4":5124,"NA":5135},{"trials":5117,"activeCount":103},[],{"trials":5119,"activeCount":103},[],{"trials":5121,"activeCount":103},[],{"trials":5123,"activeCount":103},[],{"trials":5125,"activeCount":103},[5126],{"nctId":5127,"briefTitle":5128,"status":150,"phases":5129,"primaryCompletion":5130,"completion":82,"start":5131,"enrollment":5132,"conditions":5133,"interventions":5134},"NCT05838430","Solriamfetol and CBT-I in Patients With Insomnia Disorder",[94],"2026-01-31","2023-07-31",115,[466],[5114],{"trials":5136,"activeCount":103},[],{"intervention":5138,"totalTrials":121,"cells":5139},"OxyCODONE 5 Mg Oral",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5146,"PHASE4":5148,"NA":5160},{"trials":5141,"activeCount":103},[],{"trials":5143,"activeCount":103},[],{"trials":5145,"activeCount":103},[],{"trials":5147,"activeCount":103},[],{"trials":5149,"activeCount":103},[5150],{"nctId":5151,"briefTitle":5152,"status":150,"phases":5153,"primaryCompletion":5154,"completion":5154,"start":5155,"enrollment":3960,"conditions":5156,"interventions":5158},"NCT03545893","Overnight Pain Treatment Investigating Opioids vs. Nonopioids",[94],"2019-02-07","2018-06-19",[5157],"Abortion Second Trimester",[5159,5138],"Ibuprofen 600 mg",{"trials":5161,"activeCount":103},[],{"intervention":5163,"totalTrials":121,"cells":5164},"Zolpidem tartrate",{"EARLY_PHASE1":5165,"PHASE1":5167,"PHASE2":5169,"PHASE3":5171,"PHASE4":5173,"NA":5185},{"trials":5166,"activeCount":103},[],{"trials":5168,"activeCount":103},[],{"trials":5170,"activeCount":103},[],{"trials":5172,"activeCount":103},[],{"trials":5174,"activeCount":103},[5175],{"nctId":5176,"briefTitle":5177,"status":150,"phases":5178,"primaryCompletion":5179,"completion":5179,"start":5180,"enrollment":5181,"conditions":5182,"interventions":5184},"NCT03774810","Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia",[94],"2024-09-30","2019-04-15",197,[466,5183],"Insomnia Chronic",[5163],{"trials":5186,"activeCount":103},[],{"intervention":5188,"totalTrials":121,"cells":5189},"Apremilast",{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5194,"PHASE3":5196,"PHASE4":5198,"NA":5209},{"trials":5191,"activeCount":103},[],{"trials":5193,"activeCount":103},[],{"trials":5195,"activeCount":103},[],{"trials":5197,"activeCount":103},[],{"trials":5199,"activeCount":103},[5200],{"nctId":5201,"briefTitle":5202,"status":150,"phases":5203,"primaryCompletion":5204,"completion":5204,"start":5205,"enrollment":3960,"conditions":5206,"interventions":5208},"NCT03082729","Vascular Inflammation in Psoriasis - Apremilast",[94],"2021-08-17","2017-04-24",[1296,5207],"Cardiovascular Diseases",[5188],{"trials":5210,"activeCount":103},[],{"intervention":5212,"totalTrials":121,"cells":5213},"Restylane-L®",{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5222,"NA":5237},{"trials":5215,"activeCount":103},[],{"trials":5217,"activeCount":103},[],{"trials":5219,"activeCount":103},[],{"trials":5221,"activeCount":103},[],{"trials":5223,"activeCount":103},[5224],{"nctId":5225,"briefTitle":5226,"status":150,"phases":5227,"primaryCompletion":5228,"completion":5229,"start":5230,"enrollment":5231,"conditions":5232,"interventions":5234},"NCT03460158","Prospective Evaluation of Facial Cosmetic Procedures",[94],"2024-02-28","2024-05-29","2020-08-21",101,[5233],"Cosmetic Techniques",[5212,5235,5236],"Restylane-L® Lyft","Restylane Silk®",{"trials":5238,"activeCount":103},[],{"intervention":5235,"totalTrials":121,"cells":5240},{"EARLY_PHASE1":5241,"PHASE1":5243,"PHASE2":5245,"PHASE3":5247,"PHASE4":5249,"NA":5255},{"trials":5242,"activeCount":103},[],{"trials":5244,"activeCount":103},[],{"trials":5246,"activeCount":103},[],{"trials":5248,"activeCount":103},[],{"trials":5250,"activeCount":103},[5251],{"nctId":5225,"briefTitle":5226,"status":150,"phases":5252,"primaryCompletion":5228,"completion":5229,"start":5230,"enrollment":5231,"conditions":5253,"interventions":5254},[94],[5233],[5212,5235,5236],{"trials":5256,"activeCount":103},[],{"intervention":5236,"totalTrials":121,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5267,"NA":5273},{"trials":5260,"activeCount":103},[],{"trials":5262,"activeCount":103},[],{"trials":5264,"activeCount":103},[],{"trials":5266,"activeCount":103},[],{"trials":5268,"activeCount":103},[5269],{"nctId":5225,"briefTitle":5226,"status":150,"phases":5270,"primaryCompletion":5228,"completion":5229,"start":5230,"enrollment":5231,"conditions":5271,"interventions":5272},[94],[5233],[5212,5235,5236],{"trials":5274,"activeCount":103},[],{"intervention":5276,"totalTrials":121,"cells":5277},"Oritavancin",{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5284,"PHASE4":5286,"NA":5298},{"trials":5279,"activeCount":103},[],{"trials":5281,"activeCount":103},[],{"trials":5283,"activeCount":103},[],{"trials":5285,"activeCount":103},[],{"trials":5287,"activeCount":103},[5288],{"nctId":5289,"briefTitle":5290,"status":4881,"phases":5291,"primaryCompletion":5292,"completion":5292,"start":5293,"enrollment":103,"conditions":5294,"interventions":5297},"NCT03761953","Oritavancin for Staphylococcus Aureus Infections in Opioid Users",[94],"2022-03-24","2019-07-01",[5295,5296],"Staphylococcus Aureus Bacteremia","Staphylococcus Aureus Endocarditis",[5276],{"trials":5299,"activeCount":103},[],{"intervention":5301,"totalTrials":121,"cells":5302},"Elbasvir 50 MG \u002F Grazoprevir 100 MG [Zepatier]",{"EARLY_PHASE1":5303,"PHASE1":5305,"PHASE2":5307,"PHASE3":5309,"PHASE4":5311,"NA":5325},{"trials":5304,"activeCount":103},[],{"trials":5306,"activeCount":103},[],{"trials":5308,"activeCount":103},[],{"trials":5310,"activeCount":103},[],{"trials":5312,"activeCount":103},[5313],{"nctId":5314,"briefTitle":5315,"status":150,"phases":5316,"primaryCompletion":5317,"completion":5318,"start":5319,"enrollment":2399,"conditions":5320,"interventions":5324},"NCT03365635","Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C",[94],"2020-05-01","2020-09-01","2019-09-22",[5321,5322,5323],"Hepatitis C","Hemodialysis","Nosocomial Infection",[5301],{"trials":5326,"activeCount":103},[],{"intervention":5328,"totalTrials":121,"cells":5329},"H1N1 vaccination",{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5336,"PHASE4":5338,"NA":5348},{"trials":5331,"activeCount":103},[],{"trials":5333,"activeCount":103},[],{"trials":5335,"activeCount":103},[],{"trials":5337,"activeCount":103},[],{"trials":5339,"activeCount":103},[5340],{"nctId":5341,"briefTitle":5342,"status":150,"phases":5343,"primaryCompletion":1012,"completion":1063,"start":5344,"enrollment":5345,"conditions":5346,"interventions":5347},"NCT01111162","H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients",[94],"2009-12",120,[2567],[5328],{"trials":5349,"activeCount":103},[],{"intervention":5351,"totalTrials":121,"cells":5352},"Benzocaine",{"EARLY_PHASE1":5353,"PHASE1":5355,"PHASE2":5357,"PHASE3":5359,"PHASE4":5361,"NA":5373},{"trials":5354,"activeCount":103},[],{"trials":5356,"activeCount":103},[],{"trials":5358,"activeCount":103},[],{"trials":5360,"activeCount":103},[],{"trials":5362,"activeCount":103},[5363],{"nctId":5364,"briefTitle":5365,"status":150,"phases":5366,"primaryCompletion":5367,"completion":5367,"start":1013,"enrollment":1150,"conditions":5368,"interventions":5371},"NCT01925469","Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram",[94],"2012-04",[5369,5370],"Pain Relief","Analgesia",[5351,5372],"Saline spray",{"trials":5374,"activeCount":103},[],{"intervention":5372,"totalTrials":121,"cells":5376},{"EARLY_PHASE1":5377,"PHASE1":5379,"PHASE2":5381,"PHASE3":5383,"PHASE4":5385,"NA":5391},{"trials":5378,"activeCount":103},[],{"trials":5380,"activeCount":103},[],{"trials":5382,"activeCount":103},[],{"trials":5384,"activeCount":103},[],{"trials":5386,"activeCount":103},[5387],{"nctId":5364,"briefTitle":5365,"status":150,"phases":5388,"primaryCompletion":5367,"completion":5367,"start":1013,"enrollment":1150,"conditions":5389,"interventions":5390},[94],[5369,5370],[5351,5372],{"trials":5392,"activeCount":103},[],{"intervention":5394,"totalTrials":121,"cells":5395},"Varenicline Nasal Spray",{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5400,"PHASE3":5402,"PHASE4":5404,"NA":5416},{"trials":5397,"activeCount":103},[],{"trials":5399,"activeCount":103},[],{"trials":5401,"activeCount":103},[],{"trials":5403,"activeCount":103},[],{"trials":5405,"activeCount":103},[5406],{"nctId":5407,"briefTitle":5408,"status":150,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":5411,"enrollment":1626,"conditions":5412,"interventions":5415},"NCT05700422","Nasal Spray Study in Sjogren's Dry Eye Disease",[94],"2023-08-31","2023-05-01",[5413,5414],"Sjogren's Syndrome","Dry Eye",[5394],{"trials":5417,"activeCount":103},[],{"intervention":4830,"totalTrials":121,"cells":5419},{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5424,"PHASE3":5426,"PHASE4":5428,"NA":5434},{"trials":5421,"activeCount":103},[],{"trials":5423,"activeCount":103},[],{"trials":5425,"activeCount":103},[],{"trials":5427,"activeCount":103},[],{"trials":5429,"activeCount":103},[5430],{"nctId":4822,"briefTitle":4823,"status":150,"phases":5431,"primaryCompletion":4825,"completion":4825,"start":970,"enrollment":4826,"conditions":5432,"interventions":5433},[94],[4828,18],[4799,4830],{"trials":5435,"activeCount":103},[],{"intervention":5437,"totalTrials":121,"cells":5438},"Exelon Patch",{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5443,"PHASE3":5445,"PHASE4":5447,"NA":5457},{"trials":5440,"activeCount":103},[],{"trials":5442,"activeCount":103},[],{"trials":5444,"activeCount":103},[],{"trials":5446,"activeCount":103},[],{"trials":5448,"activeCount":103},[5449],{"nctId":5450,"briefTitle":5451,"status":150,"phases":5452,"primaryCompletion":5453,"completion":5453,"start":1013,"enrollment":28,"conditions":5454,"interventions":5456},"NCT01519271","Mild Cognitive Impairment in Parkinson's Disease",[94],"2014-06",[5455,4502],"Parkinson's Disease",[5437],{"trials":5458,"activeCount":103},[],{"intervention":5460,"totalTrials":121,"cells":5461},"Indomethacin",{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5468,"PHASE4":5470,"NA":5480},{"trials":5463,"activeCount":103},[],{"trials":5465,"activeCount":103},[],{"trials":5467,"activeCount":103},[],{"trials":5469,"activeCount":103},[],{"trials":5471,"activeCount":103},[5472],{"nctId":5473,"briefTitle":5474,"status":1357,"phases":5475,"primaryCompletion":1513,"completion":1513,"start":4562,"conditions":5476,"interventions":5478},"NCT00116623","Magnesium Sulfate Versus Indomethacin for Preterm Labor",[94],[5477],"Labor, Premature",[5460,5479],"Magnesium sulfate",{"trials":5481,"activeCount":103},[],{"intervention":5479,"totalTrials":121,"cells":5483},{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5498},{"trials":5485,"activeCount":103},[],{"trials":5487,"activeCount":103},[],{"trials":5489,"activeCount":103},[],{"trials":5491,"activeCount":103},[],{"trials":5493,"activeCount":103},[5494],{"nctId":5473,"briefTitle":5474,"status":1357,"phases":5495,"primaryCompletion":1513,"completion":1513,"start":4562,"conditions":5496,"interventions":5497},[94],[5477],[5460,5479],{"trials":5499,"activeCount":103},[],{"intervention":5501,"totalTrials":121,"cells":5502},"Vedolizumab",{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5507,"PHASE3":5509,"PHASE4":5511,"NA":5522},{"trials":5504,"activeCount":103},[],{"trials":5506,"activeCount":103},[],{"trials":5508,"activeCount":103},[],{"trials":5510,"activeCount":103},[],{"trials":5512,"activeCount":103},[5513],{"nctId":5514,"briefTitle":5515,"status":4881,"phases":5516,"primaryCompletion":5517,"completion":5517,"start":5518,"enrollment":103,"conditions":5519,"interventions":5521},"NCT03237260","An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis",[94],"2019-02-01","2017-07-01",[5520],"Ulcerative Colitis",[5501],{"trials":5523,"activeCount":103},[],{"intervention":5525,"totalTrials":121,"cells":5526},"Semaglutide 2.4 MG\u002F0.75 ML Subcutaneous Solution [WEGOVY]",{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5531,"PHASE3":5533,"PHASE4":5535,"NA":5545},{"trials":5528,"activeCount":103},[],{"trials":5530,"activeCount":103},[],{"trials":5532,"activeCount":103},[],{"trials":5534,"activeCount":103},[],{"trials":5536,"activeCount":103},[5537],{"nctId":5538,"briefTitle":5539,"status":150,"phases":5540,"primaryCompletion":5541,"completion":5541,"start":5542,"enrollment":5345,"conditions":5543,"interventions":5544},"NCT05548647","Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects",[94],"2025-05-12","2022-07-26",[15],[5525],{"trials":5546,"activeCount":103},[],{"intervention":5548,"totalTrials":121,"cells":5549},"Acetaminophen\u002FIbuprofen",{"EARLY_PHASE1":5550,"PHASE1":5552,"PHASE2":5554,"PHASE3":5556,"PHASE4":5558,"NA":5570},{"trials":5551,"activeCount":103},[],{"trials":5553,"activeCount":103},[],{"trials":5555,"activeCount":103},[],{"trials":5557,"activeCount":103},[],{"trials":5559,"activeCount":103},[5560],{"nctId":5561,"briefTitle":5562,"status":150,"phases":5563,"primaryCompletion":5564,"completion":5564,"start":1030,"enrollment":5565,"conditions":5566,"interventions":5568},"NCT02647788","Acetaminophen\u002FCodeine vs Acetaminophen\u002FIbuprofen for Pain Control and Patient Satisfaction After Hand Surgery",[94],"2018-01-19",144,[5567],"Pain, Postoperative",[5548,5569],"Acetaminophen\u002FCodeine",{"trials":5571,"activeCount":103},[],{"intervention":5569,"totalTrials":121,"cells":5573},{"EARLY_PHASE1":5574,"PHASE1":5576,"PHASE2":5578,"PHASE3":5580,"PHASE4":5582,"NA":5588},{"trials":5575,"activeCount":103},[],{"trials":5577,"activeCount":103},[],{"trials":5579,"activeCount":103},[],{"trials":5581,"activeCount":103},[],{"trials":5583,"activeCount":103},[5584],{"nctId":5561,"briefTitle":5562,"status":150,"phases":5585,"primaryCompletion":5564,"completion":5564,"start":1030,"enrollment":5565,"conditions":5586,"interventions":5587},[94],[5567],[5548,5569],{"trials":5589,"activeCount":103},[],{"intervention":5591,"totalTrials":121,"cells":5592},"Secukinumab Auto-Injector",{"EARLY_PHASE1":5593,"PHASE1":5595,"PHASE2":5597,"PHASE3":5599,"PHASE4":5601,"NA":5611},{"trials":5594,"activeCount":103},[],{"trials":5596,"activeCount":103},[],{"trials":5598,"activeCount":103},[],{"trials":5600,"activeCount":103},[],{"trials":5602,"activeCount":103},[5603],{"nctId":5604,"briefTitle":5605,"status":150,"phases":5606,"primaryCompletion":5607,"completion":5607,"start":5608,"enrollment":3729,"conditions":5609,"interventions":5610},"NCT04535999","Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)",[94],"2025-05-30","2022-02-07",[1296],[5591],{"trials":5612,"activeCount":103},[],{"intervention":5614,"totalTrials":121,"cells":5615},"Iron oxide nanoparticles treatment Ferumoxytol\u002FH2O2",{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5622,"PHASE4":5624,"NA":5638},{"trials":5617,"activeCount":103},[],{"trials":5619,"activeCount":103},[],{"trials":5621,"activeCount":103},[],{"trials":5623,"activeCount":103},[],{"trials":5625,"activeCount":103},[5626],{"nctId":5627,"briefTitle":5628,"status":150,"phases":5629,"primaryCompletion":5630,"completion":5630,"start":5631,"enrollment":3913,"conditions":5632,"interventions":5634},"NCT06110494","A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment",[94],"2022-03-10","2020-07-13",[626,5633],"Pulp Disease, Dental",[5614,5635,5636,5637],"NaOCl","NaCl","supplementary irrigation",{"trials":5639,"activeCount":103},[],{"intervention":5635,"totalTrials":121,"cells":5641},{"EARLY_PHASE1":5642,"PHASE1":5644,"PHASE2":5646,"PHASE3":5648,"PHASE4":5650,"NA":5656},{"trials":5643,"activeCount":103},[],{"trials":5645,"activeCount":103},[],{"trials":5647,"activeCount":103},[],{"trials":5649,"activeCount":103},[],{"trials":5651,"activeCount":103},[5652],{"nctId":5627,"briefTitle":5628,"status":150,"phases":5653,"primaryCompletion":5630,"completion":5630,"start":5631,"enrollment":3913,"conditions":5654,"interventions":5655},[94],[626,5633],[5614,5635,5636,5637],{"trials":5657,"activeCount":103},[],{"intervention":5636,"totalTrials":121,"cells":5659},{"EARLY_PHASE1":5660,"PHASE1":5662,"PHASE2":5664,"PHASE3":5666,"PHASE4":5668,"NA":5674},{"trials":5661,"activeCount":103},[],{"trials":5663,"activeCount":103},[],{"trials":5665,"activeCount":103},[],{"trials":5667,"activeCount":103},[],{"trials":5669,"activeCount":103},[5670],{"nctId":5627,"briefTitle":5628,"status":150,"phases":5671,"primaryCompletion":5630,"completion":5630,"start":5631,"enrollment":3913,"conditions":5672,"interventions":5673},[94],[626,5633],[5614,5635,5636,5637],{"trials":5675,"activeCount":103},[],{"intervention":5637,"totalTrials":121,"cells":5677},{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5682,"PHASE3":5684,"PHASE4":5686,"NA":5692},{"trials":5679,"activeCount":103},[],{"trials":5681,"activeCount":103},[],{"trials":5683,"activeCount":103},[],{"trials":5685,"activeCount":103},[],{"trials":5687,"activeCount":103},[5688],{"nctId":5627,"briefTitle":5628,"status":150,"phases":5689,"primaryCompletion":5630,"completion":5630,"start":5631,"enrollment":3913,"conditions":5690,"interventions":5691},[94],[626,5633],[5614,5635,5636,5637],{"trials":5693,"activeCount":103},[],{"intervention":5695,"totalTrials":121,"cells":5696},"Nicoderm Transdermal Patch",{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5718},{"trials":5698,"activeCount":103},[],{"trials":5700,"activeCount":103},[],{"trials":5702,"activeCount":103},[],{"trials":5704,"activeCount":103},[],{"trials":5706,"activeCount":103},[5707],{"nctId":5708,"briefTitle":5709,"status":150,"phases":5710,"primaryCompletion":5711,"completion":5711,"start":5712,"enrollment":5713,"conditions":5714,"interventions":5716},"NCT00326781","Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)",[94],"2004-08","1999-12",674,[5715],"Smoking",[5695,5717],"Nicotine Nasal Spray",{"trials":5719,"activeCount":103},[],{"intervention":5717,"totalTrials":121,"cells":5721},{"EARLY_PHASE1":5722,"PHASE1":5724,"PHASE2":5726,"PHASE3":5728,"PHASE4":5730,"NA":5736},{"trials":5723,"activeCount":103},[],{"trials":5725,"activeCount":103},[],{"trials":5727,"activeCount":103},[],{"trials":5729,"activeCount":103},[],{"trials":5731,"activeCount":103},[5732],{"nctId":5708,"briefTitle":5709,"status":150,"phases":5733,"primaryCompletion":5711,"completion":5711,"start":5712,"enrollment":5713,"conditions":5734,"interventions":5735},[94],[5715],[5695,5717],{"trials":5737,"activeCount":103},[],{"intervention":5739,"totalTrials":121,"cells":5740},"Niacin\u002Fsimvastatin compared to simvastatin alone at 2 doses",{"EARLY_PHASE1":5741,"PHASE1":5743,"PHASE2":5745,"PHASE3":5747,"PHASE4":5749,"NA":5758},{"trials":5742,"activeCount":103},[],{"trials":5744,"activeCount":103},[],{"trials":5746,"activeCount":103},[],{"trials":5748,"activeCount":103},[],{"trials":5750,"activeCount":103},[5751],{"nctId":5752,"briefTitle":5753,"status":150,"phases":5754,"completion":5018,"start":4611,"enrollment":16,"conditions":5755,"interventions":5757},"NCT00307307","Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.",[94],[5756],"Established Carotid Atherosclerosis",[5739],{"trials":5759,"activeCount":103},[],{"intervention":5761,"totalTrials":121,"cells":5762},"Plan B",{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5769,"PHASE4":5771,"NA":5782},{"trials":5764,"activeCount":103},[],{"trials":5766,"activeCount":103},[],{"trials":5768,"activeCount":103},[],{"trials":5770,"activeCount":103},[],{"trials":5772,"activeCount":103},[5773],{"nctId":5774,"briefTitle":5775,"status":150,"phases":5776,"primaryCompletion":5777,"completion":5777,"start":5778,"enrollment":1587,"conditions":5779,"interventions":5781},"NCT00433004","Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens",[94],"2010-10","2007-02",[5780],"Post Partum",[5761],{"trials":5783,"activeCount":103},[],{"intervention":5785,"totalTrials":121,"cells":5786},"Fluzone®",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5795,"NA":5805},{"trials":5788,"activeCount":103},[],{"trials":5790,"activeCount":103},[],{"trials":5792,"activeCount":103},[],{"trials":5794,"activeCount":103},[],{"trials":5796,"activeCount":103},[5797],{"nctId":5798,"briefTitle":5799,"status":150,"phases":5800,"primaryCompletion":1003,"completion":1003,"start":1094,"enrollment":5801,"conditions":5802,"interventions":5804},"NCT01262846","Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals",[94],195,[5803],"HIV Infection",[5785,5785],{"trials":5806,"activeCount":103},[],{"intervention":4900,"totalTrials":121,"cells":5808},{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5817,"NA":5823},{"trials":5810,"activeCount":103},[],{"trials":5812,"activeCount":103},[],{"trials":5814,"activeCount":103},[],{"trials":5816,"activeCount":103},[],{"trials":5818,"activeCount":103},[5819],{"nctId":4892,"briefTitle":4893,"status":1357,"phases":5820,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":2592,"conditions":5821,"interventions":5822},[94],[4898],[4868,4900,4901],{"trials":5824,"activeCount":103},[],{"intervention":4901,"totalTrials":121,"cells":5826},{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5831,"PHASE3":5833,"PHASE4":5835,"NA":5841},{"trials":5828,"activeCount":103},[],{"trials":5830,"activeCount":103},[],{"trials":5832,"activeCount":103},[],{"trials":5834,"activeCount":103},[],{"trials":5836,"activeCount":103},[5837],{"nctId":4892,"briefTitle":4893,"status":1357,"phases":5838,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":2592,"conditions":5839,"interventions":5840},[94],[4898],[4868,4900,4901],{"trials":5842,"activeCount":103},[],{"intervention":5844,"totalTrials":121,"cells":5845},"Dexmedetomidine load",{"EARLY_PHASE1":5846,"PHASE1":5848,"PHASE2":5850,"PHASE3":5852,"PHASE4":5854,"NA":5872},{"trials":5847,"activeCount":103},[],{"trials":5849,"activeCount":103},[],{"trials":5851,"activeCount":103},[],{"trials":5853,"activeCount":103},[],{"trials":5855,"activeCount":103},[5856],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5859,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5861,"interventions":5863},"NCT01158820","Alternative Sedation During Bronchoscopy",[94],"2012-05",[5862],"Sedation",[5844,5864,5865,5866,5867,5868,5869,5870,5871],"Ketamine load","Midazolam load","Fentanyl load","Dexmedetomidine maintenance","Ketamine maintenance","Midazolam demand","Fentanyl demand","Benadryl demand",{"trials":5873,"activeCount":103},[],{"intervention":5864,"totalTrials":121,"cells":5875},{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5880,"PHASE3":5882,"PHASE4":5884,"NA":5890},{"trials":5877,"activeCount":103},[],{"trials":5879,"activeCount":103},[],{"trials":5881,"activeCount":103},[],{"trials":5883,"activeCount":103},[],{"trials":5885,"activeCount":103},[5886],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5887,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5888,"interventions":5889},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5891,"activeCount":103},[],{"intervention":5865,"totalTrials":121,"cells":5893},{"EARLY_PHASE1":5894,"PHASE1":5896,"PHASE2":5898,"PHASE3":5900,"PHASE4":5902,"NA":5908},{"trials":5895,"activeCount":103},[],{"trials":5897,"activeCount":103},[],{"trials":5899,"activeCount":103},[],{"trials":5901,"activeCount":103},[],{"trials":5903,"activeCount":103},[5904],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5905,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5906,"interventions":5907},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5909,"activeCount":103},[],{"intervention":5866,"totalTrials":121,"cells":5911},{"EARLY_PHASE1":5912,"PHASE1":5914,"PHASE2":5916,"PHASE3":5918,"PHASE4":5920,"NA":5926},{"trials":5913,"activeCount":103},[],{"trials":5915,"activeCount":103},[],{"trials":5917,"activeCount":103},[],{"trials":5919,"activeCount":103},[],{"trials":5921,"activeCount":103},[5922],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5923,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5924,"interventions":5925},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5927,"activeCount":103},[],{"intervention":5867,"totalTrials":121,"cells":5929},{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5934,"PHASE3":5936,"PHASE4":5938,"NA":5944},{"trials":5931,"activeCount":103},[],{"trials":5933,"activeCount":103},[],{"trials":5935,"activeCount":103},[],{"trials":5937,"activeCount":103},[],{"trials":5939,"activeCount":103},[5940],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5941,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5942,"interventions":5943},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5945,"activeCount":103},[],{"intervention":5868,"totalTrials":121,"cells":5947},{"EARLY_PHASE1":5948,"PHASE1":5950,"PHASE2":5952,"PHASE3":5954,"PHASE4":5956,"NA":5962},{"trials":5949,"activeCount":103},[],{"trials":5951,"activeCount":103},[],{"trials":5953,"activeCount":103},[],{"trials":5955,"activeCount":103},[],{"trials":5957,"activeCount":103},[5958],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5959,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5960,"interventions":5961},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5963,"activeCount":103},[],{"intervention":5869,"totalTrials":121,"cells":5965},{"EARLY_PHASE1":5966,"PHASE1":5968,"PHASE2":5970,"PHASE3":5972,"PHASE4":5974,"NA":5980},{"trials":5967,"activeCount":103},[],{"trials":5969,"activeCount":103},[],{"trials":5971,"activeCount":103},[],{"trials":5973,"activeCount":103},[],{"trials":5975,"activeCount":103},[5976],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5977,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5978,"interventions":5979},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5981,"activeCount":103},[],{"intervention":5870,"totalTrials":121,"cells":5983},{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":5988,"PHASE3":5990,"PHASE4":5992,"NA":5998},{"trials":5985,"activeCount":103},[],{"trials":5987,"activeCount":103},[],{"trials":5989,"activeCount":103},[],{"trials":5991,"activeCount":103},[],{"trials":5993,"activeCount":103},[5994],{"nctId":5857,"briefTitle":5858,"status":150,"phases":5995,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":5996,"interventions":5997},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":5999,"activeCount":103},[],{"intervention":5871,"totalTrials":121,"cells":6001},{"EARLY_PHASE1":6002,"PHASE1":6004,"PHASE2":6006,"PHASE3":6008,"PHASE4":6010,"NA":6016},{"trials":6003,"activeCount":103},[],{"trials":6005,"activeCount":103},[],{"trials":6007,"activeCount":103},[],{"trials":6009,"activeCount":103},[],{"trials":6011,"activeCount":103},[6012],{"nctId":5857,"briefTitle":5858,"status":150,"phases":6013,"primaryCompletion":5860,"completion":5860,"start":4622,"enrollment":1587,"conditions":6014,"interventions":6015},[94],[5862],[5844,5864,5865,5866,5867,5868,5869,5870,5871],{"trials":6017,"activeCount":103},[],{"intervention":4925,"totalTrials":121,"cells":6019},{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6026,"PHASE4":6028,"NA":6034},{"trials":6021,"activeCount":103},[],{"trials":6023,"activeCount":103},[],{"trials":6025,"activeCount":103},[],{"trials":6027,"activeCount":103},[],{"trials":6029,"activeCount":103},[6030],{"nctId":4918,"briefTitle":4919,"status":1357,"phases":6031,"primaryCompletion":4921,"completion":4921,"start":4550,"enrollment":2695,"conditions":6032,"interventions":6033},[94],[4923],[4925,4926,4927,4928,4905,4905],{"trials":6035,"activeCount":103},[],{"intervention":4926,"totalTrials":121,"cells":6037},{"EARLY_PHASE1":6038,"PHASE1":6040,"PHASE2":6042,"PHASE3":6044,"PHASE4":6046,"NA":6052},{"trials":6039,"activeCount":103},[],{"trials":6041,"activeCount":103},[],{"trials":6043,"activeCount":103},[],{"trials":6045,"activeCount":103},[],{"trials":6047,"activeCount":103},[6048],{"nctId":4918,"briefTitle":4919,"status":1357,"phases":6049,"primaryCompletion":4921,"completion":4921,"start":4550,"enrollment":2695,"conditions":6050,"interventions":6051},[94],[4923],[4925,4926,4927,4928,4905,4905],{"trials":6053,"activeCount":103},[],{"intervention":4927,"totalTrials":121,"cells":6055},{"EARLY_PHASE1":6056,"PHASE1":6058,"PHASE2":6060,"PHASE3":6062,"PHASE4":6064,"NA":6070},{"trials":6057,"activeCount":103},[],{"trials":6059,"activeCount":103},[],{"trials":6061,"activeCount":103},[],{"trials":6063,"activeCount":103},[],{"trials":6065,"activeCount":103},[6066],{"nctId":4918,"briefTitle":4919,"status":1357,"phases":6067,"primaryCompletion":4921,"completion":4921,"start":4550,"enrollment":2695,"conditions":6068,"interventions":6069},[94],[4923],[4925,4926,4927,4928,4905,4905],{"trials":6071,"activeCount":103},[],{"intervention":4937,"totalTrials":121,"cells":6073},{"EARLY_PHASE1":6074,"PHASE1":6076,"PHASE2":6078,"PHASE3":6080,"PHASE4":6082,"NA":6088},{"trials":6075,"activeCount":103},[],{"trials":6077,"activeCount":103},[],{"trials":6079,"activeCount":103},[],{"trials":6081,"activeCount":103},[],{"trials":6083,"activeCount":103},[6084],{"nctId":4930,"briefTitle":4931,"status":1357,"phases":6085,"primaryCompletion":4933,"completion":4933,"start":4934,"enrollment":971,"conditions":6086,"interventions":6087},[94],[4923],[4937,4905],{"trials":6089,"activeCount":103},[],{"intervention":4795,"totalTrials":121,"cells":6091},{"EARLY_PHASE1":6092,"PHASE1":6094,"PHASE2":6096,"PHASE3":6098,"PHASE4":6100,"NA":6106},{"trials":6093,"activeCount":103},[],{"trials":6095,"activeCount":103},[],{"trials":6097,"activeCount":103},[],{"trials":6099,"activeCount":103},[],{"trials":6101,"activeCount":103},[6102],{"nctId":4788,"briefTitle":4789,"status":150,"phases":6103,"primaryCompletion":4791,"completion":188,"start":4792,"enrollment":1869,"conditions":6104,"interventions":6105},[94],[15],[4795,4768],{"trials":6107,"activeCount":103},[],{"intervention":6109,"totalTrials":121,"cells":6110},"HA filler",{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6117,"PHASE4":6119,"NA":6130},{"trials":6112,"activeCount":103},[],{"trials":6114,"activeCount":103},[],{"trials":6116,"activeCount":103},[],{"trials":6118,"activeCount":103},[],{"trials":6120,"activeCount":103},[6121],{"nctId":6122,"briefTitle":6123,"status":150,"phases":6124,"primaryCompletion":6125,"completion":6125,"start":6126,"enrollment":957,"conditions":6127,"interventions":6129},"NCT06694857","A Prospective Evaluation of the Filler for Jaw Contouring",[94],"2025-11-01","2024-10-31",[6128],"Dermal Fillers",[6109],{"trials":6131,"activeCount":103},[],{"intervention":6133,"totalTrials":121,"cells":6134},"Amlodipine Besylate",{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6141,"PHASE4":6143,"NA":6155},{"trials":6136,"activeCount":103},[],{"trials":6138,"activeCount":103},[],{"trials":6140,"activeCount":103},[],{"trials":6142,"activeCount":103},[],{"trials":6144,"activeCount":103},[6145],{"nctId":6146,"briefTitle":6147,"status":150,"phases":6148,"primaryCompletion":6149,"completion":6150,"start":6151,"enrollment":1587,"conditions":6152,"interventions":6153},"NCT04434664","BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF",[94],"2024-12-03","2024-12-20","2021-12-01",[1400,24],[6133,6154],"Metoprolol Succinate",{"trials":6156,"activeCount":103},[],{"intervention":6154,"totalTrials":121,"cells":6158},{"EARLY_PHASE1":6159,"PHASE1":6161,"PHASE2":6163,"PHASE3":6165,"PHASE4":6167,"NA":6173},{"trials":6160,"activeCount":103},[],{"trials":6162,"activeCount":103},[],{"trials":6164,"activeCount":103},[],{"trials":6166,"activeCount":103},[],{"trials":6168,"activeCount":103},[6169],{"nctId":6146,"briefTitle":6147,"status":150,"phases":6170,"primaryCompletion":6149,"completion":6150,"start":6151,"enrollment":1587,"conditions":6171,"interventions":6172},[94],[1400,24],[6133,6154],{"trials":6174,"activeCount":103},[],{"intervention":6176,"totalTrials":121,"cells":6177},"Lithium",{"EARLY_PHASE1":6178,"PHASE1":6180,"PHASE2":6182,"PHASE3":6184,"PHASE4":6186,"NA":6198},{"trials":6179,"activeCount":103},[],{"trials":6181,"activeCount":103},[],{"trials":6183,"activeCount":103},[],{"trials":6185,"activeCount":103},[],{"trials":6187,"activeCount":103},[6188],{"nctId":6189,"briefTitle":6190,"status":150,"phases":6191,"primaryCompletion":6192,"completion":6192,"start":6193,"enrollment":6194,"conditions":6195,"interventions":6196},"NCT00044616","Relapse Prevention for Bipolar Type-II Disorder",[94],"2007-01","2001-02",180,[4828,18],[6197,6176],"Fluoxetine",{"trials":6199,"activeCount":103},[],{"intervention":6201,"totalTrials":121,"cells":6202},"Lithium \u002F Fluoxetine",{"EARLY_PHASE1":6203,"PHASE1":6205,"PHASE2":6207,"PHASE3":6209,"PHASE4":6211,"NA":6223},{"trials":6204,"activeCount":103},[],{"trials":6206,"activeCount":103},[],{"trials":6208,"activeCount":103},[],{"trials":6210,"activeCount":103},[],{"trials":6212,"activeCount":103},[6213],{"nctId":6214,"briefTitle":6215,"status":150,"phases":6216,"primaryCompletion":6217,"completion":6217,"start":6218,"enrollment":6219,"conditions":6220,"interventions":6221},"NCT00961961","Prevention of Relapse & Recurrence of Bipolar Depression",[94],"2016-09-01","2009-07-01",177,[4828],[6201,6222],"Lithium \u002F Placebo",{"trials":6224,"activeCount":103},[],{"intervention":6222,"totalTrials":121,"cells":6226},{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6233,"PHASE4":6235,"NA":6241},{"trials":6228,"activeCount":103},[],{"trials":6230,"activeCount":103},[],{"trials":6232,"activeCount":103},[],{"trials":6234,"activeCount":103},[],{"trials":6236,"activeCount":103},[6237],{"nctId":6214,"briefTitle":6215,"status":150,"phases":6238,"primaryCompletion":6217,"completion":6217,"start":6218,"enrollment":6219,"conditions":6239,"interventions":6240},[94],[4828],[6201,6222],{"trials":6242,"activeCount":103},[],{"intervention":6244,"totalTrials":121,"cells":6245},"Teriparatide",{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6250,"PHASE3":6252,"PHASE4":6254,"NA":6265},{"trials":6247,"activeCount":103},[],{"trials":6249,"activeCount":103},[],{"trials":6251,"activeCount":103},[],{"trials":6253,"activeCount":103},[],{"trials":6255,"activeCount":103},[6256],{"nctId":6257,"briefTitle":6258,"status":150,"phases":6259,"primaryCompletion":4638,"completion":4638,"start":4630,"enrollment":6260,"conditions":6261,"interventions":6263},"NCT01153425","µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis",[94],33,[6262],"Osteoporosis, Osteopenia",[6244,6264],"Zoledronic Acid",{"trials":6266,"activeCount":103},[],{"intervention":6264,"totalTrials":121,"cells":6268},{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6275,"PHASE4":6277,"NA":6283},{"trials":6270,"activeCount":103},[],{"trials":6272,"activeCount":103},[],{"trials":6274,"activeCount":103},[],{"trials":6276,"activeCount":103},[],{"trials":6278,"activeCount":103},[6279],{"nctId":6257,"briefTitle":6258,"status":150,"phases":6280,"primaryCompletion":4638,"completion":4638,"start":4630,"enrollment":6260,"conditions":6281,"interventions":6282},[94],[6262],[6244,6264],{"trials":6284,"activeCount":103},[],{"intervention":6286,"totalTrials":121,"cells":6287},"Escitalopram 20mg for 2 weeks",{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6292,"PHASE3":6294,"PHASE4":6296,"NA":6310},{"trials":6289,"activeCount":103},[],{"trials":6291,"activeCount":103},[],{"trials":6293,"activeCount":103},[],{"trials":6295,"activeCount":103},[],{"trials":6297,"activeCount":103},[6298],{"nctId":6299,"briefTitle":6300,"status":150,"phases":6301,"primaryCompletion":6302,"completion":6303,"start":5453,"enrollment":6304,"conditions":6305,"interventions":6307},"NCT02161458","Escitalopram Effects on CSF Amyloid Beta",[94],"2017-08","2019-01",98,[6306],"Amyloid Beta Protein",[6286,6308,6309],"Escitalopram 20mg for 8 weeks","Escitalopram 30mg for 8 weeks",{"trials":6311,"activeCount":103},[],{"intervention":6308,"totalTrials":121,"cells":6313},{"EARLY_PHASE1":6314,"PHASE1":6316,"PHASE2":6318,"PHASE3":6320,"PHASE4":6322,"NA":6328},{"trials":6315,"activeCount":103},[],{"trials":6317,"activeCount":103},[],{"trials":6319,"activeCount":103},[],{"trials":6321,"activeCount":103},[],{"trials":6323,"activeCount":103},[6324],{"nctId":6299,"briefTitle":6300,"status":150,"phases":6325,"primaryCompletion":6302,"completion":6303,"start":5453,"enrollment":6304,"conditions":6326,"interventions":6327},[94],[6306],[6286,6308,6309],{"trials":6329,"activeCount":103},[],{"intervention":6309,"totalTrials":121,"cells":6331},{"EARLY_PHASE1":6332,"PHASE1":6334,"PHASE2":6336,"PHASE3":6338,"PHASE4":6340,"NA":6346},{"trials":6333,"activeCount":103},[],{"trials":6335,"activeCount":103},[],{"trials":6337,"activeCount":103},[],{"trials":6339,"activeCount":103},[],{"trials":6341,"activeCount":103},[6342],{"nctId":6299,"briefTitle":6300,"status":150,"phases":6343,"primaryCompletion":6302,"completion":6303,"start":5453,"enrollment":6304,"conditions":6344,"interventions":6345},[94],[6306],[6286,6308,6309],{"trials":6347,"activeCount":103},[],{"intervention":6349,"totalTrials":121,"cells":6350},"medication for opioid use disorder",{"EARLY_PHASE1":6351,"PHASE1":6353,"PHASE2":6355,"PHASE3":6357,"PHASE4":6359,"NA":6371},{"trials":6352,"activeCount":103},[],{"trials":6354,"activeCount":103},[],{"trials":6356,"activeCount":103},[],{"trials":6358,"activeCount":103},[],{"trials":6360,"activeCount":103},[6361],{"nctId":6362,"briefTitle":6363,"status":150,"phases":6364,"primaryCompletion":6365,"completion":6366,"start":6367,"enrollment":6368,"conditions":6369,"interventions":6370},"NCT05368675","Medication-assisted Treatment for Injecting Drug Users in Vietnam",[94],"2017-08-31","2018-08-31","2013-12-18",448,[2030,2567],[6349],{"trials":6372,"activeCount":103},[],{"intervention":6374,"totalTrials":121,"cells":6375},"Escitalopram + Celecoxib",{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6382,"PHASE4":6384,"NA":6396},{"trials":6377,"activeCount":103},[],{"trials":6379,"activeCount":103},[],{"trials":6381,"activeCount":103},[],{"trials":6383,"activeCount":103},[],{"trials":6385,"activeCount":103},[6386],{"nctId":6387,"briefTitle":6388,"status":150,"phases":6389,"primaryCompletion":6390,"completion":6390,"start":6391,"enrollment":6392,"conditions":6393,"interventions":6394},"NCT02389465","Stress and Inflammation in Late-Life Depression",[94],"2022-07-18","2014-08",119,[18,4704],[6374,6395],"Escitalopram + Placebo",{"trials":6397,"activeCount":103},[],{"intervention":6395,"totalTrials":121,"cells":6399},{"EARLY_PHASE1":6400,"PHASE1":6402,"PHASE2":6404,"PHASE3":6406,"PHASE4":6408,"NA":6414},{"trials":6401,"activeCount":103},[],{"trials":6403,"activeCount":103},[],{"trials":6405,"activeCount":103},[],{"trials":6407,"activeCount":103},[],{"trials":6409,"activeCount":103},[6410],{"nctId":6387,"briefTitle":6388,"status":150,"phases":6411,"primaryCompletion":6390,"completion":6390,"start":6391,"enrollment":6392,"conditions":6412,"interventions":6413},[94],[18,4704],[6374,6395],{"trials":6415,"activeCount":103},[],{"intervention":6417,"totalTrials":121,"cells":6418},"MDD diagnosis and Estrogen treatment",{"EARLY_PHASE1":6419,"PHASE1":6421,"PHASE2":6423,"PHASE3":6425,"PHASE4":6427,"NA":6440},{"trials":6420,"activeCount":103},[],{"trials":6422,"activeCount":103},[],{"trials":6424,"activeCount":103},[],{"trials":6426,"activeCount":103},[],{"trials":6428,"activeCount":103},[6429],{"nctId":6430,"briefTitle":6431,"status":150,"phases":6432,"primaryCompletion":4630,"completion":4630,"start":6433,"enrollment":2695,"conditions":6434,"interventions":6436},"NCT00626340","Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder",[94],"1999-07",[6435,18],"Menopause",[6417,6437,6438,6439],"MDD diagnosis and Fluoxetine treatment","MDD diagnosis with both Estrogen and Fluoxetine treatment","No depression and estrogen treatment",{"trials":6441,"activeCount":103},[],{"intervention":6437,"totalTrials":121,"cells":6443},{"EARLY_PHASE1":6444,"PHASE1":6446,"PHASE2":6448,"PHASE3":6450,"PHASE4":6452,"NA":6458},{"trials":6445,"activeCount":103},[],{"trials":6447,"activeCount":103},[],{"trials":6449,"activeCount":103},[],{"trials":6451,"activeCount":103},[],{"trials":6453,"activeCount":103},[6454],{"nctId":6430,"briefTitle":6431,"status":150,"phases":6455,"primaryCompletion":4630,"completion":4630,"start":6433,"enrollment":2695,"conditions":6456,"interventions":6457},[94],[6435,18],[6417,6437,6438,6439],{"trials":6459,"activeCount":103},[],{"intervention":6438,"totalTrials":121,"cells":6461},{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6476},{"trials":6463,"activeCount":103},[],{"trials":6465,"activeCount":103},[],{"trials":6467,"activeCount":103},[],{"trials":6469,"activeCount":103},[],{"trials":6471,"activeCount":103},[6472],{"nctId":6430,"briefTitle":6431,"status":150,"phases":6473,"primaryCompletion":4630,"completion":4630,"start":6433,"enrollment":2695,"conditions":6474,"interventions":6475},[94],[6435,18],[6417,6437,6438,6439],{"trials":6477,"activeCount":103},[],{"intervention":6439,"totalTrials":121,"cells":6479},{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6494},{"trials":6481,"activeCount":103},[],{"trials":6483,"activeCount":103},[],{"trials":6485,"activeCount":103},[],{"trials":6487,"activeCount":103},[],{"trials":6489,"activeCount":103},[6490],{"nctId":6430,"briefTitle":6431,"status":150,"phases":6491,"primaryCompletion":4630,"completion":4630,"start":6433,"enrollment":2695,"conditions":6492,"interventions":6493},[94],[6435,18],[6417,6437,6438,6439],{"trials":6495,"activeCount":103},[],{"intervention":6497,"totalTrials":121,"cells":6498},"Fesoterodine",{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6505,"PHASE4":6507,"NA":6519},{"trials":6500,"activeCount":103},[],{"trials":6502,"activeCount":103},[],{"trials":6504,"activeCount":103},[],{"trials":6506,"activeCount":103},[],{"trials":6508,"activeCount":103},[6509],{"nctId":6510,"briefTitle":6511,"status":150,"phases":6512,"primaryCompletion":6513,"completion":6513,"start":6514,"enrollment":6515,"conditions":6516,"interventions":6518},"NCT03946124","Fall Prevention in Older Adults With OAB",[94],"2017-07-19","2015-07-25",74,[6517],"Overactive Bladder",[6497],{"trials":6520,"activeCount":103},[],{"intervention":4705,"totalTrials":1139,"cells":6522},{"EARLY_PHASE1":6523,"PHASE1":6525,"PHASE2":6527,"PHASE3":6533,"PHASE4":6550,"NA":6552},{"trials":6524,"activeCount":103},[],{"trials":6526,"activeCount":103},[],{"trials":6528,"activeCount":103},[6529],{"nctId":4695,"briefTitle":4696,"status":1357,"phases":6530,"primaryCompletion":4698,"completion":4698,"start":4699,"enrollment":735,"conditions":6531,"interventions":6532},[92],[4701,4702,4703,4704,4705,2187,4528,4706],[4705,4686,4708],{"trials":6534,"activeCount":103},[6535,6541],{"nctId":6536,"briefTitle":6537,"status":150,"phases":6538,"primaryCompletion":5777,"completion":5777,"start":1014,"enrollment":1587,"conditions":6539,"interventions":6540},"NCT00351026","Methadone Maintenance & HIV Risk in Ukraine",[93],[4604],[4705],{"nctId":6542,"briefTitle":6543,"status":150,"phases":6544,"primaryCompletion":980,"completion":980,"start":4622,"enrollment":6545,"conditions":6546,"interventions":6547},"NCT01131273","HIV Risk Reduction in Subutex Injectors in Tbilisi",[93],68,[4853],[6548,6549],"methadone","buprenorphine-naloxone (Suboxone) for 12 weeks",{"trials":6551,"activeCount":103},[],{"trials":6553,"activeCount":103},[],{"intervention":6555,"totalTrials":99,"cells":6556},"Oral Naltrexone",{"EARLY_PHASE1":6557,"PHASE1":6559,"PHASE2":6561,"PHASE3":6572,"PHASE4":6585,"NA":6587},{"trials":6558,"activeCount":103},[],{"trials":6560,"activeCount":103},[],{"trials":6562,"activeCount":103},[6563],{"nctId":6564,"briefTitle":6565,"status":150,"phases":6566,"primaryCompletion":6567,"completion":6567,"start":4622,"enrollment":4418,"conditions":6568,"interventions":6570},"NCT01101815","Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX",[92],"2016-12",[4853,6569,2567],"Substance Abuse",[6555,6571],"Naltrexone Implant",{"trials":6573,"activeCount":103},[6574],{"nctId":6575,"briefTitle":6576,"status":150,"phases":6577,"primaryCompletion":4813,"completion":6578,"start":5108,"enrollment":6579,"conditions":6580,"interventions":6581},"NCT00218426","Addiction Treatment in Russia: Oral vs. Naltrexone Implant",[92,93],"2010-11-04",306,[4603,3984],[6582,6583,6584],"naltrexone implant","oral naltrexone","oral placebo naltrexone",{"trials":6586,"activeCount":103},[],{"trials":6588,"activeCount":103},[],{"intervention":6571,"totalTrials":99,"cells":6590},{"EARLY_PHASE1":6591,"PHASE1":6593,"PHASE2":6595,"PHASE3":6601,"PHASE4":6607,"NA":6609},{"trials":6592,"activeCount":103},[],{"trials":6594,"activeCount":103},[],{"trials":6596,"activeCount":103},[6597],{"nctId":6564,"briefTitle":6565,"status":150,"phases":6598,"primaryCompletion":6567,"completion":6567,"start":4622,"enrollment":4418,"conditions":6599,"interventions":6600},[92],[4853,6569,2567],[6555,6571],{"trials":6602,"activeCount":103},[6603],{"nctId":6575,"briefTitle":6576,"status":150,"phases":6604,"primaryCompletion":4813,"completion":6578,"start":5108,"enrollment":6579,"conditions":6605,"interventions":6606},[92,93],[4603,3984],[6582,6583,6584],{"trials":6608,"activeCount":103},[],{"trials":6610,"activeCount":103},[],{"intervention":6612,"totalTrials":99,"cells":6613},"Seroquel",{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6626,"PHASE4":6636,"NA":6638},{"trials":6615,"activeCount":103},[],{"trials":6617,"activeCount":103},[],{"trials":6619,"activeCount":103},[6620],{"nctId":6621,"briefTitle":6622,"status":150,"phases":6623,"primaryCompletion":1074,"completion":1250,"start":4540,"enrollment":994,"conditions":6624,"interventions":6625},"NCT00674765","Seroquel for Frequent, Heavy Drinkers",[92],[673],[6612],{"trials":6627,"activeCount":103},[6628],{"nctId":6629,"briefTitle":6630,"status":150,"phases":6631,"primaryCompletion":5018,"completion":4550,"start":6632,"enrollment":6633,"conditions":6634,"interventions":6635},"NCT00124059","Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.",[93],"2003-03",61,[673],[6612],{"trials":6637,"activeCount":103},[],{"trials":6639,"activeCount":103},[],{"intervention":6641,"totalTrials":121,"cells":6642},"ADAM SPECT plus Cognitive Therapy",{"EARLY_PHASE1":6643,"PHASE1":6645,"PHASE2":6647,"PHASE3":6649,"PHASE4":6658,"NA":6660},{"trials":6644,"activeCount":103},[],{"trials":6646,"activeCount":103},[],{"trials":6648,"activeCount":103},[],{"trials":6650,"activeCount":103},[6651],{"nctId":6652,"briefTitle":6653,"status":150,"phases":6654,"primaryCompletion":1013,"completion":1013,"start":4540,"enrollment":1150,"conditions":6655,"interventions":6656},"NCT00641108","Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression",[92,93],[18],[6641,6657],"ADAM SPECT plus No Therapy",{"trials":6659,"activeCount":103},[],{"trials":6661,"activeCount":103},[],{"intervention":6657,"totalTrials":121,"cells":6663},{"EARLY_PHASE1":6664,"PHASE1":6666,"PHASE2":6668,"PHASE3":6670,"PHASE4":6676,"NA":6678},{"trials":6665,"activeCount":103},[],{"trials":6667,"activeCount":103},[],{"trials":6669,"activeCount":103},[],{"trials":6671,"activeCount":103},[6672],{"nctId":6652,"briefTitle":6653,"status":150,"phases":6673,"primaryCompletion":1013,"completion":1013,"start":4540,"enrollment":1150,"conditions":6674,"interventions":6675},[92,93],[18],[6641,6657],{"trials":6677,"activeCount":103},[],{"trials":6679,"activeCount":103},[],{"intervention":6681,"totalTrials":121,"cells":6682},"Terlipressin",{"EARLY_PHASE1":6683,"PHASE1":6685,"PHASE2":6687,"PHASE3":6689,"PHASE4":6700,"NA":6702},{"trials":6684,"activeCount":103},[],{"trials":6686,"activeCount":103},[],{"trials":6688,"activeCount":103},[],{"trials":6690,"activeCount":103},[6691],{"nctId":6692,"briefTitle":6693,"status":150,"phases":6694,"primaryCompletion":6695,"completion":6695,"start":6696,"enrollment":1587,"conditions":6697,"interventions":6699},"NCT04460560","Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)",[93],"2023-12-27","2020-12-11",[6698],"Hepatorenal Syndrome",[6681],{"trials":6701,"activeCount":103},[],{"trials":6703,"activeCount":103},[],{"intervention":6705,"totalTrials":121,"cells":6706},"extended release naltrexone",{"EARLY_PHASE1":6707,"PHASE1":6709,"PHASE2":6711,"PHASE3":6713,"PHASE4":6725,"NA":6727},{"trials":6708,"activeCount":103},[],{"trials":6710,"activeCount":103},[],{"trials":6712,"activeCount":103},[],{"trials":6714,"activeCount":103},[6715],{"nctId":6716,"briefTitle":6717,"status":150,"phases":6718,"primaryCompletion":6719,"completion":6719,"start":6720,"enrollment":6721,"conditions":6722,"interventions":6724},"NCT02617628","Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone",[92,93],"2018-12-31","2016-01-01",146,[6723],"Opiate Dependence",[6705],{"trials":6726,"activeCount":103},[],{"trials":6728,"activeCount":103},[],{"intervention":6730,"totalTrials":121,"cells":6731},"Chamomile",{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6738,"PHASE4":6747,"NA":6749},{"trials":6733,"activeCount":103},[],{"trials":6735,"activeCount":103},[],{"trials":6737,"activeCount":103},[],{"trials":6739,"activeCount":103},[6740],{"nctId":6741,"briefTitle":6742,"status":150,"phases":6743,"primaryCompletion":2418,"completion":2418,"start":6744,"enrollment":6194,"conditions":6745,"interventions":6746},"NCT01072344","Long Term Chamomile Therapy for Anxiety",[93],"2010-02",[4750],[6730],{"trials":6748,"activeCount":103},[],{"trials":6750,"activeCount":103},[],{"intervention":6752,"totalTrials":121,"cells":6753},"Glucocorticoids [Standard Dose]",{"EARLY_PHASE1":6754,"PHASE1":6756,"PHASE2":6758,"PHASE3":6760,"PHASE4":6773,"NA":6775},{"trials":6755,"activeCount":103},[],{"trials":6757,"activeCount":103},[],{"trials":6759,"activeCount":103},[],{"trials":6761,"activeCount":103},[6762],{"nctId":6763,"briefTitle":6764,"status":150,"phases":6765,"primaryCompletion":6302,"completion":6302,"start":6766,"enrollment":6767,"conditions":6768,"interventions":6771},"NCT00987389","Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis",[93],"2010-05",704,[6769,6770],"Granulomatosis With Polyangiitis (Wegener's) (GPA)","Microscopic Polyangiitis (MPA)",[6752,6772],"Glucocorticoids [Reduced Dose]",{"trials":6774,"activeCount":103},[],{"trials":6776,"activeCount":103},[],{"intervention":6772,"totalTrials":121,"cells":6778},{"EARLY_PHASE1":6779,"PHASE1":6781,"PHASE2":6783,"PHASE3":6785,"PHASE4":6791,"NA":6793},{"trials":6780,"activeCount":103},[],{"trials":6782,"activeCount":103},[],{"trials":6784,"activeCount":103},[],{"trials":6786,"activeCount":103},[6787],{"nctId":6763,"briefTitle":6764,"status":150,"phases":6788,"primaryCompletion":6302,"completion":6302,"start":6766,"enrollment":6767,"conditions":6789,"interventions":6790},[93],[6769,6770],[6752,6772],{"trials":6792,"activeCount":103},[],{"trials":6794,"activeCount":103},[],{"intervention":6796,"totalTrials":121,"cells":6797},"VIVITROL injection and VIVITROL Placebo Injection , 24 weeks",{"EARLY_PHASE1":6798,"PHASE1":6800,"PHASE2":6802,"PHASE3":6804,"PHASE4":6813,"NA":6815},{"trials":6799,"activeCount":103},[],{"trials":6801,"activeCount":103},[],{"trials":6803,"activeCount":103},[],{"trials":6805,"activeCount":103},[6806],{"nctId":6807,"briefTitle":6808,"status":150,"phases":6809,"primaryCompletion":1359,"completion":1359,"start":6766,"enrollment":1376,"conditions":6810,"interventions":6812},"NCT01100853","Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland",[93],[6811],"Amphetamine Dependence",[6796],{"trials":6814,"activeCount":103},[],{"trials":6816,"activeCount":103},[],{"intervention":6818,"totalTrials":121,"cells":6819},"5 mg Prednisone",{"EARLY_PHASE1":6820,"PHASE1":6822,"PHASE2":6824,"PHASE3":6826,"PHASE4":6838,"NA":6840},{"trials":6821,"activeCount":103},[],{"trials":6823,"activeCount":103},[],{"trials":6825,"activeCount":103},[],{"trials":6827,"activeCount":103},[6828],{"nctId":6829,"briefTitle":6830,"status":150,"phases":6831,"primaryCompletion":6832,"completion":6832,"start":6833,"enrollment":6834,"conditions":6835,"interventions":6836},"NCT01940094","The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach",[93],"2024-12","2014-02",159,[1940],[6818,6837],"0 mg Prednisone",{"trials":6839,"activeCount":103},[],{"trials":6841,"activeCount":103},[],{"intervention":6837,"totalTrials":121,"cells":6843},{"EARLY_PHASE1":6844,"PHASE1":6846,"PHASE2":6848,"PHASE3":6850,"PHASE4":6856,"NA":6858},{"trials":6845,"activeCount":103},[],{"trials":6847,"activeCount":103},[],{"trials":6849,"activeCount":103},[],{"trials":6851,"activeCount":103},[6852],{"nctId":6829,"briefTitle":6830,"status":150,"phases":6853,"primaryCompletion":6832,"completion":6832,"start":6833,"enrollment":6834,"conditions":6854,"interventions":6855},[93],[1940],[6818,6837],{"trials":6857,"activeCount":103},[],{"trials":6859,"activeCount":103},[],{"intervention":6549,"totalTrials":121,"cells":6861},{"EARLY_PHASE1":6862,"PHASE1":6864,"PHASE2":6866,"PHASE3":6868,"PHASE4":6874,"NA":6876},{"trials":6863,"activeCount":103},[],{"trials":6865,"activeCount":103},[],{"trials":6867,"activeCount":103},[],{"trials":6869,"activeCount":103},[6870],{"nctId":6542,"briefTitle":6543,"status":150,"phases":6871,"primaryCompletion":980,"completion":980,"start":4622,"enrollment":6545,"conditions":6872,"interventions":6873},[93],[4853],[6548,6549],{"trials":6875,"activeCount":103},[],{"trials":6877,"activeCount":103},[],{"intervention":6879,"totalTrials":121,"cells":6880},"Omega-3 supplements",{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6887,"PHASE4":6898,"NA":6900},{"trials":6882,"activeCount":103},[],{"trials":6884,"activeCount":103},[],{"trials":6886,"activeCount":103},[],{"trials":6888,"activeCount":103},[6889],{"nctId":6890,"briefTitle":6891,"status":150,"phases":6892,"primaryCompletion":6893,"completion":6894,"start":154,"enrollment":6895,"conditions":6896,"interventions":6897},"NCT02128763","Dry Eye Assessment and Management Study",[93],"2017-09-05","2020-01-31",535,[5414],[6879],{"trials":6899,"activeCount":103},[],{"trials":6901,"activeCount":103},[],{"intervention":6903,"totalTrials":121,"cells":6904},"AndroGel®",{"EARLY_PHASE1":6905,"PHASE1":6907,"PHASE2":6909,"PHASE3":6911,"PHASE4":6921,"NA":6923},{"trials":6906,"activeCount":103},[],{"trials":6908,"activeCount":103},[],{"trials":6910,"activeCount":103},[],{"trials":6912,"activeCount":103},[6913],{"nctId":6914,"briefTitle":6915,"status":150,"phases":6916,"primaryCompletion":5061,"completion":188,"start":4639,"enrollment":6917,"conditions":6918,"interventions":6920},"NCT00799617","The Testosterone Trials in Older Men",[93],790,[6919],"Andropause",[6903],{"trials":6922,"activeCount":103},[],{"trials":6924,"activeCount":103},[],{"intervention":6926,"totalTrials":121,"cells":6927},"Hormone Replacement Therapy",{"EARLY_PHASE1":6928,"PHASE1":6930,"PHASE2":6932,"PHASE3":6934,"PHASE4":6946,"NA":6948},{"trials":6929,"activeCount":103},[],{"trials":6931,"activeCount":103},[],{"trials":6933,"activeCount":103},[],{"trials":6935,"activeCount":103},[6936],{"nctId":6937,"briefTitle":6938,"status":4881,"phases":6939,"primaryCompletion":6940,"completion":6940,"start":6941,"enrollment":103,"conditions":6942,"interventions":6944},"NCT02922348","Hormone Replacement for Premature Ovarian Insufficiency",[93],"2018-12-01","2016-03-01",[6943],"Primary Ovarian Insufficiency",[6926,6945],"Combined Oral Contraceptives",{"trials":6947,"activeCount":103},[],{"trials":6949,"activeCount":103},[],{"intervention":6945,"totalTrials":121,"cells":6951},{"EARLY_PHASE1":6952,"PHASE1":6954,"PHASE2":6956,"PHASE3":6958,"PHASE4":6964,"NA":6966},{"trials":6953,"activeCount":103},[],{"trials":6955,"activeCount":103},[],{"trials":6957,"activeCount":103},[],{"trials":6959,"activeCount":103},[6960],{"nctId":6937,"briefTitle":6938,"status":4881,"phases":6961,"primaryCompletion":6940,"completion":6940,"start":6941,"enrollment":103,"conditions":6962,"interventions":6963},[93],[6943],[6926,6945],{"trials":6965,"activeCount":103},[],{"trials":6967,"activeCount":103},[],{"intervention":4818,"totalTrials":121,"cells":6969},{"EARLY_PHASE1":6970,"PHASE1":6972,"PHASE2":6974,"PHASE3":6976,"PHASE4":6982,"NA":6984},{"trials":6971,"activeCount":103},[],{"trials":6973,"activeCount":103},[],{"trials":6975,"activeCount":103},[],{"trials":6977,"activeCount":103},[6978],{"nctId":4810,"briefTitle":4811,"status":150,"phases":6979,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":994,"conditions":6980,"interventions":6981},[93],[18],[4817,4818,4799],{"trials":6983,"activeCount":103},[],{"trials":6985,"activeCount":103},[],{"intervention":6987,"totalTrials":121,"cells":6988},"injectable naltrexone",{"EARLY_PHASE1":6989,"PHASE1":6991,"PHASE2":6993,"PHASE3":6995,"PHASE4":7006,"NA":7008},{"trials":6990,"activeCount":103},[],{"trials":6992,"activeCount":103},[],{"trials":6994,"activeCount":103},[],{"trials":6996,"activeCount":103},[6997],{"nctId":6998,"briefTitle":6999,"status":150,"phases":7000,"primaryCompletion":7001,"completion":7001,"start":4825,"enrollment":7002,"conditions":7003,"interventions":7005},"NCT01882361","Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone",[92,93],"2020-07-31",77,[6723,7004],"Human Immunodeficiency Virus",[6987],{"trials":7007,"activeCount":103},[],{"trials":7009,"activeCount":103},[],{"intervention":7011,"totalTrials":121,"cells":7012},"rozerem",{"EARLY_PHASE1":7013,"PHASE1":7015,"PHASE2":7017,"PHASE3":7019,"PHASE4":7028,"NA":7030},{"trials":7014,"activeCount":103},[],{"trials":7016,"activeCount":103},[],{"trials":7018,"activeCount":103},[],{"trials":7020,"activeCount":103},[7021],{"nctId":7022,"briefTitle":7023,"status":150,"phases":7024,"primaryCompletion":4921,"completion":4921,"start":5108,"enrollment":3031,"conditions":7025,"interventions":7027},"NCT01048242","Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)",[93],[466,7026],"Obstructive Sleep Apnea",[7011],{"trials":7029,"activeCount":103},[],{"trials":7031,"activeCount":103},[],{"intervention":7033,"totalTrials":121,"cells":7034},"medication management",{"EARLY_PHASE1":7035,"PHASE1":7037,"PHASE2":7039,"PHASE3":7041,"PHASE4":7051,"NA":7053},{"trials":7036,"activeCount":103},[],{"trials":7038,"activeCount":103},[],{"trials":7040,"activeCount":103},[],{"trials":7042,"activeCount":103},[7043],{"nctId":7044,"briefTitle":7045,"status":150,"phases":7046,"primaryCompletion":981,"completion":981,"start":7047,"enrollment":2452,"conditions":7048,"interventions":7050},"NCT01032135","Adaptive Treatment for Alcohol and Cocaine Dependence",[92,93],"2008-10",[7049],"Substance Use Disorders",[7033],{"trials":7052,"activeCount":103},[],{"trials":7054,"activeCount":103},[],{"intervention":7056,"totalTrials":121,"cells":7057},"Standard Patch Treatment",{"EARLY_PHASE1":7058,"PHASE1":7060,"PHASE2":7062,"PHASE3":7064,"PHASE4":7076,"NA":7078},{"trials":7059,"activeCount":103},[],{"trials":7061,"activeCount":103},[],{"trials":7063,"activeCount":103},[],{"trials":7065,"activeCount":103},[7066],{"nctId":7067,"briefTitle":7068,"status":150,"phases":7069,"primaryCompletion":4629,"completion":4591,"start":7070,"enrollment":7071,"conditions":7072,"interventions":7074},"NCT00364156","Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation",[93],"2004-06",568,[7073],"TOBACCO USE CESSATION",[7056,7075],"24-weeks of nicotine patch",{"trials":7077,"activeCount":103},[],{"trials":7079,"activeCount":103},[],{"intervention":7075,"totalTrials":121,"cells":7081},{"EARLY_PHASE1":7082,"PHASE1":7084,"PHASE2":7086,"PHASE3":7088,"PHASE4":7094,"NA":7096},{"trials":7083,"activeCount":103},[],{"trials":7085,"activeCount":103},[],{"trials":7087,"activeCount":103},[],{"trials":7089,"activeCount":103},[7090],{"nctId":7067,"briefTitle":7068,"status":150,"phases":7091,"primaryCompletion":4629,"completion":4591,"start":7070,"enrollment":7071,"conditions":7092,"interventions":7093},[93],[7073],[7056,7075],{"trials":7095,"activeCount":103},[],{"trials":7097,"activeCount":103},[],{"intervention":1254,"totalTrials":121,"cells":7099},{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7104,"PHASE3":7106,"PHASE4":7112,"NA":7114},{"trials":7101,"activeCount":103},[],{"trials":7103,"activeCount":103},[],{"trials":7105,"activeCount":103},[],{"trials":7107,"activeCount":103},[7108],{"nctId":1245,"briefTitle":1246,"status":150,"phases":7109,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":784,"conditions":7110,"interventions":7111},[93],[1252],[1224,1254],{"trials":7113,"activeCount":103},[],{"trials":7115,"activeCount":103},[],{"intervention":7117,"totalTrials":121,"cells":7118},"ranibizumab",{"EARLY_PHASE1":7119,"PHASE1":7121,"PHASE2":7123,"PHASE3":7125,"PHASE4":7136,"NA":7138},{"trials":7120,"activeCount":103},[],{"trials":7122,"activeCount":103},[],{"trials":7124,"activeCount":103},[],{"trials":7126,"activeCount":103},[7127],{"nctId":7128,"briefTitle":7129,"status":150,"phases":7130,"primaryCompletion":1063,"completion":2652,"start":723,"enrollment":7131,"conditions":7132,"interventions":7134},"NCT00593450","Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial",[93],1208,[7133],"Age Related Macular Degeneration",[7117,7135],"bevacizumab",{"trials":7137,"activeCount":103},[],{"trials":7139,"activeCount":103},[],{"intervention":7135,"totalTrials":121,"cells":7141},{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7146,"PHASE3":7148,"PHASE4":7154,"NA":7156},{"trials":7143,"activeCount":103},[],{"trials":7145,"activeCount":103},[],{"trials":7147,"activeCount":103},[],{"trials":7149,"activeCount":103},[7150],{"nctId":7128,"briefTitle":7129,"status":150,"phases":7151,"primaryCompletion":1063,"completion":2652,"start":723,"enrollment":7131,"conditions":7152,"interventions":7153},[93],[7133],[7117,7135],{"trials":7155,"activeCount":103},[],{"trials":7157,"activeCount":103},[],{"intervention":6584,"totalTrials":121,"cells":7159},{"EARLY_PHASE1":7160,"PHASE1":7162,"PHASE2":7164,"PHASE3":7166,"PHASE4":7172,"NA":7174},{"trials":7161,"activeCount":103},[],{"trials":7163,"activeCount":103},[],{"trials":7165,"activeCount":103},[],{"trials":7167,"activeCount":103},[7168],{"nctId":6575,"briefTitle":6576,"status":150,"phases":7169,"primaryCompletion":4813,"completion":6578,"start":5108,"enrollment":6579,"conditions":7170,"interventions":7171},[92,93],[4603,3984],[6582,6583,6584],{"trials":7173,"activeCount":103},[],{"trials":7175,"activeCount":103},[],{"intervention":7177,"totalTrials":121,"cells":7178},"S-citalopram",{"EARLY_PHASE1":7179,"PHASE1":7181,"PHASE2":7183,"PHASE3":7185,"PHASE4":7194,"NA":7196},{"trials":7180,"activeCount":103},[],{"trials":7182,"activeCount":103},[],{"trials":7184,"activeCount":103},[],{"trials":7186,"activeCount":103},[7187],{"nctId":7188,"briefTitle":7189,"status":150,"phases":7190,"primaryCompletion":4658,"completion":5344,"start":4550,"enrollment":7191,"conditions":7192,"interventions":7193},"NCT00655057","Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression",[92,93],66,[18],[7177],{"trials":7195,"activeCount":103},[],{"trials":7197,"activeCount":103},[],{"intervention":7199,"totalTrials":121,"cells":7200},"escitalopram oxalate",{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7205,"PHASE3":7207,"PHASE4":7217,"NA":7219},{"trials":7202,"activeCount":103},[],{"trials":7204,"activeCount":103},[],{"trials":7206,"activeCount":103},[],{"trials":7208,"activeCount":103},[7209],{"nctId":7210,"briefTitle":7211,"status":150,"phases":7212,"primaryCompletion":4673,"completion":4673,"start":5344,"enrollment":7213,"conditions":7214,"interventions":7216},"NCT01401595","Brain Imaging and Treatment Studies of the Night Eating Syndrome",[93],87,[7215],"Night Eating Syndrome",[7199],{"trials":7218,"activeCount":103},[],{"trials":7220,"activeCount":103},[],{"intervention":1068,"totalTrials":121,"cells":7222},{"EARLY_PHASE1":7223,"PHASE1":7225,"PHASE2":7227,"PHASE3":7229,"PHASE4":7235,"NA":7237},{"trials":7224,"activeCount":103},[],{"trials":7226,"activeCount":103},[],{"trials":7228,"activeCount":103},[],{"trials":7230,"activeCount":103},[7231],{"nctId":1059,"briefTitle":1060,"status":150,"phases":7232,"primaryCompletion":981,"completion":1062,"start":1063,"enrollment":1064,"conditions":7233,"interventions":7234},[93],[1066],[956,1068],{"trials":7236,"activeCount":103},[],{"trials":7238,"activeCount":103},[],{"intervention":4888,"totalTrials":121,"cells":7240},{"EARLY_PHASE1":7241,"PHASE1":7243,"PHASE2":7245,"PHASE3":7247,"PHASE4":7253,"NA":7255},{"trials":7242,"activeCount":103},[],{"trials":7244,"activeCount":103},[],{"trials":7246,"activeCount":103},[],{"trials":7248,"activeCount":103},[7249],{"nctId":4879,"briefTitle":4880,"status":4881,"phases":7250,"primaryCompletion":4883,"completion":4883,"start":4884,"enrollment":103,"conditions":7251,"interventions":7252},[93],[4886],[4868,4888],{"trials":7254,"activeCount":103},[],{"trials":7256,"activeCount":103},[],{"intervention":7258,"totalTrials":121,"cells":7259},"ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee",{"EARLY_PHASE1":7260,"PHASE1":7262,"PHASE2":7264,"PHASE3":7266,"PHASE4":7278,"NA":7280},{"trials":7261,"activeCount":103},[],{"trials":7263,"activeCount":103},[],{"trials":7265,"activeCount":103},[],{"trials":7267,"activeCount":103},[7268],{"nctId":7269,"briefTitle":7270,"status":150,"phases":7271,"primaryCompletion":7272,"completion":7273,"start":7274,"enrollment":5345,"conditions":7275,"interventions":7277},"NCT03703206","The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA)",[93],"2019-08-27","2021-08-27","2018-07-01",[7276],"Knee Arthroplasty, Total",[7258],{"trials":7279,"activeCount":103},[],{"trials":7281,"activeCount":103},[],{"intervention":7283,"totalTrials":121,"cells":7284},"Anti Arrhythmics",{"EARLY_PHASE1":7285,"PHASE1":7287,"PHASE2":7289,"PHASE3":7291,"PHASE4":7302,"NA":7304},{"trials":7286,"activeCount":103},[],{"trials":7288,"activeCount":103},[],{"trials":7290,"activeCount":103},[],{"trials":7292,"activeCount":103},[7293],{"nctId":7294,"briefTitle":7295,"status":150,"phases":7296,"primaryCompletion":7297,"completion":7297,"start":7298,"enrollment":3822,"conditions":7299,"interventions":7301},"NCT04037397","First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)",[93],"2024-10-01","2019-09-24",[7300],"Atrial Fibrillation",[7283],{"trials":7303,"activeCount":103},[],{"trials":7305,"activeCount":103},[],{"intervention":7307,"totalTrials":121,"cells":7308},"Sacubitril\u002FValsartan 200mg",{"EARLY_PHASE1":7309,"PHASE1":7311,"PHASE2":7313,"PHASE3":7315,"PHASE4":7328,"NA":7330},{"trials":7310,"activeCount":103},[],{"trials":7312,"activeCount":103},[],{"trials":7314,"activeCount":103},[],{"trials":7316,"activeCount":103},[7317],{"nctId":7318,"briefTitle":7319,"status":7320,"phases":7321,"primaryCompletion":4050,"completion":1984,"start":7322,"enrollment":3822,"conditions":7323,"interventions":7326},"NCT03508739","Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition","SUSPENDED",[93],"2018-06-01",[4423,7324,24,7325],"Pre-diabetic","Elevated Blood Pressure",[7307,7327],"Valsartan 160mg",{"trials":7329,"activeCount":103},[],{"trials":7331,"activeCount":103},[],{"intervention":7327,"totalTrials":121,"cells":7333},{"EARLY_PHASE1":7334,"PHASE1":7336,"PHASE2":7338,"PHASE3":7340,"PHASE4":7346,"NA":7348},{"trials":7335,"activeCount":103},[],{"trials":7337,"activeCount":103},[],{"trials":7339,"activeCount":103},[],{"trials":7341,"activeCount":103},[7342],{"nctId":7318,"briefTitle":7319,"status":7320,"phases":7343,"primaryCompletion":4050,"completion":1984,"start":7322,"enrollment":3822,"conditions":7344,"interventions":7345},[93],[4423,7324,24,7325],[7307,7327],{"trials":7347,"activeCount":103},[],{"trials":7349,"activeCount":103},[],{"intervention":7351,"totalTrials":2399,"cells":7352},"CART-19",{"EARLY_PHASE1":7353,"PHASE1":7355,"PHASE2":7397,"PHASE3":7439,"PHASE4":7441,"NA":7443},{"trials":7354,"activeCount":103},[],{"trials":7356,"activeCount":103},[7357,7389],{"nctId":7358,"briefTitle":7359,"status":150,"phases":7360,"primaryCompletion":7361,"completion":7362,"start":7363,"enrollment":2565,"conditions":7364,"interventions":7388},"NCT01029366","CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",[91],"2015-07","2016-05","2010-03-17",[7365,7366,7367,7368,7369,7370,7371,7372,7373,7374,7375,7376,7377,7378,7379,7380,7381,7382,7383,7384,7385,7386,7387],"Hematopoietic\u002FLymphoid Cancer","Adult Acute Lymphoblastic Leukemia in Remission","B-cell Adult Acute Lymphoblastic Leukemia","B-cell Chronic Lymphocytic Leukemia","Prolymphocytic Leukemia","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Refractory Chronic Lymphocytic Leukemia","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma",[7351],{"nctId":7390,"briefTitle":7391,"status":1357,"phases":7392,"primaryCompletion":2674,"completion":2334,"start":7393,"enrollment":99,"conditions":7394,"interventions":7396},"NCT01551043","Allo CART-19 Protocol",[91],"2010-09",[7395],"Acute Lymphocytic Leukemia",[7351],{"trials":7398,"activeCount":103},[7399,7409,7418,7430],{"nctId":7400,"briefTitle":7401,"status":150,"phases":7402,"primaryCompletion":7403,"completion":7404,"start":7405,"enrollment":3753,"conditions":7406,"interventions":7408},"NCT01747486","Dose Optimization Trial of CD19 Redirected Autologous T Cells",[92],"2017-12-13","2018-04-06","2013-01-02",[7407],"Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL",[7351],{"nctId":7410,"briefTitle":7411,"status":150,"phases":7412,"primaryCompletion":7413,"completion":5318,"start":7414,"enrollment":902,"conditions":7415,"interventions":7417},"NCT02030834","Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas",[92],"2019-09-16","2014-02-05",[7416],"Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas",[7351],{"nctId":7419,"briefTitle":7420,"status":150,"phases":7421,"primaryCompletion":7422,"completion":7423,"start":7424,"enrollment":7425,"conditions":7426,"interventions":7429},"NCT01626495","Phase I\u002FIIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma",[91,92],"2018-05-07","2019-07-11","2011-08-17",73,[7427,7428],"B Cell Leukemia","B Cell Lymphoma",[7351],{"nctId":7431,"briefTitle":7432,"status":150,"phases":7433,"primaryCompletion":7434,"completion":7434,"start":7435,"enrollment":3753,"conditions":7436,"interventions":7438},"NCT02030847","Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia",[92],"2018-04-26","2014-02-27",[7437],"Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options",[7351,7351,7351,7351],{"trials":7440,"activeCount":103},[],{"trials":7442,"activeCount":103},[],{"trials":7444,"activeCount":103},[],{"intervention":7446,"totalTrials":2475,"cells":7447},"Topiramate",{"EARLY_PHASE1":7448,"PHASE1":7461,"PHASE2":7463,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7449,"activeCount":103},[7450],{"nctId":7451,"briefTitle":7452,"status":1357,"phases":7453,"primaryCompletion":7454,"completion":7454,"start":7455,"enrollment":2399,"conditions":7456,"interventions":7458},"NCT00598923","Preventing Epilepsy After Traumatic Brain Injury With Topiramate",[90],"2009-02","2004-11",[1797,7457],"Epilepsy",[7459,7459,7460],"topiramate","phenytoin",{"trials":7462,"activeCount":103},[],{"trials":7464,"activeCount":103},[7465,7472,7482],{"nctId":7466,"briefTitle":7467,"status":1357,"phases":7468,"primaryCompletion":1250,"completion":1250,"start":1074,"enrollment":2475,"conditions":7469,"interventions":7471},"NCT01764685","Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers",[92],[7470,4853,985],"Heavy Drinking",[7446],{"nctId":7473,"briefTitle":7474,"status":150,"phases":7475,"primaryCompletion":7476,"completion":7476,"start":7477,"enrollment":7478,"conditions":7479,"interventions":7480},"NCT02371889","A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers",[92],"2020-02","2014-12-18",320,[673,702],[7446,7481],"Inactive Placebo",{"nctId":7483,"briefTitle":7484,"status":1357,"phases":7485,"primaryCompletion":7486,"completion":7486,"start":2674,"enrollment":121,"conditions":7487,"interventions":7488},"NCT02074904","Topiramate's Effects on Heavy Drinking",[92],"2017-03",[703],[7446],{"trials":7490,"activeCount":103},[],{"trials":7492,"activeCount":103},[],{"trials":7494,"activeCount":103},[],{"intervention":7496,"totalTrials":1139,"cells":7497},"Zepatier",{"EARLY_PHASE1":7498,"PHASE1":7500,"PHASE2":7502,"PHASE3":7535,"PHASE4":7537,"NA":7539},{"trials":7499,"activeCount":103},[],{"trials":7501,"activeCount":103},[],{"trials":7503,"activeCount":103},[7504,7513,7524],{"nctId":7505,"briefTitle":7506,"status":150,"phases":7507,"primaryCompletion":7508,"completion":7509,"start":7510,"enrollment":329,"conditions":7511,"interventions":7512},"NCT03146741","Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)",[91,92],"2019-09-10","2019-11-30","2017-05-16",[33],[7496],{"nctId":7514,"briefTitle":7515,"status":150,"phases":7516,"primaryCompletion":7517,"completion":7518,"start":7519,"enrollment":1087,"conditions":7520,"interventions":7522},"NCT02743897","Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients",[91,92],"2022-03","2022-12","2016-05-01",[7521],"End Stage Renal Disease",[7496,7523],"Mavyret",{"nctId":7525,"briefTitle":7526,"status":150,"phases":7527,"primaryCompletion":7528,"completion":7529,"start":7530,"enrollment":2440,"conditions":7531,"interventions":7533},"NCT03724149","Transplanting Hepatitis C Lungs Into Negative Lung Recipients",[91,92],"2021-12-31","2022-12-31","2018-12-12",[7532],"Lung Diseases",[7496,7534],"Epclusa",{"trials":7536,"activeCount":103},[],{"trials":7538,"activeCount":103},[],{"trials":7540,"activeCount":103},[],{"intervention":7542,"totalTrials":1139,"cells":7543},"Metformin",{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7582,"PHASE4":7584,"NA":7586},{"trials":7545,"activeCount":103},[],{"trials":7547,"activeCount":103},[],{"trials":7549,"activeCount":103},[7550,7562,7570],{"nctId":7551,"briefTitle":7552,"status":150,"phases":7553,"primaryCompletion":7554,"completion":7555,"start":1074,"enrollment":329,"conditions":7556,"interventions":7560},"NCT01965756","Effect of Insulin Sensitizer Metformin on AD Biomarkers",[92],"2015-12-22","2017-04",[4327,7557,7558,7559],"Vascular Dementia","Dementia","Memory Impairment",[7542,7561],"Placebos",{"nctId":7563,"briefTitle":7564,"status":150,"phases":7565,"primaryCompletion":7566,"completion":7566,"start":7567,"enrollment":1165,"conditions":7568,"interventions":7569},"NCT03593538","Effects of Metformin During Nicotine Withdrawal",[92],"2020-03-13","2016-04-01",[5715,4702],[7542],{"nctId":7571,"briefTitle":7572,"status":150,"phases":7573,"primaryCompletion":1013,"completion":1013,"start":7574,"enrollment":7575,"conditions":7576,"interventions":7579},"NCT00123110","Insulin Resistance and Testosterone in Women",[92],"2005-07",35,[7577,7578],"Insulin Resistance","Postmenopause",[7580,7581],"metformin","leuprolide",{"trials":7583,"activeCount":103},[],{"trials":7585,"activeCount":103},[],{"trials":7587,"activeCount":103},[],{"intervention":1446,"totalTrials":1139,"cells":7589},{"EARLY_PHASE1":7590,"PHASE1":7592,"PHASE2":7613,"PHASE3":7619,"PHASE4":7621,"NA":7623},{"trials":7591,"activeCount":103},[],{"trials":7593,"activeCount":103},[7594,7604],{"nctId":7595,"briefTitle":7596,"status":150,"phases":7597,"primaryCompletion":7598,"completion":7598,"start":7599,"enrollment":1410,"conditions":7600,"interventions":7601},"NCT03092453","Dendritic Cell Vaccination in Patients With Advanced Melanoma",[91],"2023-03-31","2017-05-01",[2685],[7602,7603,1446],"Mature dendritic cell (DC) vaccine","Cyclophosphamide 300mg\u002Fm^2",{"nctId":7605,"briefTitle":7606,"status":150,"phases":7607,"primaryCompletion":7608,"completion":7608,"start":7609,"enrollment":1986,"conditions":7610,"interventions":7611},"NCT03726515","CART-EGFRvIII + Pembrolizumab in GBM",[91],"2021-02-27","2019-03-11",[1628],[7612,1446],"CART-EGFRvIII T cells",{"trials":7614,"activeCount":103},[7615],{"nctId":1438,"briefTitle":1439,"status":1357,"phases":7616,"primaryCompletion":1441,"completion":1397,"start":1442,"enrollment":31,"conditions":7617,"interventions":7618},[92],[1444],[53,1446],{"trials":7620,"activeCount":103},[],{"trials":7622,"activeCount":103},[],{"trials":7624,"activeCount":103},[],{"intervention":7626,"totalTrials":1139,"cells":7627},"Vivitrol",{"EARLY_PHASE1":7628,"PHASE1":7630,"PHASE2":7632,"PHASE3":7661,"PHASE4":7663,"NA":7665},{"trials":7629,"activeCount":103},[],{"trials":7631,"activeCount":103},[],{"trials":7633,"activeCount":103},[7634,7643,7652],{"nctId":7635,"briefTitle":7636,"status":150,"phases":7637,"primaryCompletion":1293,"completion":7638,"start":7639,"enrollment":1165,"conditions":7640,"interventions":7641},"NCT00777062","VIVITROL as a Treatment for Cocaine and Alcohol Dependence",[92],"2013-09","2009-07",[973,985],[7642],"VIVITROL",{"nctId":7644,"briefTitle":7645,"status":1357,"phases":7646,"primaryCompletion":7647,"completion":7647,"start":7648,"enrollment":1139,"conditions":7649,"interventions":7650},"NCT04454411","Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder",[92],"2024-08-31","2022-08-01",[4604],[7651,7626],"Brixadi",{"nctId":7653,"briefTitle":7654,"status":150,"phases":7655,"primaryCompletion":7656,"completion":7656,"start":7657,"enrollment":624,"conditions":7658,"interventions":7660},"NCT01587196","CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery",[92],"2021-01-01","2012-01",[7659],"Prescription Opiate\u002FMedication Dependence",[7626],{"trials":7662,"activeCount":103},[],{"trials":7664,"activeCount":103},[],{"trials":7666,"activeCount":103},[],{"intervention":1169,"totalTrials":1139,"cells":7668},{"EARLY_PHASE1":7669,"PHASE1":7681,"PHASE2":7687,"PHASE3":7697,"PHASE4":7699,"NA":7701},{"trials":7670,"activeCount":103},[7671],{"nctId":7672,"briefTitle":7673,"status":1357,"phases":7674,"primaryCompletion":7675,"completion":7676,"start":7677,"enrollment":329,"conditions":7678,"interventions":7680},"NCT02640209","Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)",[90],"2018-10-15","2019-07-16","2016-01-29",[7679],"LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)",[1169],{"trials":7682,"activeCount":103},[7683],{"nctId":1160,"briefTitle":1161,"status":150,"phases":7684,"primaryCompletion":1163,"completion":1164,"start":189,"enrollment":1165,"conditions":7685,"interventions":7686},[91],[1167],[1138,1138,1169],{"trials":7688,"activeCount":103},[7689],{"nctId":7690,"briefTitle":7691,"status":1357,"phases":7692,"primaryCompletion":7530,"completion":7530,"start":7693,"enrollment":121,"conditions":7694,"interventions":7696},"NCT02935543","CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL",[92],"2016-10",[7695],"Leukemia, Acute Lymphoblastic",[1169],{"trials":7698,"activeCount":103},[],{"trials":7700,"activeCount":103},[],{"trials":7702,"activeCount":103},[],{"intervention":7704,"totalTrials":99,"cells":7705},"Anastrozole",{"EARLY_PHASE1":7706,"PHASE1":7708,"PHASE2":7710,"PHASE3":7728,"PHASE4":7730,"NA":7732},{"trials":7707,"activeCount":103},[],{"trials":7709,"activeCount":103},[],{"trials":7711,"activeCount":103},[7712,7721],{"nctId":7713,"briefTitle":7714,"status":150,"phases":7715,"primaryCompletion":7716,"completion":7716,"start":7717,"enrollment":1420,"conditions":7718,"interventions":7720},"NCT03229499","Pulmonary Hypertension and Anastrozole Trial",[92],"2022-07-22","2017-12-07",[7719],"Pulmonary Arterial Hypertension",[7704],{"nctId":7722,"briefTitle":7723,"status":150,"phases":7724,"primaryCompletion":2418,"completion":7725,"start":1001,"enrollment":2695,"conditions":7726,"interventions":7727},"NCT01545336","Anastrozole in Patients With Pulmonary Arterial Hypertension",[92],"2015-09",[7719],[7704],{"trials":7729,"activeCount":103},[],{"trials":7731,"activeCount":103},[],{"trials":7733,"activeCount":103},[],{"intervention":1414,"totalTrials":99,"cells":7735},{"EARLY_PHASE1":7736,"PHASE1":7738,"PHASE2":7740,"PHASE3":7750,"PHASE4":7752,"NA":7754},{"trials":7737,"activeCount":103},[],{"trials":7739,"activeCount":103},[],{"trials":7741,"activeCount":103},[7742,7746],{"nctId":1404,"briefTitle":1405,"status":150,"phases":7743,"primaryCompletion":1407,"completion":1408,"start":1409,"enrollment":1410,"conditions":7744,"interventions":7745},[92],[1412],[1384,1414],{"nctId":1416,"briefTitle":1417,"status":150,"phases":7747,"primaryCompletion":1419,"completion":1419,"start":189,"enrollment":1420,"conditions":7748,"interventions":7749},[92],[33],[1384,1414],{"trials":7751,"activeCount":103},[],{"trials":7753,"activeCount":103},[],{"trials":7755,"activeCount":103},[],{"intervention":7757,"totalTrials":99,"cells":7758},"huCART19",{"EARLY_PHASE1":7759,"PHASE1":7761,"PHASE2":7772,"PHASE3":7781,"PHASE4":7783,"NA":7785},{"trials":7760,"activeCount":103},[],{"trials":7762,"activeCount":103},[7763],{"nctId":7764,"briefTitle":7765,"status":150,"phases":7766,"primaryCompletion":7767,"completion":7767,"start":7768,"enrollment":1304,"conditions":7769,"interventions":7771},"NCT02374333","Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy",[91],"2021-09-02","2014-03-25",[7395,7770],"Diffuse Large Cell Lymphoma",[7757],{"trials":7773,"activeCount":103},[7774],{"nctId":7775,"briefTitle":7776,"status":150,"phases":7777,"primaryCompletion":2360,"completion":2360,"start":7778,"enrollment":4522,"conditions":7779,"interventions":7780},"NCT03792633","Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL",[92],"2019-01-18",[3311],[7757],{"trials":7782,"activeCount":103},[],{"trials":7784,"activeCount":103},[],{"trials":7786,"activeCount":103},[],{"intervention":7788,"totalTrials":99,"cells":7789},"Simvastatin",{"EARLY_PHASE1":7790,"PHASE1":7792,"PHASE2":7794,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7791,"activeCount":103},[],{"trials":7793,"activeCount":103},[],{"trials":7795,"activeCount":103},[7796,7804],{"nctId":7797,"briefTitle":7798,"status":1357,"phases":7799,"primaryCompletion":4860,"completion":4860,"start":1086,"enrollment":4552,"conditions":7800,"interventions":7802},"NCT00384865","A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension",[92],[7801],"Hypertension, Pulmonary",[7788,7803],"Aspirin",{"nctId":7805,"briefTitle":7806,"status":150,"phases":7807,"primaryCompletion":7808,"completion":7808,"start":7809,"enrollment":2440,"conditions":7810,"interventions":7813},"NCT02061397","Safety of Simvastatin in LAM and TSC",[91,92],"2019-12-13","2014-03",[7811,7812],"Lymphangioleiomyomatosis","Tuberous Sclerosis Complex",[7788,7814,7815],"Sirolimus Oral Product","Everolimus Oral Product",{"trials":7817,"activeCount":103},[],{"trials":7819,"activeCount":103},[],{"trials":7821,"activeCount":103},[],{"intervention":7823,"totalTrials":99,"cells":7824},"Tolcapone",{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7846,"PHASE4":7848,"NA":7850},{"trials":7826,"activeCount":103},[],{"trials":7828,"activeCount":103},[],{"trials":7830,"activeCount":103},[7831,7838],{"nctId":7832,"briefTitle":7833,"status":150,"phases":7834,"primaryCompletion":1337,"completion":4813,"start":4630,"enrollment":7835,"conditions":7836,"interventions":7837},"NCT01202955","Pilot Study of Tolcapone in Smokers",[92],19,[1024],[7823],{"nctId":7839,"briefTitle":7840,"status":150,"phases":7841,"primaryCompletion":1001,"completion":1001,"start":7842,"enrollment":7843,"conditions":7844,"interventions":7845},"NCT01001520","Neural Substrates in Nicotine Withdrawal",[92],"2010-01",218,[1006],[7823],{"trials":7847,"activeCount":103},[],{"trials":7849,"activeCount":103},[],{"trials":7851,"activeCount":103},[],{"intervention":7853,"totalTrials":99,"cells":7854},"Galantamine",{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7856,"activeCount":103},[],{"trials":7858,"activeCount":103},[],{"trials":7860,"activeCount":103},[7861,7870],{"nctId":7862,"briefTitle":7863,"status":150,"phases":7864,"primaryCompletion":7865,"completion":7865,"start":7866,"enrollment":902,"conditions":7867,"interventions":7869},"NCT03384784","Effect of Galantamine on Inflammation and Cognition",[92],"2022-05-31","2017-10-30",[7868],"HIV Associated Cognitive Motor Complex",[7853],{"nctId":7871,"briefTitle":7872,"status":150,"phases":7873,"primaryCompletion":2673,"completion":2673,"start":993,"enrollment":6304,"conditions":7874,"interventions":7875},"NCT01669538","Effect of Galantamine on Short-term Abstinence",[92],[1006],[7853],{"trials":7877,"activeCount":103},[],{"trials":7879,"activeCount":103},[],{"trials":7881,"activeCount":103},[],{"intervention":7883,"totalTrials":99,"cells":7884},"Baclofen",{"EARLY_PHASE1":7885,"PHASE1":7887,"PHASE2":7889,"PHASE3":7906,"PHASE4":7908,"NA":7910},{"trials":7886,"activeCount":103},[],{"trials":7888,"activeCount":103},[],{"trials":7890,"activeCount":103},[7891,7898],{"nctId":7892,"briefTitle":7893,"status":150,"phases":7894,"primaryCompletion":152,"completion":152,"start":7895,"enrollment":3913,"conditions":7896,"interventions":7897},"NCT01821560","Baclofen Effects in Cigarette Smokers",[92],"2013-03",[1024],[7883],{"nctId":7899,"briefTitle":7900,"status":150,"phases":7901,"primaryCompletion":2418,"completion":2418,"start":981,"enrollment":7902,"conditions":7903,"interventions":7905},"NCT02011516","Baclofen Effects on Marijuana Dependence",[92],47,[7904],"Marijuana Dependence",[7883],{"trials":7907,"activeCount":103},[],{"trials":7909,"activeCount":103},[],{"trials":7911,"activeCount":103},[],{"intervention":7913,"totalTrials":99,"cells":7914},"11C-acetate",{"EARLY_PHASE1":7915,"PHASE1":7917,"PHASE2":7919,"PHASE3":7936,"PHASE4":7938,"NA":7940},{"trials":7916,"activeCount":103},[],{"trials":7918,"activeCount":103},[],{"trials":7920,"activeCount":103},[7921,7928],{"nctId":7922,"briefTitle":7923,"status":150,"phases":7924,"primaryCompletion":2466,"completion":2466,"start":980,"enrollment":37,"conditions":7925,"interventions":7926},"NCT01917136","11C-acetate\u002F18Fluorodeoxyglucose-FDG PET\u002FCT and Cardiac MRI in Pulmonary Hypertension",[92],[2227],[7913,7927],"[18F]Fluoro-2-deoxy-2-D-glucose",{"nctId":7929,"briefTitle":7930,"status":1357,"phases":7931,"primaryCompletion":7932,"completion":7932,"start":7933,"enrollment":2592,"conditions":7934,"interventions":7935},"NCT02811744","11C-Acetate PET\u002FCT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation",[92],"2022-02-28","2017-01",[4502],[7913],{"trials":7937,"activeCount":103},[],{"trials":7939,"activeCount":103},[],{"trials":7941,"activeCount":103},[],{"intervention":7534,"totalTrials":99,"cells":7943},{"EARLY_PHASE1":7944,"PHASE1":7946,"PHASE2":7948,"PHASE3":7964,"PHASE4":7966,"NA":7968},{"trials":7945,"activeCount":103},[],{"trials":7947,"activeCount":103},[],{"trials":7949,"activeCount":103},[7950,7960],{"nctId":7951,"briefTitle":7952,"status":150,"phases":7953,"primaryCompletion":7954,"completion":7955,"start":7956,"enrollment":7957,"conditions":7958,"interventions":7959},"NCT04075916","A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients",[92],"2025-07-15","2026-02-25","2021-06-22",201,[7521],[7534],{"nctId":7525,"briefTitle":7526,"status":150,"phases":7961,"primaryCompletion":7528,"completion":7529,"start":7530,"enrollment":2440,"conditions":7962,"interventions":7963},[91,92],[7532],[7496,7534],{"trials":7965,"activeCount":103},[],{"trials":7967,"activeCount":103},[],{"trials":7969,"activeCount":103},[],{"intervention":1519,"totalTrials":99,"cells":7971},{"EARLY_PHASE1":7972,"PHASE1":7988,"PHASE2":7990,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7973,"activeCount":103},[7974],{"nctId":7975,"briefTitle":7976,"status":150,"phases":7977,"primaryCompletion":7978,"completion":7979,"start":7980,"enrollment":2582,"conditions":7981,"interventions":7986},"NCT03079921","Adrenergic System in Islet Transplantation",[90],"2019-04-30","2025-12-31","2017-01-20",[7982,7983,7984,7985],"Type1diabetes","Hypoglycemia","Hypoglycemia Unawareness","Islet Cell Transplantation",[7987,1519],"Phentolamine",{"trials":7989,"activeCount":103},[],{"trials":7991,"activeCount":103},[7992],{"nctId":1509,"briefTitle":1510,"status":150,"phases":7993,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":1515,"conditions":7994,"interventions":7995},[92],[1517],[1519,1489],{"trials":7997,"activeCount":103},[],{"trials":7999,"activeCount":103},[],{"trials":8001,"activeCount":103},[],{"intervention":8003,"totalTrials":99,"cells":8004},"Penn Microbiome Therapy - 001",{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8009,"PHASE3":8034,"PHASE4":8036,"NA":8038},{"trials":8006,"activeCount":103},[],{"trials":8008,"activeCount":103},[],{"trials":8010,"activeCount":103},[8011,8025],{"nctId":8012,"briefTitle":8013,"status":1357,"phases":8014,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":983,"conditions":8018,"interventions":8021},"NCT03970200","Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)",[92],"2021-11-21","2022-05-14","2020-01-16",[8019,8020],"Severe Clostridium Difficile Infection","Severe-Complicated\u002FFulminant Clostridium Difficile Infection",[8003,8022,8023,8024],"Penn Microbiome Therapy - 002","Penn Microbiome Therapy - 003","Antibiotics",{"nctId":8026,"briefTitle":8027,"status":1357,"phases":8028,"primaryCompletion":8029,"completion":7528,"start":8030,"enrollment":2582,"conditions":8031,"interventions":8033},"NCT03973697","Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection",[92],"2021-08-11","2020-01-13",[8032],"Recurrent Clostridium Difficile Infection",[8003,8022,8023],{"trials":8035,"activeCount":103},[],{"trials":8037,"activeCount":103},[],{"trials":8039,"activeCount":103},[],{"intervention":8022,"totalTrials":99,"cells":8041},{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8046,"PHASE3":8056,"PHASE4":8058,"NA":8060},{"trials":8043,"activeCount":103},[],{"trials":8045,"activeCount":103},[],{"trials":8047,"activeCount":103},[8048,8052],{"nctId":8012,"briefTitle":8013,"status":1357,"phases":8049,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":983,"conditions":8050,"interventions":8051},[92],[8019,8020],[8003,8022,8023,8024],{"nctId":8026,"briefTitle":8027,"status":1357,"phases":8053,"primaryCompletion":8029,"completion":7528,"start":8030,"enrollment":2582,"conditions":8054,"interventions":8055},[92],[8032],[8003,8022,8023],{"trials":8057,"activeCount":103},[],{"trials":8059,"activeCount":103},[],{"trials":8061,"activeCount":103},[],{"intervention":8023,"totalTrials":99,"cells":8063},{"EARLY_PHASE1":8064,"PHASE1":8066,"PHASE2":8068,"PHASE3":8078,"PHASE4":8080,"NA":8082},{"trials":8065,"activeCount":103},[],{"trials":8067,"activeCount":103},[],{"trials":8069,"activeCount":103},[8070,8074],{"nctId":8012,"briefTitle":8013,"status":1357,"phases":8071,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":983,"conditions":8072,"interventions":8073},[92],[8019,8020],[8003,8022,8023,8024],{"nctId":8026,"briefTitle":8027,"status":1357,"phases":8075,"primaryCompletion":8029,"completion":7528,"start":8030,"enrollment":2582,"conditions":8076,"interventions":8077},[92],[8032],[8003,8022,8023],{"trials":8079,"activeCount":103},[],{"trials":8081,"activeCount":103},[],{"trials":8083,"activeCount":103},[],{"intervention":8085,"totalTrials":99,"cells":8086},"ghrelin",{"EARLY_PHASE1":8087,"PHASE1":8089,"PHASE2":8091,"PHASE3":8110,"PHASE4":8112,"NA":8114},{"trials":8088,"activeCount":103},[],{"trials":8090,"activeCount":103},[],{"trials":8092,"activeCount":103},[8093,8100],{"nctId":8094,"briefTitle":8095,"status":150,"phases":8096,"primaryCompletion":4825,"completion":4825,"start":1359,"enrollment":1410,"conditions":8097,"interventions":8099},"NCT01833078","Ghrelin Repeated Dose Study",[92],[8098],"Frailty in Aging",[8085],{"nctId":8101,"briefTitle":8102,"status":150,"phases":8103,"primaryCompletion":8104,"completion":8104,"start":8105,"enrollment":3729,"conditions":8106,"interventions":8108},"NCT01898611","Ghrelin Plus Strength Training in Frail Elderly Study",[92],"2016-08-31","2013-07-01",[8107],"Frailty Syndrome",[8109],"Ghrelin",{"trials":8111,"activeCount":103},[],{"trials":8113,"activeCount":103},[],{"trials":8115,"activeCount":103},[],{"intervention":8117,"totalTrials":99,"cells":8118},"Sorafenib",{"EARLY_PHASE1":8119,"PHASE1":8121,"PHASE2":8123,"PHASE3":8144,"PHASE4":8146,"NA":8148},{"trials":8120,"activeCount":103},[],{"trials":8122,"activeCount":103},[],{"trials":8124,"activeCount":103},[8125,8132],{"nctId":8126,"briefTitle":8127,"status":1357,"phases":8128,"primaryCompletion":991,"completion":991,"start":7809,"enrollment":28,"conditions":8129,"interventions":8131},"NCT02021929","Sorafenib for Hepatopulmonary Syndrome",[92],[8130],"Hepatopulmonary Syndrome",[8117],{"nctId":8133,"briefTitle":8134,"status":150,"phases":8135,"primaryCompletion":1063,"completion":8136,"start":1513,"enrollment":8137,"conditions":8138,"interventions":8142},"NCT00654238","Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer",[92],"2011-03",59,[8139,8140,8141,2697],"Metastatic Differentiated Thyroid Cancer","Metastatic Poorly Differentiated Thyroid Cancer","Metastatic Anaplastic Thyroid Cancer",[8143],"sorafenib",{"trials":8145,"activeCount":103},[],{"trials":8147,"activeCount":103},[],{"trials":8149,"activeCount":103},[],{"intervention":8151,"totalTrials":121,"cells":8152},"Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide",{"EARLY_PHASE1":8153,"PHASE1":8155,"PHASE2":8157,"PHASE3":8169,"PHASE4":8171,"NA":8173},{"trials":8154,"activeCount":103},[],{"trials":8156,"activeCount":103},[],{"trials":8158,"activeCount":103},[8159],{"nctId":8160,"briefTitle":8161,"status":4881,"phases":8162,"primaryCompletion":8163,"completion":8163,"start":8164,"enrollment":103,"conditions":8165,"interventions":8168},"NCT05404919","Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates",[92],"2024-08-01","2022-09-06",[8166,8167],"Lung Transplant","Hepatitis B",[8151],{"trials":8170,"activeCount":103},[],{"trials":8172,"activeCount":103},[],{"trials":8174,"activeCount":103},[],{"intervention":8176,"totalTrials":121,"cells":8177},"Ghrelin Group 1",{"EARLY_PHASE1":8178,"PHASE1":8180,"PHASE2":8182,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8179,"activeCount":103},[],{"trials":8181,"activeCount":103},[],{"trials":8183,"activeCount":103},[8184],{"nctId":8185,"briefTitle":8186,"status":150,"phases":8187,"primaryCompletion":4638,"completion":4638,"start":5860,"enrollment":1410,"conditions":8188,"interventions":8190},"NCT01605435","Ghrelin Dose Finding In Frail Elderly",[92],[8189],"The Frailty Syndrome",[8176,8191],"Ghrelin Group 2",{"trials":8193,"activeCount":103},[],{"trials":8195,"activeCount":103},[],{"trials":8197,"activeCount":103},[],{"intervention":8191,"totalTrials":121,"cells":8199},{"EARLY_PHASE1":8200,"PHASE1":8202,"PHASE2":8204,"PHASE3":8210,"PHASE4":8212,"NA":8214},{"trials":8201,"activeCount":103},[],{"trials":8203,"activeCount":103},[],{"trials":8205,"activeCount":103},[8206],{"nctId":8185,"briefTitle":8186,"status":150,"phases":8207,"primaryCompletion":4638,"completion":4638,"start":5860,"enrollment":1410,"conditions":8208,"interventions":8209},[92],[8189],[8176,8191],{"trials":8211,"activeCount":103},[],{"trials":8213,"activeCount":103},[],{"trials":8215,"activeCount":103},[],{"intervention":8217,"totalTrials":121,"cells":8218},"Recombinant human Growth Hormone",{"EARLY_PHASE1":8219,"PHASE1":8221,"PHASE2":8223,"PHASE3":8232,"PHASE4":8234,"NA":8236},{"trials":8220,"activeCount":103},[],{"trials":8222,"activeCount":103},[],{"trials":8224,"activeCount":103},[8225],{"nctId":8226,"briefTitle":8227,"status":150,"phases":8228,"primaryCompletion":4825,"completion":981,"start":8229,"enrollment":902,"conditions":8230,"interventions":8231},"NCT00766038","Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.",[92],"2008-09",[1797],[8217],{"trials":8233,"activeCount":103},[],{"trials":8235,"activeCount":103},[],{"trials":8237,"activeCount":103},[],{"intervention":8239,"totalTrials":121,"cells":8240},"CART-19 cells",{"EARLY_PHASE1":8241,"PHASE1":8243,"PHASE2":8245,"PHASE3":8255,"PHASE4":8257,"NA":8259},{"trials":8242,"activeCount":103},[],{"trials":8244,"activeCount":103},[],{"trials":8246,"activeCount":103},[8247],{"nctId":8248,"briefTitle":8249,"status":1357,"phases":8250,"primaryCompletion":8251,"completion":8252,"start":2334,"enrollment":2399,"conditions":8253,"interventions":8254},"NCT02794246","CART-19 Post-ASCT for Multiple Myeloma",[92],"2019-02","2019-05",[2709],[8239],{"trials":8256,"activeCount":103},[],{"trials":8258,"activeCount":103},[],{"trials":8260,"activeCount":103},[],{"intervention":8262,"totalTrials":121,"cells":8263},"alpha lipoic acid",{"EARLY_PHASE1":8264,"PHASE1":8266,"PHASE2":8268,"PHASE3":8279,"PHASE4":8281,"NA":8283},{"trials":8265,"activeCount":103},[],{"trials":8267,"activeCount":103},[],{"trials":8269,"activeCount":103},[8270],{"nctId":8271,"briefTitle":8272,"status":150,"phases":8273,"primaryCompletion":8274,"completion":8275,"start":1021,"enrollment":6545,"conditions":8276,"interventions":8278},"NCT02613572","Alpha Lipoic Acid in Geographic Atrophy",[91,92],"2019-02-15","2019-03-01",[8277],"Age-Related Macular Degeneration",[8262],{"trials":8280,"activeCount":103},[],{"trials":8282,"activeCount":103},[],{"trials":8284,"activeCount":103},[],{"intervention":8286,"totalTrials":121,"cells":8287},"Baclofen ER",{"EARLY_PHASE1":8288,"PHASE1":8290,"PHASE2":8292,"PHASE3":8300,"PHASE4":8302,"NA":8304},{"trials":8289,"activeCount":103},[],{"trials":8291,"activeCount":103},[],{"trials":8293,"activeCount":103},[8294],{"nctId":8295,"briefTitle":8296,"status":4881,"phases":8297,"primaryCompletion":154,"completion":154,"start":2429,"enrollment":103,"conditions":8298,"interventions":8299},"NCT02003664","A Study of Baclofen ER",[92],[973],[8286],{"trials":8301,"activeCount":103},[],{"trials":8303,"activeCount":103},[],{"trials":8305,"activeCount":103},[],{"intervention":8307,"totalTrials":121,"cells":8308},"Selegiline",{"EARLY_PHASE1":8309,"PHASE1":8311,"PHASE2":8313,"PHASE3":8323,"PHASE4":8325,"NA":8327},{"trials":8310,"activeCount":103},[],{"trials":8312,"activeCount":103},[],{"trials":8314,"activeCount":103},[8315],{"nctId":8316,"briefTitle":8317,"status":150,"phases":8318,"primaryCompletion":8319,"completion":8319,"start":8320,"enrollment":1587,"conditions":8321,"interventions":8322},"NCT00000188","Selegiline in Treatment of Cocaine Dependence - 2",[92],"1995-10","1994-09",[1517],[8307],{"trials":8324,"activeCount":103},[],{"trials":8326,"activeCount":103},[],{"trials":8328,"activeCount":103},[],{"intervention":4662,"totalTrials":121,"cells":8330},{"EARLY_PHASE1":8331,"PHASE1":8333,"PHASE2":8335,"PHASE3":8341,"PHASE4":8343,"NA":8345},{"trials":8332,"activeCount":103},[],{"trials":8334,"activeCount":103},[],{"trials":8336,"activeCount":103},[8337],{"nctId":4655,"briefTitle":4656,"status":150,"phases":8338,"primaryCompletion":4658,"completion":4658,"start":1014,"enrollment":3822,"conditions":8339,"interventions":8340},[92],[4660],[4646,4662,4663],{"trials":8342,"activeCount":103},[],{"trials":8344,"activeCount":103},[],{"trials":8346,"activeCount":103},[],{"intervention":4663,"totalTrials":121,"cells":8348},{"EARLY_PHASE1":8349,"PHASE1":8351,"PHASE2":8353,"PHASE3":8359,"PHASE4":8361,"NA":8363},{"trials":8350,"activeCount":103},[],{"trials":8352,"activeCount":103},[],{"trials":8354,"activeCount":103},[8355],{"nctId":4655,"briefTitle":4656,"status":150,"phases":8356,"primaryCompletion":4658,"completion":4658,"start":1014,"enrollment":3822,"conditions":8357,"interventions":8358},[92],[4660],[4646,4662,4663],{"trials":8360,"activeCount":103},[],{"trials":8362,"activeCount":103},[],{"trials":8364,"activeCount":103},[],{"intervention":8366,"totalTrials":121,"cells":8367},"Testosterone plus somatropin",{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8372,"PHASE3":8384,"PHASE4":8386,"NA":8388},{"trials":8369,"activeCount":103},[],{"trials":8371,"activeCount":103},[],{"trials":8373,"activeCount":103},[8374],{"nctId":8375,"briefTitle":8376,"status":150,"phases":8377,"primaryCompletion":7393,"completion":7393,"start":4551,"enrollment":7575,"conditions":8378,"interventions":8382},"NCT00080483","Testosterone and Growth Hormone for Bone Loss in Men",[92],[8379,8380,8381],"Hypopituitarism","Hypogonadism","Growth Hormone Deficiency",[8366,8383],"testosterone",{"trials":8385,"activeCount":103},[],{"trials":8387,"activeCount":103},[],{"trials":8389,"activeCount":103},[],{"intervention":8383,"totalTrials":121,"cells":8391},{"EARLY_PHASE1":8392,"PHASE1":8394,"PHASE2":8396,"PHASE3":8402,"PHASE4":8404,"NA":8406},{"trials":8393,"activeCount":103},[],{"trials":8395,"activeCount":103},[],{"trials":8397,"activeCount":103},[8398],{"nctId":8375,"briefTitle":8376,"status":150,"phases":8399,"primaryCompletion":7393,"completion":7393,"start":4551,"enrollment":7575,"conditions":8400,"interventions":8401},[92],[8379,8380,8381],[8366,8383],{"trials":8403,"activeCount":103},[],{"trials":8405,"activeCount":103},[],{"trials":8407,"activeCount":103},[],{"intervention":8409,"totalTrials":121,"cells":8410},"Fulvestrant",{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8415,"PHASE3":8425,"PHASE4":8427,"NA":8429},{"trials":8412,"activeCount":103},[],{"trials":8414,"activeCount":103},[],{"trials":8416,"activeCount":103},[8417],{"nctId":8418,"briefTitle":8419,"status":150,"phases":8420,"primaryCompletion":8421,"completion":8421,"start":8422,"enrollment":1410,"conditions":8423,"interventions":8424},"NCT02911844","Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension",[92],"2018-12-05","2017-04-10",[7719],[8409],{"trials":8426,"activeCount":103},[],{"trials":8428,"activeCount":103},[],{"trials":8430,"activeCount":103},[],{"intervention":8432,"totalTrials":121,"cells":8433},"Growth hormone releasing hormone\u002F placebo",{"EARLY_PHASE1":8434,"PHASE1":8436,"PHASE2":8438,"PHASE3":8447,"PHASE4":8449,"NA":8451},{"trials":8435,"activeCount":103},[],{"trials":8437,"activeCount":103},[],{"trials":8439,"activeCount":103},[8440],{"nctId":8441,"briefTitle":8442,"status":150,"phases":8443,"primaryCompletion":722,"completion":722,"start":4551,"enrollment":1139,"conditions":8444,"interventions":8446},"NCT00791843","The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure",[92],[8445],"Congestive Heart Failure",[8432],{"trials":8448,"activeCount":103},[],{"trials":8450,"activeCount":103},[],{"trials":8452,"activeCount":103},[],{"intervention":8454,"totalTrials":121,"cells":8455},"Curcuminoids C3 Complex®",{"EARLY_PHASE1":8456,"PHASE1":8458,"PHASE2":8460,"PHASE3":8468,"PHASE4":8470,"NA":8472},{"trials":8457,"activeCount":103},[],{"trials":8459,"activeCount":103},[],{"trials":8461,"activeCount":103},[8462],{"nctId":8463,"briefTitle":8464,"status":150,"phases":8465,"completion":1105,"start":4550,"enrollment":2964,"conditions":8466,"interventions":8467},"NCT00235625","Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris",[92],[1296],[8454],{"trials":8469,"activeCount":103},[],{"trials":8471,"activeCount":103},[],{"trials":8473,"activeCount":103},[],{"intervention":7481,"totalTrials":121,"cells":8475},{"EARLY_PHASE1":8476,"PHASE1":8478,"PHASE2":8480,"PHASE3":8486,"PHASE4":8488,"NA":8490},{"trials":8477,"activeCount":103},[],{"trials":8479,"activeCount":103},[],{"trials":8481,"activeCount":103},[8482],{"nctId":7473,"briefTitle":7474,"status":150,"phases":8483,"primaryCompletion":7476,"completion":7476,"start":7477,"enrollment":7478,"conditions":8484,"interventions":8485},[92],[673,702],[7446,7481],{"trials":8487,"activeCount":103},[],{"trials":8489,"activeCount":103},[],{"trials":8491,"activeCount":103},[],{"intervention":8493,"totalTrials":121,"cells":8494},"Nicoderm CQ transdermal nicotine",{"EARLY_PHASE1":8495,"PHASE1":8497,"PHASE2":8499,"PHASE3":8507,"PHASE4":8509,"NA":8511},{"trials":8496,"activeCount":103},[],{"trials":8498,"activeCount":103},[],{"trials":8500,"activeCount":103},[8501],{"nctId":8502,"briefTitle":8503,"status":150,"phases":8504,"primaryCompletion":722,"completion":722,"start":4658,"enrollment":7213,"conditions":8505,"interventions":8506},"NCT00956943","Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine",[92],[1024],[8493],{"trials":8508,"activeCount":103},[],{"trials":8510,"activeCount":103},[],{"trials":8512,"activeCount":103},[],{"intervention":7927,"totalTrials":121,"cells":8514},{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8525,"PHASE4":8527,"NA":8529},{"trials":8516,"activeCount":103},[],{"trials":8518,"activeCount":103},[],{"trials":8520,"activeCount":103},[8521],{"nctId":7922,"briefTitle":7923,"status":150,"phases":8522,"primaryCompletion":2466,"completion":2466,"start":980,"enrollment":37,"conditions":8523,"interventions":8524},[92],[2227],[7913,7927],{"trials":8526,"activeCount":103},[],{"trials":8528,"activeCount":103},[],{"trials":8530,"activeCount":103},[],{"intervention":8532,"totalTrials":121,"cells":8533},"Zaleplon",{"EARLY_PHASE1":8534,"PHASE1":8536,"PHASE2":8538,"PHASE3":8549,"PHASE4":8551,"NA":8553},{"trials":8535,"activeCount":103},[],{"trials":8537,"activeCount":103},[],{"trials":8539,"activeCount":103},[8540],{"nctId":8541,"briefTitle":8542,"status":150,"phases":8543,"primaryCompletion":8544,"completion":8544,"start":8545,"enrollment":329,"conditions":8546,"interventions":8548},"NCT03489304","Zaleplon in HIV Patients With Depression",[92],"2015-02-04","2014-04-03",[1055,8547],"Clinical Depression",[8532],{"trials":8550,"activeCount":103},[],{"trials":8552,"activeCount":103},[],{"trials":8554,"activeCount":103},[],{"intervention":7651,"totalTrials":121,"cells":8556},{"EARLY_PHASE1":8557,"PHASE1":8559,"PHASE2":8561,"PHASE3":8567,"PHASE4":8569,"NA":8571},{"trials":8558,"activeCount":103},[],{"trials":8560,"activeCount":103},[],{"trials":8562,"activeCount":103},[8563],{"nctId":7644,"briefTitle":7645,"status":1357,"phases":8564,"primaryCompletion":7647,"completion":7647,"start":7648,"enrollment":1139,"conditions":8565,"interventions":8566},[92],[4604],[7651,7626],{"trials":8568,"activeCount":103},[],{"trials":8570,"activeCount":103},[],{"trials":8572,"activeCount":103},[],{"intervention":8574,"totalTrials":121,"cells":8575},"Ghrelin Infusion - Healthy",{"EARLY_PHASE1":8576,"PHASE1":8578,"PHASE2":8580,"PHASE3":8591,"PHASE4":8593,"NA":8595},{"trials":8577,"activeCount":103},[],{"trials":8579,"activeCount":103},[],{"trials":8581,"activeCount":103},[8582],{"nctId":8583,"briefTitle":8584,"status":150,"phases":8585,"primaryCompletion":8586,"completion":8586,"start":4934,"enrollment":2440,"conditions":8587,"interventions":8589},"NCT00520884","Ghrelin in Healthy and Frail Older Women",[91,92],"2008-12",[8588],"Frailty",[8574,8590],"Ghrelin Infusion - Frail",{"trials":8592,"activeCount":103},[],{"trials":8594,"activeCount":103},[],{"trials":8596,"activeCount":103},[],{"intervention":8590,"totalTrials":121,"cells":8598},{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8609,"PHASE4":8611,"NA":8613},{"trials":8600,"activeCount":103},[],{"trials":8602,"activeCount":103},[],{"trials":8604,"activeCount":103},[8605],{"nctId":8583,"briefTitle":8584,"status":150,"phases":8606,"primaryCompletion":8586,"completion":8586,"start":4934,"enrollment":2440,"conditions":8607,"interventions":8608},[91,92],[8588],[8574,8590],{"trials":8610,"activeCount":103},[],{"trials":8612,"activeCount":103},[],{"trials":8614,"activeCount":103},[],{"intervention":8616,"totalTrials":121,"cells":8617},"1% topical cidofovir",{"EARLY_PHASE1":8618,"PHASE1":8620,"PHASE2":8622,"PHASE3":8632,"PHASE4":8634,"NA":8636},{"trials":8619,"activeCount":103},[],{"trials":8621,"activeCount":103},[],{"trials":8623,"activeCount":103},[8624],{"nctId":8625,"briefTitle":8626,"status":150,"phases":8627,"primaryCompletion":2439,"completion":2439,"start":7639,"enrollment":329,"conditions":8628,"interventions":8630},"NCT00948506","Trial of Topical Cidofovir for the Prevention of Hair Growth",[92],[8629],"Prevention of Hair Growth",[8616,8631],"3% topical cidofovir",{"trials":8633,"activeCount":103},[],{"trials":8635,"activeCount":103},[],{"trials":8637,"activeCount":103},[],{"intervention":8631,"totalTrials":121,"cells":8639},{"EARLY_PHASE1":8640,"PHASE1":8642,"PHASE2":8644,"PHASE3":8650,"PHASE4":8652,"NA":8654},{"trials":8641,"activeCount":103},[],{"trials":8643,"activeCount":103},[],{"trials":8645,"activeCount":103},[8646],{"nctId":8625,"briefTitle":8626,"status":150,"phases":8647,"primaryCompletion":2439,"completion":2439,"start":7639,"enrollment":329,"conditions":8648,"interventions":8649},[92],[8629],[8616,8631],{"trials":8651,"activeCount":103},[],{"trials":8653,"activeCount":103},[],{"trials":8655,"activeCount":103},[],{"intervention":8657,"totalTrials":121,"cells":8658},"Deutetrabenazine 6 MG",{"EARLY_PHASE1":8659,"PHASE1":8661,"PHASE2":8663,"PHASE3":8674,"PHASE4":8676,"NA":8678},{"trials":8660,"activeCount":103},[],{"trials":8662,"activeCount":103},[],{"trials":8664,"activeCount":103},[8665],{"nctId":8666,"briefTitle":8667,"status":150,"phases":8668,"primaryCompletion":8669,"completion":7647,"start":8670,"enrollment":983,"conditions":8671,"interventions":8673},"NCT04173260","An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia",[91,92],"2024-03-15","2021-04-29",[8672],"Dystonia, Primary",[8657],{"trials":8675,"activeCount":103},[],{"trials":8677,"activeCount":103},[],{"trials":8679,"activeCount":103},[],{"intervention":8681,"totalTrials":121,"cells":8682},"Omega 3 fatty acid",{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8698,"PHASE4":8700,"NA":8702},{"trials":8684,"activeCount":103},[],{"trials":8686,"activeCount":103},[],{"trials":8688,"activeCount":103},[8689],{"nctId":8690,"briefTitle":8691,"status":4881,"phases":8692,"primaryCompletion":8693,"completion":8694,"start":7933,"enrollment":103,"conditions":8695,"interventions":8697},"NCT02990091","Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury",[92],"2023-01","2023-12",[8696],"TBI",[8681],{"trials":8699,"activeCount":103},[],{"trials":8701,"activeCount":103},[],{"trials":8703,"activeCount":103},[],{"intervention":8705,"totalTrials":121,"cells":8706},"fecal microbial transplantation",{"EARLY_PHASE1":8707,"PHASE1":8709,"PHASE2":8711,"PHASE3":8722,"PHASE4":8724,"NA":8726},{"trials":8708,"activeCount":103},[],{"trials":8710,"activeCount":103},[],{"trials":8712,"activeCount":103},[8713],{"nctId":8714,"briefTitle":8715,"status":1357,"phases":8716,"primaryCompletion":8717,"completion":8717,"start":8718,"enrollment":2440,"conditions":8719,"interventions":8721},"NCT04201821","Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women",[91,92],"2023-01-18","2021-01-14",[8720],"Fecal Incontinence",[8705],{"trials":8723,"activeCount":103},[],{"trials":8725,"activeCount":103},[],{"trials":8727,"activeCount":103},[],{"intervention":8729,"totalTrials":121,"cells":8730},"[18F]FES",{"EARLY_PHASE1":8731,"PHASE1":8733,"PHASE2":8735,"PHASE3":8744,"PHASE4":8746,"NA":8748},{"trials":8732,"activeCount":103},[],{"trials":8734,"activeCount":103},[],{"trials":8736,"activeCount":103},[8737],{"nctId":8738,"briefTitle":8739,"status":150,"phases":8740,"primaryCompletion":1176,"completion":1176,"start":2674,"enrollment":2399,"conditions":8741,"interventions":8743},"NCT02409316","[18F]FES PET\u002FCT in Endocrine Refractory Breast Cancer",[92],[8742,3094,3221],"Estrogen Receptor Positive Breast Cancer",[8729],{"trials":8745,"activeCount":103},[],{"trials":8747,"activeCount":103},[],{"trials":8749,"activeCount":103},[],{"intervention":8751,"totalTrials":121,"cells":8752},"Niraparib + Nivolumab",{"EARLY_PHASE1":8753,"PHASE1":8755,"PHASE2":8757,"PHASE3":8769,"PHASE4":8771,"NA":8773},{"trials":8754,"activeCount":103},[],{"trials":8756,"activeCount":103},[],{"trials":8758,"activeCount":103},[8759],{"nctId":8760,"briefTitle":8761,"status":150,"phases":8762,"primaryCompletion":8763,"completion":8764,"start":8765,"enrollment":4727,"conditions":8766,"interventions":8767},"NCT03404960","Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy",[91,92],"2022-04-05","2024-10-09","2018-01-31",[1155],[8751,8768],"Niraparib + Ipilimumab",{"trials":8770,"activeCount":103},[],{"trials":8772,"activeCount":103},[],{"trials":8774,"activeCount":103},[],{"intervention":8768,"totalTrials":121,"cells":8776},{"EARLY_PHASE1":8777,"PHASE1":8779,"PHASE2":8781,"PHASE3":8787,"PHASE4":8789,"NA":8791},{"trials":8778,"activeCount":103},[],{"trials":8780,"activeCount":103},[],{"trials":8782,"activeCount":103},[8783],{"nctId":8760,"briefTitle":8761,"status":150,"phases":8784,"primaryCompletion":8763,"completion":8764,"start":8765,"enrollment":4727,"conditions":8785,"interventions":8786},[91,92],[1155],[8751,8768],{"trials":8788,"activeCount":103},[],{"trials":8790,"activeCount":103},[],{"trials":8792,"activeCount":103},[],{"intervention":8794,"totalTrials":121,"cells":8795},"Allopurinol",{"EARLY_PHASE1":8796,"PHASE1":8798,"PHASE2":8800,"PHASE3":8813,"PHASE4":8815,"NA":8817},{"trials":8797,"activeCount":103},[],{"trials":8799,"activeCount":103},[],{"trials":8801,"activeCount":103},[8802],{"nctId":8803,"briefTitle":8804,"status":4881,"phases":8805,"primaryCompletion":4825,"completion":4825,"start":8806,"enrollment":103,"conditions":8807,"interventions":8811},"NCT00281255","Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy",[91,92],"2003-06",[5207,8808,8809,8810],"Cardiomyopathy, Dilated","Heart Diseases","Heart Failure, Congestive",[8794,8812],"Dobutamine",{"trials":8814,"activeCount":103},[],{"trials":8816,"activeCount":103},[],{"trials":8818,"activeCount":103},[],{"intervention":8812,"totalTrials":121,"cells":8820},{"EARLY_PHASE1":8821,"PHASE1":8823,"PHASE2":8825,"PHASE3":8831,"PHASE4":8833,"NA":8835},{"trials":8822,"activeCount":103},[],{"trials":8824,"activeCount":103},[],{"trials":8826,"activeCount":103},[8827],{"nctId":8803,"briefTitle":8804,"status":4881,"phases":8828,"primaryCompletion":4825,"completion":4825,"start":8806,"enrollment":103,"conditions":8829,"interventions":8830},[91,92],[5207,8808,8809,8810],[8794,8812],{"trials":8832,"activeCount":103},[],{"trials":8834,"activeCount":103},[],{"trials":8836,"activeCount":103},[],{"intervention":8838,"totalTrials":121,"cells":8839},"Belimumab",{"EARLY_PHASE1":8840,"PHASE1":8842,"PHASE2":8844,"PHASE3":8854,"PHASE4":8856,"NA":8858},{"trials":8841,"activeCount":103},[],{"trials":8843,"activeCount":103},[],{"trials":8845,"activeCount":103},[8846],{"nctId":8847,"briefTitle":8848,"status":1357,"phases":8849,"primaryCompletion":4601,"completion":8850,"start":6744,"enrollment":190,"conditions":8851,"interventions":8853},"NCT01025193","Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant",[92],"2011-11",[8852],"Desensitization",[8838],{"trials":8855,"activeCount":103},[],{"trials":8857,"activeCount":103},[],{"trials":8859,"activeCount":103},[],{"intervention":7814,"totalTrials":121,"cells":8861},{"EARLY_PHASE1":8862,"PHASE1":8864,"PHASE2":8866,"PHASE3":8872,"PHASE4":8874,"NA":8876},{"trials":8863,"activeCount":103},[],{"trials":8865,"activeCount":103},[],{"trials":8867,"activeCount":103},[8868],{"nctId":7805,"briefTitle":7806,"status":150,"phases":8869,"primaryCompletion":7808,"completion":7808,"start":7809,"enrollment":2440,"conditions":8870,"interventions":8871},[91,92],[7811,7812],[7788,7814,7815],{"trials":8873,"activeCount":103},[],{"trials":8875,"activeCount":103},[],{"trials":8877,"activeCount":103},[],{"intervention":7815,"totalTrials":121,"cells":8879},{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8884,"PHASE3":8890,"PHASE4":8892,"NA":8894},{"trials":8881,"activeCount":103},[],{"trials":8883,"activeCount":103},[],{"trials":8885,"activeCount":103},[8886],{"nctId":7805,"briefTitle":7806,"status":150,"phases":8887,"primaryCompletion":7808,"completion":7808,"start":7809,"enrollment":2440,"conditions":8888,"interventions":8889},[91,92],[7811,7812],[7788,7814,7815],{"trials":8891,"activeCount":103},[],{"trials":8893,"activeCount":103},[],{"trials":8895,"activeCount":103},[],{"intervention":8897,"totalTrials":121,"cells":8898},"Lapatinib",{"EARLY_PHASE1":8899,"PHASE1":8901,"PHASE2":8903,"PHASE3":8912,"PHASE4":8914,"NA":8916},{"trials":8900,"activeCount":103},[],{"trials":8902,"activeCount":103},[],{"trials":8904,"activeCount":103},[8905],{"nctId":8906,"briefTitle":8907,"status":4881,"phases":8908,"primaryCompletion":1337,"completion":5344,"start":8909,"enrollment":103,"conditions":8910,"interventions":8911},"NCT00343759","Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR\u002FerbB2 Targeted Therapy",[92],"2006-06",[2894],[8897],{"trials":8913,"activeCount":103},[],{"trials":8915,"activeCount":103},[],{"trials":8917,"activeCount":103},[],{"intervention":8919,"totalTrials":121,"cells":8920},"chantix",{"EARLY_PHASE1":8921,"PHASE1":8923,"PHASE2":8925,"PHASE3":8934,"PHASE4":8936,"NA":8938},{"trials":8922,"activeCount":103},[],{"trials":8924,"activeCount":103},[],{"trials":8926,"activeCount":103},[8927],{"nctId":8928,"briefTitle":8929,"status":4881,"phases":8930,"primaryCompletion":981,"completion":981,"start":970,"enrollment":103,"conditions":8931,"interventions":8933},"NCT00895557","Assessing the Impact of Varenicline on Brain-Behavior Vulnerability",[92],[8932],"Varenicline and the Blunting of Cocaine Cues",[8919],{"trials":8935,"activeCount":103},[],{"trials":8937,"activeCount":103},[],{"trials":8939,"activeCount":103},[],{"intervention":8941,"totalTrials":121,"cells":8942},"Low Dose Modafinil",{"EARLY_PHASE1":8943,"PHASE1":8945,"PHASE2":8947,"PHASE3":8957,"PHASE4":8959,"NA":8961},{"trials":8944,"activeCount":103},[],{"trials":8946,"activeCount":103},[],{"trials":8948,"activeCount":103},[8949],{"nctId":8950,"briefTitle":8951,"status":150,"phases":8952,"primaryCompletion":4540,"completion":4629,"start":5084,"enrollment":8953,"conditions":8954,"interventions":8955},"NCT00129285","Modafinil Treatment for Cocaine-Dependent Individuals",[92],210,[1517],[8941,8956],"High Dose Modafinil",{"trials":8958,"activeCount":103},[],{"trials":8960,"activeCount":103},[],{"trials":8962,"activeCount":103},[],{"intervention":8956,"totalTrials":121,"cells":8964},{"EARLY_PHASE1":8965,"PHASE1":8967,"PHASE2":8969,"PHASE3":8975,"PHASE4":8977,"NA":8979},{"trials":8966,"activeCount":103},[],{"trials":8968,"activeCount":103},[],{"trials":8970,"activeCount":103},[8971],{"nctId":8950,"briefTitle":8951,"status":150,"phases":8972,"primaryCompletion":4540,"completion":4629,"start":5084,"enrollment":8953,"conditions":8973,"interventions":8974},[92],[1517],[8941,8956],{"trials":8976,"activeCount":103},[],{"trials":8978,"activeCount":103},[],{"trials":8980,"activeCount":103},[],{"intervention":7523,"totalTrials":121,"cells":8982},{"EARLY_PHASE1":8983,"PHASE1":8985,"PHASE2":8987,"PHASE3":8993,"PHASE4":8995,"NA":8997},{"trials":8984,"activeCount":103},[],{"trials":8986,"activeCount":103},[],{"trials":8988,"activeCount":103},[8989],{"nctId":7514,"briefTitle":7515,"status":150,"phases":8990,"primaryCompletion":7517,"completion":7518,"start":7519,"enrollment":1087,"conditions":8991,"interventions":8992},[91,92],[7521],[7496,7523],{"trials":8994,"activeCount":103},[],{"trials":8996,"activeCount":103},[],{"trials":8998,"activeCount":103},[],{"intervention":9000,"totalTrials":121,"cells":9001},"Olaparib Pill",{"EARLY_PHASE1":9002,"PHASE1":9004,"PHASE2":9006,"PHASE3":9019,"PHASE4":9021,"NA":9023},{"trials":9003,"activeCount":103},[],{"trials":9005,"activeCount":103},[],{"trials":9007,"activeCount":103},[9008],{"nctId":9009,"briefTitle":9010,"status":150,"phases":9011,"primaryCompletion":9012,"completion":9012,"start":9013,"enrollment":9014,"conditions":9015,"interventions":9017},"NCT03462342","Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer",[92],"2025-07-21","2018-03-09",123,[9016],"High Grade Serous Carcinoma",[9000,9018],"AZD6738",{"trials":9020,"activeCount":103},[],{"trials":9022,"activeCount":103},[],{"trials":9024,"activeCount":103},[],{"intervention":9018,"totalTrials":121,"cells":9026},{"EARLY_PHASE1":9027,"PHASE1":9029,"PHASE2":9031,"PHASE3":9037,"PHASE4":9039,"NA":9041},{"trials":9028,"activeCount":103},[],{"trials":9030,"activeCount":103},[],{"trials":9032,"activeCount":103},[9033],{"nctId":9009,"briefTitle":9010,"status":150,"phases":9034,"primaryCompletion":9012,"completion":9012,"start":9013,"enrollment":9014,"conditions":9035,"interventions":9036},[92],[9016],[9000,9018],{"trials":9038,"activeCount":103},[],{"trials":9040,"activeCount":103},[],{"trials":9042,"activeCount":103},[],{"intervention":9044,"totalTrials":121,"cells":9045},"Xenon",{"EARLY_PHASE1":9046,"PHASE1":9048,"PHASE2":9050,"PHASE3":9061,"PHASE4":9063,"NA":9065},{"trials":9047,"activeCount":103},[],{"trials":9049,"activeCount":103},[],{"trials":9051,"activeCount":103},[9052],{"nctId":9053,"briefTitle":9054,"status":150,"phases":9055,"primaryCompletion":9056,"completion":6151,"start":9057,"enrollment":37,"conditions":9058,"interventions":9060},"NCT02768727","A Test of Neural Inertia in Humans With Xenon",[92],"2019-12-01","2016-04",[9059],"Neurocognitive Dysfunction",[9044],{"trials":9062,"activeCount":103},[],{"trials":9064,"activeCount":103},[],{"trials":9066,"activeCount":103},[],{"intervention":8024,"totalTrials":121,"cells":9068},{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9073,"PHASE3":9079,"PHASE4":9081,"NA":9083},{"trials":9070,"activeCount":103},[],{"trials":9072,"activeCount":103},[],{"trials":9074,"activeCount":103},[9075],{"nctId":8012,"briefTitle":8013,"status":1357,"phases":9076,"primaryCompletion":8015,"completion":8016,"start":8017,"enrollment":983,"conditions":9077,"interventions":9078},[92],[8019,8020],[8003,8022,8023,8024],{"trials":9080,"activeCount":103},[],{"trials":9082,"activeCount":103},[],{"trials":9084,"activeCount":103},[],{"intervention":9086,"totalTrials":121,"cells":9087},"Pioglitazone",{"EARLY_PHASE1":9088,"PHASE1":9090,"PHASE2":9092,"PHASE3":9101,"PHASE4":9103,"NA":9105},{"trials":9089,"activeCount":103},[],{"trials":9091,"activeCount":103},[],{"trials":9093,"activeCount":103},[9094],{"nctId":9095,"briefTitle":9096,"status":150,"phases":9097,"primaryCompletion":4993,"completion":4993,"start":4592,"enrollment":19,"conditions":9098,"interventions":9099},"NCT00300365","Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL",[92],[1915],[9086,9100,7803],"Niacin ER",{"trials":9102,"activeCount":103},[],{"trials":9104,"activeCount":103},[],{"trials":9106,"activeCount":103},[],{"intervention":9100,"totalTrials":121,"cells":9108},{"EARLY_PHASE1":9109,"PHASE1":9111,"PHASE2":9113,"PHASE3":9119,"PHASE4":9121,"NA":9123},{"trials":9110,"activeCount":103},[],{"trials":9112,"activeCount":103},[],{"trials":9114,"activeCount":103},[9115],{"nctId":9095,"briefTitle":9096,"status":150,"phases":9116,"primaryCompletion":4993,"completion":4993,"start":4592,"enrollment":19,"conditions":9117,"interventions":9118},[92],[1915],[9086,9100,7803],{"trials":9120,"activeCount":103},[],{"trials":9122,"activeCount":103},[],{"trials":9124,"activeCount":103},[],{"intervention":9126,"totalTrials":121,"cells":9127},"Prevnar- Pneumococcal Conjugate Vaccine",{"EARLY_PHASE1":9128,"PHASE1":9130,"PHASE2":9132,"PHASE3":9143,"PHASE4":9145,"NA":9147},{"trials":9129,"activeCount":103},[],{"trials":9131,"activeCount":103},[],{"trials":9133,"activeCount":103},[9134],{"nctId":9135,"briefTitle":9136,"status":150,"phases":9137,"primaryCompletion":1030,"completion":188,"start":9138,"enrollment":28,"conditions":9139,"interventions":9140},"NCT01245673","Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma",[92],"2011-05-10",[2313],[9126,9141,9142],"Revlamid®","MAGE-A3\u002FGM-GSF, Hiltonol®",{"trials":9144,"activeCount":103},[],{"trials":9146,"activeCount":103},[],{"trials":9148,"activeCount":103},[],{"intervention":9141,"totalTrials":121,"cells":9150},{"EARLY_PHASE1":9151,"PHASE1":9153,"PHASE2":9155,"PHASE3":9161,"PHASE4":9163,"NA":9165},{"trials":9152,"activeCount":103},[],{"trials":9154,"activeCount":103},[],{"trials":9156,"activeCount":103},[9157],{"nctId":9135,"briefTitle":9136,"status":150,"phases":9158,"primaryCompletion":1030,"completion":188,"start":9138,"enrollment":28,"conditions":9159,"interventions":9160},[92],[2313],[9126,9141,9142],{"trials":9162,"activeCount":103},[],{"trials":9164,"activeCount":103},[],{"trials":9166,"activeCount":103},[],{"intervention":9142,"totalTrials":121,"cells":9168},{"EARLY_PHASE1":9169,"PHASE1":9171,"PHASE2":9173,"PHASE3":9179,"PHASE4":9181,"NA":9183},{"trials":9170,"activeCount":103},[],{"trials":9172,"activeCount":103},[],{"trials":9174,"activeCount":103},[9175],{"nctId":9135,"briefTitle":9136,"status":150,"phases":9176,"primaryCompletion":1030,"completion":188,"start":9138,"enrollment":28,"conditions":9177,"interventions":9178},[92],[2313],[9126,9141,9142],{"trials":9180,"activeCount":103},[],{"trials":9182,"activeCount":103},[],{"trials":9184,"activeCount":103},[],{"intervention":4708,"totalTrials":121,"cells":9186},{"EARLY_PHASE1":9187,"PHASE1":9189,"PHASE2":9191,"PHASE3":9197,"PHASE4":9199,"NA":9201},{"trials":9188,"activeCount":103},[],{"trials":9190,"activeCount":103},[],{"trials":9192,"activeCount":103},[9193],{"nctId":4695,"briefTitle":4696,"status":1357,"phases":9194,"primaryCompletion":4698,"completion":4698,"start":4699,"enrollment":735,"conditions":9195,"interventions":9196},[92],[4701,4702,4703,4704,4705,2187,4528,4706],[4705,4686,4708],{"trials":9198,"activeCount":103},[],{"trials":9200,"activeCount":103},[],{"trials":9202,"activeCount":103},[],{"intervention":7581,"totalTrials":121,"cells":9204},{"EARLY_PHASE1":9205,"PHASE1":9207,"PHASE2":9209,"PHASE3":9215,"PHASE4":9217,"NA":9219},{"trials":9206,"activeCount":103},[],{"trials":9208,"activeCount":103},[],{"trials":9210,"activeCount":103},[9211],{"nctId":7571,"briefTitle":7572,"status":150,"phases":9212,"primaryCompletion":1013,"completion":1013,"start":7574,"enrollment":7575,"conditions":9213,"interventions":9214},[92],[7577,7578],[7580,7581],{"trials":9216,"activeCount":103},[],{"trials":9218,"activeCount":103},[],{"trials":9220,"activeCount":103},[],{"intervention":9222,"totalTrials":121,"cells":9223},"Pregabalin 200 MG",{"EARLY_PHASE1":9224,"PHASE1":9226,"PHASE2":9228,"PHASE3":9239,"PHASE4":9241,"NA":9243},{"trials":9225,"activeCount":103},[],{"trials":9227,"activeCount":103},[],{"trials":9229,"activeCount":103},[9230],{"nctId":9231,"briefTitle":9232,"status":150,"phases":9233,"primaryCompletion":5410,"completion":5410,"start":9234,"enrollment":1204,"conditions":9235,"interventions":9237},"NCT04218240","Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal",[92],"2020-12-17",[9236],"Opioid Withdrawal",[9222,9238],"Lofexidine 0.18Mg Tab",{"trials":9240,"activeCount":103},[],{"trials":9242,"activeCount":103},[],{"trials":9244,"activeCount":103},[],{"intervention":9238,"totalTrials":121,"cells":9246},{"EARLY_PHASE1":9247,"PHASE1":9249,"PHASE2":9251,"PHASE3":9257,"PHASE4":9259,"NA":9261},{"trials":9248,"activeCount":103},[],{"trials":9250,"activeCount":103},[],{"trials":9252,"activeCount":103},[9253],{"nctId":9231,"briefTitle":9232,"status":150,"phases":9254,"primaryCompletion":5410,"completion":5410,"start":9234,"enrollment":1204,"conditions":9255,"interventions":9256},[92],[9236],[9222,9238],{"trials":9258,"activeCount":103},[],{"trials":9260,"activeCount":103},[],{"trials":9262,"activeCount":103},[],{"intervention":9264,"totalTrials":121,"cells":9265},"KNO3",{"EARLY_PHASE1":9266,"PHASE1":9268,"PHASE2":9270,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9267,"activeCount":103},[],{"trials":9269,"activeCount":103},[],{"trials":9271,"activeCount":103},[9272],{"nctId":9273,"briefTitle":9274,"status":150,"phases":9275,"primaryCompletion":2334,"completion":2334,"start":3373,"enrollment":2964,"conditions":9276,"interventions":9278},"NCT02256345","Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF",[92],[33,9277],"Diastolic Heart Failure",[9264,9279],"KCl",{"trials":9281,"activeCount":103},[],{"trials":9283,"activeCount":103},[],{"trials":9285,"activeCount":103},[],{"intervention":9279,"totalTrials":121,"cells":9287},{"EARLY_PHASE1":9288,"PHASE1":9290,"PHASE2":9292,"PHASE3":9298,"PHASE4":9300,"NA":9302},{"trials":9289,"activeCount":103},[],{"trials":9291,"activeCount":103},[],{"trials":9293,"activeCount":103},[9294],{"nctId":9273,"briefTitle":9274,"status":150,"phases":9295,"primaryCompletion":2334,"completion":2334,"start":3373,"enrollment":2964,"conditions":9296,"interventions":9297},[92],[33,9277],[9264,9279],{"trials":9299,"activeCount":103},[],{"trials":9301,"activeCount":103},[],{"trials":9303,"activeCount":103},[],{"intervention":9305,"totalTrials":121,"cells":9306},"Vasopressin",{"EARLY_PHASE1":9307,"PHASE1":9309,"PHASE2":9311,"PHASE3":9322,"PHASE4":9324,"NA":9326},{"trials":9308,"activeCount":103},[],{"trials":9310,"activeCount":103},[],{"trials":9312,"activeCount":103},[9313],{"nctId":9314,"briefTitle":9315,"status":150,"phases":9316,"primaryCompletion":9317,"completion":9317,"start":9318,"enrollment":5231,"conditions":9319,"interventions":9321},"NCT01611935","AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock",[92],"2016-09-06","2013-05-01",[9320],"Traumatic Shock",[9305],{"trials":9323,"activeCount":103},[],{"trials":9325,"activeCount":103},[],{"trials":9327,"activeCount":103},[],{"intervention":9329,"totalTrials":121,"cells":9330},"Darbepoetin alfa",{"EARLY_PHASE1":9331,"PHASE1":9333,"PHASE2":9335,"PHASE3":9345,"PHASE4":9347,"NA":9349},{"trials":9332,"activeCount":103},[],{"trials":9334,"activeCount":103},[],{"trials":9336,"activeCount":103},[9337],{"nctId":9338,"briefTitle":9339,"status":150,"phases":9340,"primaryCompletion":982,"completion":5777,"start":4540,"enrollment":2695,"conditions":9341,"interventions":9344},"NCT00647998","The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial",[92],[9342,30,9343],"Spinal Ischemia","Neuroprotection",[9329],{"trials":9346,"activeCount":103},[],{"trials":9348,"activeCount":103},[],{"trials":9350,"activeCount":103},[],{"intervention":9352,"totalTrials":121,"cells":9353},"Study drugs: Metformin and fenofibrate",{"EARLY_PHASE1":9354,"PHASE1":9356,"PHASE2":9358,"PHASE3":9370,"PHASE4":9372,"NA":9374},{"trials":9355,"activeCount":103},[],{"trials":9357,"activeCount":103},[],{"trials":9359,"activeCount":103},[9360],{"nctId":9361,"briefTitle":9362,"status":150,"phases":9363,"primaryCompletion":970,"completion":4747,"start":4610,"enrollment":1022,"conditions":9364,"interventions":9366},"NCT00400231","The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study",[92],[9365],"Metabolic Syndrome x",[9352,9367,9368,9369],"Study Drug: Metformin","Study Drug: fenofibrate","Metformin and Fenofibrate placebo",{"trials":9371,"activeCount":103},[],{"trials":9373,"activeCount":103},[],{"trials":9375,"activeCount":103},[],{"intervention":9367,"totalTrials":121,"cells":9377},{"EARLY_PHASE1":9378,"PHASE1":9380,"PHASE2":9382,"PHASE3":9388,"PHASE4":9390,"NA":9392},{"trials":9379,"activeCount":103},[],{"trials":9381,"activeCount":103},[],{"trials":9383,"activeCount":103},[9384],{"nctId":9361,"briefTitle":9362,"status":150,"phases":9385,"primaryCompletion":970,"completion":4747,"start":4610,"enrollment":1022,"conditions":9386,"interventions":9387},[92],[9365],[9352,9367,9368,9369],{"trials":9389,"activeCount":103},[],{"trials":9391,"activeCount":103},[],{"trials":9393,"activeCount":103},[],{"intervention":9368,"totalTrials":121,"cells":9395},{"EARLY_PHASE1":9396,"PHASE1":9398,"PHASE2":9400,"PHASE3":9406,"PHASE4":9408,"NA":9410},{"trials":9397,"activeCount":103},[],{"trials":9399,"activeCount":103},[],{"trials":9401,"activeCount":103},[9402],{"nctId":9361,"briefTitle":9362,"status":150,"phases":9403,"primaryCompletion":970,"completion":4747,"start":4610,"enrollment":1022,"conditions":9404,"interventions":9405},[92],[9365],[9352,9367,9368,9369],{"trials":9407,"activeCount":103},[],{"trials":9409,"activeCount":103},[],{"trials":9411,"activeCount":103},[],{"intervention":9369,"totalTrials":121,"cells":9413},{"EARLY_PHASE1":9414,"PHASE1":9416,"PHASE2":9418,"PHASE3":9424,"PHASE4":9426,"NA":9428},{"trials":9415,"activeCount":103},[],{"trials":9417,"activeCount":103},[],{"trials":9419,"activeCount":103},[9420],{"nctId":9361,"briefTitle":9362,"status":150,"phases":9421,"primaryCompletion":970,"completion":4747,"start":4610,"enrollment":1022,"conditions":9422,"interventions":9423},[92],[9365],[9352,9367,9368,9369],{"trials":9425,"activeCount":103},[],{"trials":9427,"activeCount":103},[],{"trials":9429,"activeCount":103},[],{"intervention":9431,"totalTrials":121,"cells":9432},"ISMN",{"EARLY_PHASE1":9433,"PHASE1":9435,"PHASE2":9437,"PHASE3":9445,"PHASE4":9447,"NA":9449},{"trials":9434,"activeCount":103},[],{"trials":9436,"activeCount":103},[],{"trials":9438,"activeCount":103},[9439],{"nctId":9440,"briefTitle":9441,"status":1357,"phases":9442,"primaryCompletion":2651,"completion":2651,"start":7362,"enrollment":190,"conditions":9443,"interventions":9444},"NCT02791906","Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease",[92],[4422],[9431],{"trials":9446,"activeCount":103},[],{"trials":9448,"activeCount":103},[],{"trials":9450,"activeCount":103},[],{"intervention":9452,"totalTrials":121,"cells":9453},"CD3\u002FCD28",{"EARLY_PHASE1":9454,"PHASE1":9456,"PHASE2":9458,"PHASE3":9466,"PHASE4":9468,"NA":9470},{"trials":9455,"activeCount":103},[],{"trials":9457,"activeCount":103},[],{"trials":9459,"activeCount":103},[9460],{"nctId":9461,"briefTitle":9462,"status":150,"phases":9463,"primaryCompletion":2334,"completion":4957,"start":722,"enrollment":289,"conditions":9464,"interventions":9465},"NCT01426828","Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant",[92],[2709],[9452],{"trials":9467,"activeCount":103},[],{"trials":9469,"activeCount":103},[],{"trials":9471,"activeCount":103},[],{"intervention":9473,"totalTrials":121,"cells":9474},"Naltrexone Hydrochloride",{"EARLY_PHASE1":9475,"PHASE1":9477,"PHASE2":9479,"PHASE3":9493,"PHASE4":9495,"NA":9497},{"trials":9476,"activeCount":103},[],{"trials":9478,"activeCount":103},[],{"trials":9480,"activeCount":103},[9481],{"nctId":9482,"briefTitle":9483,"status":150,"phases":9484,"primaryCompletion":7979,"completion":7979,"start":9485,"enrollment":114,"conditions":9486,"interventions":9492},"NCT03482479","Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis",[92],"2019-02-04",[9487,9488,737,1940,9489,9490,9491],"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Churg-Strauss Syndrome (CSS)","Microscopic Polyangiitis","Polyarteritis Nodosa","Takayasu Arteritis",[9473],{"trials":9494,"activeCount":103},[],{"trials":9496,"activeCount":103},[],{"trials":9498,"activeCount":103},[],{"intervention":9500,"totalTrials":121,"cells":9501},"Ramelteon",{"EARLY_PHASE1":9502,"PHASE1":9504,"PHASE2":9506,"PHASE3":9515,"PHASE4":9517,"NA":9519},{"trials":9503,"activeCount":103},[],{"trials":9505,"activeCount":103},[],{"trials":9507,"activeCount":103},[9508],{"nctId":9509,"briefTitle":9510,"status":150,"phases":9511,"primaryCompletion":9512,"completion":9512,"start":7725,"enrollment":4826,"conditions":9513,"interventions":9514},"NCT02560324","Effect of Ramelteon on Smoking Abstinence",[92],"2018-08",[1006],[9500],{"trials":9516,"activeCount":103},[],{"trials":9518,"activeCount":103},[],{"trials":9520,"activeCount":103},[],{"intervention":9522,"totalTrials":121,"cells":9523},"Olanzapine",{"EARLY_PHASE1":9524,"PHASE1":9526,"PHASE2":9528,"PHASE3":9537,"PHASE4":9539,"NA":9541},{"trials":9525,"activeCount":103},[],{"trials":9527,"activeCount":103},[],{"trials":9529,"activeCount":103},[9530],{"nctId":9531,"briefTitle":9532,"status":4881,"phases":9533,"primaryCompletion":4699,"completion":4699,"start":9534,"enrollment":103,"conditions":9535,"interventions":9536},"NCT05179772","Olanzapine in OUD Patients",[92],"2022-07-28",[2030],[9522],{"trials":9538,"activeCount":103},[],{"trials":9540,"activeCount":103},[],{"trials":9542,"activeCount":103},[],{"intervention":9544,"totalTrials":121,"cells":9545},"ACE2 Chewing Gum",{"EARLY_PHASE1":9546,"PHASE1":9548,"PHASE2":9550,"PHASE3":9561,"PHASE4":9563,"NA":9565},{"trials":9547,"activeCount":103},[],{"trials":9549,"activeCount":103},[],{"trials":9551,"activeCount":103},[9552],{"nctId":9553,"briefTitle":9554,"status":4881,"phases":9555,"primaryCompletion":9556,"completion":9556,"start":9557,"enrollment":103,"conditions":9558,"interventions":9560},"NCT05433181","ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)",[91,92],"2025-04-01","2025-02",[9559],"SARS-CoV-2",[9544],{"trials":9562,"activeCount":103},[],{"trials":9564,"activeCount":103},[],{"trials":9566,"activeCount":103},[],{"intervention":9568,"totalTrials":121,"cells":9569},"Growth Hormone Releasing Hormone",{"EARLY_PHASE1":9570,"PHASE1":9572,"PHASE2":9574,"PHASE3":9585,"PHASE4":9587,"NA":9589},{"trials":9571,"activeCount":103},[],{"trials":9573,"activeCount":103},[],{"trials":9575,"activeCount":103},[9576],{"nctId":9577,"briefTitle":9578,"status":1357,"phases":9579,"primaryCompletion":9580,"completion":722,"start":2439,"enrollment":2881,"conditions":9581,"interventions":9584},"NCT01410799","Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly",[92],"2011-06",[9582,9583],"Hormone Deficiency","Aging",[9568],{"trials":9586,"activeCount":103},[],{"trials":9588,"activeCount":103},[],{"trials":9590,"activeCount":103},[],{"intervention":9592,"totalTrials":121,"cells":9593},"Ritanserin",{"EARLY_PHASE1":9594,"PHASE1":9596,"PHASE2":9598,"PHASE3":9608,"PHASE4":9610,"NA":9612},{"trials":9595,"activeCount":103},[],{"trials":9597,"activeCount":103},[],{"trials":9599,"activeCount":103},[9600],{"nctId":9601,"briefTitle":9602,"status":150,"phases":9603,"primaryCompletion":9604,"start":9605,"enrollment":1165,"conditions":9606,"interventions":9607},"NCT00000187","Ritanserin in Treatment of Cocaine Dependence - 1",[92],"1994-06","1992-07",[1517],[9592],{"trials":9609,"activeCount":103},[],{"trials":9611,"activeCount":103},[],{"trials":9613,"activeCount":103},[],{"intervention":9615,"totalTrials":121,"cells":9616},"pasireotide LAR",{"EARLY_PHASE1":9617,"PHASE1":9619,"PHASE2":9621,"PHASE3":9630,"PHASE4":9632,"NA":9634},{"trials":9618,"activeCount":103},[],{"trials":9620,"activeCount":103},[],{"trials":9622,"activeCount":103},[9623],{"nctId":9624,"briefTitle":9625,"status":1357,"phases":9626,"primaryCompletion":8850,"completion":8850,"start":4813,"enrollment":99,"conditions":9627,"interventions":9629},"NCT00929669","Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas",[92],[9628],"Gonadotroph Adenomas",[9615],{"trials":9631,"activeCount":103},[],{"trials":9633,"activeCount":103},[],{"trials":9635,"activeCount":103},[],{"intervention":9637,"totalTrials":121,"cells":9638},"etanercept",{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9643,"PHASE3":9654,"PHASE4":9656,"NA":9658},{"trials":9640,"activeCount":103},[],{"trials":9642,"activeCount":103},[],{"trials":9644,"activeCount":103},[9645],{"nctId":9646,"briefTitle":9647,"status":150,"phases":9648,"primaryCompletion":1104,"completion":9649,"start":9650,"enrollment":983,"conditions":9651,"interventions":9653},"NCT00107991","Etanercept for Treatment of Hidradenitis",[92],"2008-11","2005-04",[9652],"Hidradenitis Suppurativa",[9637],{"trials":9655,"activeCount":103},[],{"trials":9657,"activeCount":103},[],{"trials":9659,"activeCount":103},[],{"intervention":9661,"totalTrials":121,"cells":9662},"Imiquimod 5% cream",{"EARLY_PHASE1":9663,"PHASE1":9665,"PHASE2":9667,"PHASE3":9678,"PHASE4":9680,"NA":9682},{"trials":9664,"activeCount":103},[],{"trials":9666,"activeCount":103},[],{"trials":9668,"activeCount":103},[9669],{"nctId":9670,"briefTitle":9671,"status":1357,"phases":9672,"primaryCompletion":9673,"completion":5318,"start":9674,"enrollment":2399,"conditions":9675,"interventions":9677},"NCT03760250","Imiquimod for Preventing Keloid Recurrence",[92],"2019-09-05","2019-02-05",[9676],"Keloid",[9661],{"trials":9679,"activeCount":103},[],{"trials":9681,"activeCount":103},[],{"trials":9683,"activeCount":103},[],{"intervention":9685,"totalTrials":121,"cells":9686},"Carbamazepine",{"EARLY_PHASE1":9687,"PHASE1":9689,"PHASE2":9691,"PHASE3":9701,"PHASE4":9703,"NA":9705},{"trials":9688,"activeCount":103},[],{"trials":9690,"activeCount":103},[],{"trials":9692,"activeCount":103},[9693],{"nctId":9694,"briefTitle":9695,"status":150,"phases":9696,"primaryCompletion":9697,"completion":9697,"start":9698,"enrollment":103,"conditions":9699,"interventions":9700},"NCT00000191","Carbamazepine Treatment for Cocaine Dependence - 5",[92],"1994-02","1991-01",[1517],[9685],{"trials":9702,"activeCount":103},[],{"trials":9704,"activeCount":103},[],{"trials":9706,"activeCount":103},[],{"intervention":4545,"totalTrials":121,"cells":9708},{"EARLY_PHASE1":9709,"PHASE1":9711,"PHASE2":9713,"PHASE3":9719,"PHASE4":9721,"NA":9723},{"trials":9710,"activeCount":103},[],{"trials":9712,"activeCount":103},[],{"trials":9714,"activeCount":103},[9715],{"nctId":4537,"briefTitle":4538,"status":150,"phases":9716,"primaryCompletion":1512,"completion":4540,"start":1514,"enrollment":4541,"conditions":9717,"interventions":9718},[92],[4543,673,1517],[4528,4545],{"trials":9720,"activeCount":103},[],{"trials":9722,"activeCount":103},[],{"trials":9724,"activeCount":103},[],{"intervention":9726,"totalTrials":121,"cells":9727},"Mouth rinse",{"EARLY_PHASE1":9728,"PHASE1":9730,"PHASE2":9732,"PHASE3":9743,"PHASE4":9745,"NA":9747},{"trials":9729,"activeCount":103},[],{"trials":9731,"activeCount":103},[],{"trials":9733,"activeCount":103},[9734],{"nctId":9735,"briefTitle":9736,"status":150,"phases":9737,"primaryCompletion":9738,"completion":9739,"start":5608,"enrollment":289,"conditions":9740,"interventions":9742},"NCT05239598","Povidone-Iodine Oral Rinse Study",[92],"2022-07-07","2022-07-13",[9741],"COVID-19",[9726],{"trials":9744,"activeCount":103},[],{"trials":9746,"activeCount":103},[],{"trials":9748,"activeCount":103},[],{"intervention":9750,"totalTrials":121,"cells":9751},"PET\u002FCT with 18-FDG",{"EARLY_PHASE1":9752,"PHASE1":9754,"PHASE2":9756,"PHASE3":9766,"PHASE4":9768,"NA":9770},{"trials":9753,"activeCount":103},[],{"trials":9755,"activeCount":103},[],{"trials":9757,"activeCount":103},[9758],{"nctId":9759,"briefTitle":9760,"status":4881,"phases":9761,"primaryCompletion":1001,"completion":1001,"start":1013,"enrollment":103,"conditions":9762,"interventions":9765},"NCT01471418","The Use of PET\u002FCT to Evaluate Synovitis in the Temporomandibular Joint (TMJ)",[92],[9763,9764],"Temporomandibular Joint","Conservative Treatment Therapy",[9750],{"trials":9767,"activeCount":103},[],{"trials":9769,"activeCount":103},[],{"trials":9771,"activeCount":103},[],{"intervention":9773,"totalTrials":121,"cells":9774},"Dronabinol",{"EARLY_PHASE1":9775,"PHASE1":9777,"PHASE2":9779,"PHASE3":9788,"PHASE4":9790,"NA":9792},{"trials":9776,"activeCount":103},[],{"trials":9778,"activeCount":103},[],{"trials":9780,"activeCount":103},[9781],{"nctId":9782,"briefTitle":9783,"status":150,"phases":9784,"primaryCompletion":4813,"completion":7639,"start":9785,"enrollment":6633,"conditions":9786,"interventions":9787},"NCT00480441","Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal",[92],"2006-08",[7904],[9773],{"trials":9789,"activeCount":103},[],{"trials":9791,"activeCount":103},[],{"trials":9793,"activeCount":103},[],{"intervention":9795,"totalTrials":121,"cells":9796},"Gepirone",{"EARLY_PHASE1":9797,"PHASE1":9799,"PHASE2":9801,"PHASE3":9811,"PHASE4":9813,"NA":9815},{"trials":9798,"activeCount":103},[],{"trials":9800,"activeCount":103},[],{"trials":9802,"activeCount":103},[9803],{"nctId":9804,"briefTitle":9805,"status":150,"phases":9806,"primaryCompletion":9807,"completion":9807,"start":9808,"enrollment":2311,"conditions":9809,"interventions":9810},"NCT00000189","Gepirone vs Placebo in Treatment of Cocaine Dependence - 3",[92],"1991-02","1990-01",[1517],[9795],{"trials":9812,"activeCount":103},[],{"trials":9814,"activeCount":103},[],{"trials":9816,"activeCount":103},[],{"intervention":9818,"totalTrials":121,"cells":9819},"Galantamine ER",{"EARLY_PHASE1":9820,"PHASE1":9822,"PHASE2":9824,"PHASE3":9833,"PHASE4":9835,"NA":9837},{"trials":9821,"activeCount":103},[],{"trials":9823,"activeCount":103},[],{"trials":9825,"activeCount":103},[9826],{"nctId":9827,"briefTitle":9828,"status":150,"phases":9829,"primaryCompletion":993,"completion":1002,"start":9830,"enrollment":2881,"conditions":9831,"interventions":9832},"NCT01548638","Effect of Galantamine on Smoking Abstinence",[92],"2012-02",[1066],[9818],{"trials":9834,"activeCount":103},[],{"trials":9836,"activeCount":103},[],{"trials":9838,"activeCount":103},[],{"intervention":9840,"totalTrials":121,"cells":9841},"nicotine transdermal system",{"EARLY_PHASE1":9842,"PHASE1":9844,"PHASE2":9846,"PHASE3":9856,"PHASE4":9858,"NA":9860},{"trials":9843,"activeCount":103},[],{"trials":9845,"activeCount":103},[],{"trials":9847,"activeCount":103},[9848],{"nctId":9849,"briefTitle":9850,"status":150,"phases":9851,"primaryCompletion":4629,"completion":4813,"start":4631,"enrollment":9852,"conditions":9853,"interventions":9854},"NCT00086411","Comparing Smoking Treatment Programs for Lighter Smokers - 1",[92],260,[1006],[9840,9855],"bupropion",{"trials":9857,"activeCount":103},[],{"trials":9859,"activeCount":103},[],{"trials":9861,"activeCount":103},[],{"intervention":9855,"totalTrials":121,"cells":9863},{"EARLY_PHASE1":9864,"PHASE1":9866,"PHASE2":9868,"PHASE3":9874,"PHASE4":9876,"NA":9878},{"trials":9865,"activeCount":103},[],{"trials":9867,"activeCount":103},[],{"trials":9869,"activeCount":103},[9870],{"nctId":9849,"briefTitle":9850,"status":150,"phases":9871,"primaryCompletion":4629,"completion":4813,"start":4631,"enrollment":9852,"conditions":9872,"interventions":9873},[92],[1006],[9840,9855],{"trials":9875,"activeCount":103},[],{"trials":9877,"activeCount":103},[],{"trials":9879,"activeCount":103},[],{"intervention":9881,"totalTrials":121,"cells":9882},"NS2359",{"EARLY_PHASE1":9883,"PHASE1":9885,"PHASE2":9887,"PHASE3":9899,"PHASE4":9901,"NA":9903},{"trials":9884,"activeCount":103},[],{"trials":9886,"activeCount":103},[],{"trials":9888,"activeCount":103},[9889],{"nctId":9890,"briefTitle":9891,"status":150,"phases":9892,"primaryCompletion":9893,"completion":9894,"start":7362,"enrollment":9895,"conditions":9896,"interventions":9898},"NCT02798627","Trial Of NS2359 For The Treatment of Cocaine Dependence",[92],"2020-03","2020-10",55,[9897],"Cocaine Use Disorder",[9881],{"trials":9900,"activeCount":103},[],{"trials":9902,"activeCount":103},[],{"trials":9904,"activeCount":103},[],{"intervention":9906,"totalTrials":121,"cells":9907},"Anakinra",{"EARLY_PHASE1":9908,"PHASE1":9910,"PHASE2":9912,"PHASE3":9921,"PHASE4":9923,"NA":9925},{"trials":9909,"activeCount":103},[],{"trials":9911,"activeCount":103},[],{"trials":9913,"activeCount":103},[9914],{"nctId":9915,"briefTitle":9916,"status":150,"phases":9917,"primaryCompletion":7767,"completion":7767,"start":9918,"enrollment":1165,"conditions":9919,"interventions":9920},"NCT03141983","Anti-Cytokine Therapy for Hemodialysis InflammatION",[92],"2017-12-15",[157],[9906],{"trials":9922,"activeCount":103},[],{"trials":9924,"activeCount":103},[],{"trials":9926,"activeCount":103},[],{"intervention":9928,"totalTrials":121,"cells":9929},"Oral furosemide",{"EARLY_PHASE1":9930,"PHASE1":9932,"PHASE2":9934,"PHASE3":9947,"PHASE4":9949,"NA":9951},{"trials":9931,"activeCount":103},[],{"trials":9933,"activeCount":103},[],{"trials":9935,"activeCount":103},[9936],{"nctId":9937,"briefTitle":9938,"status":150,"phases":9939,"primaryCompletion":9940,"completion":9941,"start":9942,"enrollment":9943,"conditions":9944,"interventions":9946},"NCT03556761","Furosemide for Accelerated Recovery of Blood Pressure Postpartum",[92],"2019-12-04","2020-02-05","2018-06-20",384,[9945],"Hypertension, Pregnancy-Induced",[9928],{"trials":9948,"activeCount":103},[],{"trials":9950,"activeCount":103},[],{"trials":9952,"activeCount":103},[],{"intervention":9954,"totalTrials":121,"cells":9955},"Quinine Sulfate",{"EARLY_PHASE1":9956,"PHASE1":9958,"PHASE2":9960,"PHASE3":9972,"PHASE4":9974,"NA":9976},{"trials":9957,"activeCount":103},[],{"trials":9959,"activeCount":103},[],{"trials":9961,"activeCount":103},[9962],{"nctId":9963,"briefTitle":9964,"status":1357,"phases":9965,"primaryCompletion":9966,"completion":9966,"start":9967,"enrollment":2440,"conditions":9968,"interventions":9971},"NCT02630472","Topical Irrigation Therapy for CRS",[91,92],"2017-05-04","2015-10",[9969,9970],"Rhinitis","Sinusitis",[9954],{"trials":9973,"activeCount":103},[],{"trials":9975,"activeCount":103},[],{"trials":9977,"activeCount":103},[],{"intervention":9979,"totalTrials":121,"cells":9980},"ABT-089",{"EARLY_PHASE1":9981,"PHASE1":9983,"PHASE2":9985,"PHASE3":9993,"PHASE4":9995,"NA":9997},{"trials":9982,"activeCount":103},[],{"trials":9984,"activeCount":103},[],{"trials":9986,"activeCount":103},[9987],{"nctId":9988,"briefTitle":9989,"status":1357,"phases":9990,"primaryCompletion":1250,"completion":1250,"start":7895,"enrollment":2683,"conditions":9991,"interventions":9992},"NCT01756053","Effects of ABT-089 on Smoking Abstinence Symptoms and Reward",[92],[1066],[9979],{"trials":9994,"activeCount":103},[],{"trials":9996,"activeCount":103},[],{"trials":9998,"activeCount":103},[],{"intervention":10000,"totalTrials":121,"cells":10001},"Propofol",{"EARLY_PHASE1":10002,"PHASE1":10004,"PHASE2":10006,"PHASE3":10018,"PHASE4":10020,"NA":10022},{"trials":10003,"activeCount":103},[],{"trials":10005,"activeCount":103},[],{"trials":10007,"activeCount":103},[10008],{"nctId":10009,"briefTitle":10010,"status":7320,"phases":10011,"primaryCompletion":10012,"completion":10012,"start":10013,"enrollment":289,"conditions":10014,"interventions":10016},"NCT03498391","A Study of Human Multi-Sensory Integration",[92],"2023-05","2018-07-30",[10015],"Anesthesia Awareness",[10000,10017],"Ketamine Injectable Product",{"trials":10019,"activeCount":103},[],{"trials":10021,"activeCount":103},[],{"trials":10023,"activeCount":103},[],{"intervention":10017,"totalTrials":121,"cells":10025},{"EARLY_PHASE1":10026,"PHASE1":10028,"PHASE2":10030,"PHASE3":10036,"PHASE4":10038,"NA":10040},{"trials":10027,"activeCount":103},[],{"trials":10029,"activeCount":103},[],{"trials":10031,"activeCount":103},[10032],{"nctId":10009,"briefTitle":10010,"status":7320,"phases":10033,"primaryCompletion":10012,"completion":10012,"start":10013,"enrollment":289,"conditions":10034,"interventions":10035},[92],[10015],[10000,10017],{"trials":10037,"activeCount":103},[],{"trials":10039,"activeCount":103},[],{"trials":10041,"activeCount":103},[],{"intervention":10043,"totalTrials":121,"cells":10044},"acamprosate",{"EARLY_PHASE1":10045,"PHASE1":10047,"PHASE2":10049,"PHASE3":10058,"PHASE4":10060,"NA":10062},{"trials":10046,"activeCount":103},[],{"trials":10048,"activeCount":103},[],{"trials":10050,"activeCount":103},[10051],{"nctId":10052,"briefTitle":10053,"status":150,"phases":10054,"primaryCompletion":4591,"completion":4630,"start":10055,"enrollment":114,"conditions":10056,"interventions":10057},"NCT00385268","Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence",[92],"2006-11",[973],[10043],{"trials":10059,"activeCount":103},[],{"trials":10061,"activeCount":103},[],{"trials":10063,"activeCount":103},[],{"intervention":10065,"totalTrials":121,"cells":10066},"Methylphenidate",{"EARLY_PHASE1":10067,"PHASE1":10069,"PHASE2":10071,"PHASE3":10083,"PHASE4":10085,"NA":10087},{"trials":10068,"activeCount":103},[],{"trials":10070,"activeCount":103},[],{"trials":10072,"activeCount":103},[10073],{"nctId":10074,"briefTitle":10075,"status":150,"phases":10076,"primaryCompletion":10077,"completion":10077,"start":10078,"enrollment":2592,"conditions":10079,"interventions":10082},"NCT02225106","Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI",[92],"2017-06-21","2014-08-06",[10080,10081,1797],"Cognition Disorder","Attention Deficit Disorder",[10065],{"trials":10084,"activeCount":103},[],{"trials":10086,"activeCount":103},[],{"trials":10088,"activeCount":103},[],{"intervention":10090,"totalTrials":121,"cells":10091},"Dapagliflozin 10Mg Tab",{"EARLY_PHASE1":10092,"PHASE1":10094,"PHASE2":10096,"PHASE3":10107,"PHASE4":10109,"NA":10111},{"trials":10093,"activeCount":103},[],{"trials":10095,"activeCount":103},[],{"trials":10097,"activeCount":103},[10098],{"nctId":10099,"briefTitle":10100,"status":150,"phases":10101,"primaryCompletion":10102,"completion":10102,"start":10103,"enrollment":1139,"conditions":10104,"interventions":10106},"NCT04956809","Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure",[92],"2023-06-01","2021-10-22",[10105],"HFrEF",[10090],{"trials":10108,"activeCount":103},[],{"trials":10110,"activeCount":103},[],{"trials":10112,"activeCount":103},[],{"intervention":10114,"totalTrials":121,"cells":10115},"Pravastatin",{"EARLY_PHASE1":10116,"PHASE1":10118,"PHASE2":10120,"PHASE3":10130,"PHASE4":10132,"NA":10134},{"trials":10117,"activeCount":103},[],{"trials":10119,"activeCount":103},[],{"trials":10121,"activeCount":103},[10122],{"nctId":10123,"briefTitle":10124,"status":150,"phases":10125,"primaryCompletion":4630,"completion":7047,"start":4540,"enrollment":4593,"conditions":10126,"interventions":10129},"NCT00639223","Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance",[92],[10127,10128],"Hypercholesterolemia","Statin-Associated Myopathy",[10114],{"trials":10131,"activeCount":103},[],{"trials":10133,"activeCount":103},[],{"trials":10135,"activeCount":103},[],{"intervention":10137,"totalTrials":121,"cells":10138},"DCVax-L and T Cells",{"EARLY_PHASE1":10139,"PHASE1":10141,"PHASE2":10143,"PHASE3":10152,"PHASE4":10154,"NA":10156},{"trials":10140,"activeCount":103},[],{"trials":10142,"activeCount":103},[],{"trials":10144,"activeCount":103},[10145],{"nctId":10146,"briefTitle":10147,"status":4881,"phases":10148,"primaryCompletion":1074,"completion":7895,"start":7657,"enrollment":103,"conditions":10149,"interventions":10151},"NCT00603460","DCVax-L Vaccination With CD3\u002FCD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer",[91,92],[2859,10150],"Primary Peritoneal Cancer",[10137],{"trials":10153,"activeCount":103},[],{"trials":10155,"activeCount":103},[],{"trials":10157,"activeCount":103},[],{"intervention":10159,"totalTrials":121,"cells":10160},"Tamoxifen",{"EARLY_PHASE1":10161,"PHASE1":10163,"PHASE2":10165,"PHASE3":10174,"PHASE4":10176,"NA":10178},{"trials":10162,"activeCount":103},[],{"trials":10164,"activeCount":103},[],{"trials":10166,"activeCount":103},[10167],{"nctId":10168,"briefTitle":10169,"status":150,"phases":10170,"completion":5108,"start":10171,"enrollment":735,"conditions":10172,"interventions":10173},"NCT00295100","Tamoxifen-MRI Study",[92],"2000-09",[2894],[10159],{"trials":10175,"activeCount":103},[],{"trials":10177,"activeCount":103},[],{"trials":10179,"activeCount":103},[],{"intervention":194,"totalTrials":121,"cells":10181},{"EARLY_PHASE1":10182,"PHASE1":10184,"PHASE2":10186,"PHASE3":10192,"PHASE4":10194,"NA":10196},{"trials":10183,"activeCount":103},[],{"trials":10185,"activeCount":103},[],{"trials":10187,"activeCount":103},[10188],{"nctId":185,"briefTitle":186,"status":150,"phases":10189,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":10190,"interventions":10191},[92],[192],[194,176,195,196,197,198,199],{"trials":10193,"activeCount":103},[],{"trials":10195,"activeCount":103},[],{"trials":10197,"activeCount":103},[],{"intervention":195,"totalTrials":121,"cells":10199},{"EARLY_PHASE1":10200,"PHASE1":10202,"PHASE2":10204,"PHASE3":10210,"PHASE4":10212,"NA":10214},{"trials":10201,"activeCount":103},[],{"trials":10203,"activeCount":103},[],{"trials":10205,"activeCount":103},[10206],{"nctId":185,"briefTitle":186,"status":150,"phases":10207,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":10208,"interventions":10209},[92],[192],[194,176,195,196,197,198,199],{"trials":10211,"activeCount":103},[],{"trials":10213,"activeCount":103},[],{"trials":10215,"activeCount":103},[],{"intervention":197,"totalTrials":121,"cells":10217},{"EARLY_PHASE1":10218,"PHASE1":10220,"PHASE2":10222,"PHASE3":10228,"PHASE4":10230,"NA":10232},{"trials":10219,"activeCount":103},[],{"trials":10221,"activeCount":103},[],{"trials":10223,"activeCount":103},[10224],{"nctId":185,"briefTitle":186,"status":150,"phases":10225,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":10226,"interventions":10227},[92],[192],[194,176,195,196,197,198,199],{"trials":10229,"activeCount":103},[],{"trials":10231,"activeCount":103},[],{"trials":10233,"activeCount":103},[],{"intervention":198,"totalTrials":121,"cells":10235},{"EARLY_PHASE1":10236,"PHASE1":10238,"PHASE2":10240,"PHASE3":10246,"PHASE4":10248,"NA":10250},{"trials":10237,"activeCount":103},[],{"trials":10239,"activeCount":103},[],{"trials":10241,"activeCount":103},[10242],{"nctId":185,"briefTitle":186,"status":150,"phases":10243,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":10244,"interventions":10245},[92],[192],[194,176,195,196,197,198,199],{"trials":10247,"activeCount":103},[],{"trials":10249,"activeCount":103},[],{"trials":10251,"activeCount":103},[],{"intervention":199,"totalTrials":121,"cells":10253},{"EARLY_PHASE1":10254,"PHASE1":10256,"PHASE2":10258,"PHASE3":10264,"PHASE4":10266,"NA":10268},{"trials":10255,"activeCount":103},[],{"trials":10257,"activeCount":103},[],{"trials":10259,"activeCount":103},[10260],{"nctId":185,"briefTitle":186,"status":150,"phases":10261,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":10262,"interventions":10263},[92],[192],[194,176,195,196,197,198,199],{"trials":10265,"activeCount":103},[],{"trials":10267,"activeCount":103},[],{"trials":10269,"activeCount":103},[],{"intervention":10271,"totalTrials":121,"cells":10272},"LY518674",{"EARLY_PHASE1":10273,"PHASE1":10275,"PHASE2":10277,"PHASE3":10286,"PHASE4":10288,"NA":10290},{"trials":10274,"activeCount":103},[],{"trials":10276,"activeCount":103},[],{"trials":10278,"activeCount":103},[10279],{"nctId":10280,"briefTitle":10281,"status":150,"phases":10282,"primaryCompletion":1086,"completion":10055,"start":4715,"enrollment":289,"conditions":10283,"interventions":10285},"NCT00327002","A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism",[92],[10284],"Metabolic Syndrome X",[10271],{"trials":10287,"activeCount":103},[],{"trials":10289,"activeCount":103},[],{"trials":10291,"activeCount":103},[],{"intervention":10293,"totalTrials":2475,"cells":10294},"EC17",{"EARLY_PHASE1":10295,"PHASE1":10304,"PHASE2":10328,"PHASE3":10330,"PHASE4":10332,"NA":10334},{"trials":10296,"activeCount":103},[10297],{"nctId":10298,"briefTitle":10299,"status":150,"phases":10300,"primaryCompletion":1062,"completion":1062,"start":4261,"enrollment":2440,"conditions":10301,"interventions":10303},"NCT01778933","Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)",[90],[10302],"Renal Cell Carcinoma",[10293],{"trials":10305,"activeCount":103},[10306,10313,10320],{"nctId":10307,"briefTitle":10308,"status":150,"phases":10309,"primaryCompletion":10310,"completion":10310,"start":2429,"enrollment":2440,"conditions":10311,"interventions":10312},"NCT02000778","EC17 for Intraoperative Imaging in Occult Ovarian Cancer",[91],"2014-11-12",[2859],[10293],{"nctId":10314,"briefTitle":10315,"status":150,"phases":10316,"primaryCompletion":1062,"completion":1062,"start":2429,"enrollment":2440,"conditions":10317,"interventions":10319},"NCT01996072","EC17 for Intraoperative Imaging for Parathyroidectomy",[91],[10318],"Primary Hyperparathyroidism",[10293],{"nctId":10321,"briefTitle":10322,"status":150,"phases":10323,"primaryCompletion":154,"completion":154,"start":10324,"enrollment":2440,"conditions":10325,"interventions":10327},"NCT01994369","Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)",[91],"2014-05",[10326],"Resectable Breast Cancer",[10293],{"trials":10329,"activeCount":103},[],{"trials":10331,"activeCount":103},[],{"trials":10333,"activeCount":103},[],{"trials":10335,"activeCount":103},[],{"intervention":10337,"totalTrials":99,"cells":10338},"Piracetam",{"EARLY_PHASE1":10339,"PHASE1":10341,"PHASE2":10357,"PHASE3":10359,"PHASE4":10361,"NA":10363},{"trials":10340,"activeCount":103},[],{"trials":10342,"activeCount":103},[10343,10351],{"nctId":10344,"briefTitle":10345,"status":150,"phases":10346,"primaryCompletion":10347,"completion":10347,"start":10348,"enrollment":103,"conditions":10349,"interventions":10350},"NCT00000198","Piracetam for Treatment of Cocaine Addiction - 3",[91],"1997-10","1996-10",[1517],[10337],{"nctId":10352,"briefTitle":10353,"status":4881,"phases":10354,"enrollment":103,"conditions":10355,"interventions":10356},"NCT00000199","Piracetam for Treatment of Cocaine Addiction, Phase II - 4",[91],[1517],[10337],{"trials":10358,"activeCount":103},[],{"trials":10360,"activeCount":103},[],{"trials":10362,"activeCount":103},[],{"trials":10364,"activeCount":103},[],{"intervention":10366,"totalTrials":99,"cells":10367},"Naproxen",{"EARLY_PHASE1":10368,"PHASE1":10370,"PHASE2":10389,"PHASE3":10391,"PHASE4":10393,"NA":10395},{"trials":10369,"activeCount":103},[],{"trials":10371,"activeCount":103},[10372,10382],{"nctId":10373,"briefTitle":10374,"status":1357,"phases":10375,"primaryCompletion":4965,"completion":4965,"start":7047,"enrollment":2565,"conditions":10376,"interventions":10378},"NCT00780325","Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition",[91],[10377],"Healthy Volunteers",[10379,10380,10366,10381,10379],"CG100649","Celecoxib","Acetazolamide",{"nctId":10383,"briefTitle":10384,"status":1357,"phases":10385,"primaryCompletion":10386,"completion":10386,"start":1021,"enrollment":3729,"conditions":10387,"interventions":10388},"NCT02502006","Variability in Response to Non-steroidal Anti-inflammatory Drugs",[91],"2022-09",[21],[10380,10366],{"trials":10390,"activeCount":103},[],{"trials":10392,"activeCount":103},[],{"trials":10394,"activeCount":103},[],{"trials":10396,"activeCount":103},[],{"intervention":10398,"totalTrials":99,"cells":10399},"COVID-19 Convalescent Plasma",{"EARLY_PHASE1":10400,"PHASE1":10402,"PHASE2":10423,"PHASE3":10425,"PHASE4":10427,"NA":10429},{"trials":10401,"activeCount":103},[],{"trials":10403,"activeCount":103},[10404,10414],{"nctId":10405,"briefTitle":10406,"status":150,"phases":10407,"primaryCompletion":10408,"completion":10409,"start":10410,"enrollment":1325,"conditions":10411,"interventions":10413},"NCT04388527","COVID-19 Convalescent Plasma for Mechanically Ventilated Population",[91],"2021-01-25","2021-01-30","2020-04-30",[10412],"Covid-19",[10398],{"nctId":10415,"briefTitle":10416,"status":150,"phases":10417,"primaryCompletion":10418,"completion":10419,"start":10420,"enrollment":1165,"conditions":10421,"interventions":10422},"NCT04397757","COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.",[91],"2021-02-06","2021-03-08","2020-05-13",[9741],[10398],{"trials":10424,"activeCount":103},[],{"trials":10426,"activeCount":103},[],{"trials":10428,"activeCount":103},[],{"trials":10430,"activeCount":103},[],{"intervention":7612,"totalTrials":99,"cells":10432},{"EARLY_PHASE1":10433,"PHASE1":10435,"PHASE2":10450,"PHASE3":10452,"PHASE4":10454,"NA":10456},{"trials":10434,"activeCount":103},[],{"trials":10436,"activeCount":103},[10437,10441],{"nctId":7605,"briefTitle":7606,"status":150,"phases":10438,"primaryCompletion":7608,"completion":7608,"start":7609,"enrollment":1986,"conditions":10439,"interventions":10440},[91],[1628],[7612,1446],{"nctId":10442,"briefTitle":10443,"status":1357,"phases":10444,"primaryCompletion":10445,"completion":10445,"start":10446,"enrollment":2592,"conditions":10447,"interventions":10449},"NCT02209376","Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma",[91],"2018-04-04","2014-11-18",[10448],"Patients With Residual or Reccurent EGFRvIII+ Glioma",[7612],{"trials":10451,"activeCount":103},[],{"trials":10453,"activeCount":103},[],{"trials":10455,"activeCount":103},[],{"trials":10457,"activeCount":103},[],{"intervention":10459,"totalTrials":121,"cells":10460},"CART-BCMA",{"EARLY_PHASE1":10461,"PHASE1":10463,"PHASE2":10474,"PHASE3":10476,"PHASE4":10478,"NA":10480},{"trials":10462,"activeCount":103},[],{"trials":10464,"activeCount":103},[10465],{"nctId":10466,"briefTitle":10467,"status":150,"phases":10468,"primaryCompletion":10469,"completion":10470,"start":10471,"enrollment":3822,"conditions":10472,"interventions":10473},"NCT02546167","CART-BCMA Cells for Multiple Myeloma",[91],"2019-08-21","2020-07-27","2015-09-03",[2709],[10459],{"trials":10475,"activeCount":103},[],{"trials":10477,"activeCount":103},[],{"trials":10479,"activeCount":103},[],{"trials":10481,"activeCount":103},[],{"intervention":10483,"totalTrials":121,"cells":10484},"Icosapent Ethyl 1000 MG [Vascepa]",{"EARLY_PHASE1":10485,"PHASE1":10487,"PHASE2":10500,"PHASE3":10502,"PHASE4":10504,"NA":10506},{"trials":10486,"activeCount":103},[],{"trials":10488,"activeCount":103},[10489],{"nctId":10490,"briefTitle":10491,"status":150,"phases":10492,"primaryCompletion":9512,"completion":10493,"start":10494,"enrollment":329,"conditions":10495,"interventions":10499},"NCT03885661","Vascepa to Accelerate Lipoprotein Uptake and Elimination",[91],"2021-06","2016-01-11",[10496,10497,10498],"Lipid Disorder","Triglycerides High","Dyslipidemias",[10483],{"trials":10501,"activeCount":103},[],{"trials":10503,"activeCount":103},[],{"trials":10505,"activeCount":103},[],{"trials":10507,"activeCount":103},[],{"intervention":10509,"totalTrials":121,"cells":10510},"TCR1020-CD8 T cells",{"EARLY_PHASE1":10511,"PHASE1":10513,"PHASE2":10525,"PHASE3":10527,"PHASE4":10529,"NA":10531},{"trials":10512,"activeCount":103},[],{"trials":10514,"activeCount":103},[10515],{"nctId":10516,"briefTitle":10517,"status":4881,"phases":10518,"primaryCompletion":10519,"completion":10520,"start":10521,"enrollment":103,"conditions":10522,"interventions":10524},"NCT06707896","TCR1020-CD8 T Cells in KRAS-mutated Cancers",[91],"2029-02-01","2044-02-01","2025-06-01",[10523,1153],"Metastatic Pancreatic Adenocarcinoma",[10509],{"trials":10526,"activeCount":103},[],{"trials":10528,"activeCount":103},[],{"trials":10530,"activeCount":103},[],{"trials":10532,"activeCount":103},[],{"intervention":10534,"totalTrials":121,"cells":10535},"Bexxar",{"EARLY_PHASE1":10536,"PHASE1":10538,"PHASE2":10548,"PHASE3":10550,"PHASE4":10552,"NA":10554},{"trials":10537,"activeCount":103},[],{"trials":10539,"activeCount":103},[10540],{"nctId":10541,"briefTitle":10542,"status":150,"phases":10543,"primaryCompletion":2674,"completion":2674,"start":5778,"enrollment":3729,"conditions":10544,"interventions":10547},"NCT00434629","Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed\u002FResidual B-Cell Lymphoma After Autologous Transplant",[91],[10545,10546],"B-cell Lymphoma","Non-Hodgkin's Lymphoma",[10534],{"trials":10549,"activeCount":103},[],{"trials":10551,"activeCount":103},[],{"trials":10553,"activeCount":103},[],{"trials":10555,"activeCount":103},[],{"intervention":10557,"totalTrials":121,"cells":10558},"HAART",{"EARLY_PHASE1":10559,"PHASE1":10561,"PHASE2":10574,"PHASE3":10576,"PHASE4":10578,"NA":10580},{"trials":10560,"activeCount":103},[],{"trials":10562,"activeCount":103},[10563],{"nctId":10564,"briefTitle":10565,"status":150,"phases":10566,"primaryCompletion":10567,"completion":10568,"start":10569,"enrollment":2683,"conditions":10570,"interventions":10572},"NCT01013415","CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients",[91],"2005-06","2021-08","2001-09",[10571],"HIV-1 Infections",[10557,10573],"T cells",{"trials":10575,"activeCount":103},[],{"trials":10577,"activeCount":103},[],{"trials":10579,"activeCount":103},[],{"trials":10581,"activeCount":103},[],{"intervention":10573,"totalTrials":121,"cells":10583},{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10592,"PHASE3":10594,"PHASE4":10596,"NA":10598},{"trials":10585,"activeCount":103},[],{"trials":10587,"activeCount":103},[10588],{"nctId":10564,"briefTitle":10565,"status":150,"phases":10589,"primaryCompletion":10567,"completion":10568,"start":10569,"enrollment":2683,"conditions":10590,"interventions":10591},[91],[10571],[10557,10573],{"trials":10593,"activeCount":103},[],{"trials":10595,"activeCount":103},[],{"trials":10597,"activeCount":103},[],{"trials":10599,"activeCount":103},[],{"intervention":10601,"totalTrials":121,"cells":10602},"CART-19 T cells",{"EARLY_PHASE1":10603,"PHASE1":10605,"PHASE2":10614,"PHASE3":10616,"PHASE4":10618,"NA":10620},{"trials":10604,"activeCount":103},[],{"trials":10606,"activeCount":103},[10607],{"nctId":10608,"briefTitle":10609,"status":150,"phases":10610,"primaryCompletion":7725,"completion":10611,"start":10324,"enrollment":2881,"conditions":10612,"interventions":10613},"NCT02135406","CART-19 for Multiple Myeloma",[91],"2018-01-18",[2709],[10601],{"trials":10615,"activeCount":103},[],{"trials":10617,"activeCount":103},[],{"trials":10619,"activeCount":103},[],{"trials":10621,"activeCount":103},[],{"intervention":10623,"totalTrials":121,"cells":10624},"Toviaz",{"EARLY_PHASE1":10625,"PHASE1":10627,"PHASE2":10635,"PHASE3":10637,"PHASE4":10639,"NA":10641},{"trials":10626,"activeCount":103},[],{"trials":10628,"activeCount":103},[10629],{"nctId":10630,"briefTitle":10631,"status":150,"phases":10632,"primaryCompletion":981,"completion":981,"start":2439,"enrollment":353,"conditions":10633,"interventions":10634},"NCT01925456","Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder",[91],[6517],[10623],{"trials":10636,"activeCount":103},[],{"trials":10638,"activeCount":103},[],{"trials":10640,"activeCount":103},[],{"trials":10642,"activeCount":103},[],{"intervention":10644,"totalTrials":121,"cells":10645},"ER Niacin Oral Fat Challenge",{"EARLY_PHASE1":10646,"PHASE1":10648,"PHASE2":10658,"PHASE3":10660,"PHASE4":10662,"NA":10664},{"trials":10647,"activeCount":103},[],{"trials":10649,"activeCount":103},[10650],{"nctId":10651,"briefTitle":10652,"status":150,"phases":10653,"primaryCompletion":10654,"completion":10654,"start":4638,"enrollment":2565,"conditions":10655,"interventions":10656},"NCT01984073","Effects of Niacin On Fatty Acid Trapping",[91],"2019-12",[4660],[10644,10657],"IR Niacin Oral Fat Challenge",{"trials":10659,"activeCount":103},[],{"trials":10661,"activeCount":103},[],{"trials":10663,"activeCount":103},[],{"trials":10665,"activeCount":103},[],{"intervention":10657,"totalTrials":121,"cells":10667},{"EARLY_PHASE1":10668,"PHASE1":10670,"PHASE2":10676,"PHASE3":10678,"PHASE4":10680,"NA":10682},{"trials":10669,"activeCount":103},[],{"trials":10671,"activeCount":103},[10672],{"nctId":10651,"briefTitle":10652,"status":150,"phases":10673,"primaryCompletion":10654,"completion":10654,"start":4638,"enrollment":2565,"conditions":10674,"interventions":10675},[91],[4660],[10644,10657],{"trials":10677,"activeCount":103},[],{"trials":10679,"activeCount":103},[],{"trials":10681,"activeCount":103},[],{"trials":10683,"activeCount":103},[],{"intervention":10685,"totalTrials":121,"cells":10686},"WT-gag-TCR modified T cells",{"EARLY_PHASE1":10687,"PHASE1":10689,"PHASE2":10698,"PHASE3":10700,"PHASE4":10702,"NA":10704},{"trials":10688,"activeCount":103},[],{"trials":10690,"activeCount":103},[10691],{"nctId":10692,"briefTitle":10693,"status":150,"phases":10694,"primaryCompletion":1250,"completion":1250,"start":4639,"enrollment":99,"conditions":10695,"interventions":10696},"NCT00991224","Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy",[91],[2567],[10685,10697],"α\u002F6-gag-TCR modified T cells",{"trials":10699,"activeCount":103},[],{"trials":10701,"activeCount":103},[],{"trials":10703,"activeCount":103},[],{"trials":10705,"activeCount":103},[],{"intervention":10697,"totalTrials":121,"cells":10707},{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10716,"PHASE3":10718,"PHASE4":10720,"NA":10722},{"trials":10709,"activeCount":103},[],{"trials":10711,"activeCount":103},[10712],{"nctId":10692,"briefTitle":10693,"status":150,"phases":10713,"primaryCompletion":1250,"completion":1250,"start":4639,"enrollment":99,"conditions":10714,"interventions":10715},[91],[2567],[10685,10697],{"trials":10717,"activeCount":103},[],{"trials":10719,"activeCount":103},[],{"trials":10721,"activeCount":103},[],{"trials":10723,"activeCount":103},[],{"intervention":10725,"totalTrials":121,"cells":10726},"Ortho-cyclen, Ethinyl estradiol\u002Fnorgestimate, 0.035 mg\u002F0.250 mg",{"EARLY_PHASE1":10727,"PHASE1":10729,"PHASE2":10738,"PHASE3":10740,"PHASE4":10742,"NA":10744},{"trials":10728,"activeCount":103},[],{"trials":10730,"activeCount":103},[10731],{"nctId":10732,"briefTitle":10733,"status":1357,"phases":10734,"primaryCompletion":7361,"start":10324,"enrollment":1410,"conditions":10735,"interventions":10737},"NCT02144246","Contraceptive Hormones and Women With Cystic Fibrosis",[91],[10736],"Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception",[10725],{"trials":10739,"activeCount":103},[],{"trials":10741,"activeCount":103},[],{"trials":10743,"activeCount":103},[],{"trials":10745,"activeCount":103},[],{"intervention":10747,"totalTrials":121,"cells":10748},"PDGF-B\u002FAd5",{"EARLY_PHASE1":10749,"PHASE1":10751,"PHASE2":10761,"PHASE3":10763,"PHASE4":10765,"NA":10767},{"trials":10750,"activeCount":103},[],{"trials":10752,"activeCount":103},[10753],{"nctId":10754,"briefTitle":10755,"status":150,"phases":10756,"primaryCompletion":4630,"completion":8136,"start":10757,"enrollment":1470,"conditions":10758,"interventions":10760},"NCT00000431","Preliminary Testing of New Treatment for Chronic Leg Wounds",[91],"2005-01",[10759],"Varicose Ulcer",[10747],{"trials":10762,"activeCount":103},[],{"trials":10764,"activeCount":103},[],{"trials":10766,"activeCount":103},[],{"trials":10768,"activeCount":103},[],{"intervention":7602,"totalTrials":121,"cells":10770},{"EARLY_PHASE1":10771,"PHASE1":10773,"PHASE2":10779,"PHASE3":10781,"PHASE4":10783,"NA":10785},{"trials":10772,"activeCount":103},[],{"trials":10774,"activeCount":103},[10775],{"nctId":7595,"briefTitle":7596,"status":150,"phases":10776,"primaryCompletion":7598,"completion":7598,"start":7599,"enrollment":1410,"conditions":10777,"interventions":10778},[91],[2685],[7602,7603,1446],{"trials":10780,"activeCount":103},[],{"trials":10782,"activeCount":103},[],{"trials":10784,"activeCount":103},[],{"trials":10786,"activeCount":103},[],{"intervention":7603,"totalTrials":121,"cells":10788},{"EARLY_PHASE1":10789,"PHASE1":10791,"PHASE2":10797,"PHASE3":10799,"PHASE4":10801,"NA":10803},{"trials":10790,"activeCount":103},[],{"trials":10792,"activeCount":103},[10793],{"nctId":7595,"briefTitle":7596,"status":150,"phases":10794,"primaryCompletion":7598,"completion":7598,"start":7599,"enrollment":1410,"conditions":10795,"interventions":10796},[91],[2685],[7602,7603,1446],{"trials":10798,"activeCount":103},[],{"trials":10800,"activeCount":103},[],{"trials":10802,"activeCount":103},[],{"trials":10804,"activeCount":103},[],{"intervention":10806,"totalTrials":121,"cells":10807},"Ibuprofen",{"EARLY_PHASE1":10808,"PHASE1":10810,"PHASE2":10824,"PHASE3":10826,"PHASE4":10828,"NA":10830},{"trials":10809,"activeCount":103},[],{"trials":10811,"activeCount":103},[10812],{"nctId":10813,"briefTitle":10814,"status":150,"phases":10815,"primaryCompletion":2880,"completion":2880,"start":10816,"enrollment":10817,"conditions":10818,"interventions":10821},"NCT03893175","Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction",[91],"2019-05-10",86,[10819,10820],"Impacted Third Molar Tooth","Pain, Acute",[10806,10822,10823],"Acetaminophen","Oxycodone",{"trials":10825,"activeCount":103},[],{"trials":10827,"activeCount":103},[],{"trials":10829,"activeCount":103},[],{"trials":10831,"activeCount":103},[],{"intervention":10822,"totalTrials":121,"cells":10833},{"EARLY_PHASE1":10834,"PHASE1":10836,"PHASE2":10842,"PHASE3":10844,"PHASE4":10846,"NA":10848},{"trials":10835,"activeCount":103},[],{"trials":10837,"activeCount":103},[10838],{"nctId":10813,"briefTitle":10814,"status":150,"phases":10839,"primaryCompletion":2880,"completion":2880,"start":10816,"enrollment":10817,"conditions":10840,"interventions":10841},[91],[10819,10820],[10806,10822,10823],{"trials":10843,"activeCount":103},[],{"trials":10845,"activeCount":103},[],{"trials":10847,"activeCount":103},[],{"trials":10849,"activeCount":103},[],{"intervention":10823,"totalTrials":121,"cells":10851},{"EARLY_PHASE1":10852,"PHASE1":10854,"PHASE2":10860,"PHASE3":10862,"PHASE4":10864,"NA":10866},{"trials":10853,"activeCount":103},[],{"trials":10855,"activeCount":103},[10856],{"nctId":10813,"briefTitle":10814,"status":150,"phases":10857,"primaryCompletion":2880,"completion":2880,"start":10816,"enrollment":10817,"conditions":10858,"interventions":10859},[91],[10819,10820],[10806,10822,10823],{"trials":10861,"activeCount":103},[],{"trials":10863,"activeCount":103},[],{"trials":10865,"activeCount":103},[],{"trials":10867,"activeCount":103},[],{"intervention":10869,"totalTrials":121,"cells":10870},"Ex Vivo CD3\u002FCD28 costimulated Umbilical Cord Blood T cells",{"EARLY_PHASE1":10871,"PHASE1":10873,"PHASE2":10887,"PHASE3":10889,"PHASE4":10891,"NA":10893},{"trials":10872,"activeCount":103},[],{"trials":10874,"activeCount":103},[10875],{"nctId":10876,"briefTitle":10877,"status":150,"phases":10878,"primaryCompletion":8850,"completion":7362,"start":1031,"enrollment":1410,"conditions":10879,"interventions":10886},"NCT00891592","Umbilical Cord Blood Transplant for Hematological Malignancies",[91],[10880,10881,10882,10883,10884,2709,10885],"CML","AML","MDS","ALL","NHL","Hodgkin's Disease",[10869],{"trials":10888,"activeCount":103},[],{"trials":10890,"activeCount":103},[],{"trials":10892,"activeCount":103},[],{"trials":10894,"activeCount":103},[],{"intervention":10896,"totalTrials":121,"cells":10897},"Adenoviral Vector-Mediated Gene Transfer",{"EARLY_PHASE1":10898,"PHASE1":10900,"PHASE2":10910,"PHASE3":10912,"PHASE4":10914,"NA":10916},{"trials":10899,"activeCount":103},[],{"trials":10901,"activeCount":103},[10902],{"nctId":10903,"briefTitle":10904,"status":1357,"phases":10905,"completion":10171,"start":10906,"enrollment":37,"conditions":10907,"interventions":10909},"NCT00004498","Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency",[91],"1998-07",[10908],"Ornithine Transcarbamylase Deficiency Disease",[10896],{"trials":10911,"activeCount":103},[],{"trials":10913,"activeCount":103},[],{"trials":10915,"activeCount":103},[],{"trials":10917,"activeCount":103},[],{"intervention":10919,"totalTrials":121,"cells":10920},"ZFN modified T cells",{"EARLY_PHASE1":10921,"PHASE1":10923,"PHASE2":10931,"PHASE3":10933,"PHASE4":10935,"NA":10937},{"trials":10922,"activeCount":103},[],{"trials":10924,"activeCount":103},[10925],{"nctId":10926,"briefTitle":10927,"status":150,"phases":10928,"primaryCompletion":1074,"completion":1074,"start":1031,"enrollment":2964,"conditions":10929,"interventions":10930},"NCT00842634","Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV",[91],[4853,2567],[10919],{"trials":10932,"activeCount":103},[],{"trials":10934,"activeCount":103},[],{"trials":10936,"activeCount":103},[],{"trials":10938,"activeCount":103},[],{"intervention":10940,"totalTrials":121,"cells":10941},"hTERT vaccine, GM-CSF, PCV, T cell",{"EARLY_PHASE1":10942,"PHASE1":10944,"PHASE2":10953,"PHASE3":10955,"PHASE4":10957,"NA":10959},{"trials":10943,"activeCount":103},[],{"trials":10945,"activeCount":103},[10946],{"nctId":10947,"briefTitle":10948,"status":150,"phases":10949,"primaryCompletion":4957,"completion":4957,"start":5017,"enrollment":8137,"conditions":10950,"interventions":10951},"NCT00834665","Phase I\u002FII Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma",[91],[2709],[10940,10952],"GM-CSF, PCV, T cell",{"trials":10954,"activeCount":103},[],{"trials":10956,"activeCount":103},[],{"trials":10958,"activeCount":103},[],{"trials":10960,"activeCount":103},[],{"intervention":10952,"totalTrials":121,"cells":10962},{"EARLY_PHASE1":10963,"PHASE1":10965,"PHASE2":10971,"PHASE3":10973,"PHASE4":10975,"NA":10977},{"trials":10964,"activeCount":103},[],{"trials":10966,"activeCount":103},[10967],{"nctId":10947,"briefTitle":10948,"status":150,"phases":10968,"primaryCompletion":4957,"completion":4957,"start":5017,"enrollment":8137,"conditions":10969,"interventions":10970},[91],[2709],[10940,10952],{"trials":10972,"activeCount":103},[],{"trials":10974,"activeCount":103},[],{"trials":10976,"activeCount":103},[],{"trials":10978,"activeCount":103},[],{"intervention":10379,"totalTrials":121,"cells":10980},{"EARLY_PHASE1":10981,"PHASE1":10983,"PHASE2":10989,"PHASE3":10991,"PHASE4":10993,"NA":10995},{"trials":10982,"activeCount":103},[],{"trials":10984,"activeCount":103},[10985],{"nctId":10373,"briefTitle":10374,"status":1357,"phases":10986,"primaryCompletion":4965,"completion":4965,"start":7047,"enrollment":2565,"conditions":10987,"interventions":10988},[91],[10377],[10379,10380,10366,10381,10379],{"trials":10990,"activeCount":103},[],{"trials":10992,"activeCount":103},[],{"trials":10994,"activeCount":103},[],{"trials":10996,"activeCount":103},[],{"intervention":10381,"totalTrials":121,"cells":10998},{"EARLY_PHASE1":10999,"PHASE1":11001,"PHASE2":11007,"PHASE3":11009,"PHASE4":11011,"NA":11013},{"trials":11000,"activeCount":103},[],{"trials":11002,"activeCount":103},[11003],{"nctId":10373,"briefTitle":10374,"status":1357,"phases":11004,"primaryCompletion":4965,"completion":4965,"start":7047,"enrollment":2565,"conditions":11005,"interventions":11006},[91],[10377],[10379,10380,10366,10381,10379],{"trials":11008,"activeCount":103},[],{"trials":11010,"activeCount":103},[],{"trials":11012,"activeCount":103},[],{"trials":11014,"activeCount":103},[],{"intervention":11016,"totalTrials":121,"cells":11017},"CD3\u002FCD28 Activated T cells",{"EARLY_PHASE1":11018,"PHASE1":11020,"PHASE2":11031,"PHASE3":11033,"PHASE4":11035,"NA":11037},{"trials":11019,"activeCount":103},[],{"trials":11021,"activeCount":103},[11022],{"nctId":11023,"briefTitle":11024,"status":1357,"phases":11025,"primaryCompletion":7657,"completion":7657,"start":4540,"enrollment":2881,"conditions":11026,"interventions":11030},"NCT00674427","Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant",[91],[11027,11028,3311,11029,10546,10885,2709,3309],"Chronic Myelogenous Leukemia","Acute Myelogenous Leukemia","Myelodysplastic Syndrome",[11016,11016],{"trials":11032,"activeCount":103},[],{"trials":11034,"activeCount":103},[],{"trials":11036,"activeCount":103},[],{"trials":11038,"activeCount":103},[],{"intervention":2642,"totalTrials":121,"cells":11040},{"EARLY_PHASE1":11041,"PHASE1":11043,"PHASE2":11049,"PHASE3":11051,"PHASE4":11053,"NA":11055},{"trials":11042,"activeCount":103},[],{"trials":11044,"activeCount":103},[11045],{"nctId":2633,"briefTitle":2634,"status":1357,"phases":11046,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2592,"conditions":11047,"interventions":11048},[91],[2639,2640],[2642,2643,2644,2645,2617,2646],{"trials":11050,"activeCount":103},[],{"trials":11052,"activeCount":103},[],{"trials":11054,"activeCount":103},[],{"trials":11056,"activeCount":103},[],{"intervention":2643,"totalTrials":121,"cells":11058},{"EARLY_PHASE1":11059,"PHASE1":11061,"PHASE2":11067,"PHASE3":11069,"PHASE4":11071,"NA":11073},{"trials":11060,"activeCount":103},[],{"trials":11062,"activeCount":103},[11063],{"nctId":2633,"briefTitle":2634,"status":1357,"phases":11064,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2592,"conditions":11065,"interventions":11066},[91],[2639,2640],[2642,2643,2644,2645,2617,2646],{"trials":11068,"activeCount":103},[],{"trials":11070,"activeCount":103},[],{"trials":11072,"activeCount":103},[],{"trials":11074,"activeCount":103},[],{"intervention":2644,"totalTrials":121,"cells":11076},{"EARLY_PHASE1":11077,"PHASE1":11079,"PHASE2":11085,"PHASE3":11087,"PHASE4":11089,"NA":11091},{"trials":11078,"activeCount":103},[],{"trials":11080,"activeCount":103},[11081],{"nctId":2633,"briefTitle":2634,"status":1357,"phases":11082,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2592,"conditions":11083,"interventions":11084},[91],[2639,2640],[2642,2643,2644,2645,2617,2646],{"trials":11086,"activeCount":103},[],{"trials":11088,"activeCount":103},[],{"trials":11090,"activeCount":103},[],{"trials":11092,"activeCount":103},[],{"intervention":2645,"totalTrials":121,"cells":11094},{"EARLY_PHASE1":11095,"PHASE1":11097,"PHASE2":11103,"PHASE3":11105,"PHASE4":11107,"NA":11109},{"trials":11096,"activeCount":103},[],{"trials":11098,"activeCount":103},[11099],{"nctId":2633,"briefTitle":2634,"status":1357,"phases":11100,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2592,"conditions":11101,"interventions":11102},[91],[2639,2640],[2642,2643,2644,2645,2617,2646],{"trials":11104,"activeCount":103},[],{"trials":11106,"activeCount":103},[],{"trials":11108,"activeCount":103},[],{"trials":11110,"activeCount":103},[],{"intervention":11112,"totalTrials":121,"cells":11113},"INO-A002",{"EARLY_PHASE1":11114,"PHASE1":11116,"PHASE2":11125,"PHASE3":11127,"PHASE4":11129,"NA":11131},{"trials":11115,"activeCount":103},[],{"trials":11117,"activeCount":103},[11118],{"nctId":11119,"briefTitle":11120,"status":150,"phases":11121,"primaryCompletion":11122,"completion":11122,"start":5154,"enrollment":1150,"conditions":11123,"interventions":11124},"NCT03831503","A Study of INO-A002 in Healthy Dengue Virus-naive Adults",[91],"2022-10-03",[10377],[11112],{"trials":11126,"activeCount":103},[],{"trials":11128,"activeCount":103},[],{"trials":11130,"activeCount":103},[],{"trials":11132,"activeCount":103},[],{"intervention":11134,"totalTrials":121,"cells":11135},"Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.",{"EARLY_PHASE1":11136,"PHASE1":11138,"PHASE2":11147,"PHASE3":11149,"PHASE4":11151,"NA":11153},{"trials":11137,"activeCount":103},[],{"trials":11139,"activeCount":103},[11140],{"nctId":11141,"briefTitle":11142,"status":150,"phases":11143,"primaryCompletion":11144,"completion":11144,"start":4638,"enrollment":2440,"conditions":11145,"interventions":11146},"NCT01787994","Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy",[91],"2017-07",[4853],[11134],{"trials":11148,"activeCount":103},[],{"trials":11150,"activeCount":103},[],{"trials":11152,"activeCount":103},[],{"trials":11154,"activeCount":103},[],{"intervention":11156,"totalTrials":121,"cells":11157},"mDC3\u002F8-KRAS Vaccine",{"EARLY_PHASE1":11158,"PHASE1":11160,"PHASE2":11170,"PHASE3":11172,"PHASE4":11174,"NA":11176},{"trials":11159,"activeCount":103},[],{"trials":11161,"activeCount":103},[11162],{"nctId":11163,"briefTitle":11164,"status":150,"phases":11165,"primaryCompletion":11166,"completion":11166,"start":11167,"enrollment":2467,"conditions":11168,"interventions":11169},"NCT03592888","DC Vaccine in Pancreatic Cancer",[91],"2024-02-12","2018-11-20",[2141],[11156],{"trials":11171,"activeCount":103},[],{"trials":11173,"activeCount":103},[],{"trials":11175,"activeCount":103},[],{"trials":11177,"activeCount":103},[],{"intervention":11179,"totalTrials":121,"cells":11180},"EC17 imaging contrast agent",{"EARLY_PHASE1":11181,"PHASE1":11183,"PHASE2":11194,"PHASE3":11196,"PHASE4":11198,"NA":11200},{"trials":11182,"activeCount":103},[],{"trials":11184,"activeCount":103},[11185],{"nctId":11186,"briefTitle":11187,"status":150,"phases":11188,"primaryCompletion":9057,"completion":7362,"start":5367,"enrollment":1095,"conditions":11189,"interventions":11193},"NCT01778920","Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)",[91],[11190,2411,11191,11192],"Lung and Pleural Malignancies","Nodules","Adenocarcinoma",[11179],{"trials":11195,"activeCount":103},[],{"trials":11197,"activeCount":103},[],{"trials":11199,"activeCount":103},[],{"trials":11201,"activeCount":103},[],{"intervention":11203,"totalTrials":121,"cells":11204},"PENNVAX-B",{"EARLY_PHASE1":11205,"PHASE1":11207,"PHASE2":11217,"PHASE3":11219,"PHASE4":11221,"NA":11223},{"trials":11206,"activeCount":103},[],{"trials":11208,"activeCount":103},[11209],{"nctId":11210,"briefTitle":11211,"status":150,"phases":11212,"primaryCompletion":4622,"completion":4622,"start":8229,"enrollment":19,"conditions":11213,"interventions":11214},"NCT00775424","PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection",[91],[5803],[11203,11215,11216],"GENEVAX IL-12-4532","IL-15 adjuvant",{"trials":11218,"activeCount":103},[],{"trials":11220,"activeCount":103},[],{"trials":11222,"activeCount":103},[],{"trials":11224,"activeCount":103},[],{"intervention":11215,"totalTrials":121,"cells":11226},{"EARLY_PHASE1":11227,"PHASE1":11229,"PHASE2":11235,"PHASE3":11237,"PHASE4":11239,"NA":11241},{"trials":11228,"activeCount":103},[],{"trials":11230,"activeCount":103},[11231],{"nctId":11210,"briefTitle":11211,"status":150,"phases":11232,"primaryCompletion":4622,"completion":4622,"start":8229,"enrollment":19,"conditions":11233,"interventions":11234},[91],[5803],[11203,11215,11216],{"trials":11236,"activeCount":103},[],{"trials":11238,"activeCount":103},[],{"trials":11240,"activeCount":103},[],{"trials":11242,"activeCount":103},[],{"intervention":11216,"totalTrials":121,"cells":11244},{"EARLY_PHASE1":11245,"PHASE1":11247,"PHASE2":11253,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11246,"activeCount":103},[],{"trials":11248,"activeCount":103},[11249],{"nctId":11210,"briefTitle":11211,"status":150,"phases":11250,"primaryCompletion":4622,"completion":4622,"start":8229,"enrollment":19,"conditions":11251,"interventions":11252},[91],[5803],[11203,11215,11216],{"trials":11254,"activeCount":103},[],{"trials":11256,"activeCount":103},[],{"trials":11258,"activeCount":103},[],{"trials":11260,"activeCount":103},[],{"intervention":11262,"totalTrials":121,"cells":11263},"PF 03654746",{"EARLY_PHASE1":11264,"PHASE1":11266,"PHASE2":11276,"PHASE3":11278,"PHASE4":11280,"NA":11282},{"trials":11265,"activeCount":103},[],{"trials":11267,"activeCount":103},[11268],{"nctId":11269,"briefTitle":11270,"status":150,"phases":11271,"primaryCompletion":1094,"completion":1094,"start":11272,"enrollment":3729,"conditions":11273,"interventions":11275},"NCT01346163","Add On Treatment for Cognitive Deficits in Schizophrenia",[91],"2009-04",[11274],"Schizophrenia",[11262],{"trials":11277,"activeCount":103},[],{"trials":11279,"activeCount":103},[],{"trials":11281,"activeCount":103},[],{"trials":11283,"activeCount":103},[],{"intervention":11285,"totalTrials":121,"cells":11286},"Autologous T cells",{"EARLY_PHASE1":11287,"PHASE1":11289,"PHASE2":11298,"PHASE3":11300,"PHASE4":11302,"NA":11304},{"trials":11288,"activeCount":103},[],{"trials":11290,"activeCount":103},[11291],{"nctId":11292,"briefTitle":11293,"status":150,"phases":11294,"primaryCompletion":7361,"completion":9967,"start":2439,"enrollment":2695,"conditions":11295,"interventions":11297},"NCT01355965","Autologous Redirected RNA Meso-CIR T Cells",[91],[11296],"Malignant Pleural Mesothelioma",[11285],{"trials":11299,"activeCount":103},[],{"trials":11301,"activeCount":103},[],{"trials":11303,"activeCount":103},[],{"trials":11305,"activeCount":103},[],{"intervention":11307,"totalTrials":121,"cells":11308},"Tenofovir Douche",{"EARLY_PHASE1":11309,"PHASE1":11311,"PHASE2":11322,"PHASE3":11324,"PHASE4":11326,"NA":11328},{"trials":11310,"activeCount":103},[],{"trials":11312,"activeCount":103},[11313],{"nctId":11314,"briefTitle":11315,"status":150,"phases":11316,"primaryCompletion":11317,"completion":11317,"start":11318,"enrollment":190,"conditions":11319,"interventions":11321},"NCT04686279","Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)",[91],"2022-11-30","2021-04-01",[1055,11320],"HIV Prevention",[11307],{"trials":11323,"activeCount":103},[],{"trials":11325,"activeCount":103},[],{"trials":11327,"activeCount":103},[],{"trials":11329,"activeCount":103},[],{"intervention":11331,"totalTrials":121,"cells":11332},"DC vaccine",{"EARLY_PHASE1":11333,"PHASE1":11335,"PHASE2":11346,"PHASE3":11348,"PHASE4":11350,"NA":11352},{"trials":11334,"activeCount":103},[],{"trials":11336,"activeCount":103},[11337],{"nctId":11338,"briefTitle":11339,"status":1357,"phases":11340,"primaryCompletion":11341,"completion":11342,"start":11343,"enrollment":2475,"conditions":11344,"interventions":11345},"NCT03730948","DC Vaccine in Colorectal Cancer",[91],"2022-02-22","2022-12-01","2019-03-12",[1153],[11331],{"trials":11347,"activeCount":103},[],{"trials":11349,"activeCount":103},[],{"trials":11351,"activeCount":103},[],{"trials":11353,"activeCount":103},[],{"intervention":11355,"totalTrials":121,"cells":11356},"GI-4000 Vaccine",{"EARLY_PHASE1":11357,"PHASE1":11359,"PHASE2":11369,"PHASE3":11371,"PHASE4":11373,"NA":11375},{"trials":11358,"activeCount":103},[],{"trials":11360,"activeCount":103},[11361],{"nctId":11362,"briefTitle":11363,"status":4881,"phases":11364,"primaryCompletion":4860,"completion":4860,"start":4540,"enrollment":103,"conditions":11365,"interventions":11366},"NCT00837135","GI-4000 With Adoptive Transfer in Pancreatic Cancer",[91],[2676],[11355,11367,11368],"GI-4000 Vaccine + Activated T Cells","Surgical Evaluation after Vaccine #4",{"trials":11370,"activeCount":103},[],{"trials":11372,"activeCount":103},[],{"trials":11374,"activeCount":103},[],{"trials":11376,"activeCount":103},[],{"intervention":11367,"totalTrials":121,"cells":11378},{"EARLY_PHASE1":11379,"PHASE1":11381,"PHASE2":11387,"PHASE3":11389,"PHASE4":11391,"NA":11393},{"trials":11380,"activeCount":103},[],{"trials":11382,"activeCount":103},[11383],{"nctId":11362,"briefTitle":11363,"status":4881,"phases":11384,"primaryCompletion":4860,"completion":4860,"start":4540,"enrollment":103,"conditions":11385,"interventions":11386},[91],[2676],[11355,11367,11368],{"trials":11388,"activeCount":103},[],{"trials":11390,"activeCount":103},[],{"trials":11392,"activeCount":103},[],{"trials":11394,"activeCount":103},[],{"intervention":11368,"totalTrials":121,"cells":11396},{"EARLY_PHASE1":11397,"PHASE1":11399,"PHASE2":11405,"PHASE3":11407,"PHASE4":11409,"NA":11411},{"trials":11398,"activeCount":103},[],{"trials":11400,"activeCount":103},[11401],{"nctId":11362,"briefTitle":11363,"status":4881,"phases":11402,"primaryCompletion":4860,"completion":4860,"start":4540,"enrollment":103,"conditions":11403,"interventions":11404},[91],[2676],[11355,11367,11368],{"trials":11406,"activeCount":103},[],{"trials":11408,"activeCount":103},[],{"trials":11410,"activeCount":103},[],{"trials":11412,"activeCount":103},[],{"intervention":11414,"totalTrials":121,"cells":11415},"11C-Trimethoprim",{"EARLY_PHASE1":11416,"PHASE1":11418,"PHASE2":11428,"PHASE3":11430,"PHASE4":11432,"NA":11434},{"trials":11417,"activeCount":103},[],{"trials":11419,"activeCount":103},[11420],{"nctId":11421,"briefTitle":11422,"status":150,"phases":11423,"primaryCompletion":11424,"completion":72,"start":11425,"enrollment":3729,"conditions":11426,"interventions":11427},"NCT03424525","11C-Trimethoprim PET\u002FCT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects",[91],"2023-10-17","2018-02-01",[2766],[11414],{"trials":11429,"activeCount":103},[],{"trials":11431,"activeCount":103},[],{"trials":11433,"activeCount":103},[],{"trials":11435,"activeCount":103},[],{"intervention":11437,"totalTrials":121,"cells":11438},"18F-FMISO",{"EARLY_PHASE1":11439,"PHASE1":11441,"PHASE2":11451,"PHASE3":11453,"PHASE4":11455,"NA":11457},{"trials":11440,"activeCount":103},[],{"trials":11442,"activeCount":103},[11443],{"nctId":11444,"briefTitle":11445,"status":1357,"phases":11446,"primaryCompletion":11447,"completion":11447,"start":5517,"enrollment":1410,"conditions":11448,"interventions":11450},"NCT03730077","FMISO PET\u002FCT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas",[91],"2021-02-18",[11449],"Soft Tissue Sarcoma",[11437],{"trials":11452,"activeCount":103},[],{"trials":11454,"activeCount":103},[],{"trials":11456,"activeCount":103},[],{"trials":11458,"activeCount":103},[],{"intervention":2656,"totalTrials":121,"cells":11460},{"EARLY_PHASE1":11461,"PHASE1":11463,"PHASE2":11469,"PHASE3":11471,"PHASE4":11473,"NA":11475},{"trials":11462,"activeCount":103},[],{"trials":11464,"activeCount":103},[11465],{"nctId":2648,"briefTitle":2649,"status":150,"phases":11466,"primaryCompletion":1043,"completion":2651,"start":2652,"enrollment":957,"conditions":11467,"interventions":11468},[91],[2654],[2656,2617],{"trials":11470,"activeCount":103},[],{"trials":11472,"activeCount":103},[],{"trials":11474,"activeCount":103},[],{"trials":11476,"activeCount":103},[],{"intervention":11478,"totalTrials":121,"cells":11479},"Adenoviral-mediated Interferon-beta",{"EARLY_PHASE1":11480,"PHASE1":11482,"PHASE2":11494,"PHASE3":11496,"PHASE4":11498,"NA":11500},{"trials":11481,"activeCount":103},[],{"trials":11483,"activeCount":103},[11484],{"nctId":11485,"briefTitle":11486,"status":150,"phases":11487,"primaryCompletion":4591,"completion":4860,"start":11488,"enrollment":2683,"conditions":11489,"interventions":11492},"NCT00299962","Gene Therapy for Pleural Malignancies",[91],"2006-03",[11490,11491],"Pleural Mesothelioma","Metastatic Pleural Effusions",[11478,11493],"SCH 721015",{"trials":11495,"activeCount":103},[],{"trials":11497,"activeCount":103},[],{"trials":11499,"activeCount":103},[],{"trials":11501,"activeCount":103},[],{"intervention":11493,"totalTrials":121,"cells":11503},{"EARLY_PHASE1":11504,"PHASE1":11506,"PHASE2":11512,"PHASE3":11514,"PHASE4":11516,"NA":11518},{"trials":11505,"activeCount":103},[],{"trials":11507,"activeCount":103},[11508],{"nctId":11485,"briefTitle":11486,"status":150,"phases":11509,"primaryCompletion":4591,"completion":4860,"start":11488,"enrollment":2683,"conditions":11510,"interventions":11511},[91],[11490,11491],[11478,11493],{"trials":11513,"activeCount":103},[],{"trials":11515,"activeCount":103},[],{"trials":11517,"activeCount":103},[],{"trials":11519,"activeCount":103},[],{"intervention":11521,"totalTrials":121,"cells":11522},"cMet RNA CAR T cells",{"EARLY_PHASE1":11523,"PHASE1":11525,"PHASE2":11535,"PHASE3":11537,"PHASE4":11539,"NA":11541},{"trials":11524,"activeCount":103},[],{"trials":11526,"activeCount":103},[11527],{"nctId":11528,"briefTitle":11529,"status":150,"phases":11530,"primaryCompletion":11531,"completion":11531,"start":1303,"enrollment":2399,"conditions":11532,"interventions":11534},"NCT01837602","cMet CAR RNA T Cells Targeting Breast Cancer",[91],"2018-08-13",[3221,11533],"Triple Negative Breast Cancer",[11521],{"trials":11536,"activeCount":103},[],{"trials":11538,"activeCount":103},[],{"trials":11540,"activeCount":103},[],{"trials":11542,"activeCount":103},[],{"intervention":11544,"totalTrials":121,"cells":11545},"DC-Ova",{"EARLY_PHASE1":11546,"PHASE1":11548,"PHASE2":11557,"PHASE3":11559,"PHASE4":11561,"NA":11563},{"trials":11547,"activeCount":103},[],{"trials":11549,"activeCount":103},[11550],{"nctId":11551,"briefTitle":11552,"status":150,"phases":11553,"primaryCompletion":1104,"completion":1104,"start":4610,"enrollment":957,"conditions":11554,"interventions":11555},"NCT00478452","Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients",[91],[2859,2861,2930],[11544,11556],"DC Ova with Cyclophosphamide",{"trials":11558,"activeCount":103},[],{"trials":11560,"activeCount":103},[],{"trials":11562,"activeCount":103},[],{"trials":11564,"activeCount":103},[],{"intervention":11556,"totalTrials":121,"cells":11566},{"EARLY_PHASE1":11567,"PHASE1":11569,"PHASE2":11575,"PHASE3":11577,"PHASE4":11579,"NA":11581},{"trials":11568,"activeCount":103},[],{"trials":11570,"activeCount":103},[11571],{"nctId":11551,"briefTitle":11552,"status":150,"phases":11572,"primaryCompletion":1104,"completion":1104,"start":4610,"enrollment":957,"conditions":11573,"interventions":11574},[91],[2859,2861,2930],[11544,11556],{"trials":11576,"activeCount":103},[],{"trials":11578,"activeCount":103},[],{"trials":11580,"activeCount":103},[],{"trials":11582,"activeCount":103},[],{"intervention":2678,"totalTrials":121,"cells":11584},{"EARLY_PHASE1":11585,"PHASE1":11587,"PHASE2":11593,"PHASE3":11595,"PHASE4":11597,"NA":11599},{"trials":11586,"activeCount":103},[],{"trials":11588,"activeCount":103},[11589],{"nctId":2669,"briefTitle":2670,"status":1357,"phases":11590,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":2475,"conditions":11591,"interventions":11592},[91],[2676],[2678,2617],{"trials":11594,"activeCount":103},[],{"trials":11596,"activeCount":103},[],{"trials":11598,"activeCount":103},[],{"trials":11600,"activeCount":103},[],{"intervention":2688,"totalTrials":121,"cells":11602},{"EARLY_PHASE1":11603,"PHASE1":11605,"PHASE2":11611,"PHASE3":11613,"PHASE4":11615,"NA":11617},{"trials":11604,"activeCount":103},[],{"trials":11606,"activeCount":103},[11607],{"nctId":2680,"briefTitle":2681,"status":150,"phases":11608,"primaryCompletion":2334,"completion":2334,"start":1104,"enrollment":2683,"conditions":11609,"interventions":11610},[91],[2685],[2687,2688],{"trials":11612,"activeCount":103},[],{"trials":11614,"activeCount":103},[],{"trials":11616,"activeCount":103},[],{"trials":11618,"activeCount":103},[],{"intervention":11620,"totalTrials":121,"cells":11621},"Cyclosporine",{"EARLY_PHASE1":11622,"PHASE1":11624,"PHASE2":11634,"PHASE3":11636,"PHASE4":11638,"NA":11640},{"trials":11623,"activeCount":103},[],{"trials":11625,"activeCount":103},[11626],{"nctId":11627,"briefTitle":11628,"status":150,"phases":11629,"primaryCompletion":11630,"completion":11630,"start":11631,"enrollment":2592,"conditions":11632,"interventions":11633},"NCT04412785","Cyclosporine in Patients With Moderate COVID-19",[91],"2021-10-25","2020-06-30",[9741],[11620],{"trials":11635,"activeCount":103},[],{"trials":11637,"activeCount":103},[],{"trials":11639,"activeCount":103},[],{"trials":11641,"activeCount":103},[],{"intervention":11643,"totalTrials":121,"cells":11644},"CART22 cells",{"EARLY_PHASE1":11645,"PHASE1":11647,"PHASE2":11656,"PHASE3":11658,"PHASE4":11660,"NA":11662},{"trials":11646,"activeCount":103},[],{"trials":11648,"activeCount":103},[11649],{"nctId":11650,"briefTitle":11651,"status":1357,"phases":11652,"primaryCompletion":2672,"completion":2672,"start":9967,"enrollment":1410,"conditions":11653,"interventions":11655},"NCT02588456","Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia",[91],[11654],"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia",[11643],{"trials":11657,"activeCount":103},[],{"trials":11659,"activeCount":103},[],{"trials":11661,"activeCount":103},[],{"trials":11663,"activeCount":103},[],{"intervention":2713,"totalTrials":121,"cells":11665},{"EARLY_PHASE1":11666,"PHASE1":11668,"PHASE2":11674,"PHASE3":11676,"PHASE4":11678,"NA":11680},{"trials":11667,"activeCount":103},[],{"trials":11669,"activeCount":103},[11670],{"nctId":2702,"briefTitle":2703,"status":1357,"phases":11671,"primaryCompletion":2705,"completion":2706,"start":2707,"enrollment":1139,"conditions":11672,"interventions":11673},[91],[2709,2685,2710,2711],[2713,2617,2646],{"trials":11675,"activeCount":103},[],{"trials":11677,"activeCount":103},[],{"trials":11679,"activeCount":103},[],{"trials":11681,"activeCount":103},[],{"intervention":11683,"totalTrials":121,"cells":11684},"Infusion of CD3\u002FCD28 stimulated T cells",{"EARLY_PHASE1":11685,"PHASE1":11687,"PHASE2":11695,"PHASE3":11697,"PHASE4":11699,"NA":11701},{"trials":11686,"activeCount":103},[],{"trials":11688,"activeCount":103},[11689],{"nctId":11690,"briefTitle":11691,"status":150,"phases":11692,"primaryCompletion":188,"completion":188,"start":4921,"enrollment":329,"conditions":11693,"interventions":11694},"NCT01013441","CD3\u002FCD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia",[91],[3309],[11683],{"trials":11696,"activeCount":103},[],{"trials":11698,"activeCount":103},[],{"trials":11700,"activeCount":103},[],{"trials":11702,"activeCount":103},[],{"intervention":11704,"totalTrials":121,"cells":11705},"H5.020CMV.PDGF-b and limb compression bandage",{"EARLY_PHASE1":11706,"PHASE1":11708,"PHASE2":11717,"PHASE3":11719,"PHASE4":11721,"NA":11723},{"trials":11707,"activeCount":103},[],{"trials":11709,"activeCount":103},[11710],{"nctId":11711,"briefTitle":10755,"status":150,"phases":11712,"primaryCompletion":1104,"completion":4813,"start":11713,"enrollment":983,"conditions":11714,"interventions":11716},"NCT01858272",[91],"2004-09",[11715],"Venous Ulcer",[11704],{"trials":11718,"activeCount":103},[],{"trials":11720,"activeCount":103},[],{"trials":11722,"activeCount":103},[],{"trials":11724,"activeCount":103},[],{"intervention":11726,"totalTrials":121,"cells":11727},"hTERT\u002FSurvivin Multi-Peptide Vaccine",{"EARLY_PHASE1":11728,"PHASE1":11730,"PHASE2":11741,"PHASE3":11743,"PHASE4":11745,"NA":11747},{"trials":11729,"activeCount":103},[],{"trials":11731,"activeCount":103},[11732],{"nctId":11733,"briefTitle":11734,"status":150,"phases":11735,"primaryCompletion":11736,"completion":1359,"start":1105,"enrollment":2592,"conditions":11737,"interventions":11740},"NCT00573495","Multipeptide Vaccine for Advanced Breast Cancer",[91],"2011-07",[3094,2894,11738,11739],"Cancer of the Breast","Carcinoma, Ductal",[11726],{"trials":11742,"activeCount":103},[],{"trials":11744,"activeCount":103},[],{"trials":11746,"activeCount":103},[],{"trials":11748,"activeCount":103},[],{"intervention":11750,"totalTrials":121,"cells":11751},"Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1",{"EARLY_PHASE1":11752,"PHASE1":11754,"PHASE2":11763,"PHASE3":11765,"PHASE4":11767,"NA":11769},{"trials":11753,"activeCount":103},[],{"trials":11755,"activeCount":103},[11756],{"nctId":11757,"briefTitle":11758,"status":150,"phases":11759,"primaryCompletion":1030,"completion":7486,"start":4965,"enrollment":3729,"conditions":11760,"interventions":11762},"NCT01897415","Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer",[91],[11761],"Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (PDA)",[11750],{"trials":11764,"activeCount":103},[],{"trials":11766,"activeCount":103},[],{"trials":11768,"activeCount":103},[],{"trials":11770,"activeCount":103},[],{"intervention":11772,"totalTrials":121,"cells":11773},"PACE CART19",{"EARLY_PHASE1":11774,"PHASE1":11776,"PHASE2":11787,"PHASE3":11789,"PHASE4":11791,"NA":11793},{"trials":11775,"activeCount":103},[],{"trials":11777,"activeCount":103},[11778],{"nctId":11779,"briefTitle":11780,"status":4881,"phases":11781,"primaryCompletion":11782,"completion":11783,"start":11784,"enrollment":103,"conditions":11785,"interventions":11786},"NCT05037669","Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma",[91],"2025-01","2038-01","2022-07",[3311,3309,3285],[11772],{"trials":11788,"activeCount":103},[],{"trials":11790,"activeCount":103},[],{"trials":11792,"activeCount":103},[],{"trials":11794,"activeCount":103},[],{"intervention":11796,"totalTrials":121,"cells":11797},"GLP 1",{"EARLY_PHASE1":11798,"PHASE1":11800,"PHASE2":11810,"PHASE3":11812,"PHASE4":11814,"NA":11816},{"trials":11799,"activeCount":103},[],{"trials":11801,"activeCount":103},[11802],{"nctId":11803,"briefTitle":11804,"status":150,"phases":11805,"primaryCompletion":2439,"completion":2439,"start":8586,"enrollment":1165,"conditions":11806,"interventions":11808},"NCT00882492","GLP 1 for Intraoperative Glycemic Control",[91],[11807,7983],"Hyperglycemia",[11796,11809],"normal saline solution placebo",{"trials":11811,"activeCount":103},[],{"trials":11813,"activeCount":103},[],{"trials":11815,"activeCount":103},[],{"trials":11817,"activeCount":103},[],{"intervention":11809,"totalTrials":121,"cells":11819},{"EARLY_PHASE1":11820,"PHASE1":11822,"PHASE2":11828,"PHASE3":11830,"PHASE4":11832,"NA":11834},{"trials":11821,"activeCount":103},[],{"trials":11823,"activeCount":103},[11824],{"nctId":11803,"briefTitle":11804,"status":150,"phases":11825,"primaryCompletion":2439,"completion":2439,"start":8586,"enrollment":1165,"conditions":11826,"interventions":11827},[91],[11807,7983],[11796,11809],{"trials":11829,"activeCount":103},[],{"trials":11831,"activeCount":103},[],{"trials":11833,"activeCount":103},[],{"trials":11835,"activeCount":103},[],{"intervention":11837,"totalTrials":121,"cells":11838},"VRX496",{"EARLY_PHASE1":11839,"PHASE1":11841,"PHASE2":11849,"PHASE3":11851,"PHASE4":11853,"NA":11855},{"trials":11840,"activeCount":103},[],{"trials":11842,"activeCount":103},[11843],{"nctId":11844,"briefTitle":11845,"status":150,"phases":11846,"primaryCompletion":4621,"completion":981,"start":4715,"enrollment":3822,"conditions":11847,"interventions":11848},"NCT00295477","Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV",[91],[4853],[11837],{"trials":11850,"activeCount":103},[],{"trials":11852,"activeCount":103},[],{"trials":11854,"activeCount":103},[],{"trials":11856,"activeCount":103},[],{"intervention":11858,"totalTrials":121,"cells":11859},"Tasquinimod",{"EARLY_PHASE1":11860,"PHASE1":11862,"PHASE2":11874,"PHASE3":11876,"PHASE4":11878,"NA":11880},{"trials":11861,"activeCount":103},[],{"trials":11863,"activeCount":103},[11864],{"nctId":11865,"briefTitle":11866,"status":1357,"phases":11867,"primaryCompletion":11868,"completion":11869,"start":11870,"enrollment":1150,"conditions":11871,"interventions":11872},"NCT04405167","Tasquinimod for the Treatment of Relapsed or Refractory Myeloma",[91],"2025-05-19","2025-07-01","2020-07-10",[2709],[11858,11873],"IRd chemotherapy",{"trials":11875,"activeCount":103},[],{"trials":11877,"activeCount":103},[],{"trials":11879,"activeCount":103},[],{"trials":11881,"activeCount":103},[],{"intervention":11873,"totalTrials":121,"cells":11883},{"EARLY_PHASE1":11884,"PHASE1":11886,"PHASE2":11892,"PHASE3":11894,"PHASE4":11896,"NA":11898},{"trials":11885,"activeCount":103},[],{"trials":11887,"activeCount":103},[11888],{"nctId":11865,"briefTitle":11866,"status":1357,"phases":11889,"primaryCompletion":11868,"completion":11869,"start":11870,"enrollment":1150,"conditions":11890,"interventions":11891},[91],[2709],[11858,11873],{"trials":11893,"activeCount":103},[],{"trials":11895,"activeCount":103},[],{"trials":11897,"activeCount":103},[],{"trials":11899,"activeCount":103},[],{"intervention":11901,"totalTrials":121,"cells":11902},"CART-meso",{"EARLY_PHASE1":11903,"PHASE1":11905,"PHASE2":11916,"PHASE3":11918,"PHASE4":11920,"NA":11922},{"trials":11904,"activeCount":103},[],{"trials":11906,"activeCount":103},[11907],{"nctId":11908,"briefTitle":11909,"status":150,"phases":11910,"primaryCompletion":1021,"completion":1021,"start":5453,"enrollment":7835,"conditions":11911,"interventions":11915},"NCT02159716","CART-meso in Mesothelin Expressing Cancers",[91],[11912,11913,11914],"Metastatic Pancreatic (Ductal) Adenocarcinoma","Epithelial Ovarian Cancer","Malignant Epithelial Pleural Mesothelioma",[11901],{"trials":11917,"activeCount":103},[],{"trials":11919,"activeCount":103},[],{"trials":11921,"activeCount":103},[],{"trials":11923,"activeCount":103},[],{"intervention":11925,"totalTrials":121,"cells":11926},"[11C]-PBR28",{"EARLY_PHASE1":11927,"PHASE1":11929,"PHASE2":11940,"PHASE3":11942,"PHASE4":11944,"NA":11946},{"trials":11928,"activeCount":103},[],{"trials":11930,"activeCount":103},[11931],{"nctId":11932,"briefTitle":11933,"status":1357,"phases":11934,"primaryCompletion":11935,"completion":11935,"start":11936,"enrollment":99,"conditions":11937,"interventions":11939},"NCT04490096","Multimodal Imaging Outcome Measures for ALS (Image ALS)",[91],"2022-03-17","2021-02-25",[11938],"ALS",[11925],{"trials":11941,"activeCount":103},[],{"trials":11943,"activeCount":103},[],{"trials":11945,"activeCount":103},[],{"trials":11947,"activeCount":103},[],{"intervention":11949,"totalTrials":121,"cells":11950},"Ferumoxytol\u002FHydrogen peroxide",{"EARLY_PHASE1":11951,"PHASE1":11964,"PHASE2":11966,"PHASE3":11968,"PHASE4":11970,"NA":11972},{"trials":11952,"activeCount":103},[11953],{"nctId":11954,"briefTitle":11955,"status":150,"phases":11956,"primaryCompletion":11957,"completion":11957,"start":11958,"enrollment":3729,"conditions":11959,"interventions":11961},"NCT03678012","Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model",[90],"2018-08-16","2018-06-07",[11960],"Dental Caries",[11949,11962,11963],"Hydrogen Peroxide","Water",{"trials":11965,"activeCount":103},[],{"trials":11967,"activeCount":103},[],{"trials":11969,"activeCount":103},[],{"trials":11971,"activeCount":103},[],{"trials":11973,"activeCount":103},[],{"intervention":11962,"totalTrials":121,"cells":11975},{"EARLY_PHASE1":11976,"PHASE1":11982,"PHASE2":11984,"PHASE3":11986,"PHASE4":11988,"NA":11990},{"trials":11977,"activeCount":103},[11978],{"nctId":11954,"briefTitle":11955,"status":150,"phases":11979,"primaryCompletion":11957,"completion":11957,"start":11958,"enrollment":3729,"conditions":11980,"interventions":11981},[90],[11960],[11949,11962,11963],{"trials":11983,"activeCount":103},[],{"trials":11985,"activeCount":103},[],{"trials":11987,"activeCount":103},[],{"trials":11989,"activeCount":103},[],{"trials":11991,"activeCount":103},[],{"intervention":11963,"totalTrials":121,"cells":11993},{"EARLY_PHASE1":11994,"PHASE1":12000,"PHASE2":12002,"PHASE3":12004,"PHASE4":12006,"NA":12008},{"trials":11995,"activeCount":103},[11996],{"nctId":11954,"briefTitle":11955,"status":150,"phases":11997,"primaryCompletion":11957,"completion":11957,"start":11958,"enrollment":3729,"conditions":11998,"interventions":11999},[90],[11960],[11949,11962,11963],{"trials":12001,"activeCount":103},[],{"trials":12003,"activeCount":103},[],{"trials":12005,"activeCount":103},[],{"trials":12007,"activeCount":103},[],{"trials":12009,"activeCount":103},[],{"intervention":12011,"totalTrials":121,"cells":12012},"Intralipid, 20% Intravenous Emulsion",{"EARLY_PHASE1":12013,"PHASE1":12024,"PHASE2":12026,"PHASE3":12028,"PHASE4":12030,"NA":12032},{"trials":12014,"activeCount":103},[12015],{"nctId":12016,"briefTitle":12017,"status":150,"phases":12018,"primaryCompletion":12019,"completion":12019,"start":12020,"enrollment":2582,"conditions":12021,"interventions":12023},"NCT03479671","Low Dose Fat-Induced Insulin Resistance",[90],"2024-11-19","2020-01-01",[4423,7577,12022],"Insulin Sensitivity",[12011],{"trials":12025,"activeCount":103},[],{"trials":12027,"activeCount":103},[],{"trials":12029,"activeCount":103},[],{"trials":12031,"activeCount":103},[],{"trials":12033,"activeCount":103},[],{"intervention":12035,"totalTrials":121,"cells":12036},"DMSO",{"EARLY_PHASE1":12037,"PHASE1":12048,"PHASE2":12050,"PHASE3":12052,"PHASE4":12054,"NA":12056},{"trials":12038,"activeCount":103},[12039],{"nctId":12040,"briefTitle":12041,"status":150,"phases":12042,"primaryCompletion":189,"completion":7555,"start":12043,"enrollment":99,"conditions":12044,"interventions":12046},"NCT03103594","Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A",[90],"2015-08",[12045],"Bladder Pain Syndrome",[12035,12047],"Botox",{"trials":12049,"activeCount":103},[],{"trials":12051,"activeCount":103},[],{"trials":12053,"activeCount":103},[],{"trials":12055,"activeCount":103},[],{"trials":12057,"activeCount":103},[],{"intervention":12047,"totalTrials":121,"cells":12059},{"EARLY_PHASE1":12060,"PHASE1":12066,"PHASE2":12068,"PHASE3":12070,"PHASE4":12072,"NA":12074},{"trials":12061,"activeCount":103},[12062],{"nctId":12040,"briefTitle":12041,"status":150,"phases":12063,"primaryCompletion":189,"completion":7555,"start":12043,"enrollment":99,"conditions":12064,"interventions":12065},[90],[12045],[12035,12047],{"trials":12067,"activeCount":103},[],{"trials":12069,"activeCount":103},[],{"trials":12071,"activeCount":103},[],{"trials":12073,"activeCount":103},[],{"trials":12075,"activeCount":103},[],{"intervention":12077,"totalTrials":121,"cells":12078},"epsilon-aminocaproic acid",{"EARLY_PHASE1":12079,"PHASE1":12088,"PHASE2":12090,"PHASE3":12092,"PHASE4":12094,"NA":12096},{"trials":12080,"activeCount":103},[12081],{"nctId":12082,"briefTitle":12083,"status":1357,"phases":12084,"primaryCompletion":5453,"completion":5453,"start":1074,"enrollment":190,"conditions":12085,"interventions":12087},"NCT01965730","Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery",[90],[12086],"Aortic Disease",[12077],{"trials":12089,"activeCount":103},[],{"trials":12091,"activeCount":103},[],{"trials":12093,"activeCount":103},[],{"trials":12095,"activeCount":103},[],{"trials":12097,"activeCount":103},[],{"intervention":12099,"totalTrials":121,"cells":12100},"Electronic Cigarette Aerosol",{"EARLY_PHASE1":12101,"PHASE1":12113,"PHASE2":12115,"PHASE3":12117,"PHASE4":12119,"NA":12121},{"trials":12102,"activeCount":103},[12103],{"nctId":12104,"briefTitle":12105,"status":150,"phases":12106,"primaryCompletion":12107,"completion":12107,"start":12108,"enrollment":25,"conditions":12109,"interventions":12112},"NCT03479203","Acute Effects of E-Cigarette Aerosol Inhalation",[90],"2022-08-31","2018-05-22",[12110,12111],"Endothelial Dysfunction","Biochemical Markers",[12099],{"trials":12114,"activeCount":103},[],{"trials":12116,"activeCount":103},[],{"trials":12118,"activeCount":103},[],{"trials":12120,"activeCount":103},[],{"trials":12122,"activeCount":103},[],{"intervention":7987,"totalTrials":121,"cells":12124},{"EARLY_PHASE1":12125,"PHASE1":12131,"PHASE2":12133,"PHASE3":12135,"PHASE4":12137,"NA":12139},{"trials":12126,"activeCount":103},[12127],{"nctId":7975,"briefTitle":7976,"status":150,"phases":12128,"primaryCompletion":7978,"completion":7979,"start":7980,"enrollment":2582,"conditions":12129,"interventions":12130},[90],[7982,7983,7984,7985],[7987,1519],{"trials":12132,"activeCount":103},[],{"trials":12134,"activeCount":103},[],{"trials":12136,"activeCount":103},[],{"trials":12138,"activeCount":103},[],{"trials":12140,"activeCount":103},[],{"intervention":12142,"totalTrials":121,"cells":12143},"Dexmedetomidine",{"EARLY_PHASE1":12144,"PHASE1":12154,"PHASE2":12156,"PHASE3":12158,"PHASE4":12160,"NA":12162},{"trials":12145,"activeCount":103},[12146],{"nctId":12147,"briefTitle":12148,"status":150,"phases":12149,"primaryCompletion":12150,"completion":4957,"start":5061,"enrollment":2683,"conditions":12151,"interventions":12153},"NCT02768688","MRI of Glymphatic Clearance During Anesthetic Sedation",[90],"2017-02-09",[12152],"Glymphatic Flow",[12142],{"trials":12155,"activeCount":103},[],{"trials":12157,"activeCount":103},[],{"trials":12159,"activeCount":103},[],{"trials":12161,"activeCount":103},[],{"trials":12163,"activeCount":103},[],{"intervention":12165,"totalTrials":121,"cells":12166},"18F-FluorThanatrace",{"EARLY_PHASE1":12167,"PHASE1":12177,"PHASE2":12179,"PHASE3":12181,"PHASE4":12183,"NA":12185},{"trials":12168,"activeCount":103},[12169],{"nctId":12170,"briefTitle":12171,"status":1357,"phases":12172,"primaryCompletion":12173,"completion":12173,"start":12174,"enrollment":1139,"conditions":12175,"interventions":12176},"NCT04221061","18F-FluorThanatrace (PET\u002FCT) in Glioblastoma",[90],"2024-06-10","2020-02-20",[1628],[12165],{"trials":12178,"activeCount":103},[],{"trials":12180,"activeCount":103},[],{"trials":12182,"activeCount":103},[],{"trials":12184,"activeCount":103},[],{"trials":12186,"activeCount":103},[],{"intervention":12188,"totalTrials":121,"cells":12189},"T cells modified with RNA anti -cMET CAR",{"EARLY_PHASE1":12190,"PHASE1":12201,"PHASE2":12203,"PHASE3":12205,"PHASE4":12207,"NA":12209},{"trials":12191,"activeCount":103},[12192],{"nctId":12193,"briefTitle":12194,"status":1357,"phases":12195,"primaryCompletion":12196,"completion":12196,"start":12197,"enrollment":7002,"conditions":12198,"interventions":12200},"NCT03060356","Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)",[90],"2020-03-27","2016-12-21",[12199,2894],"Malignant Melanoma",[12188],{"trials":12202,"activeCount":103},[],{"trials":12204,"activeCount":103},[],{"trials":12206,"activeCount":103},[],{"trials":12208,"activeCount":103},[],{"trials":12210,"activeCount":103},[],{"intervention":2629,"totalTrials":121,"cells":12212},{"EARLY_PHASE1":12213,"PHASE1":12219,"PHASE2":12221,"PHASE3":12223,"PHASE4":12225,"NA":12227},{"trials":12214,"activeCount":103},[12215],{"nctId":2622,"briefTitle":2623,"status":1357,"phases":12216,"primaryCompletion":1963,"completion":2625,"start":1030,"enrollment":1986,"conditions":12217,"interventions":12218},[90],[2627],[2629,2617],{"trials":12220,"activeCount":103},[],{"trials":12222,"activeCount":103},[],{"trials":12224,"activeCount":103},[],{"trials":12226,"activeCount":103},[],{"trials":12228,"activeCount":103},[],{"intervention":12230,"totalTrials":121,"cells":12231},"IMCgp100",{"EARLY_PHASE1":12232,"PHASE1":12242,"PHASE2":12244,"PHASE3":12246,"PHASE4":12248,"NA":12250},{"trials":12233,"activeCount":103},[12234],{"nctId":12235,"briefTitle":12236,"status":150,"phases":12237,"primaryCompletion":7895,"start":7393,"enrollment":121,"conditions":12238,"interventions":12241},"NCT01209676","IMCgp100 in Advanced Unresectable Melanoma",[90],[2685,12239,12240],"Advanced Disease","Unresectable",[12230],{"trials":12243,"activeCount":103},[],{"trials":12245,"activeCount":103},[],{"trials":12247,"activeCount":103},[],{"trials":12249,"activeCount":103},[],{"trials":12251,"activeCount":103},[],{"intervention":12253,"totalTrials":121,"cells":12254},"FNOS",{"EARLY_PHASE1":12255,"PHASE1":12267,"PHASE2":12269,"PHASE3":12271,"PHASE4":12273,"NA":12275},{"trials":12256,"activeCount":103},[12257],{"nctId":12258,"briefTitle":12259,"status":1357,"phases":12260,"primaryCompletion":12261,"completion":12261,"start":12262,"enrollment":1139,"conditions":12263,"interventions":12265},"NCT04105634","Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET\u002FCT",[90],"2024-10-14","2019-10-01",[12264],"Cardiac Amyloidosis",[12253,12266],"Florbetaben",{"trials":12268,"activeCount":103},[],{"trials":12270,"activeCount":103},[],{"trials":12272,"activeCount":103},[],{"trials":12274,"activeCount":103},[],{"trials":12276,"activeCount":103},[],{"intervention":12266,"totalTrials":121,"cells":12278},{"EARLY_PHASE1":12279,"PHASE1":12285,"PHASE2":12287,"PHASE3":12289,"PHASE4":12291,"NA":12293},{"trials":12280,"activeCount":103},[12281],{"nctId":12258,"briefTitle":12259,"status":1357,"phases":12282,"primaryCompletion":12261,"completion":12261,"start":12262,"enrollment":1139,"conditions":12283,"interventions":12284},[90],[12264],[12253,12266],{"trials":12286,"activeCount":103},[],{"trials":12288,"activeCount":103},[],{"trials":12290,"activeCount":103},[],{"trials":12292,"activeCount":103},[],{"trials":12294,"activeCount":103},[],{"intervention":7460,"totalTrials":121,"cells":12296},{"EARLY_PHASE1":12297,"PHASE1":12303,"PHASE2":12305,"PHASE3":12307,"PHASE4":12309,"NA":12311},{"trials":12298,"activeCount":103},[12299],{"nctId":7451,"briefTitle":7452,"status":1357,"phases":12300,"primaryCompletion":7454,"completion":7454,"start":7455,"enrollment":2399,"conditions":12301,"interventions":12302},[90],[1797,7457],[7459,7459,7460],{"trials":12304,"activeCount":103},[],{"trials":12306,"activeCount":103},[],{"trials":12308,"activeCount":103},[],{"trials":12310,"activeCount":103},[],{"trials":12312,"activeCount":103},[],{"intervention":12314,"totalTrials":121,"cells":12315},"RNA anti-CD19 CAR T cells",{"EARLY_PHASE1":12316,"PHASE1":12327,"PHASE2":12329,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12317,"activeCount":103},[12318],{"nctId":12319,"briefTitle":12320,"status":1357,"phases":12321,"primaryCompletion":2409,"completion":12322,"start":12323,"enrollment":2475,"conditions":12324,"interventions":12326},"NCT02277522","CD19 Redirected Autologous T Cells for Hodgkin Lymphoma",[90],"2017-06-27","2014-10",[12325],"Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis",[12314],{"trials":12328,"activeCount":103},[],{"trials":12330,"activeCount":103},[],{"trials":12332,"activeCount":103},[],{"trials":12334,"activeCount":103},[],{"trials":12336,"activeCount":103},[],{"intervention":12338,"totalTrials":121,"cells":12339},"Autologous CD4 T-Cells",{"EARLY_PHASE1":12340,"PHASE1":12349,"PHASE2":12351,"PHASE3":12353,"PHASE4":12355,"NA":12357},{"trials":12341,"activeCount":103},[12342],{"nctId":12343,"briefTitle":12344,"status":150,"phases":12345,"primaryCompletion":12346,"completion":9893,"start":7933,"enrollment":2582,"conditions":12347,"interventions":12348},"NCT03020524","Autologous CD4 T-Cells in HIV (C34-CXCR4)",[90],"2019-11",[3462],[12338],{"trials":12350,"activeCount":103},[],{"trials":12352,"activeCount":103},[],{"trials":12354,"activeCount":103},[],{"trials":12356,"activeCount":103},[],{"trials":12358,"activeCount":103},[],{"intervention":12360,"totalTrials":121,"cells":12361},"CD19 RNA redirected autologous T-cells",{"EARLY_PHASE1":12362,"PHASE1":12372,"PHASE2":12374,"PHASE3":12376,"PHASE4":12378,"NA":12380},{"trials":12363,"activeCount":103},[12364],{"nctId":12365,"briefTitle":12366,"status":1357,"phases":12367,"primaryCompletion":12368,"completion":12369,"start":1021,"enrollment":99,"conditions":12370,"interventions":12371},"NCT02624258","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",[90],"2019-06-05","2019-12-06",[3758],[12360],{"trials":12373,"activeCount":103},[],{"trials":12375,"activeCount":103},[],{"trials":12377,"activeCount":103},[],{"trials":12379,"activeCount":103},[],{"trials":12381,"activeCount":103},[],{"intervention":12383,"totalTrials":1410,"cells":12384},"Lisdexamfetamine",{"EARLY_PHASE1":12385,"PHASE1":12387,"PHASE2":12389,"PHASE3":12391,"PHASE4":12393,"NA":12422},{"trials":12386,"activeCount":103},[],{"trials":12388,"activeCount":103},[],{"trials":12390,"activeCount":103},[],{"trials":12392,"activeCount":103},[],{"trials":12394,"activeCount":103},[12395,12404,12414],{"nctId":12396,"briefTitle":12397,"status":150,"phases":12398,"primaryCompletion":12399,"completion":12399,"start":2439,"enrollment":7575,"conditions":12400,"interventions":12403},"NCT01324024","Attention & Memory Impairments in Menopausal Women",[94],"2014-04",[12401,12402],"Symptomatic Menopause","Cognitive Impairments",[12383],{"nctId":12405,"briefTitle":12406,"status":150,"phases":12407,"primaryCompletion":12408,"completion":12408,"start":12409,"enrollment":16,"conditions":12410,"interventions":12413},"NCT03187353","IMProving Executive Function Study",[94],"2022-04-30","2017-09-22",[12411,12412],"Cognitive Impairment","RRSO",[12383],{"nctId":12415,"briefTitle":12416,"status":150,"phases":12417,"primaryCompletion":12399,"completion":12399,"start":1013,"enrollment":2695,"conditions":12418,"interventions":12421},"NCT01977625","LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women",[94],[6435,12419,12420],"Brain Activity","Cognition",[12383],{"trials":12423,"activeCount":103},[12424,12431],{"nctId":12425,"briefTitle":12426,"status":4881,"phases":12427,"primaryCompletion":981,"completion":981,"start":4965,"enrollment":103,"conditions":12428,"interventions":12429},"NCT01986777","LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy",[95],[12402,12412],[12430],"lisdexamfetamine",{"nctId":12432,"briefTitle":12433,"status":4881,"phases":12434,"primaryCompletion":8105,"completion":8105,"start":8105,"enrollment":103,"conditions":12435,"interventions":12437},"NCT01986764","E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy",[95],[12436],"Planned RRSO",[12383,12438],"Estradiol",{"intervention":4817,"totalTrials":1410,"cells":12440},{"EARLY_PHASE1":12441,"PHASE1":12443,"PHASE2":12445,"PHASE3":12447,"PHASE4":12469,"NA":12475},{"trials":12442,"activeCount":103},[],{"trials":12444,"activeCount":103},[],{"trials":12446,"activeCount":103},[],{"trials":12448,"activeCount":103},[12449,12456,12465],{"nctId":12450,"briefTitle":12451,"status":150,"phases":12452,"primaryCompletion":4965,"completion":4965,"start":4622,"enrollment":12453,"conditions":12454,"interventions":12455},"NCT01098318","Rhodiola Rosea Therapy of Major Depressive Disorder",[93],58,[18],[4817],{"nctId":12457,"briefTitle":12458,"status":150,"phases":12459,"completion":12460,"start":12461,"conditions":12462,"interventions":12464},"NCT00000384","Treatment of Obsessive-Compulsive Disorder (OCD) in Children",[93],"2002-04","1997-05",[12463],"Obsessive-Compulsive Disorder",[4817],{"nctId":4810,"briefTitle":4811,"status":150,"phases":12466,"primaryCompletion":4813,"completion":4813,"start":4814,"enrollment":994,"conditions":12467,"interventions":12468},[93],[18],[4817,4818,4799],{"trials":12470,"activeCount":103},[12471],{"nctId":4607,"briefTitle":4608,"status":150,"phases":12472,"primaryCompletion":4610,"completion":1513,"start":4611,"enrollment":4612,"conditions":12473,"interventions":12474},[94],[673,18],[4615,4616],{"trials":12476,"activeCount":103},[12477],{"nctId":12478,"briefTitle":12479,"status":150,"phases":12480,"primaryCompletion":1338,"completion":1338,"start":12481,"enrollment":4541,"conditions":12482,"interventions":12484},"NCT00045773","Treatment Outcome of Vascular Depression",[],"2001-04",[12483,18],"Depressive Disorder",[4817],{"intervention":7803,"totalTrials":2475,"cells":12486},{"EARLY_PHASE1":12487,"PHASE1":12489,"PHASE2":12500,"PHASE3":12510,"PHASE4":12512,"NA":12514},{"trials":12488,"activeCount":103},[],{"trials":12490,"activeCount":103},[12491],{"nctId":12492,"briefTitle":12493,"status":150,"phases":12494,"primaryCompletion":4860,"completion":4860,"start":11713,"enrollment":12495,"conditions":12496,"interventions":12499},"NCT00948987","Mechanism Based Resistance to Aspirin",[91],400,[12497,12498],"Aspirin Resistance","Pharmacological Aspirin Non-responsiveness",[7803],{"trials":12501,"activeCount":103},[12502,12506],{"nctId":7797,"briefTitle":7798,"status":1357,"phases":12503,"primaryCompletion":4860,"completion":4860,"start":1086,"enrollment":4552,"conditions":12504,"interventions":12505},[92],[7801],[7788,7803],{"nctId":9095,"briefTitle":9096,"status":150,"phases":12507,"primaryCompletion":4993,"completion":4993,"start":4592,"enrollment":19,"conditions":12508,"interventions":12509},[92],[1915],[9086,9100,7803],{"trials":12511,"activeCount":103},[],{"trials":12513,"activeCount":103},[],{"trials":12515,"activeCount":103},[12516],{"nctId":12517,"briefTitle":12518,"status":150,"phases":12519,"primaryCompletion":7657,"completion":7657,"start":3480,"enrollment":2582,"conditions":12520,"interventions":12522},"NCT01275300","Biosynthesis of PGD2 in Vivo",[95],[12521],"Hyperlipidemia",[7803,12523],"Niacin",{"intervention":12525,"totalTrials":2475,"cells":12526},"Aprepitant",{"EARLY_PHASE1":12527,"PHASE1":12529,"PHASE2":12550,"PHASE3":12552,"PHASE4":12554,"NA":12556},{"trials":12528,"activeCount":103},[],{"trials":12530,"activeCount":103},[12531,12538,12544],{"nctId":12532,"briefTitle":12533,"status":150,"phases":12534,"primaryCompletion":980,"completion":980,"start":1063,"enrollment":2695,"conditions":12535,"interventions":12536},"NCT01300988","Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose",[91],[5803],[12525,12537],"Aprepitant placebo",{"nctId":12539,"briefTitle":12540,"status":150,"phases":12541,"primaryCompletion":5344,"completion":5344,"start":6192,"enrollment":1150,"conditions":12542,"interventions":12543},"NCT00428519","Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals",[91],[2567],[12525,12525],{"nctId":12545,"briefTitle":12546,"status":150,"phases":12547,"primaryCompletion":1030,"completion":2334,"start":10324,"enrollment":2964,"conditions":12548,"interventions":12549},"NCT02154360","Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects",[91],[5803],[12525],{"trials":12551,"activeCount":103},[],{"trials":12553,"activeCount":103},[],{"trials":12555,"activeCount":103},[],{"trials":12557,"activeCount":103},[12558],{"nctId":12559,"briefTitle":12560,"status":150,"phases":12561,"primaryCompletion":7657,"completion":7657,"start":6766,"enrollment":12562,"conditions":12563,"interventions":12566},"NCT00956215","Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients",[95],125,[12564,12565],"Nausea","Vomiting",[12525,12537],{"intervention":10380,"totalTrials":1139,"cells":12568},{"EARLY_PHASE1":12569,"PHASE1":12571,"PHASE2":12581,"PHASE3":12583,"PHASE4":12585,"NA":12587},{"trials":12570,"activeCount":103},[],{"trials":12572,"activeCount":103},[12573,12577],{"nctId":10373,"briefTitle":10374,"status":1357,"phases":12574,"primaryCompletion":4965,"completion":4965,"start":7047,"enrollment":2565,"conditions":12575,"interventions":12576},[91],[10377],[10379,10380,10366,10381,10379],{"nctId":10383,"briefTitle":10384,"status":1357,"phases":12578,"primaryCompletion":10386,"completion":10386,"start":1021,"enrollment":3729,"conditions":12579,"interventions":12580},[91],[21],[10380,10366],{"trials":12582,"activeCount":103},[],{"trials":12584,"activeCount":103},[],{"trials":12586,"activeCount":103},[],{"trials":12588,"activeCount":103},[12589],{"nctId":12590,"briefTitle":12591,"status":150,"phases":12592,"primaryCompletion":1021,"completion":1021,"start":12593,"enrollment":329,"conditions":12594,"interventions":12595},"NCT02413203","Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B",[95],"2015-03",[21],[10380],{"intervention":6197,"totalTrials":1139,"cells":12597},{"EARLY_PHASE1":12598,"PHASE1":12600,"PHASE2":12602,"PHASE3":12604,"PHASE4":12606,"NA":12622},{"trials":12599,"activeCount":103},[],{"trials":12601,"activeCount":103},[],{"trials":12603,"activeCount":103},[],{"trials":12605,"activeCount":103},[],{"trials":12607,"activeCount":103},[12608,12618],{"nctId":12609,"briefTitle":12610,"status":150,"phases":12611,"primaryCompletion":8586,"completion":8586,"start":12612,"enrollment":4262,"conditions":12613,"interventions":12616},"NCT00678574","The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder",[94],"1998-03",[12614,12615],"Premenstrual Dysphoric Disorder","Premenstrual Syndrome",[12617],"fluoxetine",{"nctId":6189,"briefTitle":6190,"status":150,"phases":12619,"primaryCompletion":6192,"completion":6192,"start":6193,"enrollment":6194,"conditions":12620,"interventions":12621},[94],[4828,18],[6197,6176],{"trials":12623,"activeCount":103},[12624],{"nctId":12625,"briefTitle":12626,"status":150,"phases":12627,"primaryCompletion":7454,"completion":7454,"start":12628,"enrollment":190,"conditions":12629,"interventions":12630},"NCT00676026","Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women",[95],"2005-05",[21],[6197,12631,12632],"Zolpidem","Progesterone",{"intervention":12634,"totalTrials":1139,"cells":12635},"Midazolam",{"EARLY_PHASE1":12636,"PHASE1":12638,"PHASE2":12640,"PHASE3":12652,"PHASE4":12662,"NA":12664},{"trials":12637,"activeCount":103},[],{"trials":12639,"activeCount":103},[],{"trials":12641,"activeCount":103},[12642],{"nctId":12643,"briefTitle":12644,"status":1357,"phases":12645,"primaryCompletion":12646,"completion":12646,"start":12647,"enrollment":22,"conditions":12648,"interventions":12651},"NCT05610969","Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks",[91,92],"2023-05-08","2021-09-01",[12649,36,12650],"Peripheral Nerve Block","Preoperative Anxiety",[12634],{"trials":12653,"activeCount":103},[12654],{"nctId":12655,"briefTitle":12656,"status":150,"phases":12657,"primaryCompletion":12658,"completion":12658,"start":12659,"enrollment":2249,"conditions":12660,"interventions":12661},"NCT03069677","Music vs Midazolam During Preop Nerve Block Placement",[93],"2018-05-11","2017-04-12",[36,12649],[12634],{"trials":12663,"activeCount":103},[],{"trials":12665,"activeCount":103},[12666],{"nctId":12667,"briefTitle":12668,"status":4881,"phases":12669,"primaryCompletion":12670,"completion":12670,"start":4792,"enrollment":103,"conditions":12671,"interventions":12674},"NCT02970097","Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery",[95],"2018-10-05",[12672,12673],"Wrist Injuries","Postoperative Pain Control",[12675,12676,12634,12677],"20ml bolus of 0.5% ropivicaine","10 ml of 0.5% ropivicaine","Fentanyl",{"intervention":12679,"totalTrials":1139,"cells":12680},"OTL38",{"EARLY_PHASE1":12681,"PHASE1":12683,"PHASE2":12701,"PHASE3":12703,"PHASE4":12705,"NA":12707},{"trials":12682,"activeCount":103},[],{"trials":12684,"activeCount":103},[12685,12693],{"nctId":12686,"briefTitle":12687,"status":150,"phases":12688,"primaryCompletion":12689,"completion":12689,"start":2674,"enrollment":12690,"conditions":12691,"interventions":12692},"NCT02602119","Intraoperative Imaging of Pulmonary Nodules by OTL38",[91],"2022-05",262,[2411],[12679],{"nctId":12694,"briefTitle":12695,"status":1357,"phases":12696,"primaryCompletion":12697,"completion":12697,"start":9967,"enrollment":6260,"conditions":12698,"interventions":12700},"NCT02629549","Intraoperative Imaging of Pituitary Adenomas by OTL",[91],"2018-08-03",[2411,12699],"Pituitary Neoplasms",[12679],{"trials":12702,"activeCount":103},[],{"trials":12704,"activeCount":103},[],{"trials":12706,"activeCount":103},[],{"trials":12708,"activeCount":103},[12709],{"nctId":12710,"briefTitle":12711,"status":150,"phases":12712,"primaryCompletion":7476,"completion":7476,"start":4958,"enrollment":12713,"conditions":12714,"interventions":12717},"NCT02852252","Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry",[],291,[12715,12716],"Bladder Cancer","Gastric Cancer",[12679,12718],"ICG",{"intervention":12523,"totalTrials":1139,"cells":12720},{"EARLY_PHASE1":12721,"PHASE1":12723,"PHASE2":12725,"PHASE3":12727,"PHASE4":12729,"NA":12731},{"trials":12722,"activeCount":103},[],{"trials":12724,"activeCount":103},[],{"trials":12726,"activeCount":103},[],{"trials":12728,"activeCount":103},[],{"trials":12730,"activeCount":103},[],{"trials":12732,"activeCount":103},[12733,12737,12746],{"nctId":12517,"briefTitle":12518,"status":150,"phases":12734,"primaryCompletion":7657,"completion":7657,"start":3480,"enrollment":2582,"conditions":12735,"interventions":12736},[95],[12521],[7803,12523],{"nctId":12738,"briefTitle":12739,"status":150,"phases":12740,"primaryCompletion":1074,"completion":1074,"start":12741,"enrollment":2582,"conditions":12742,"interventions":12745},"NCT02003638","Assessment Of Vascular Health After Niacin Therapy (AVANT)",[95],"2012-03",[12743,12744,1472],"Coronary Artery Disease","Carotid Artery Disease",[12523],{"nctId":12747,"briefTitle":12748,"status":150,"phases":12749,"primaryCompletion":2439,"completion":2439,"start":1094,"enrollment":34,"conditions":12750,"interventions":12751},"NCT01250990","Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis",[95],[10498],[12523],{"intervention":12753,"totalTrials":1139,"cells":12754},"Transdermal nicotine patch",{"EARLY_PHASE1":12755,"PHASE1":12757,"PHASE2":12759,"PHASE3":12761,"PHASE4":12763,"NA":12772},{"trials":12756,"activeCount":103},[],{"trials":12758,"activeCount":103},[],{"trials":12760,"activeCount":103},[],{"trials":12762,"activeCount":103},[],{"trials":12764,"activeCount":103},[12765],{"nctId":12766,"briefTitle":12767,"status":150,"phases":12768,"primaryCompletion":12399,"completion":12399,"start":4813,"enrollment":12769,"conditions":12770,"interventions":12771},"NCT01047527","An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence",[94],525,[1024],[12753],{"trials":12773,"activeCount":103},[12774,12782],{"nctId":12775,"briefTitle":12776,"status":150,"phases":12777,"primaryCompletion":10055,"completion":5017,"start":12778,"enrollment":9895,"conditions":12779,"interventions":12780},"NCT00954096","Nicotine Patch, Blood Flow and Oxidative Stress Study",[95],"2002-10",[21],[12781],"transdermal nicotine patch",{"nctId":12783,"briefTitle":12784,"status":150,"phases":12785,"primaryCompletion":1013,"completion":9830,"start":1084,"enrollment":12786,"conditions":12787,"interventions":12788},"NCT00596440","Assessment of a Teachable Moment for Smoking Cessation",[],234,[1024],[12753],{"intervention":12675,"totalTrials":1139,"cells":12790},{"EARLY_PHASE1":12791,"PHASE1":12793,"PHASE2":12795,"PHASE3":12797,"PHASE4":12799,"NA":12801},{"trials":12792,"activeCount":103},[],{"trials":12794,"activeCount":103},[],{"trials":12796,"activeCount":103},[],{"trials":12798,"activeCount":103},[],{"trials":12800,"activeCount":103},[],{"trials":12802,"activeCount":103},[12803,12807,12816],{"nctId":12667,"briefTitle":12668,"status":4881,"phases":12804,"primaryCompletion":12670,"completion":12670,"start":4792,"enrollment":103,"conditions":12805,"interventions":12806},[95],[12672,12673],[12675,12676,12634,12677],{"nctId":12808,"briefTitle":12809,"status":1357,"phases":12810,"primaryCompletion":12670,"completion":12670,"start":7693,"enrollment":190,"conditions":12811,"interventions":12814},"NCT02744352","Single Shot vs Catheter Infraclavicular Brachial Plexus Block After Distal Radius Fracture Repair",[95],[12812,12813],"Distal Radius Fracture","Post Operative Pain Control",[12675,12815],"0.2% of ropivacaine at 8 milliliter\u002Fhour",{"nctId":12817,"briefTitle":12818,"status":150,"phases":12819,"primaryCompletion":12820,"completion":1203,"start":12821,"enrollment":6834,"conditions":12822,"interventions":12825},"NCT02730728","Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA",[95],"2016-06-30","2015-11-01",[12823,12824,12813],"Total Knee Arthroplasty","Osteoarthritis",[12675,12826,12827],"0.2% Ropivicaine at 8 milliliter\u002Fhour","5ml bolus of 0.5% ropivicaine",{"intervention":12829,"totalTrials":99,"cells":12830},"Sitagliptin",{"EARLY_PHASE1":12831,"PHASE1":12833,"PHASE2":12835,"PHASE3":12837,"PHASE4":12839,"NA":12841},{"trials":12832,"activeCount":103},[],{"trials":12834,"activeCount":103},[],{"trials":12836,"activeCount":103},[],{"trials":12838,"activeCount":103},[],{"trials":12840,"activeCount":103},[],{"trials":12842,"activeCount":103},[12843,12854],{"nctId":12844,"briefTitle":12845,"status":150,"phases":12846,"primaryCompletion":12847,"completion":12847,"start":7047,"enrollment":7902,"conditions":12848,"interventions":12851},"NCT00775684","Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass",[95],"2012-11",[12849,12850],"Pre-diabetes","Type 2 Diabetes",[12852,12829,12853],"Exenatide","Glimepiride",{"nctId":12855,"briefTitle":12856,"status":150,"phases":12857,"primaryCompletion":10654,"completion":9893,"start":4825,"enrollment":2565,"conditions":12858,"interventions":12859},"NCT01879228","Effect of Chronic Incretin-based Therapy in Cystic Fibrosis",[95],[2387,2388],[12829],{"intervention":12537,"totalTrials":99,"cells":12861},{"EARLY_PHASE1":12862,"PHASE1":12864,"PHASE2":12870,"PHASE3":12872,"PHASE4":12874,"NA":12876},{"trials":12863,"activeCount":103},[],{"trials":12865,"activeCount":103},[12866],{"nctId":12532,"briefTitle":12533,"status":150,"phases":12867,"primaryCompletion":980,"completion":980,"start":1063,"enrollment":2695,"conditions":12868,"interventions":12869},[91],[5803],[12525,12537],{"trials":12871,"activeCount":103},[],{"trials":12873,"activeCount":103},[],{"trials":12875,"activeCount":103},[],{"trials":12877,"activeCount":103},[12878],{"nctId":12559,"briefTitle":12560,"status":150,"phases":12879,"primaryCompletion":7657,"completion":7657,"start":6766,"enrollment":12562,"conditions":12880,"interventions":12881},[95],[12564,12565],[12525,12537],{"intervention":7561,"totalTrials":99,"cells":12883},{"EARLY_PHASE1":12884,"PHASE1":12886,"PHASE2":12888,"PHASE3":12894,"PHASE4":12896,"NA":12898},{"trials":12885,"activeCount":103},[],{"trials":12887,"activeCount":103},[],{"trials":12889,"activeCount":103},[12890],{"nctId":7551,"briefTitle":7552,"status":150,"phases":12891,"primaryCompletion":7554,"completion":7555,"start":1074,"enrollment":329,"conditions":12892,"interventions":12893},[92],[4327,7557,7558,7559],[7542,7561],{"trials":12895,"activeCount":103},[],{"trials":12897,"activeCount":103},[],{"trials":12899,"activeCount":103},[12900],{"nctId":12901,"briefTitle":12902,"status":150,"phases":12903,"primaryCompletion":4825,"completion":4825,"start":5108,"enrollment":155,"conditions":12904,"interventions":12906},"NCT00662155","The Role of Partial Reinforcement in the Long Term Management of Insomnia",[95],[12905],"Primary Insomnia",[12631,7561],{"intervention":5159,"totalTrials":99,"cells":12908},{"EARLY_PHASE1":12909,"PHASE1":12911,"PHASE2":12913,"PHASE3":12915,"PHASE4":12917,"NA":12923},{"trials":12910,"activeCount":103},[],{"trials":12912,"activeCount":103},[],{"trials":12914,"activeCount":103},[],{"trials":12916,"activeCount":103},[],{"trials":12918,"activeCount":103},[12919],{"nctId":5151,"briefTitle":5152,"status":150,"phases":12920,"primaryCompletion":5154,"completion":5154,"start":5155,"enrollment":3960,"conditions":12921,"interventions":12922},[94],[5157],[5159,5138],{"trials":12924,"activeCount":103},[12925],{"nctId":12926,"briefTitle":12927,"status":1357,"phases":12928,"primaryCompletion":12929,"completion":12929,"start":12930,"enrollment":12931,"conditions":12932,"interventions":12934},"NCT03437460","The Economic and Cognitive Effects of Pain Reduction",[95],"2017-08-12","2017-05-10",139,[12933],"Pain, Chronic",[5159],{"intervention":12936,"totalTrials":99,"cells":12937},"Fenofibrate",{"EARLY_PHASE1":12938,"PHASE1":12940,"PHASE2":12942,"PHASE3":12944,"PHASE4":12946,"NA":12948},{"trials":12939,"activeCount":103},[],{"trials":12941,"activeCount":103},[],{"trials":12943,"activeCount":103},[],{"trials":12945,"activeCount":103},[],{"trials":12947,"activeCount":103},[],{"trials":12949,"activeCount":103},[12950,12958],{"nctId":12951,"briefTitle":12952,"status":150,"phases":12953,"primaryCompletion":12954,"completion":12954,"start":8029,"enrollment":2964,"conditions":12955,"interventions":12957},"NCT05080192","Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate",[],"2022-05-10",[12956],"Covid19",[12936],{"nctId":12959,"briefTitle":12960,"status":150,"phases":12961,"primaryCompletion":2439,"completion":2439,"start":7842,"enrollment":1376,"conditions":12962,"interventions":12963},"NCT01048502","Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia",[95],[1297],[12964,12965],"Fenofibrate (Tricor)","Lovaza",{"intervention":12631,"totalTrials":99,"cells":12967},{"EARLY_PHASE1":12968,"PHASE1":12970,"PHASE2":12972,"PHASE3":12974,"PHASE4":12976,"NA":12978},{"trials":12969,"activeCount":103},[],{"trials":12971,"activeCount":103},[],{"trials":12973,"activeCount":103},[],{"trials":12975,"activeCount":103},[],{"trials":12977,"activeCount":103},[],{"trials":12979,"activeCount":103},[12980,12984],{"nctId":12625,"briefTitle":12626,"status":150,"phases":12981,"primaryCompletion":7454,"completion":7454,"start":12628,"enrollment":190,"conditions":12982,"interventions":12983},[95],[21],[6197,12631,12632],{"nctId":12901,"briefTitle":12902,"status":150,"phases":12985,"primaryCompletion":4825,"completion":4825,"start":5108,"enrollment":155,"conditions":12986,"interventions":12987},[95],[12905],[12631,7561],{"intervention":12632,"totalTrials":99,"cells":12989},{"EARLY_PHASE1":12990,"PHASE1":12992,"PHASE2":12994,"PHASE3":12996,"PHASE4":12998,"NA":13007},{"trials":12991,"activeCount":103},[],{"trials":12993,"activeCount":103},[],{"trials":12995,"activeCount":103},[],{"trials":12997,"activeCount":103},[],{"trials":12999,"activeCount":103},[13000],{"nctId":13001,"briefTitle":13002,"status":150,"phases":13003,"primaryCompletion":4600,"completion":4600,"start":1094,"enrollment":1304,"conditions":13004,"interventions":13006},"NCT01954966","Progesterone and Brain Imaging Study",[94],[1024,13005],"Nicotine Withdrawal",[12632],{"trials":13008,"activeCount":103},[13009],{"nctId":12625,"briefTitle":12626,"status":150,"phases":13010,"primaryCompletion":7454,"completion":7454,"start":12628,"enrollment":190,"conditions":13011,"interventions":13012},[95],[21],[6197,12631,12632],{"intervention":13014,"totalTrials":99,"cells":13015},"Atomoxetine",{"EARLY_PHASE1":13016,"PHASE1":13018,"PHASE2":13020,"PHASE3":13022,"PHASE4":13024,"NA":13032},{"trials":13017,"activeCount":103},[],{"trials":13019,"activeCount":103},[],{"trials":13021,"activeCount":103},[],{"trials":13023,"activeCount":103},[],{"trials":13025,"activeCount":103},[13026],{"nctId":13027,"briefTitle":13028,"status":150,"phases":13029,"primaryCompletion":8586,"completion":8586,"start":5084,"enrollment":9895,"conditions":13030,"interventions":13031},"NCT00304161","Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease",[94],[12483,2594],[13014],{"trials":13033,"activeCount":103},[13034],{"nctId":13035,"briefTitle":13036,"status":150,"phases":13037,"primaryCompletion":4629,"completion":4629,"start":13038,"enrollment":3729,"conditions":13039,"interventions":13041},"NCT00611533","Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women",[95],"2004-05",[6435,13040],"Cognitive Disturbances",[13042],"atomoxetine",{"intervention":12965,"totalTrials":99,"cells":13044},{"EARLY_PHASE1":13045,"PHASE1":13047,"PHASE2":13049,"PHASE3":13051,"PHASE4":13053,"NA":13061},{"trials":13046,"activeCount":103},[],{"trials":13048,"activeCount":103},[],{"trials":13050,"activeCount":103},[],{"trials":13052,"activeCount":103},[],{"trials":13054,"activeCount":103},[13055],{"nctId":13056,"briefTitle":13057,"status":150,"phases":13058,"primaryCompletion":152,"completion":5518,"start":5453,"enrollment":2467,"conditions":13059,"interventions":13060},"NCT02010359","Fish Oils and Adipose Inflammation Reduction",[94],[15],[12965],{"trials":13062,"activeCount":103},[13063],{"nctId":12959,"briefTitle":12960,"status":150,"phases":13064,"primaryCompletion":2439,"completion":2439,"start":7842,"enrollment":1376,"conditions":13065,"interventions":13066},[95],[1297],[12964,12965],{"intervention":13068,"totalTrials":99,"cells":13069},"Depot Naltrexone",{"EARLY_PHASE1":13070,"PHASE1":13072,"PHASE2":13074,"PHASE3":13076,"PHASE4":13087,"NA":13089},{"trials":13071,"activeCount":103},[],{"trials":13073,"activeCount":103},[],{"trials":13075,"activeCount":103},[],{"trials":13077,"activeCount":103},[13078],{"nctId":13079,"briefTitle":13080,"status":150,"phases":13081,"primaryCompletion":12043,"completion":12043,"start":1014,"enrollment":13082,"conditions":13083,"interventions":13085},"NCT00781898","Treatment Study Using Depot Naltrexone (1\u002F6) Philadelphia Coord\u002FData Mgmt Site",[92,93],308,[13084],"Opiate Addiction",[13086],"Depot naltrexone",{"trials":13088,"activeCount":103},[],{"trials":13090,"activeCount":103},[13091],{"nctId":13092,"briefTitle":13093,"status":150,"phases":13094,"primaryCompletion":4921,"completion":722,"start":4592,"enrollment":6633,"conditions":13095,"interventions":13096},"NCT00756990","Depot Naltrexone Treatment of Opioid Dependent Parolees",[95],[4604],[13068],{"intervention":13098,"totalTrials":99,"cells":13099},"Sildenafil Citrate",{"EARLY_PHASE1":13100,"PHASE1":13102,"PHASE2":13114,"PHASE3":13116,"PHASE4":13118,"NA":13120},{"trials":13101,"activeCount":103},[],{"trials":13103,"activeCount":103},[13104],{"nctId":13105,"briefTitle":13106,"status":1357,"phases":13107,"primaryCompletion":13108,"completion":13108,"start":13109,"enrollment":1986,"conditions":13110,"interventions":13113},"NCT03417492","Cerebrovascular Reactivity in American Football Players",[91],"2022-06-30","2018-03-01",[1797,13111,13112],"Mild Traumatic Brain Injury","Post-Concussion Syndrome",[13098],{"trials":13115,"activeCount":103},[],{"trials":13117,"activeCount":103},[],{"trials":13119,"activeCount":103},[],{"trials":13121,"activeCount":103},[13122],{"nctId":13123,"briefTitle":13124,"status":1357,"phases":13125,"primaryCompletion":13108,"completion":13126,"start":6567,"enrollment":2565,"conditions":13127,"interventions":13128},"NCT02990078","Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury",[],"2022-09-30",[8696],[13129],"Sildenafil citrate",{"intervention":196,"totalTrials":99,"cells":13131},{"EARLY_PHASE1":13132,"PHASE1":13134,"PHASE2":13136,"PHASE3":13142,"PHASE4":13144,"NA":13146},{"trials":13133,"activeCount":103},[],{"trials":13135,"activeCount":103},[],{"trials":13137,"activeCount":103},[13138],{"nctId":185,"briefTitle":186,"status":150,"phases":13139,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":13140,"interventions":13141},[92],[192],[194,176,195,196,197,198,199],{"trials":13143,"activeCount":103},[],{"trials":13145,"activeCount":103},[],{"trials":13147,"activeCount":103},[13148],{"nctId":13149,"briefTitle":13150,"status":150,"phases":13151,"primaryCompletion":13152,"completion":13152,"start":2437,"enrollment":7957,"conditions":13153,"interventions":13156},"NCT02358993","Short-course Methenamine Hippurate for Prevention of Post-operative UTI",[95],"2020-09-30",[13154,13155],"Urinary Tract Infections","Catheter-Related Infections",[13157,196],"methenamine hippurate",{"intervention":13159,"totalTrials":121,"cells":13160},"Antidepressant medication",{"EARLY_PHASE1":13161,"PHASE1":13163,"PHASE2":13165,"PHASE3":13167,"PHASE4":13169,"NA":13171},{"trials":13162,"activeCount":103},[],{"trials":13164,"activeCount":103},[],{"trials":13166,"activeCount":103},[],{"trials":13168,"activeCount":103},[],{"trials":13170,"activeCount":103},[],{"trials":13172,"activeCount":103},[13173],{"nctId":13174,"briefTitle":13175,"status":150,"phases":13176,"primaryCompletion":7639,"completion":7639,"start":13177,"enrollment":13178,"conditions":13179,"interventions":13180},"NCT00076622","Medication Treatment for Depression in Nursing Home Residents",[],"2003-11",94,[18],[13159,13181],"No antidepressant medication",{"intervention":13181,"totalTrials":121,"cells":13183},{"EARLY_PHASE1":13184,"PHASE1":13186,"PHASE2":13188,"PHASE3":13190,"PHASE4":13192,"NA":13194},{"trials":13185,"activeCount":103},[],{"trials":13187,"activeCount":103},[],{"trials":13189,"activeCount":103},[],{"trials":13191,"activeCount":103},[],{"trials":13193,"activeCount":103},[],{"trials":13195,"activeCount":103},[13196],{"nctId":13174,"briefTitle":13175,"status":150,"phases":13197,"primaryCompletion":7639,"completion":7639,"start":13177,"enrollment":13178,"conditions":13198,"interventions":13199},[],[18],[13159,13181],{"intervention":12852,"totalTrials":121,"cells":13201},{"EARLY_PHASE1":13202,"PHASE1":13204,"PHASE2":13206,"PHASE3":13208,"PHASE4":13210,"NA":13212},{"trials":13203,"activeCount":103},[],{"trials":13205,"activeCount":103},[],{"trials":13207,"activeCount":103},[],{"trials":13209,"activeCount":103},[],{"trials":13211,"activeCount":103},[],{"trials":13213,"activeCount":103},[13214],{"nctId":12844,"briefTitle":12845,"status":150,"phases":13215,"primaryCompletion":12847,"completion":12847,"start":7047,"enrollment":7902,"conditions":13216,"interventions":13217},[95],[12849,12850],[12852,12829,12853],{"intervention":12853,"totalTrials":121,"cells":13219},{"EARLY_PHASE1":13220,"PHASE1":13222,"PHASE2":13224,"PHASE3":13226,"PHASE4":13228,"NA":13230},{"trials":13221,"activeCount":103},[],{"trials":13223,"activeCount":103},[],{"trials":13225,"activeCount":103},[],{"trials":13227,"activeCount":103},[],{"trials":13229,"activeCount":103},[],{"trials":13231,"activeCount":103},[13232],{"nctId":12844,"briefTitle":12845,"status":150,"phases":13233,"primaryCompletion":12847,"completion":12847,"start":7047,"enrollment":7902,"conditions":13234,"interventions":13235},[95],[12849,12850],[12852,12829,12853],{"intervention":13237,"totalTrials":121,"cells":13238},"Baseline 18F-thymidine (FLT) PET\u002FCT",{"EARLY_PHASE1":13239,"PHASE1":13241,"PHASE2":13243,"PHASE3":13245,"PHASE4":13247,"NA":13249},{"trials":13240,"activeCount":103},[],{"trials":13242,"activeCount":103},[],{"trials":13244,"activeCount":103},[],{"trials":13246,"activeCount":103},[],{"trials":13248,"activeCount":103},[],{"trials":13250,"activeCount":103},[13251],{"nctId":13252,"briefTitle":13253,"status":1357,"phases":13254,"primaryCompletion":13255,"completion":13255,"start":12593,"enrollment":1139,"conditions":13256,"interventions":13260},"NCT02274038","Serial [18F]Thymidine (FLT)PET\u002FCT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer",[95],"2018-07",[13257,13258,13259],"Non-small Cell Lung Cancer","Starting Pemetrexed Based Therapy","Unresectable Cancer",[13237,13261,13262],"Post-therapy 18F-thymidine (FLT) PET\u002FCT to assess for pemetrexed induced tumor FLT \"flare\"","Post-therapy 18F-thymidine (FLT) PET\u002FCT to assess for pemetrexed induced changes in tumor proliferation",{"intervention":13261,"totalTrials":121,"cells":13264},{"EARLY_PHASE1":13265,"PHASE1":13267,"PHASE2":13269,"PHASE3":13271,"PHASE4":13273,"NA":13275},{"trials":13266,"activeCount":103},[],{"trials":13268,"activeCount":103},[],{"trials":13270,"activeCount":103},[],{"trials":13272,"activeCount":103},[],{"trials":13274,"activeCount":103},[],{"trials":13276,"activeCount":103},[13277],{"nctId":13252,"briefTitle":13253,"status":1357,"phases":13278,"primaryCompletion":13255,"completion":13255,"start":12593,"enrollment":1139,"conditions":13279,"interventions":13280},[95],[13257,13258,13259],[13237,13261,13262],{"intervention":13262,"totalTrials":121,"cells":13282},{"EARLY_PHASE1":13283,"PHASE1":13285,"PHASE2":13287,"PHASE3":13289,"PHASE4":13291,"NA":13293},{"trials":13284,"activeCount":103},[],{"trials":13286,"activeCount":103},[],{"trials":13288,"activeCount":103},[],{"trials":13290,"activeCount":103},[],{"trials":13292,"activeCount":103},[],{"trials":13294,"activeCount":103},[13295],{"nctId":13252,"briefTitle":13253,"status":1357,"phases":13296,"primaryCompletion":13255,"completion":13255,"start":12593,"enrollment":1139,"conditions":13297,"interventions":13298},[95],[13257,13258,13259],[13237,13261,13262],{"intervention":13300,"totalTrials":121,"cells":13301},"Gallium-68 DOTATATE",{"EARLY_PHASE1":13302,"PHASE1":13304,"PHASE2":13306,"PHASE3":13308,"PHASE4":13310,"NA":13312},{"trials":13303,"activeCount":103},[],{"trials":13305,"activeCount":103},[],{"trials":13307,"activeCount":103},[],{"trials":13309,"activeCount":103},[],{"trials":13311,"activeCount":103},[],{"trials":13313,"activeCount":103},[13314],{"nctId":13315,"briefTitle":13316,"status":150,"phases":13317,"primaryCompletion":11342,"completion":11342,"start":6940,"enrollment":329,"conditions":13318,"interventions":13319},"NCT03746847","PET Imaging in Patients With Suspected Cardiac Sarcoidosis",[],[3900],[13300],{"intervention":13321,"totalTrials":121,"cells":13322},"Ambrisentan",{"EARLY_PHASE1":13323,"PHASE1":13325,"PHASE2":13327,"PHASE3":13329,"PHASE4":13331,"NA":13333},{"trials":13324,"activeCount":103},[],{"trials":13326,"activeCount":103},[],{"trials":13328,"activeCount":103},[],{"trials":13330,"activeCount":103},[],{"trials":13332,"activeCount":103},[],{"trials":13334,"activeCount":103},[13335],{"nctId":13336,"briefTitle":13337,"status":150,"phases":13338,"primaryCompletion":4958,"completion":4958,"start":6744,"enrollment":983,"conditions":13339,"interventions":13342},"NCT01093885","Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis",[95],[13340,13341],"Systemic Sclerosis","Scleroderma",[13321],{"intervention":13344,"totalTrials":121,"cells":13345},"Desipramine",{"EARLY_PHASE1":13346,"PHASE1":13348,"PHASE2":13350,"PHASE3":13352,"PHASE4":13354,"NA":13356},{"trials":13347,"activeCount":103},[],{"trials":13349,"activeCount":103},[],{"trials":13351,"activeCount":103},[],{"trials":13353,"activeCount":103},[],{"trials":13355,"activeCount":103},[],{"trials":13357,"activeCount":103},[13358],{"nctId":13359,"briefTitle":13360,"status":150,"phases":13361,"completion":13362,"start":13363,"conditions":13364,"interventions":13367},"NCT00000376","Cognitive and Drug Therapy for Drug-Resistant Depression",[95],"1999-02","1996-03",[18,4763,13365,13366],"Personality Disorders","Drug-resistant Depression",[13344],{"intervention":13369,"totalTrials":121,"cells":13370},"Fluorometholone 0.1% ophthalmic solution",{"EARLY_PHASE1":13371,"PHASE1":13373,"PHASE2":13375,"PHASE3":13377,"PHASE4":13379,"NA":13381},{"trials":13372,"activeCount":103},[],{"trials":13374,"activeCount":103},[],{"trials":13376,"activeCount":103},[],{"trials":13378,"activeCount":103},[],{"trials":13380,"activeCount":103},[],{"trials":13382,"activeCount":103},[13383],{"nctId":13384,"briefTitle":13385,"status":150,"phases":13386,"primaryCompletion":9057,"completion":9057,"start":2429,"enrollment":13387,"conditions":13388,"interventions":13392},"NCT01949454","Fluorometholone as Ancillary Therapy for TT Surgery",[95],154,[13389,13390,13391],"Trichiasis","Trachoma","Bilamellar Tarsal Rotation",[13369],{"intervention":13394,"totalTrials":121,"cells":13395},"TPA",{"EARLY_PHASE1":13396,"PHASE1":13398,"PHASE2":13400,"PHASE3":13402,"PHASE4":13404,"NA":13406},{"trials":13397,"activeCount":103},[],{"trials":13399,"activeCount":103},[],{"trials":13401,"activeCount":103},[],{"trials":13403,"activeCount":103},[],{"trials":13405,"activeCount":103},[],{"trials":13407,"activeCount":103},[13408],{"nctId":13409,"briefTitle":13410,"status":1357,"phases":13411,"completion":1512,"start":6632,"enrollment":289,"conditions":13412,"interventions":13416},"NCT00194181","Rt-PA Infusion Versus Catheter Exchange for Dialysis Catheter Malfunction Due to Fibrin Sheath",[95],[13413,13414,13415],"Dialysis Catheter Fibrin Sheath","Clotted Dialysis Catheter","Catheter Malfunction",[13394],{"intervention":13418,"totalTrials":121,"cells":13419},"Broad gene panel for young adult cancers",{"EARLY_PHASE1":13420,"PHASE1":13422,"PHASE2":13424,"PHASE3":13426,"PHASE4":13428,"NA":13430},{"trials":13421,"activeCount":103},[],{"trials":13423,"activeCount":103},[],{"trials":13425,"activeCount":103},[],{"trials":13427,"activeCount":103},[],{"trials":13429,"activeCount":103},[],{"trials":13431,"activeCount":103},[13432],{"nctId":13433,"briefTitle":13434,"status":150,"phases":13435,"primaryCompletion":13436,"completion":13436,"start":13437,"enrollment":13438,"conditions":13439,"interventions":13441},"NCT04533555","Genetic Testing in Young Adults With Cancer Study",[95],"2025-09-26","2020-12-01",749,[13440],"Cancer",[13418,13442],"Standard",{"intervention":13442,"totalTrials":121,"cells":13444},{"EARLY_PHASE1":13445,"PHASE1":13447,"PHASE2":13449,"PHASE3":13451,"PHASE4":13453,"NA":13455},{"trials":13446,"activeCount":103},[],{"trials":13448,"activeCount":103},[],{"trials":13450,"activeCount":103},[],{"trials":13452,"activeCount":103},[],{"trials":13454,"activeCount":103},[],{"trials":13456,"activeCount":103},[13457],{"nctId":13433,"briefTitle":13434,"status":150,"phases":13458,"primaryCompletion":13436,"completion":13436,"start":13437,"enrollment":13438,"conditions":13459,"interventions":13460},[95],[13440],[13418,13442],{"intervention":13462,"totalTrials":121,"cells":13463},"Endotoxin",{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13468,"PHASE3":13470,"PHASE4":13472,"NA":13474},{"trials":13465,"activeCount":103},[],{"trials":13467,"activeCount":103},[],{"trials":13469,"activeCount":103},[],{"trials":13471,"activeCount":103},[],{"trials":13473,"activeCount":103},[],{"trials":13475,"activeCount":103},[13476],{"nctId":13477,"briefTitle":13478,"status":150,"phases":13479,"primaryCompletion":1105,"completion":1105,"start":13480,"enrollment":1587,"conditions":13481,"interventions":13482},"NCT00954824","Inflammation and the Metabolic Syndrome in Humans",[95],"2003-08",[10284],[13462],{"intervention":13484,"totalTrials":121,"cells":13485},"lidocaine",{"EARLY_PHASE1":13486,"PHASE1":13488,"PHASE2":13490,"PHASE3":13492,"PHASE4":13494,"NA":13496},{"trials":13487,"activeCount":103},[],{"trials":13489,"activeCount":103},[],{"trials":13491,"activeCount":103},[],{"trials":13493,"activeCount":103},[],{"trials":13495,"activeCount":103},[],{"trials":13497,"activeCount":103},[13498],{"nctId":13499,"briefTitle":13500,"status":150,"phases":13501,"completion":1085,"start":1374,"enrollment":13502,"conditions":13503,"interventions":13505},"NCT00594542","Comparison of the Total Dose and Efficacy of Two Lidocaine Concentrations Needed for Cutaneous Surgery Local Anesthesia",[95],149,[13504],"Anesthesia",[13484],{"intervention":13507,"totalTrials":121,"cells":13508},"Chlorhexidine Gluconate",{"EARLY_PHASE1":13509,"PHASE1":13511,"PHASE2":13513,"PHASE3":13515,"PHASE4":13517,"NA":13519},{"trials":13510,"activeCount":103},[],{"trials":13512,"activeCount":103},[],{"trials":13514,"activeCount":103},[],{"trials":13516,"activeCount":103},[],{"trials":13518,"activeCount":103},[],{"trials":13520,"activeCount":103},[13521],{"nctId":13522,"briefTitle":13523,"status":1357,"phases":13524,"primaryCompletion":13525,"completion":13525,"start":13526,"enrollment":7835,"conditions":13527,"interventions":13528},"NCT06590675","Development and Evaluation of a ChlorHexidine Gluconate bAthing pRotocol for Healthcare Settings in Low- and Middle-income Countries",[95],"2025-03-19","2025-02-19",[1542],[13507],{"intervention":13530,"totalTrials":121,"cells":13531},"propafenone; flecainide; sotalol; dofetilide",{"EARLY_PHASE1":13532,"PHASE1":13534,"PHASE2":13536,"PHASE3":13538,"PHASE4":13540,"NA":13542},{"trials":13533,"activeCount":103},[],{"trials":13535,"activeCount":103},[],{"trials":13537,"activeCount":103},[],{"trials":13539,"activeCount":103},[],{"trials":13541,"activeCount":103},[],{"trials":13543,"activeCount":103},[13544],{"nctId":13545,"briefTitle":13546,"status":150,"phases":13547,"primaryCompletion":4629,"completion":1014,"start":10055,"enrollment":13548,"conditions":13549,"interventions":13550},"NCT00408200","A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation",[95],110,[7300],[13530],{"intervention":13552,"totalTrials":121,"cells":13553},"multimodal perioperative pain protocol",{"EARLY_PHASE1":13554,"PHASE1":13556,"PHASE2":13558,"PHASE3":13560,"PHASE4":13562,"NA":13564},{"trials":13555,"activeCount":103},[],{"trials":13557,"activeCount":103},[],{"trials":13559,"activeCount":103},[],{"trials":13561,"activeCount":103},[],{"trials":13563,"activeCount":103},[],{"trials":13565,"activeCount":103},[13566],{"nctId":13567,"briefTitle":13568,"status":150,"phases":13569,"primaryCompletion":9057,"completion":11144,"start":4965,"enrollment":13570,"conditions":13571,"interventions":13574},"NCT03427775","Multimodal Analgesia After Shoulder Arthroscopy",[],252,[5370,13572,13573],"Arthroscopy","Shoulder Joint",[13552],{"intervention":13576,"totalTrials":121,"cells":13577},"Misoprostol Alone",{"EARLY_PHASE1":13578,"PHASE1":13580,"PHASE2":13582,"PHASE3":13584,"PHASE4":13586,"NA":13588},{"trials":13579,"activeCount":103},[],{"trials":13581,"activeCount":103},[],{"trials":13583,"activeCount":103},[],{"trials":13585,"activeCount":103},[],{"trials":13587,"activeCount":103},[],{"trials":13589,"activeCount":103},[13590],{"nctId":13591,"briefTitle":13592,"status":150,"phases":13593,"primaryCompletion":2418,"completion":2418,"start":4261,"enrollment":13594,"conditions":13595,"interventions":13597},"NCT01916681","Foley OR MisO for the Management of Induction",[95],491,[13596],"Delivery; Prolonged",[13576],{"intervention":13599,"totalTrials":121,"cells":13600},"DMPA immediately postpartum",{"EARLY_PHASE1":13601,"PHASE1":13603,"PHASE2":13605,"PHASE3":13607,"PHASE4":13609,"NA":13611},{"trials":13602,"activeCount":103},[],{"trials":13604,"activeCount":103},[],{"trials":13606,"activeCount":103},[],{"trials":13608,"activeCount":103},[],{"trials":13610,"activeCount":103},[],{"trials":13612,"activeCount":103},[13613],{"nctId":13614,"briefTitle":13615,"status":150,"phases":13616,"primaryCompletion":1001,"completion":1001,"start":1003,"enrollment":1376,"conditions":13617,"interventions":13619},"NCT02144259","The Impact of Contraception on Postpartum Weight Loss",[95],[13618],"Weight",[13599,13620],"Implanon immediately postpartum",{"intervention":13620,"totalTrials":121,"cells":13622},{"EARLY_PHASE1":13623,"PHASE1":13625,"PHASE2":13627,"PHASE3":13629,"PHASE4":13631,"NA":13633},{"trials":13624,"activeCount":103},[],{"trials":13626,"activeCount":103},[],{"trials":13628,"activeCount":103},[],{"trials":13630,"activeCount":103},[],{"trials":13632,"activeCount":103},[],{"trials":13634,"activeCount":103},[13635],{"nctId":13614,"briefTitle":13615,"status":150,"phases":13636,"primaryCompletion":1001,"completion":1001,"start":1003,"enrollment":1376,"conditions":13637,"interventions":13638},[95],[13618],[13599,13620],{"intervention":13640,"totalTrials":121,"cells":13641},"vilazodone",{"EARLY_PHASE1":13642,"PHASE1":13644,"PHASE2":13646,"PHASE3":13648,"PHASE4":13650,"NA":13652},{"trials":13643,"activeCount":103},[],{"trials":13645,"activeCount":103},[],{"trials":13647,"activeCount":103},[],{"trials":13649,"activeCount":103},[],{"trials":13651,"activeCount":103},[],{"trials":13653,"activeCount":103},[13654],{"nctId":13655,"briefTitle":13656,"status":150,"phases":13657,"primaryCompletion":980,"completion":980,"start":12847,"enrollment":22,"conditions":13658,"interventions":13660},"NCT01680900","Vilazodone for Menopausal Hot Flashes",[95],[13659],"Hot Flushes",[13640],{"intervention":13662,"totalTrials":121,"cells":13663},"Glycolic acid",{"EARLY_PHASE1":13664,"PHASE1":13666,"PHASE2":13668,"PHASE3":13670,"PHASE4":13672,"NA":13674},{"trials":13665,"activeCount":103},[],{"trials":13667,"activeCount":103},[],{"trials":13669,"activeCount":103},[],{"trials":13671,"activeCount":103},[],{"trials":13673,"activeCount":103},[],{"trials":13675,"activeCount":103},[13676],{"nctId":13677,"briefTitle":13678,"status":150,"phases":13679,"primaryCompletion":4813,"completion":5777,"start":1031,"enrollment":19,"conditions":13680,"interventions":13682},"NCT01289171","Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients",[95],[13681,4853],"Flat Warts",[13662],{"intervention":13684,"totalTrials":121,"cells":13685},"Hyperpolarized Helium-3",{"EARLY_PHASE1":13686,"PHASE1":13688,"PHASE2":13690,"PHASE3":13692,"PHASE4":13694,"NA":13696},{"trials":13687,"activeCount":103},[],{"trials":13689,"activeCount":103},[],{"trials":13691,"activeCount":103},[],{"trials":13693,"activeCount":103},[],{"trials":13695,"activeCount":103},[],{"trials":13697,"activeCount":103},[13698],{"nctId":13699,"briefTitle":13700,"status":1357,"phases":13701,"primaryCompletion":9830,"completion":12593,"start":6744,"enrollment":1398,"conditions":13702,"interventions":13704},"NCT02734368","A Prospective, Cohort Study of Hyperpolarized 3He MRI in Chronic Obstructive Pulmonary Disease",[],[13703],"Chronic Obstructive Pulmonary Disease (COPD)",[13684],{"intervention":13706,"totalTrials":121,"cells":13707},"keflex",{"EARLY_PHASE1":13708,"PHASE1":13710,"PHASE2":13712,"PHASE3":13714,"PHASE4":13716,"NA":13718},{"trials":13709,"activeCount":103},[],{"trials":13711,"activeCount":103},[],{"trials":13713,"activeCount":103},[],{"trials":13715,"activeCount":103},[],{"trials":13717,"activeCount":103},[],{"trials":13719,"activeCount":103},[13720],{"nctId":13721,"briefTitle":13722,"status":1357,"phases":13723,"primaryCompletion":722,"completion":722,"start":4658,"enrollment":2475,"conditions":13724,"interventions":13726},"NCT00957827","Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip",[95],[13725],"Through-and-through Lip Lacerations",[13706],{"intervention":13728,"totalTrials":121,"cells":13729},"Blood Transfusion",{"EARLY_PHASE1":13730,"PHASE1":13732,"PHASE2":13734,"PHASE3":13736,"PHASE4":13738,"NA":13740},{"trials":13731,"activeCount":103},[],{"trials":13733,"activeCount":103},[],{"trials":13735,"activeCount":103},[],{"trials":13737,"activeCount":103},[],{"trials":13739,"activeCount":103},[],{"trials":13741,"activeCount":103},[13742],{"nctId":13743,"briefTitle":13744,"status":150,"phases":13745,"primaryCompletion":13746,"completion":13746,"start":13109,"enrollment":7191,"conditions":13747,"interventions":13749},"NCT03419780","SMaRT Blood: Single-unit Versus Multiple-unit Packed Red Blood Cell Transfusion in Non-acute Postpartum Anemia",[95],"2020-06-01",[13748],"Postpartum Anemia Nos",[13728],{"intervention":13751,"totalTrials":121,"cells":13752},"Trimethoprim\u002FSulfamethoxazole and Warfarin",{"EARLY_PHASE1":13753,"PHASE1":13755,"PHASE2":13757,"PHASE3":13759,"PHASE4":13761,"NA":13763},{"trials":13754,"activeCount":103},[],{"trials":13756,"activeCount":103},[],{"trials":13758,"activeCount":103},[],{"trials":13760,"activeCount":103},[],{"trials":13762,"activeCount":103},[],{"trials":13764,"activeCount":103},[13765],{"nctId":13766,"briefTitle":13767,"status":1357,"phases":13768,"primaryCompletion":6192,"completion":6192,"start":9785,"enrollment":13769,"conditions":13770,"interventions":13772},"NCT00870298","Computer Stop Order Alert to Prevent Concurrent Prescribing of Trimethoprim\u002FSulfamethoxazole and Warfarin",[95],1971,[13771],"Prescribers' Drug Orders",[13751],{"intervention":12676,"totalTrials":121,"cells":13774},{"EARLY_PHASE1":13775,"PHASE1":13777,"PHASE2":13779,"PHASE3":13781,"PHASE4":13783,"NA":13785},{"trials":13776,"activeCount":103},[],{"trials":13778,"activeCount":103},[],{"trials":13780,"activeCount":103},[],{"trials":13782,"activeCount":103},[],{"trials":13784,"activeCount":103},[],{"trials":13786,"activeCount":103},[13787],{"nctId":12667,"briefTitle":12668,"status":4881,"phases":13788,"primaryCompletion":12670,"completion":12670,"start":4792,"enrollment":103,"conditions":13789,"interventions":13790},[95],[12672,12673],[12675,12676,12634,12677],{"intervention":12677,"totalTrials":121,"cells":13792},{"EARLY_PHASE1":13793,"PHASE1":13795,"PHASE2":13797,"PHASE3":13799,"PHASE4":13801,"NA":13803},{"trials":13794,"activeCount":103},[],{"trials":13796,"activeCount":103},[],{"trials":13798,"activeCount":103},[],{"trials":13800,"activeCount":103},[],{"trials":13802,"activeCount":103},[],{"trials":13804,"activeCount":103},[13805],{"nctId":12667,"briefTitle":12668,"status":4881,"phases":13806,"primaryCompletion":12670,"completion":12670,"start":4792,"enrollment":103,"conditions":13807,"interventions":13808},[95],[12672,12673],[12675,12676,12634,12677],{"intervention":13810,"totalTrials":121,"cells":13811},"HER-2\u002Fneu Pulsed DC1 vaccine",{"EARLY_PHASE1":13812,"PHASE1":13814,"PHASE2":13816,"PHASE3":13818,"PHASE4":13820,"NA":13822},{"trials":13813,"activeCount":103},[],{"trials":13815,"activeCount":103},[],{"trials":13817,"activeCount":103},[],{"trials":13819,"activeCount":103},[],{"trials":13821,"activeCount":103},[],{"trials":13823,"activeCount":103},[13824],{"nctId":13825,"briefTitle":13826,"status":13827,"phases":13828,"conditions":13829,"interventions":13831},"NCT02473653","Pilot Trial of HER-2\u002FNeu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer","NO_LONGER_AVAILABLE",[],[13830],"Metastatic Cancer",[13810],{"intervention":13833,"totalTrials":121,"cells":13834},"[18F]-T807 imaging tracer",{"EARLY_PHASE1":13835,"PHASE1":13837,"PHASE2":13839,"PHASE3":13841,"PHASE4":13843,"NA":13845},{"trials":13836,"activeCount":103},[],{"trials":13838,"activeCount":103},[],{"trials":13840,"activeCount":103},[],{"trials":13842,"activeCount":103},[],{"trials":13844,"activeCount":103},[],{"trials":13846,"activeCount":103},[13847],{"nctId":13848,"briefTitle":13849,"status":150,"phases":13850,"primaryCompletion":188,"completion":13851,"start":154,"enrollment":3729,"conditions":13852,"interventions":13856},"NCT02289118","Tau Imaging in Young Onset Dementia",[],"2019-01-31",[13853,13854,13855],"Alzheimer's Disease, Early Onset","Logopenic Progressive Aphasia","Posterior Cortical Atrophy (PCA)",[13833],{"intervention":13858,"totalTrials":121,"cells":13859},"Lenalidomide",{"EARLY_PHASE1":13860,"PHASE1":13862,"PHASE2":13864,"PHASE3":13866,"PHASE4":13868,"NA":13870},{"trials":13861,"activeCount":103},[],{"trials":13863,"activeCount":103},[],{"trials":13865,"activeCount":103},[],{"trials":13867,"activeCount":103},[],{"trials":13869,"activeCount":103},[],{"trials":13871,"activeCount":103},[13872],{"nctId":13873,"briefTitle":13874,"status":150,"phases":13875,"primaryCompletion":7639,"completion":4860,"start":1105,"enrollment":1410,"conditions":13876,"interventions":13878},"NCT00633945","Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)",[95],[13877],"Cutaneous Lupus Erythematosus (CLE)",[13858],{"intervention":13880,"totalTrials":121,"cells":13881},"Perflutren Lipid Microsphere Injectable Suspension",{"EARLY_PHASE1":13882,"PHASE1":13884,"PHASE2":13886,"PHASE3":13888,"PHASE4":13890,"NA":13892},{"trials":13883,"activeCount":103},[],{"trials":13885,"activeCount":103},[],{"trials":13887,"activeCount":103},[],{"trials":13889,"activeCount":103},[],{"trials":13891,"activeCount":103},[],{"trials":13893,"activeCount":103},[13894],{"nctId":13895,"briefTitle":13896,"status":1357,"phases":13897,"primaryCompletion":2439,"completion":2439,"start":4933,"enrollment":2399,"conditions":13898,"interventions":13899},"NCT01242020","Microvascular Flow Assessment Repeatability Study: The MARS Study",[95],[15],[13880],{"intervention":13901,"totalTrials":121,"cells":13902},"Nicotine",{"EARLY_PHASE1":13903,"PHASE1":13905,"PHASE2":13907,"PHASE3":13909,"PHASE4":13911,"NA":13913},{"trials":13904,"activeCount":103},[],{"trials":13906,"activeCount":103},[],{"trials":13908,"activeCount":103},[],{"trials":13910,"activeCount":103},[],{"trials":13912,"activeCount":103},[],{"trials":13914,"activeCount":103},[13915],{"nctId":13916,"briefTitle":13917,"status":1357,"phases":13918,"primaryCompletion":8136,"completion":8136,"start":6744,"enrollment":983,"conditions":13919,"interventions":13920},"NCT01040338","Effects of Nicotine on Brain Opioid Receptors",[],[1024],[13901],{"intervention":13922,"totalTrials":121,"cells":13923},"Aspirin First",{"EARLY_PHASE1":13924,"PHASE1":13926,"PHASE2":13928,"PHASE3":13930,"PHASE4":13932,"NA":13934},{"trials":13925,"activeCount":103},[],{"trials":13927,"activeCount":103},[],{"trials":13929,"activeCount":103},[],{"trials":13931,"activeCount":103},[],{"trials":13933,"activeCount":103},[],{"trials":13935,"activeCount":103},[13936],{"nctId":13937,"briefTitle":13938,"status":150,"phases":13939,"primaryCompletion":13940,"completion":13940,"start":13941,"enrollment":9895,"conditions":13942,"interventions":13945},"NCT00646906","Mechanisms of Action of Acetaminophen",[95],"2012-01-24","2004-06-02",[13943,13944],"Myocardial Infarction","Arthritis",[13922,13946,13947,13948,13949],"Aspirin Last","Acetaminophen 1000 mg\u002Fd","Acetaminophen 4000 mg\u002Fd","Ibuprofen 800 mg\u002Fd",{"intervention":13946,"totalTrials":121,"cells":13951},{"EARLY_PHASE1":13952,"PHASE1":13954,"PHASE2":13956,"PHASE3":13958,"PHASE4":13960,"NA":13962},{"trials":13953,"activeCount":103},[],{"trials":13955,"activeCount":103},[],{"trials":13957,"activeCount":103},[],{"trials":13959,"activeCount":103},[],{"trials":13961,"activeCount":103},[],{"trials":13963,"activeCount":103},[13964],{"nctId":13937,"briefTitle":13938,"status":150,"phases":13965,"primaryCompletion":13940,"completion":13940,"start":13941,"enrollment":9895,"conditions":13966,"interventions":13967},[95],[13943,13944],[13922,13946,13947,13948,13949],{"intervention":13947,"totalTrials":121,"cells":13969},{"EARLY_PHASE1":13970,"PHASE1":13972,"PHASE2":13974,"PHASE3":13976,"PHASE4":13978,"NA":13980},{"trials":13971,"activeCount":103},[],{"trials":13973,"activeCount":103},[],{"trials":13975,"activeCount":103},[],{"trials":13977,"activeCount":103},[],{"trials":13979,"activeCount":103},[],{"trials":13981,"activeCount":103},[13982],{"nctId":13937,"briefTitle":13938,"status":150,"phases":13983,"primaryCompletion":13940,"completion":13940,"start":13941,"enrollment":9895,"conditions":13984,"interventions":13985},[95],[13943,13944],[13922,13946,13947,13948,13949],{"intervention":13948,"totalTrials":121,"cells":13987},{"EARLY_PHASE1":13988,"PHASE1":13990,"PHASE2":13992,"PHASE3":13994,"PHASE4":13996,"NA":13998},{"trials":13989,"activeCount":103},[],{"trials":13991,"activeCount":103},[],{"trials":13993,"activeCount":103},[],{"trials":13995,"activeCount":103},[],{"trials":13997,"activeCount":103},[],{"trials":13999,"activeCount":103},[14000],{"nctId":13937,"briefTitle":13938,"status":150,"phases":14001,"primaryCompletion":13940,"completion":13940,"start":13941,"enrollment":9895,"conditions":14002,"interventions":14003},[95],[13943,13944],[13922,13946,13947,13948,13949],{"intervention":13949,"totalTrials":121,"cells":14005},{"EARLY_PHASE1":14006,"PHASE1":14008,"PHASE2":14010,"PHASE3":14012,"PHASE4":14014,"NA":14016},{"trials":14007,"activeCount":103},[],{"trials":14009,"activeCount":103},[],{"trials":14011,"activeCount":103},[],{"trials":14013,"activeCount":103},[],{"trials":14015,"activeCount":103},[],{"trials":14017,"activeCount":103},[14018],{"nctId":13937,"briefTitle":13938,"status":150,"phases":14019,"primaryCompletion":13940,"completion":13940,"start":13941,"enrollment":9895,"conditions":14020,"interventions":14021},[95],[13943,13944],[13922,13946,13947,13948,13949],{"intervention":12718,"totalTrials":121,"cells":14023},{"EARLY_PHASE1":14024,"PHASE1":14026,"PHASE2":14028,"PHASE3":14030,"PHASE4":14032,"NA":14034},{"trials":14025,"activeCount":103},[],{"trials":14027,"activeCount":103},[],{"trials":14029,"activeCount":103},[],{"trials":14031,"activeCount":103},[],{"trials":14033,"activeCount":103},[],{"trials":14035,"activeCount":103},[14036],{"nctId":12710,"briefTitle":12711,"status":150,"phases":14037,"primaryCompletion":7476,"completion":7476,"start":4958,"enrollment":12713,"conditions":14038,"interventions":14039},[],[12715,12716],[12679,12718],{"intervention":14041,"totalTrials":121,"cells":14042},"Unsupervised Decolonization",{"EARLY_PHASE1":14043,"PHASE1":14045,"PHASE2":14047,"PHASE3":14049,"PHASE4":14051,"NA":14053},{"trials":14044,"activeCount":103},[],{"trials":14046,"activeCount":103},[],{"trials":14048,"activeCount":103},[],{"trials":14050,"activeCount":103},[],{"trials":14052,"activeCount":103},[],{"trials":14054,"activeCount":103},[14055],{"nctId":14056,"briefTitle":14057,"status":150,"phases":14058,"primaryCompletion":1062,"completion":2437,"start":969,"enrollment":4716,"conditions":14059,"interventions":14061},"NCT00966446","Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community",[95],[14060],"MRSA - Methicillin Resistant Staphylococcus Aureus Infection",[14041,14062],"Supervised Decolonization",{"intervention":14062,"totalTrials":121,"cells":14064},{"EARLY_PHASE1":14065,"PHASE1":14067,"PHASE2":14069,"PHASE3":14071,"PHASE4":14073,"NA":14075},{"trials":14066,"activeCount":103},[],{"trials":14068,"activeCount":103},[],{"trials":14070,"activeCount":103},[],{"trials":14072,"activeCount":103},[],{"trials":14074,"activeCount":103},[],{"trials":14076,"activeCount":103},[14077],{"nctId":14056,"briefTitle":14057,"status":150,"phases":14078,"primaryCompletion":1062,"completion":2437,"start":969,"enrollment":4716,"conditions":14079,"interventions":14080},[95],[14060],[14041,14062],{"intervention":14082,"totalTrials":121,"cells":14083},"ropivacaine",{"EARLY_PHASE1":14084,"PHASE1":14086,"PHASE2":14088,"PHASE3":14090,"PHASE4":14092,"NA":14094},{"trials":14085,"activeCount":103},[],{"trials":14087,"activeCount":103},[],{"trials":14089,"activeCount":103},[],{"trials":14091,"activeCount":103},[],{"trials":14093,"activeCount":103},[],{"trials":14095,"activeCount":103},[14096],{"nctId":14097,"briefTitle":14098,"status":150,"phases":14099,"primaryCompletion":14100,"completion":14100,"start":5061,"enrollment":1587,"conditions":14101,"interventions":14103},"NCT02181296","Pulmonary Function and Interscalene Block",[95],"2016-02",[14102],"Shoulder Arthroscopy",[14082],{"intervention":12815,"totalTrials":121,"cells":14105},{"EARLY_PHASE1":14106,"PHASE1":14108,"PHASE2":14110,"PHASE3":14112,"PHASE4":14114,"NA":14116},{"trials":14107,"activeCount":103},[],{"trials":14109,"activeCount":103},[],{"trials":14111,"activeCount":103},[],{"trials":14113,"activeCount":103},[],{"trials":14115,"activeCount":103},[],{"trials":14117,"activeCount":103},[14118],{"nctId":12808,"briefTitle":12809,"status":1357,"phases":14119,"primaryCompletion":12670,"completion":12670,"start":7693,"enrollment":190,"conditions":14120,"interventions":14121},[95],[12812,12813],[12675,12815],{"intervention":14123,"totalTrials":121,"cells":14124},"2% Chlorhexidine Gluconate\u002F70% Isopropyl Alcohol",{"EARLY_PHASE1":14125,"PHASE1":14127,"PHASE2":14129,"PHASE3":14131,"PHASE4":14133,"NA":14135},{"trials":14126,"activeCount":103},[],{"trials":14128,"activeCount":103},[],{"trials":14130,"activeCount":103},[],{"trials":14132,"activeCount":103},[],{"trials":14134,"activeCount":103},[],{"trials":14136,"activeCount":103},[14137],{"nctId":14138,"briefTitle":14139,"status":150,"phases":14140,"primaryCompletion":2545,"completion":2545,"start":1063,"enrollment":14141,"conditions":14142,"interventions":14144},"NCT01233050","Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery",[95],802,[14143],"Colorectal Surgery",[14123,14145],"Iodine Povacrylex\u002F74% Isopropyl Alcohol",{"intervention":14145,"totalTrials":121,"cells":14147},{"EARLY_PHASE1":14148,"PHASE1":14150,"PHASE2":14152,"PHASE3":14154,"PHASE4":14156,"NA":14158},{"trials":14149,"activeCount":103},[],{"trials":14151,"activeCount":103},[],{"trials":14153,"activeCount":103},[],{"trials":14155,"activeCount":103},[],{"trials":14157,"activeCount":103},[],{"trials":14159,"activeCount":103},[14160],{"nctId":14138,"briefTitle":14139,"status":150,"phases":14161,"primaryCompletion":2545,"completion":2545,"start":1063,"enrollment":14141,"conditions":14162,"interventions":14163},[95],[14143],[14123,14145],{"intervention":14165,"totalTrials":121,"cells":14166},"Rapid pleurodesis protocol",{"EARLY_PHASE1":14167,"PHASE1":14169,"PHASE2":14171,"PHASE3":14173,"PHASE4":14175,"NA":14177},{"trials":14168,"activeCount":103},[],{"trials":14170,"activeCount":103},[],{"trials":14172,"activeCount":103},[],{"trials":14174,"activeCount":103},[],{"trials":14176,"activeCount":103},[],{"trials":14178,"activeCount":103},[14179],{"nctId":14180,"briefTitle":14181,"status":1357,"phases":14182,"primaryCompletion":14183,"completion":14183,"start":14184,"enrollment":2592,"conditions":14185,"interventions":14189},"NCT03325192","Rapid Pleurodesis Through an Indwelling Pleural Catheter",[95],"2019-07-09","2017-12-12",[14186,14187,14188],"Pleural Effusion, Malignant","Pleurodesis","Pleural Diseases",[14165],{"intervention":2521,"totalTrials":121,"cells":14191},{"EARLY_PHASE1":14192,"PHASE1":14194,"PHASE2":14196,"PHASE3":14198,"PHASE4":14200,"NA":14202},{"trials":14193,"activeCount":103},[],{"trials":14195,"activeCount":103},[],{"trials":14197,"activeCount":103},[],{"trials":14199,"activeCount":103},[],{"trials":14201,"activeCount":103},[],{"trials":14203,"activeCount":103},[14204],{"nctId":2513,"briefTitle":2514,"status":150,"phases":14205,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":957,"conditions":14206,"interventions":14207},[95],[2519],[2521,118,2522],{"intervention":2522,"totalTrials":121,"cells":14209},{"EARLY_PHASE1":14210,"PHASE1":14212,"PHASE2":14214,"PHASE3":14216,"PHASE4":14218,"NA":14220},{"trials":14211,"activeCount":103},[],{"trials":14213,"activeCount":103},[],{"trials":14215,"activeCount":103},[],{"trials":14217,"activeCount":103},[],{"trials":14219,"activeCount":103},[],{"trials":14221,"activeCount":103},[14222],{"nctId":2513,"briefTitle":2514,"status":150,"phases":14223,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":957,"conditions":14224,"interventions":14225},[95],[2519],[2521,118,2522],{"intervention":14227,"totalTrials":121,"cells":14228},"lentiviral-based CART meso therapy",{"EARLY_PHASE1":14229,"PHASE1":14231,"PHASE2":14233,"PHASE3":14235,"PHASE4":14237,"NA":14239},{"trials":14230,"activeCount":103},[],{"trials":14232,"activeCount":103},[],{"trials":14234,"activeCount":103},[],{"trials":14236,"activeCount":103},[],{"trials":14238,"activeCount":103},[],{"trials":14240,"activeCount":103},[14241],{"nctId":14242,"briefTitle":14243,"status":150,"phases":14244,"primaryCompletion":14245,"completion":14245,"start":12593,"enrollment":2440,"conditions":14246,"interventions":14248},"NCT02388828","CART-meso Long-term Follow-up",[],"2019-07",[14247],"Subjects Who Have Received Lentiviral-based CART-meso Therapy",[14227],{"intervention":12826,"totalTrials":121,"cells":14250},{"EARLY_PHASE1":14251,"PHASE1":14253,"PHASE2":14255,"PHASE3":14257,"PHASE4":14259,"NA":14261},{"trials":14252,"activeCount":103},[],{"trials":14254,"activeCount":103},[],{"trials":14256,"activeCount":103},[],{"trials":14258,"activeCount":103},[],{"trials":14260,"activeCount":103},[],{"trials":14262,"activeCount":103},[14263],{"nctId":12817,"briefTitle":12818,"status":150,"phases":14264,"primaryCompletion":12820,"completion":1203,"start":12821,"enrollment":6834,"conditions":14265,"interventions":14266},[95],[12823,12824,12813],[12675,12826,12827],{"intervention":12827,"totalTrials":121,"cells":14268},{"EARLY_PHASE1":14269,"PHASE1":14271,"PHASE2":14273,"PHASE3":14275,"PHASE4":14277,"NA":14279},{"trials":14270,"activeCount":103},[],{"trials":14272,"activeCount":103},[],{"trials":14274,"activeCount":103},[],{"trials":14276,"activeCount":103},[],{"trials":14278,"activeCount":103},[],{"trials":14280,"activeCount":103},[14281],{"nctId":12817,"briefTitle":12818,"status":150,"phases":14282,"primaryCompletion":12820,"completion":1203,"start":12821,"enrollment":6834,"conditions":14283,"interventions":14284},[95],[12823,12824,12813],[12675,12826,12827],{"intervention":14286,"totalTrials":121,"cells":14287},"30ml bolus of bupivacaine",{"EARLY_PHASE1":14288,"PHASE1":14290,"PHASE2":14292,"PHASE3":14294,"PHASE4":14296,"NA":14298},{"trials":14289,"activeCount":103},[],{"trials":14291,"activeCount":103},[],{"trials":14293,"activeCount":103},[],{"trials":14295,"activeCount":103},[],{"trials":14297,"activeCount":103},[],{"trials":14299,"activeCount":103},[14300],{"nctId":14301,"briefTitle":14302,"status":150,"phases":14303,"primaryCompletion":14304,"completion":14304,"start":1021,"enrollment":1587,"conditions":14305,"interventions":14308},"NCT02882633","Lumbar Plexus Block vs Fascia Iliaca Block After Hip Arthroscopy",[95],"2018-05",[14306,14307],"Hip Arthroscopy","Nerve Block",[14286],{"intervention":14310,"totalTrials":121,"cells":14311},"FDG-PET",{"EARLY_PHASE1":14312,"PHASE1":14314,"PHASE2":14316,"PHASE3":14318,"PHASE4":14320,"NA":14322},{"trials":14313,"activeCount":103},[],{"trials":14315,"activeCount":103},[],{"trials":14317,"activeCount":103},[],{"trials":14319,"activeCount":103},[],{"trials":14321,"activeCount":103},[],{"trials":14323,"activeCount":103},[14324],{"nctId":14325,"briefTitle":14326,"status":150,"phases":14327,"primaryCompletion":12658,"completion":1073,"start":993,"enrollment":14328,"conditions":14329,"interventions":14330},"NCT01727622","Arterial Spin Labeling (ASL) MRI for Cognitive Decline",[],102,[4502,4327],[14310],{"intervention":14332,"totalTrials":121,"cells":14333},"Lorcaserin",{"EARLY_PHASE1":14334,"PHASE1":14336,"PHASE2":14338,"PHASE3":14340,"PHASE4":14342,"NA":14344},{"trials":14335,"activeCount":103},[],{"trials":14337,"activeCount":103},[],{"trials":14339,"activeCount":103},[],{"trials":14341,"activeCount":103},[],{"trials":14343,"activeCount":103},[],{"trials":14345,"activeCount":103},[14346],{"nctId":14347,"briefTitle":14348,"status":150,"phases":14349,"primaryCompletion":152,"completion":152,"start":3373,"enrollment":14350,"conditions":14351,"interventions":14352},"NCT02388568","Lifestyle Modification and Lorcaserin for Weight Loss Maintenance",[95],137,[15],[14332],{"intervention":14354,"totalTrials":121,"cells":14355},"Basiliximab",{"EARLY_PHASE1":14356,"PHASE1":14358,"PHASE2":14360,"PHASE3":14362,"PHASE4":14364,"NA":14366},{"trials":14357,"activeCount":103},[],{"trials":14359,"activeCount":103},[],{"trials":14361,"activeCount":103},[],{"trials":14363,"activeCount":103},[],{"trials":14365,"activeCount":103},[],{"trials":14367,"activeCount":103},[14368],{"nctId":14369,"briefTitle":14370,"status":1357,"phases":14371,"primaryCompletion":14372,"completion":14372,"start":1094,"enrollment":1150,"conditions":14373,"interventions":14375},"NCT02730715","Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients",[],"2020-04",[14374],"KIDNEY TRANSPLANTATION",[14354,14376],"Thymoglobulin",{"intervention":14376,"totalTrials":121,"cells":14378},{"EARLY_PHASE1":14379,"PHASE1":14381,"PHASE2":14383,"PHASE3":14385,"PHASE4":14387,"NA":14389},{"trials":14380,"activeCount":103},[],{"trials":14382,"activeCount":103},[],{"trials":14384,"activeCount":103},[],{"trials":14386,"activeCount":103},[],{"trials":14388,"activeCount":103},[],{"trials":14390,"activeCount":103},[14391],{"nctId":14369,"briefTitle":14370,"status":1357,"phases":14392,"primaryCompletion":14372,"completion":14372,"start":1094,"enrollment":1150,"conditions":14393,"interventions":14394},[],[14374],[14354,14376],{"intervention":14396,"totalTrials":121,"cells":14397},"3H-cholesterol bound to albumin",{"EARLY_PHASE1":14398,"PHASE1":14400,"PHASE2":14402,"PHASE3":14404,"PHASE4":14406,"NA":14408},{"trials":14399,"activeCount":103},[],{"trials":14401,"activeCount":103},[],{"trials":14403,"activeCount":103},[],{"trials":14405,"activeCount":103},[],{"trials":14407,"activeCount":103},[],{"trials":14409,"activeCount":103},[14410],{"nctId":14411,"briefTitle":14412,"status":1357,"phases":14413,"primaryCompletion":14414,"completion":14414,"start":1001,"enrollment":2683,"conditions":14415,"interventions":14421},"NCT01782027","Mendelian Reverse Cholesterol Transport Study",[95],"2024-09-04",[14416,14417,14418,14419,14420],"Cholesterol, HDL","Lipid Metabolism, Inborn Errors","Tangier Disease","LCAT Deficiency","Cholesteryl Ester Transfer Protein (CETP) Deficiency",[14396],{"intervention":14423,"totalTrials":121,"cells":14424},"2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine",{"EARLY_PHASE1":14425,"PHASE1":14427,"PHASE2":14429,"PHASE3":14431,"PHASE4":14433,"NA":14435},{"trials":14426,"activeCount":103},[],{"trials":14428,"activeCount":103},[],{"trials":14430,"activeCount":103},[],{"trials":14432,"activeCount":103},[],{"trials":14434,"activeCount":103},[],{"trials":14436,"activeCount":103},[14437],{"nctId":14438,"briefTitle":14439,"status":150,"phases":14440,"primaryCompletion":12741,"completion":4638,"start":5777,"enrollment":329,"conditions":14441,"interventions":14442},"NCT01704573","Nicotinic Receptor Levels After Stopping Smoking",[],[1066],[14423],{"intervention":2551,"totalTrials":121,"cells":14444},{"EARLY_PHASE1":14445,"PHASE1":14447,"PHASE2":14449,"PHASE3":14451,"PHASE4":14453,"NA":14455},{"trials":14446,"activeCount":103},[],{"trials":14448,"activeCount":103},[],{"trials":14450,"activeCount":103},[],{"trials":14452,"activeCount":103},[],{"trials":14454,"activeCount":103},[],{"trials":14456,"activeCount":103},[14457],{"nctId":2542,"briefTitle":2543,"status":150,"phases":14458,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":2547,"conditions":14459,"interventions":14460},[95],[2549],[2551,2552,2553],{"intervention":2552,"totalTrials":121,"cells":14462},{"EARLY_PHASE1":14463,"PHASE1":14465,"PHASE2":14467,"PHASE3":14469,"PHASE4":14471,"NA":14473},{"trials":14464,"activeCount":103},[],{"trials":14466,"activeCount":103},[],{"trials":14468,"activeCount":103},[],{"trials":14470,"activeCount":103},[],{"trials":14472,"activeCount":103},[],{"trials":14474,"activeCount":103},[14475],{"nctId":2542,"briefTitle":2543,"status":150,"phases":14476,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":2547,"conditions":14477,"interventions":14478},[95],[2549],[2551,2552,2553],{"intervention":14480,"totalTrials":121,"cells":14481},"No ASA",{"EARLY_PHASE1":14482,"PHASE1":14484,"PHASE2":14486,"PHASE3":14488,"PHASE4":14490,"NA":14492},{"trials":14483,"activeCount":103},[],{"trials":14485,"activeCount":103},[],{"trials":14487,"activeCount":103},[],{"trials":14489,"activeCount":103},[],{"trials":14491,"activeCount":103},[],{"trials":14493,"activeCount":103},[14494],{"nctId":14495,"briefTitle":14496,"status":1357,"phases":14497,"primaryCompletion":4581,"completion":7657,"start":1084,"enrollment":14498,"conditions":14499,"interventions":14502},"NCT01001260","PGD2 Formation in Vascular Injury",[],51,[12743,14500,14501],"Acute Coronary Syndrome","Stable Angina",[14480,14503,14504],"Low dose ASA","325 mg ASA",{"intervention":14503,"totalTrials":121,"cells":14506},{"EARLY_PHASE1":14507,"PHASE1":14509,"PHASE2":14511,"PHASE3":14513,"PHASE4":14515,"NA":14517},{"trials":14508,"activeCount":103},[],{"trials":14510,"activeCount":103},[],{"trials":14512,"activeCount":103},[],{"trials":14514,"activeCount":103},[],{"trials":14516,"activeCount":103},[],{"trials":14518,"activeCount":103},[14519],{"nctId":14495,"briefTitle":14496,"status":1357,"phases":14520,"primaryCompletion":4581,"completion":7657,"start":1084,"enrollment":14498,"conditions":14521,"interventions":14522},[],[12743,14500,14501],[14480,14503,14504],{"intervention":14504,"totalTrials":121,"cells":14524},{"EARLY_PHASE1":14525,"PHASE1":14527,"PHASE2":14529,"PHASE3":14531,"PHASE4":14533,"NA":14535},{"trials":14526,"activeCount":103},[],{"trials":14528,"activeCount":103},[],{"trials":14530,"activeCount":103},[],{"trials":14532,"activeCount":103},[],{"trials":14534,"activeCount":103},[],{"trials":14536,"activeCount":103},[14537],{"nctId":14495,"briefTitle":14496,"status":1357,"phases":14538,"primaryCompletion":4581,"completion":7657,"start":1084,"enrollment":14498,"conditions":14539,"interventions":14540},[],[12743,14500,14501],[14480,14503,14504],{"intervention":14542,"totalTrials":121,"cells":14543},"[18F] FES",{"EARLY_PHASE1":14544,"PHASE1":14546,"PHASE2":14548,"PHASE3":14550,"PHASE4":14552,"NA":14554},{"trials":14545,"activeCount":103},[],{"trials":14547,"activeCount":103},[],{"trials":14549,"activeCount":103},[],{"trials":14551,"activeCount":103},[],{"trials":14553,"activeCount":103},[],{"trials":14555,"activeCount":103},[14556],{"nctId":14557,"briefTitle":14558,"status":1357,"phases":14559,"primaryCompletion":14560,"completion":14560,"start":4958,"enrollment":1410,"conditions":14561,"interventions":14562},"NCT02899533","[18F]FES PET\u002FCT in PAH",[],"2021-04-06",[7719],[14542],{"intervention":14564,"totalTrials":121,"cells":14565},"Nitroglycerin Topical Product",{"EARLY_PHASE1":14566,"PHASE1":14568,"PHASE2":14570,"PHASE3":14572,"PHASE4":14574,"NA":14576},{"trials":14567,"activeCount":103},[],{"trials":14569,"activeCount":103},[],{"trials":14571,"activeCount":103},[],{"trials":14573,"activeCount":103},[],{"trials":14575,"activeCount":103},[],{"trials":14577,"activeCount":103},[14578],{"nctId":14579,"briefTitle":14580,"status":150,"phases":14581,"primaryCompletion":1503,"completion":14582,"start":12647,"enrollment":3913,"conditions":14583,"interventions":14586},"NCT05102734","Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.",[],"2022-03-01",[14584,14585],"Circulatory Shock","Cardiovascular Shock",[14564],{"intervention":14588,"totalTrials":121,"cells":14589},"Immediate Release Niacin, Extended Release Niacin, Endotoxin",{"EARLY_PHASE1":14590,"PHASE1":14592,"PHASE2":14594,"PHASE3":14596,"PHASE4":14598,"NA":14600},{"trials":14591,"activeCount":103},[],{"trials":14593,"activeCount":103},[],{"trials":14595,"activeCount":103},[],{"trials":14597,"activeCount":103},[],{"trials":14599,"activeCount":103},[],{"trials":14601,"activeCount":103},[14602],{"nctId":14603,"briefTitle":14604,"status":150,"phases":14605,"primaryCompletion":4581,"completion":4581,"start":1374,"enrollment":12495,"conditions":14606,"interventions":14607},"NCT00953667","The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study",[95],[10377],[14588],{"intervention":12438,"totalTrials":121,"cells":14609},{"EARLY_PHASE1":14610,"PHASE1":14612,"PHASE2":14614,"PHASE3":14616,"PHASE4":14618,"NA":14620},{"trials":14611,"activeCount":103},[],{"trials":14613,"activeCount":103},[],{"trials":14615,"activeCount":103},[],{"trials":14617,"activeCount":103},[],{"trials":14619,"activeCount":103},[],{"trials":14621,"activeCount":103},[14622],{"nctId":12432,"briefTitle":12433,"status":4881,"phases":14623,"primaryCompletion":8105,"completion":8105,"start":8105,"enrollment":103,"conditions":14624,"interventions":14625},[95],[12436],[12383,12438],{"intervention":14627,"totalTrials":121,"cells":14628},"The current season's trivalent killed influenza vaccine",{"EARLY_PHASE1":14629,"PHASE1":14631,"PHASE2":14633,"PHASE3":14635,"PHASE4":14637,"NA":14639},{"trials":14630,"activeCount":103},[],{"trials":14632,"activeCount":103},[],{"trials":14634,"activeCount":103},[],{"trials":14636,"activeCount":103},[],{"trials":14638,"activeCount":103},[],{"trials":14640,"activeCount":103},[14641],{"nctId":14642,"briefTitle":14643,"status":150,"phases":14644,"primaryCompletion":9580,"completion":9580,"start":4748,"enrollment":971,"conditions":14645,"interventions":14646},"NCT00478387","Ovarian Cancer and Immune Response to Flu Vaccine",[],[2859],[14627],{"intervention":14648,"totalTrials":121,"cells":14649},"Armodafinil",{"EARLY_PHASE1":14650,"PHASE1":14652,"PHASE2":14654,"PHASE3":14656,"PHASE4":14658,"NA":14660},{"trials":14651,"activeCount":103},[],{"trials":14653,"activeCount":103},[],{"trials":14655,"activeCount":103},[],{"trials":14657,"activeCount":103},[],{"trials":14659,"activeCount":103},[],{"trials":14661,"activeCount":103},[14662],{"nctId":14663,"briefTitle":14664,"status":150,"phases":14665,"primaryCompletion":7361,"completion":7361,"start":12399,"enrollment":1626,"conditions":14666,"interventions":14668},"NCT02552303","The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and\u002For Cognitive Behavioral Therapy for Insomnia",[95],[14667,466],"Sleep Apnea",[14648],{"intervention":13157,"totalTrials":121,"cells":14670},{"EARLY_PHASE1":14671,"PHASE1":14673,"PHASE2":14675,"PHASE3":14677,"PHASE4":14679,"NA":14681},{"trials":14672,"activeCount":103},[],{"trials":14674,"activeCount":103},[],{"trials":14676,"activeCount":103},[],{"trials":14678,"activeCount":103},[],{"trials":14680,"activeCount":103},[],{"trials":14682,"activeCount":103},[14683],{"nctId":13149,"briefTitle":13150,"status":150,"phases":14684,"primaryCompletion":13152,"completion":13152,"start":2437,"enrollment":7957,"conditions":14685,"interventions":14686},[95],[13154,13155],[13157,196],{"intervention":14688,"totalTrials":121,"cells":14689},"Onabotulinumtoxina for",{"EARLY_PHASE1":14690,"PHASE1":14692,"PHASE2":14694,"PHASE3":14696,"PHASE4":14698,"NA":14700},{"trials":14691,"activeCount":103},[],{"trials":14693,"activeCount":103},[],{"trials":14695,"activeCount":103},[],{"trials":14697,"activeCount":103},[],{"trials":14699,"activeCount":103},[],{"trials":14701,"activeCount":103},[14702],{"nctId":14703,"briefTitle":14704,"status":150,"phases":14705,"primaryCompletion":4725,"completion":4725,"start":14706,"enrollment":14707,"conditions":14708,"interventions":14709},"NCT05167864","Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area",[95],"2022-03-04",143,[5233],[14688,14710,14711,14712],"Abobotulinumtoxina for","IncobotulinumtoxinA for","PrabotulinumtoxinA for",{"intervention":14710,"totalTrials":121,"cells":14714},{"EARLY_PHASE1":14715,"PHASE1":14717,"PHASE2":14719,"PHASE3":14721,"PHASE4":14723,"NA":14725},{"trials":14716,"activeCount":103},[],{"trials":14718,"activeCount":103},[],{"trials":14720,"activeCount":103},[],{"trials":14722,"activeCount":103},[],{"trials":14724,"activeCount":103},[],{"trials":14726,"activeCount":103},[14727],{"nctId":14703,"briefTitle":14704,"status":150,"phases":14728,"primaryCompletion":4725,"completion":4725,"start":14706,"enrollment":14707,"conditions":14729,"interventions":14730},[95],[5233],[14688,14710,14711,14712],{"intervention":14711,"totalTrials":121,"cells":14732},{"EARLY_PHASE1":14733,"PHASE1":14735,"PHASE2":14737,"PHASE3":14739,"PHASE4":14741,"NA":14743},{"trials":14734,"activeCount":103},[],{"trials":14736,"activeCount":103},[],{"trials":14738,"activeCount":103},[],{"trials":14740,"activeCount":103},[],{"trials":14742,"activeCount":103},[],{"trials":14744,"activeCount":103},[14745],{"nctId":14703,"briefTitle":14704,"status":150,"phases":14746,"primaryCompletion":4725,"completion":4725,"start":14706,"enrollment":14707,"conditions":14747,"interventions":14748},[95],[5233],[14688,14710,14711,14712],{"intervention":14712,"totalTrials":121,"cells":14750},{"EARLY_PHASE1":14751,"PHASE1":14753,"PHASE2":14755,"PHASE3":14757,"PHASE4":14759,"NA":14761},{"trials":14752,"activeCount":103},[],{"trials":14754,"activeCount":103},[],{"trials":14756,"activeCount":103},[],{"trials":14758,"activeCount":103},[],{"trials":14760,"activeCount":103},[],{"trials":14762,"activeCount":103},[14763],{"nctId":14703,"briefTitle":14704,"status":150,"phases":14764,"primaryCompletion":4725,"completion":4725,"start":14706,"enrollment":14707,"conditions":14765,"interventions":14766},[95],[5233],[14688,14710,14711,14712],{"intervention":14768,"totalTrials":121,"cells":14769},"Dipyridamole 200mg and Aspirin 25mg bid:",{"EARLY_PHASE1":14770,"PHASE1":14772,"PHASE2":14774,"PHASE3":14776,"PHASE4":14778,"NA":14780},{"trials":14771,"activeCount":103},[],{"trials":14773,"activeCount":103},[],{"trials":14775,"activeCount":103},[],{"trials":14777,"activeCount":103},[],{"trials":14779,"activeCount":103},[],{"trials":14781,"activeCount":103},[14782],{"nctId":14783,"briefTitle":14784,"status":1357,"phases":14785,"primaryCompletion":1012,"completion":4621,"start":14786,"enrollment":3822,"conditions":14787,"interventions":14789},"NCT00906035","The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)",[95],"2002-09",[14788],"Peripheral Arterial Disease",[14768,14790,14791],"Dipyridamole 200 mg bid","Aspirin 25 mg bid",{"intervention":14790,"totalTrials":121,"cells":14793},{"EARLY_PHASE1":14794,"PHASE1":14796,"PHASE2":14798,"PHASE3":14800,"PHASE4":14802,"NA":14804},{"trials":14795,"activeCount":103},[],{"trials":14797,"activeCount":103},[],{"trials":14799,"activeCount":103},[],{"trials":14801,"activeCount":103},[],{"trials":14803,"activeCount":103},[],{"trials":14805,"activeCount":103},[14806],{"nctId":14783,"briefTitle":14784,"status":1357,"phases":14807,"primaryCompletion":1012,"completion":4621,"start":14786,"enrollment":3822,"conditions":14808,"interventions":14809},[95],[14788],[14768,14790,14791],{"intervention":14791,"totalTrials":121,"cells":14811},{"EARLY_PHASE1":14812,"PHASE1":14814,"PHASE2":14816,"PHASE3":14818,"PHASE4":14820,"NA":14822},{"trials":14813,"activeCount":103},[],{"trials":14815,"activeCount":103},[],{"trials":14817,"activeCount":103},[],{"trials":14819,"activeCount":103},[],{"trials":14821,"activeCount":103},[],{"trials":14823,"activeCount":103},[14824],{"nctId":14783,"briefTitle":14784,"status":1357,"phases":14825,"primaryCompletion":1012,"completion":4621,"start":14786,"enrollment":3822,"conditions":14826,"interventions":14827},[95],[14788],[14768,14790,14791],{"intervention":14829,"totalTrials":121,"cells":14830},"glargine and aspart",{"EARLY_PHASE1":14831,"PHASE1":14833,"PHASE2":14835,"PHASE3":14837,"PHASE4":14839,"NA":14841},{"trials":14832,"activeCount":103},[],{"trials":14834,"activeCount":103},[],{"trials":14836,"activeCount":103},[],{"trials":14838,"activeCount":103},[],{"trials":14840,"activeCount":103},[],{"trials":14842,"activeCount":103},[14843],{"nctId":14844,"briefTitle":14845,"status":4881,"phases":14846,"primaryCompletion":12323,"completion":12323,"start":5453,"enrollment":103,"conditions":14847,"interventions":14849},"NCT02144441","Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy",[95],[14848],"Diabetes Mellitus",[14829],{"intervention":14851,"totalTrials":121,"cells":14852},"CYP2C19 genotyping",{"EARLY_PHASE1":14853,"PHASE1":14855,"PHASE2":14857,"PHASE3":14859,"PHASE4":14861,"NA":14863},{"trials":14854,"activeCount":103},[],{"trials":14856,"activeCount":103},[],{"trials":14858,"activeCount":103},[],{"trials":14860,"activeCount":103},[],{"trials":14862,"activeCount":103},[],{"trials":14864,"activeCount":103},[14865],{"nctId":14866,"briefTitle":14867,"status":150,"phases":14868,"primaryCompletion":14869,"completion":6302,"start":154,"enrollment":14870,"conditions":14871,"interventions":14872},"NCT02508116","Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention",[95],"2017-05",509,[14500,5207],[14851]]